{"87ed35480cef311d5722c40171b0bb84cd379e94": [["IntroductionBoth the upper and lower regions of the alimentary canal (oropharyngeal cavity and gastrointestinal [g.i.] tract) are typically sites of almost constant and sometimes intense physiologically-related activity primarily related to the processing of liquid or solid food products.", [["alimentary canal", "ANATOMY", 52, 68], ["oropharyngeal cavity", "ANATOMY", 70, 90], ["gastrointestinal", "ANATOMY", 95, 111], ["upper", "ORGANISM_SUBDIVISION", 21, 26], ["alimentary canal", "MULTI-TISSUE_STRUCTURE", 52, 68], ["oropharyngeal cavity", "ORGANISM_SUBDIVISION", 70, 90], ["gastrointestinal", "ORGAN", 95, 111], ["tract", "ORGANISM_SUBDIVISION", 119, 124], ["gastrointestinal [g.i.] tract", "TREATMENT", 95, 124], ["liquid or solid food products", "TREATMENT", 259, 288], ["upper", "ANATOMY_MODIFIER", 21, 26], ["lower", "ANATOMY_MODIFIER", 31, 36], ["regions", "ANATOMY_MODIFIER", 37, 44], ["alimentary canal", "ANATOMY", 52, 68], ["oropharyngeal cavity", "ANATOMY", 70, 90], ["gastrointestinal", "ANATOMY", 95, 111], ["almost", "OBSERVATION_MODIFIER", 149, 155], ["constant", "OBSERVATION_MODIFIER", 156, 164], ["intense", "OBSERVATION_MODIFIER", 179, 186], ["related activity", "OBSERVATION_MODIFIER", 203, 219]]], ["In these locations there is a complex and densely populated mixture of usually harmless yet essential microorganisms (the microbiome), a few potential pathogens that are capable of being inhaled, ingested or aspirated, and many complex macromolecules capable of eliciting, as well as regulating, various immune responses.", [["a complex and densely populated mixture", "PROBLEM", 28, 67], ["essential microorganisms", "PROBLEM", 92, 116], ["a few potential pathogens", "PROBLEM", 135, 160], ["complex", "OBSERVATION_MODIFIER", 30, 37], ["densely", "OBSERVATION_MODIFIER", 42, 49], ["populated", "OBSERVATION", 50, 59], ["essential", "OBSERVATION_MODIFIER", 92, 101], ["microorganisms", "OBSERVATION", 102, 116], ["few", "OBSERVATION_MODIFIER", 137, 140], ["potential", "OBSERVATION_MODIFIER", 141, 150], ["pathogens", "OBSERVATION", 151, 160], ["complex", "OBSERVATION_MODIFIER", 228, 235], ["macromolecules", "OBSERVATION", 236, 250]]], ["The local mucosal immune system has developed mechanisms for readily ignoring the \"harmless\" resident microflora and most of the inhaled/ingested substances (potential antigens/superantigens), while generating protective responses, such as locally produced immunoglobulins, especially IgA, to a wide range of pathogens.", [["mucosal", "ANATOMY", 10, 17], ["microflora", "ANATOMY", 102, 112], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 257, 272], ["IgA", "GENE_OR_GENE_PRODUCT", 285, 288], ["antigens", "PROTEIN", 168, 176], ["superantigens", "PROTEIN", 177, 190], ["immunoglobulins", "PROTEIN", 257, 272], ["IgA", "PROTEIN", 285, 288], ["the inhaled/ingested substances", "TREATMENT", 125, 156], ["potential antigens/superantigens", "PROBLEM", 158, 190], ["locally produced immunoglobulins", "PROBLEM", 240, 272], ["pathogens", "PROBLEM", 309, 318], ["mucosal immune system", "OBSERVATION", 10, 31]]], ["IgA also helps preserve the composition of the gut microbiome [1] , but it has also been shown that, under certain circumstances, it does not change significantly in the absence of secretory IgA.", [["gut microbiome", "ANATOMY", 47, 61], ["IgA", "GENE_OR_GENE_PRODUCT", 0, 3], ["gut", "ORGANISM_SUBDIVISION", 47, 50], ["IgA", "PROTEIN", 0, 3]]], ["Another example of an extensive immune network that could be affected by such events would be the gut-associated lymphoid tissue (GALT) which is distributed throughout the gastrointestinal system.", [["gut", "ANATOMY", 98, 101], ["lymphoid tissue", "ANATOMY", 113, 128], ["GALT", "ANATOMY", 130, 134], ["gastrointestinal system", "ANATOMY", 172, 195], ["immune network", "MULTI-TISSUE_STRUCTURE", 32, 46], ["gut", "ORGANISM_SUBDIVISION", 98, 101], ["lymphoid tissue", "TISSUE", 113, 128], ["GALT", "ANATOMICAL_SYSTEM", 130, 134], ["gastrointestinal system", "ANATOMICAL_SYSTEM", 172, 195], ["an extensive immune network", "PROBLEM", 19, 46], ["associated lymphoid tissue", "PROBLEM", 102, 128], ["extensive", "OBSERVATION_MODIFIER", 22, 31], ["immune network", "OBSERVATION", 32, 46], ["lymphoid tissue", "OBSERVATION", 113, 128], ["gastrointestinal system", "ANATOMY", 172, 195]]], ["In this context, the potential of nicotine to interfere with the growth of various microorganisms and/or convert them into a more potent antigenic stimulus could be a significant concern.", [["nicotine", "CHEMICAL", 34, 42], ["nicotine", "CHEMICAL", 34, 42], ["nicotine", "SIMPLE_CHEMICAL", 34, 42], ["nicotine", "TREATMENT", 34, 42], ["various microorganisms", "PROBLEM", 75, 97]]], ["Such a result would have broad range implications, since a large segment of the human population uses nicotine-containing tobacco products or nicotine alone for therapeutic purposes (primarily for withdrawal relief) [2, 3] .Effect of nicotine on various key metabolic processesWhile it is now reasonably well established that the use of tobacco is a major health hazard [4, 5] , the World Health Organization estimates that about one billion of the world's population still continue to use various tobacco products including the now more popular smokeless varieties despite the numerous deleterious effects they have on the human body [6] .", [["body", "ANATOMY", 630, 634], ["nicotine", "CHEMICAL", 102, 110], ["nicotine", "CHEMICAL", 142, 150], ["nicotine", "CHEMICAL", 234, 242], ["nicotine", "CHEMICAL", 102, 110], ["nicotine", "CHEMICAL", 142, 150], ["nicotine", "CHEMICAL", 234, 242], ["human", "ORGANISM", 80, 85], ["nicotine", "SIMPLE_CHEMICAL", 102, 110], ["tobacco", "ORGANISM", 122, 129], ["nicotine", "SIMPLE_CHEMICAL", 142, 150], ["nicotine", "SIMPLE_CHEMICAL", 234, 242], ["tobacco", "ORGANISM", 337, 344], ["tobacco", "ORGANISM", 498, 505], ["human", "ORGANISM", 624, 629], ["body", "ORGANISM_SUBDIVISION", 630, 634], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 624, 629], ["human", "SPECIES", 80, 85], ["tobacco", "SPECIES", 122, 129], ["tobacco", "SPECIES", 337, 344], ["tobacco", "SPECIES", 498, 505], ["human", "SPECIES", 624, 629], ["nicotine", "TREATMENT", 102, 110], ["nicotine", "TREATMENT", 142, 150], ["therapeutic purposes", "TREATMENT", 161, 181], ["withdrawal relief", "TREATMENT", 197, 214], ["nicotine", "TREATMENT", 234, 242], ["large", "OBSERVATION_MODIFIER", 59, 64], ["segment", "OBSERVATION_MODIFIER", 65, 72], ["metabolic processes", "OBSERVATION", 258, 277], ["numerous", "OBSERVATION_MODIFIER", 578, 586], ["deleterious", "OBSERVATION", 587, 598]]], ["Lung cancer is caused primarily by smoking, and oral cancers are strongly linked to those who use chewing tobacco or snuff.", [["Lung cancer", "ANATOMY", 0, 11], ["oral cancers", "ANATOMY", 48, 60], ["Lung cancer", "DISEASE", 0, 11], ["oral cancers", "DISEASE", 48, 60], ["Lung cancer", "CANCER", 0, 11], ["oral cancers", "CANCER", 48, 60], ["tobacco", "ORGANISM", 106, 113], ["snuff", "ORGANISM_SUBDIVISION", 117, 122], ["tobacco", "SPECIES", 106, 113], ["Lung cancer", "PROBLEM", 0, 11], ["oral cancers", "PROBLEM", 48, 60], ["cancer", "OBSERVATION", 5, 11], ["cancers", "OBSERVATION", 53, 60]]], ["Much of the damage caused by tobacco is usually attributed to the direct toxicity or carcinogenicity of some of the many chemicals present in tobacco products, making it difficult to distinguish which ones cause the most harm with nicotine being considered to be the most pharmacologically active [6] .", [["toxicity", "DISEASE", 73, 81], ["nicotine", "CHEMICAL", 231, 239], ["nicotine", "CHEMICAL", 231, 239], ["tobacco", "ORGANISM", 29, 36], ["tobacco", "ORGANISM", 142, 149], ["nicotine", "SIMPLE_CHEMICAL", 231, 239], ["tobacco", "SPECIES", 29, 36], ["tobacco", "SPECIES", 142, 149], ["the damage", "PROBLEM", 8, 18], ["the direct toxicity", "PROBLEM", 62, 81], ["nicotine", "TREATMENT", 231, 239], ["damage", "OBSERVATION", 12, 18]]], ["It is also possible that some of these same https://doi.org/10.1016/j.biopha.2020.110404 Received 16 March 2020; Received in revised form 21 May 2020; Accepted 13 June 2020 compounds present in tobacco may indirectly have deleterious effects on humans by interfering with the normal functioning of the host defense (surveillance) system leading to increased susceptibility to neoplastic diseases and/or by lowering resistance to certain infections including, more recently and now receiving considerable scrutiny, the coronavirus, COVID-19.", [["neoplastic", "ANATOMY", 376, 386], ["neoplastic diseases", "DISEASE", 376, 395], ["infections", "DISEASE", 437, 447], ["tobacco", "ORGANISM", 194, 201], ["humans", "ORGANISM", 245, 251], ["coronavirus", "ORGANISM", 518, 529], ["humans", "SPECIES", 245, 251], ["tobacco", "SPECIES", 194, 201], ["humans", "SPECIES", 245, 251], ["increased susceptibility to neoplastic diseases", "PROBLEM", 348, 395], ["lowering resistance", "PROBLEM", 406, 425], ["certain infections", "PROBLEM", 429, 447], ["the coronavirus", "TEST", 514, 529], ["COVID", "TEST", 531, 536], ["also possible", "UNCERTAINTY", 6, 19], ["increased", "OBSERVATION_MODIFIER", 348, 357], ["neoplastic diseases", "OBSERVATION", 376, 395], ["infections", "OBSERVATION", 437, 447]]], ["Some of these undesirable byproducts might possibly be due to the interaction of nicotine with the indigenous microflora [7, 8] and with various host defense mechanisms affecting both humoral and cellular immune responses involved in protecting against invading pathogens.", [["cellular", "ANATOMY", 196, 204], ["nicotine", "CHEMICAL", 81, 89], ["nicotine", "CHEMICAL", 81, 89], ["nicotine", "SIMPLE_CHEMICAL", 81, 89], ["cellular", "CELL", 196, 204], ["nicotine", "TREATMENT", 81, 89], ["invading pathogens", "PROBLEM", 253, 271], ["might possibly be due to", "UNCERTAINTY", 37, 61], ["cellular immune", "OBSERVATION", 196, 211]]], ["Indeed, several studies [9] [10] [11] have shown that tobacco smoke, smokeless tobacco and nicotine alone can be detrimental to certain components of the immune system of humans and experimentally exposed animals.", [["immune system", "ANATOMY", 154, 167], ["nicotine", "CHEMICAL", 91, 99], ["nicotine", "CHEMICAL", 91, 99], ["[9] [10] [11]", "SIMPLE_CHEMICAL", 24, 37], ["tobacco", "ORGANISM", 54, 61], ["tobacco", "ORGANISM", 79, 86], ["nicotine", "SIMPLE_CHEMICAL", 91, 99], ["immune system", "ANATOMICAL_SYSTEM", 154, 167], ["humans", "ORGANISM", 171, 177], ["humans", "SPECIES", 171, 177], ["tobacco", "SPECIES", 54, 61], ["tobacco", "SPECIES", 79, 86], ["humans", "SPECIES", 171, 177], ["several studies", "TEST", 8, 23], ["nicotine", "TREATMENT", 91, 99]]], ["It is noteworthy, however, in this regard, that although it is somewhat accepted that tobacco products have an adverse effect on humoral and cell-mediated immunity, neither the extent of this impairment nor of its mechanisms have been clearly elucidated.", [["cell", "ANATOMY", 141, 145], ["tobacco", "ORGANISM", 86, 93], ["cell", "CELL", 141, 145], ["tobacco", "SPECIES", 86, 93], ["tobacco products", "TREATMENT", 86, 102], ["an adverse effect", "PROBLEM", 108, 125], ["humoral and cell-mediated immunity", "TREATMENT", 129, 163], ["this impairment", "PROBLEM", 187, 202], ["impairment", "OBSERVATION", 192, 202]]], ["Many of these immunologic changes can occur locally, for example, in the lung and g.i. tract primarily affecting GALT [12] as well as systemically [5, 13] and they are generally reversible with cessation of tobacco exposure.", [["lung", "ANATOMY", 73, 77], ["g.i. tract", "ANATOMY", 82, 92], ["lung", "ORGAN", 73, 77], ["g.i. tract", "ORGAN", 82, 92], ["GALT [12]", "GENE_OR_GENE_PRODUCT", 113, 122], ["tobacco", "ORGANISM", 207, 214], ["tobacco", "SPECIES", 207, 214], ["these immunologic changes", "PROBLEM", 8, 33], ["immunologic", "OBSERVATION", 14, 25], ["lung", "ANATOMY", 73, 77], ["tract", "ANATOMY_MODIFIER", 87, 92], ["reversible", "OBSERVATION_MODIFIER", 178, 188], ["tobacco exposure", "OBSERVATION", 207, 223]]], ["It is not known, however, whether long-term use of tobacco can cause permanent or selective damage to the immune system or to some of its components and whether such events are associated with concomitant effects on the microbiome.Effect of nicotine on various key metabolic processesIn light of recent developments associated with maternal-fetal interactions [14] during pregnancy and the early post-partum period, it is interesting to speculate on whether the composition of the microbiome in early childhood would vary in a smokeless home environment relative to one not free of a family of smokers as a result of exposure to second-hand smoke, along with knowing when does microbial colonization become fully entrenched in the human body or changes during the course of a person's lifetime.", [["immune system", "ANATOMY", 106, 119], ["fetal", "ANATOMY", 341, 346], ["body", "ANATOMY", 737, 741], ["nicotine", "CHEMICAL", 241, 249], ["nicotine", "CHEMICAL", 241, 249], ["tobacco", "ORGANISM", 51, 58], ["nicotine", "SIMPLE_CHEMICAL", 241, 249], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 341, 346], ["human", "ORGANISM", 731, 736], ["body", "ORGANISM_SUBDIVISION", 737, 741], ["human", "SPECIES", 731, 736], ["person", "SPECIES", 776, 782], ["tobacco", "SPECIES", 51, 58], ["human", "SPECIES", 731, 736], ["permanent or selective damage to the immune system", "PROBLEM", 69, 119], ["concomitant effects on the microbiome", "PROBLEM", 193, 230], ["nicotine", "TREATMENT", 241, 249], ["maternal-fetal interactions", "PROBLEM", 332, 359], ["microbial colonization", "PROBLEM", 677, 699], ["not known", "UNCERTAINTY", 6, 15], ["selective", "OBSERVATION_MODIFIER", 82, 91], ["damage", "OBSERVATION", 92, 98], ["metabolic processes", "OBSERVATION", 265, 284], ["human body", "ANATOMY_MODIFIER", 731, 741]]], ["Also in this context, the collective role of other significant lifestyle factors such as dietary and eating patterns and certain related underlying conditions or co-morbidities (for example, asthma, diabetes and obesity) [15] in affecting the make-up of especially the commensal gut microbes and their normal function, along with the innate and adaptive immune response pattern in the gut, should be considered.", [["gut microbes", "ANATOMY", 279, 291], ["gut", "ANATOMY", 385, 388], ["asthma", "DISEASE", 191, 197], ["diabetes", "DISEASE", 199, 207], ["obesity", "DISEASE", 212, 219], ["gut", "ORGANISM_SUBDIVISION", 279, 282], ["gut", "ORGANISM_SUBDIVISION", 385, 388], ["other significant lifestyle factors", "PROBLEM", 45, 80], ["underlying conditions", "PROBLEM", 137, 158], ["co-morbidities", "PROBLEM", 162, 176], ["asthma", "PROBLEM", 191, 197], ["diabetes", "PROBLEM", 199, 207], ["obesity)", "PROBLEM", 212, 220], ["normal function", "OBSERVATION", 302, 317], ["gut", "ANATOMY", 385, 388]]], ["Perhaps equally intriguing is the possible beneficial role that one of the key components of tobacco, nicotine, may have towards interfering with unwanted inflammatory responses [16] such as those that may occur in the gastrointestinal tract with its vast and complex array of indigenous bacteria.", [["gastrointestinal tract", "ANATOMY", 219, 241], ["nicotine", "CHEMICAL", 102, 110], ["nicotine", "CHEMICAL", 102, 110], ["tobacco", "ORGANISM", 93, 100], ["nicotine", "SIMPLE_CHEMICAL", 102, 110], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 219, 241], ["tobacco", "SPECIES", 93, 100], ["nicotine", "TREATMENT", 102, 110], ["unwanted inflammatory responses", "PROBLEM", 146, 177], ["indigenous bacteria", "PROBLEM", 277, 296], ["gastrointestinal tract", "ANATOMY", 219, 241]]], ["These consist primarily of gram-negative bacilli (the so-called enterobacteriaceae) and a select group of gram-positive cocci and bacilli.", [["enterobacteriaceae", "CANCER", 64, 82], ["gram-positive cocci", "GENE_OR_GENE_PRODUCT", 106, 125], ["bacilli", "ORGANISM_SUBSTANCE", 130, 137], ["gram-negative bacilli", "PROBLEM", 27, 48], ["enterobacteriaceae", "PROBLEM", 64, 82], ["gram-positive cocci", "PROBLEM", 106, 125], ["bacilli", "PROBLEM", 130, 137], ["negative bacilli", "OBSERVATION", 32, 48], ["positive cocci", "OBSERVATION", 111, 125], ["bacilli", "OBSERVATION", 130, 137]]], ["Collectively, these include aerobes, facultative and strict anaerobes, and a small group of sporeforming organisms.", [["aerobes, facultative and strict anaerobes", "PROBLEM", 28, 69], ["a small group of sporeforming organisms", "PROBLEM", 75, 114], ["aerobes", "OBSERVATION", 28, 35], ["facultative", "OBSERVATION_MODIFIER", 37, 48], ["strict anaerobes", "OBSERVATION_MODIFIER", 53, 69], ["small", "OBSERVATION_MODIFIER", 77, 82]]], ["Also, in this context, other factors need to be considered including the recent finding [17] that the sleeping aid and therapeutic agent, melatonin, may have broad ranging effects on GALT and the metabolism of the gut microbiome.", [["gut microbiome", "ANATOMY", 214, 228], ["melatonin", "CHEMICAL", 138, 147], ["melatonin", "CHEMICAL", 138, 147], ["melatonin", "SIMPLE_CHEMICAL", 138, 147], ["GALT", "MULTI-TISSUE_STRUCTURE", 183, 187], ["gut microbiome", "MULTI-TISSUE_STRUCTURE", 214, 228], ["the sleeping aid", "TREATMENT", 98, 114], ["therapeutic agent", "TREATMENT", 119, 136], ["melatonin", "TREATMENT", 138, 147], ["broad ranging effects on GALT", "PROBLEM", 158, 187], ["gut", "ANATOMY", 214, 217]]], ["Moreover, additional studies [reviewed in ref.", [["additional studies", "TEST", 10, 28]]], ["18 ] have shown how the microbes residing in the g.i. tract may affect the efficacy of some of the more novel immunotherapeutic interventions for treating certain types of cancers especially those designed to block CTLA-4 and PD-1 immune checkpoint molecules which would then enable cytolytic CD8 + T cells to kill neoplastic cells.Interaction of nicotine with various microbes and possible modulation of immune functionApart from their possible deleterious effects on the immune system especially in the context of increasing susceptibility to infections [19] , little is known on whether tobacco-related products could have direct detrimental activity against microorganisms, including those comprising the microbiome [20] .", [["g.i. tract", "ANATOMY", 49, 59], ["cancers", "ANATOMY", 172, 179], ["CD8 + T cells", "ANATOMY", 293, 306], ["neoplastic cells", "ANATOMY", 315, 331], ["immune system", "ANATOMY", 473, 486], ["cancers", "DISEASE", 172, 179], ["nicotine", "CHEMICAL", 347, 355], ["infections", "DISEASE", 545, 555], ["nicotine", "CHEMICAL", 347, 355], ["g.i. tract", "ORGANISM_SUBDIVISION", 49, 59], ["cancers", "CANCER", 172, 179], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 215, 221], ["PD-1", "GENE_OR_GENE_PRODUCT", 226, 230], ["CD8", "GENE_OR_GENE_PRODUCT", 293, 296], ["neoplastic cells", "CELL", 315, 331], ["nicotine", "SIMPLE_CHEMICAL", 347, 355], ["immune system", "ANATOMICAL_SYSTEM", 473, 486], ["tobacco", "ORGANISM", 590, 597], ["CTLA-4", "PROTEIN", 215, 221], ["cytolytic CD8 + T cells", "CELL_TYPE", 283, 306], ["neoplastic cells", "CELL_TYPE", 315, 331], ["tobacco", "SPECIES", 590, 597], ["immunotherapeutic interventions", "TREATMENT", 110, 141], ["cancers", "PROBLEM", 172, 179], ["CTLA", "TEST", 215, 219], ["PD", "TEST", 226, 228], ["immune checkpoint molecules", "PROBLEM", 231, 258], ["cytolytic CD8", "TEST", 283, 296], ["T cells", "PROBLEM", 299, 306], ["neoplastic cells", "PROBLEM", 315, 331], ["nicotine", "TREATMENT", 347, 355], ["various microbes", "TREATMENT", 361, 377], ["immune function", "PROBLEM", 405, 420], ["deleterious effects on the immune system", "PROBLEM", 446, 486], ["increasing susceptibility to infections", "PROBLEM", 516, 555], ["microorganisms", "PROBLEM", 662, 676], ["cancers", "OBSERVATION", 172, 179], ["increasing", "OBSERVATION_MODIFIER", 516, 526], ["infections", "OBSERVATION", 545, 555]]], ["This possibility would be especially noteworthy for certain parts of the body, such as the oral cavity, where exposure to tobacco-related products occurs most commonly and would be most intense [21] .", [["body", "ANATOMY", 73, 77], ["oral cavity", "ANATOMY", 91, 102], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["oral cavity", "ORGANISM_SUBDIVISION", 91, 102], ["tobacco", "ORGANISM", 122, 129], ["tobacco", "SPECIES", 122, 129], ["body", "ANATOMY", 73, 77], ["oral cavity", "ANATOMY", 91, 102]]], ["Accordingly, any prolonged antimicrobial effects occurring here could alter the balance of, and/or the indirect protective effects afforded by, the oral microflora which could lead to colonization or overgrowth of unwanted pathogens in the oropharynx.", [["oral microflora", "ANATOMY", 148, 163], ["oropharynx", "ANATOMY", 240, 250], ["oral", "ORGANISM_SUBDIVISION", 148, 152], ["oropharynx", "ORGAN", 240, 250], ["any prolonged antimicrobial effects", "PROBLEM", 13, 48], ["the oral microflora", "PROBLEM", 144, 163], ["colonization", "PROBLEM", 184, 196], ["overgrowth of unwanted pathogens in the oropharynx", "PROBLEM", 200, 250], ["oropharynx", "ANATOMY", 240, 250]]], ["It also may have some bearing on certain periodontal diseases such as periodontitis (known to be initiated by bacteria).", [["periodontal", "ANATOMY", 41, 52], ["periodontal diseases", "DISEASE", 41, 61], ["periodontitis", "DISEASE", 70, 83], ["certain periodontal diseases", "PROBLEM", 33, 61], ["periodontitis", "PROBLEM", 70, 83], ["bacteria", "PROBLEM", 110, 118], ["periodontal", "OBSERVATION_MODIFIER", 41, 52], ["diseases", "OBSERVATION", 53, 61], ["periodontitis", "OBSERVATION", 70, 83]]], ["Such ecological alterations might also affect local immune response patterns and/or susceptibility to certain pathogens, especially with any concurrent physical damage to the oral mucosal architecture [21] .", [["oral mucosal", "ANATOMY", 175, 187], ["oral mucosal", "MULTI-TISSUE_STRUCTURE", 175, 187], ["Such ecological alterations", "PROBLEM", 0, 27], ["pathogens", "PROBLEM", 110, 119], ["any concurrent physical damage", "PROBLEM", 137, 167], ["damage", "OBSERVATION", 161, 167], ["oral mucosal", "ANATOMY", 175, 187]]], ["To our knowledge, the development of such profound microbiologic changes attributable to tobacco-related products has not been fully explored and experimental studies should be designed to analyze this issue.Interaction of nicotine with various microbes and possible modulation of immune functionA more recent development, designed for dealing with the health consequences of tobacco product use, has involved the implementation of nicotine replacement therapy such as over-the-counter gums [3] , sublingual tablets/lozenges [3] and transdermally applied patches [22] for those who need aid in attempting to cease smoking and to reduce withdrawal symptoms.", [["nicotine", "CHEMICAL", 223, 231], ["nicotine", "CHEMICAL", 432, 440], ["smoking", "CHEMICAL", 614, 621], ["nicotine", "CHEMICAL", 223, 231], ["nicotine", "CHEMICAL", 432, 440], ["tobacco", "ORGANISM", 89, 96], ["nicotine", "SIMPLE_CHEMICAL", 223, 231], ["tobacco", "ORGANISM", 376, 383], ["nicotine", "SIMPLE_CHEMICAL", 432, 440], ["sublingual tablets", "SIMPLE_CHEMICAL", 497, 515], ["tobacco", "SPECIES", 89, 96], ["tobacco", "SPECIES", 376, 383], ["such profound microbiologic changes", "PROBLEM", 37, 72], ["experimental studies", "TEST", 146, 166], ["nicotine", "TREATMENT", 223, 231], ["various microbes", "TREATMENT", 237, 253], ["immune functionA", "PROBLEM", 281, 297], ["nicotine replacement therapy", "TREATMENT", 432, 460], ["sublingual tablets/lozenges", "TREATMENT", 497, 524], ["withdrawal symptoms", "PROBLEM", 636, 655], ["profound", "OBSERVATION_MODIFIER", 42, 50], ["microbiologic", "OBSERVATION", 51, 64]]], ["Since nicotine is considered to be the most addictive substance [6] in tobacco products, its usage in these alternative forms is being touted as a safe and alternative method for dealing with nicotine withdrawal symptoms as a result of abstaining from smoking or from resorting to using smokeless tobacco.", [["nicotine", "CHEMICAL", 6, 14], ["nicotine", "CHEMICAL", 192, 200], ["smoking", "CHEMICAL", 252, 259], ["nicotine", "CHEMICAL", 6, 14], ["nicotine", "CHEMICAL", 192, 200], ["nicotine", "SIMPLE_CHEMICAL", 6, 14], ["tobacco", "ORGANISM", 71, 78], ["nicotine", "SIMPLE_CHEMICAL", 192, 200], ["tobacco", "ORGANISM", 297, 304], ["tobacco", "SPECIES", 71, 78], ["tobacco", "SPECIES", 297, 304], ["nicotine", "TREATMENT", 6, 14], ["tobacco products", "TREATMENT", 71, 87], ["nicotine withdrawal symptoms", "PROBLEM", 192, 220]]], ["Similar to tobacco in its entirety, limited information (reviewed in ref. # [23] ) exists on the manner in which nicotine might interact with microorganisms and with the host's immune system.", [["nicotine", "CHEMICAL", 113, 121], ["nicotine", "CHEMICAL", 113, 121], ["tobacco", "ORGANISM", 11, 18], ["nicotine", "SIMPLE_CHEMICAL", 113, 121], ["immune system", "ANATOMICAL_SYSTEM", 177, 190], ["tobacco", "SPECIES", 11, 18]]], ["There is some evidence [9, 13] that nicotine can influence certain aspects of humoral and cellular immunity including the lowering of IgA levels in both saliva and intestinal secretions, the inhibition of cytokine production in vitro by peripheral blood and intestinal mononuclear cells, and the induction of certain forms of both T-and B-lymphocyte anergy.", [["cellular", "ANATOMY", 90, 98], ["saliva", "ANATOMY", 153, 159], ["intestinal secretions", "ANATOMY", 164, 185], ["peripheral blood", "ANATOMY", 237, 253], ["intestinal mononuclear cells", "ANATOMY", 258, 286], ["B-lymphocyte", "ANATOMY", 337, 349], ["nicotine", "CHEMICAL", 36, 44], ["nicotine", "CHEMICAL", 36, 44], ["nicotine", "SIMPLE_CHEMICAL", 36, 44], ["cellular", "CELL", 90, 98], ["IgA", "GENE_OR_GENE_PRODUCT", 134, 137], ["saliva", "ORGANISM_SUBSTANCE", 153, 159], ["intestinal secretions", "ORGAN", 164, 185], ["peripheral blood", "ORGANISM_SUBSTANCE", 237, 253], ["intestinal mononuclear cells", "CELL", 258, 286], ["T", "CELL", 331, 332], ["B-lymphocyte", "CELL", 337, 349], ["IgA", "PROTEIN", 134, 137], ["cytokine", "PROTEIN", 205, 213], ["intestinal mononuclear cells", "CELL_TYPE", 258, 286], ["nicotine", "TREATMENT", 36, 44], ["humoral and cellular immunity", "PROBLEM", 78, 107], ["IgA levels", "TEST", 134, 144], ["both saliva and intestinal secretions", "PROBLEM", 148, 185], ["cytokine production", "PROBLEM", 205, 224], ["peripheral blood and intestinal mononuclear cells", "PROBLEM", 237, 286], ["T", "TEST", 331, 332], ["lymphocyte anergy", "PROBLEM", 339, 356], ["cellular immunity", "OBSERVATION", 90, 107], ["both", "ANATOMY_MODIFIER", 148, 152], ["saliva", "ANATOMY", 153, 159], ["intestinal", "ANATOMY", 164, 174], ["secretions", "OBSERVATION", 175, 185], ["peripheral", "ANATOMY_MODIFIER", 237, 247], ["blood", "ANATOMY", 248, 253], ["intestinal", "ANATOMY", 258, 268], ["mononuclear cells", "OBSERVATION", 269, 286], ["lymphocyte anergy", "OBSERVATION", 339, 356]]], ["Also, along these lines and from a therapeutic perspective, certain clinical studies [16] have revealed an additional partial beneficial use for nicotine: as an alternative treatment modality for inflammatory bowel disease (IBD), specifically ulcerative colitis.", [["bowel", "ANATOMY", 209, 214], ["nicotine", "CHEMICAL", 145, 153], ["inflammatory bowel disease", "DISEASE", 196, 222], ["IBD", "DISEASE", 224, 227], ["ulcerative colitis", "DISEASE", 243, 261], ["nicotine", "CHEMICAL", 145, 153], ["nicotine", "SIMPLE_CHEMICAL", 145, 153], ["bowel", "ORGAN", 209, 214], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 243, 261], ["certain clinical studies", "TEST", 60, 84], ["nicotine", "TREATMENT", 145, 153], ["an alternative treatment modality", "TREATMENT", 158, 191], ["inflammatory bowel disease", "PROBLEM", 196, 222], ["IBD)", "PROBLEM", 224, 228], ["ulcerative colitis", "PROBLEM", 243, 261], ["lines", "OBSERVATION_MODIFIER", 18, 23], ["inflammatory", "OBSERVATION_MODIFIER", 196, 208], ["bowel", "ANATOMY", 209, 214], ["disease", "OBSERVATION", 215, 222], ["ulcerative", "OBSERVATION_MODIFIER", 243, 253], ["colitis", "OBSERVATION", 254, 261]]], ["Its benefit, however, appears to be limited to treating active colitis and not for maintaining remission [16] .", [["colitis", "DISEASE", 63, 70], ["colitis", "PATHOLOGICAL_FORMATION", 63, 70], ["active colitis", "PROBLEM", 56, 70], ["active", "OBSERVATION_MODIFIER", 56, 62], ["colitis", "OBSERVATION", 63, 70]]], ["Although its mechanism of action here is not fully known, current evidence [11, 24] suggests that nicotine significantly affects cytokine levels, including pro-inflammatory mediators, in the colon.", [["colon", "ANATOMY", 191, 196], ["nicotine", "CHEMICAL", 98, 106], ["nicotine", "CHEMICAL", 98, 106], ["nicotine", "SIMPLE_CHEMICAL", 98, 106], ["colon", "ORGAN", 191, 196], ["cytokine", "PROTEIN", 129, 137], ["pro-inflammatory mediators", "PROTEIN", 156, 182], ["nicotine", "TREATMENT", 98, 106], ["cytokine levels", "TEST", 129, 144], ["pro-inflammatory mediators", "TREATMENT", 156, 182], ["colon", "ANATOMY", 191, 196]]], ["Such cytokines, especially tumor necrosis factor (TNF) play a key role in the development and progression of Crohn's disease [25] and ulcerative colitis [26] , the most severe forms of IBD.", [["tumor necrosis", "DISEASE", 27, 41], ["Crohn's disease", "DISEASE", 109, 124], ["ulcerative colitis", "DISEASE", 134, 152], ["IBD", "DISEASE", 185, 188], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 27, 48], ["TNF", "GENE_OR_GENE_PRODUCT", 50, 53], ["Crohn's disease", "CANCER", 109, 124], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 134, 152], ["cytokines", "PROTEIN", 5, 14], ["tumor necrosis factor", "PROTEIN", 27, 48], ["TNF", "PROTEIN", 50, 53], ["Such cytokines", "PROBLEM", 0, 14], ["tumor necrosis factor", "PROBLEM", 27, 48], ["Crohn's disease", "PROBLEM", 109, 124], ["ulcerative colitis", "PROBLEM", 134, 152], ["IBD", "PROBLEM", 185, 188], ["tumor", "OBSERVATION_MODIFIER", 27, 32], ["necrosis", "OBSERVATION", 33, 41], ["Crohn", "OBSERVATION", 109, 114], ["ulcerative", "OBSERVATION_MODIFIER", 134, 144], ["colitis", "OBSERVATION", 145, 152], ["most severe", "OBSERVATION_MODIFIER", 164, 175], ["IBD", "OBSERVATION", 185, 188]]], ["Over the past several years, they have become the targets for the commercial development and therapeutic use of a unique form of immunotherapy especially for Crohn's disease as well as other highly inflammatory conditions, one of which involves the infusion of a monoclonal antibody directed against TNF [25, 27] .Interaction of nicotine with various microbes and possible modulation of immune functionIt is worth noting that the current belief is that IBD results from the combined effects of changes in the host interactions with the intestinal microbiome, intestinal epithelial dysfunction, aberrant mucosal immune responses, and altered composition of the intestinal commensals [28] .", [["intestinal microbiome", "ANATOMY", 536, 557], ["intestinal epithelial", "ANATOMY", 559, 580], ["mucosal", "ANATOMY", 603, 610], ["intestinal", "ANATOMY", 660, 670], ["Crohn's disease", "DISEASE", 158, 173], ["nicotine", "CHEMICAL", 329, 337], ["IBD", "DISEASE", 453, 456], ["epithelial dysfunction", "DISEASE", 570, 592], ["nicotine", "CHEMICAL", 329, 337], ["TNF", "GENE_OR_GENE_PRODUCT", 300, 303], ["nicotine", "SIMPLE_CHEMICAL", 329, 337], ["intestinal microbiome", "MULTI-TISSUE_STRUCTURE", 536, 557], ["intestinal epithelial", "TISSUE", 559, 580], ["mucosal", "MULTI-TISSUE_STRUCTURE", 603, 610], ["intestinal", "ORGAN", 660, 670], ["monoclonal antibody", "PROTEIN", 263, 282], ["TNF", "PROTEIN", 300, 303], ["immunotherapy", "TREATMENT", 129, 142], ["Crohn's disease", "PROBLEM", 158, 173], ["other highly inflammatory conditions", "PROBLEM", 185, 221], ["the infusion", "TREATMENT", 245, 257], ["a monoclonal antibody", "TREATMENT", 261, 282], ["nicotine", "TREATMENT", 329, 337], ["various microbes", "TREATMENT", 343, 359], ["immune function", "PROBLEM", 387, 402], ["IBD", "PROBLEM", 453, 456], ["the intestinal microbiome", "PROBLEM", 532, 557], ["intestinal epithelial dysfunction", "PROBLEM", 559, 592], ["aberrant mucosal immune responses", "PROBLEM", 594, 627], ["inflammatory", "OBSERVATION", 198, 210], ["immune function", "OBSERVATION", 387, 402], ["intestinal microbiome", "ANATOMY", 536, 557], ["intestinal", "ANATOMY", 559, 569], ["epithelial dysfunction", "OBSERVATION", 570, 592], ["mucosal immune", "OBSERVATION", 603, 617], ["intestinal", "ANATOMY", 660, 670]]], ["Nucleotide oligomerization binding domain 2 (NOD2) is a gene associated with Crohn's disease.", [["Crohn's disease", "DISEASE", 77, 92], ["Nucleotide", "CHEMICAL", 0, 10], ["Nucleotide oligomerization binding domain 2", "GENE_OR_GENE_PRODUCT", 0, 43], ["NOD2", "GENE_OR_GENE_PRODUCT", 45, 49], ["Nucleotide oligomerization binding domain 2", "PROTEIN", 0, 43], ["NOD2", "PROTEIN", 45, 49], ["Nucleotide oligomerization binding domain", "TREATMENT", 0, 41], ["Crohn's disease", "PROBLEM", 77, 92]]], ["It encodes an intracellular protein that binds to bacterial peptidoglycans [28] .", [["intracellular", "ANATOMY", 14, 27], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["intracellular protein", "PROTEIN", 14, 35], ["an intracellular protein", "TREATMENT", 11, 35], ["bacterial peptidoglycans", "TEST", 50, 74]]], ["Other genes such as autophagyrelated 16-like and immunity-related GTPase M are part of the autophagy pathways that are important for cellular responses to IBD [28] .", [["cellular", "ANATOMY", 133, 141], ["IBD", "DISEASE", 155, 158], ["autophagyrelated 16-like", "GENE_OR_GENE_PRODUCT", 20, 44], ["immunity-related GTPase M", "GENE_OR_GENE_PRODUCT", 49, 74], ["cellular", "CELL", 133, 141], ["autophagyrelated 16", "DNA", 20, 39], ["GTPase M", "PROTEIN", 66, 74], ["GTPase M", "PROBLEM", 66, 74]]], ["There is evidence that supports the hypothesis that inappropriate immune reactions to luminal bacteria are important in IBD pathogenesis, since all three genes seem to be involved in recognition and response to intracellular pathogens [28] .", [["luminal bacteria", "ANATOMY", 86, 102], ["intracellular", "ANATOMY", 211, 224], ["luminal", "CHEMICAL", 86, 93], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 211, 224], ["the hypothesis", "PROBLEM", 32, 46], ["inappropriate immune reactions", "PROBLEM", 52, 82], ["luminal bacteria", "PROBLEM", 86, 102], ["IBD pathogenesis", "PROBLEM", 120, 136], ["intracellular pathogens", "PROBLEM", 211, 234]]], ["In addition, patients with Crohn's disease produce antibodies against the bacterial protein flagellin in those who have NOD2-associated disease, while anti-flagellin antibodies are uncommon in ulcerative colitis patients.", [["Crohn's disease", "DISEASE", 27, 42], ["ulcerative colitis", "DISEASE", 193, 211], ["patients", "ORGANISM", 13, 21], ["flagellin", "GENE_OR_GENE_PRODUCT", 92, 101], ["NOD2", "GENE_OR_GENE_PRODUCT", 120, 124], ["anti-flagellin antibodies", "GENE_OR_GENE_PRODUCT", 151, 176], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 193, 211], ["patients", "ORGANISM", 212, 220], ["antibodies", "PROTEIN", 51, 61], ["bacterial protein flagellin", "PROTEIN", 74, 101], ["NOD2", "PROTEIN", 120, 124], ["anti-flagellin antibodies", "PROTEIN", 151, 176], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 212, 220], ["Crohn's disease", "PROBLEM", 27, 42], ["antibodies", "TREATMENT", 51, 61], ["the bacterial protein flagellin", "TREATMENT", 70, 101], ["NOD2-associated disease", "PROBLEM", 120, 143], ["anti-flagellin antibodies", "PROBLEM", 151, 176], ["ulcerative colitis", "PROBLEM", 193, 211], ["disease", "OBSERVATION", 136, 143], ["ulcerative colitis", "OBSERVATION", 193, 211]]], ["Interestingly, the yeast Saccharomyces cerevisiae, has been shown to be a common inhabitant of the oral fungal community [29] , and it may have a possible connection with IBD.", [["oral fungal community", "ANATOMY", 99, 120], ["IBD", "DISEASE", 171, 174], ["yeast Saccharomyces cerevisiae", "ORGANISM", 19, 49], ["oral", "ORGANISM_SUBDIVISION", 99, 103], ["yeast", "SPECIES", 19, 24], ["Saccharomyces cerevisiae", "SPECIES", 25, 49], ["yeast", "SPECIES", 19, 24], ["Saccharomyces cerevisiae", "SPECIES", 25, 49], ["the yeast Saccharomyces cerevisiae", "PROBLEM", 15, 49], ["IBD", "PROBLEM", 171, 174], ["yeast Saccharomyces cerevisiae", "OBSERVATION", 19, 49], ["IBD", "OBSERVATION", 171, 174]]], ["Its relationship to IBD is largely unknown although patients with ulcerative colitis tend to lack antibodies to S. cerevisiae, which are usually present in Crohn's disease patients [28] .", [["IBD", "DISEASE", 20, 23], ["ulcerative colitis", "DISEASE", 66, 84], ["Crohn's disease", "DISEASE", 156, 171], ["patients", "ORGANISM", 52, 60], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 66, 84], ["S. cerevisiae", "ORGANISM", 112, 125], ["patients", "ORGANISM", 172, 180], ["antibodies", "PROTEIN", 98, 108], ["patients", "SPECIES", 52, 60], ["S. cerevisiae", "SPECIES", 112, 125], ["patients", "SPECIES", 172, 180], ["S. cerevisiae", "SPECIES", 112, 125], ["IBD", "PROBLEM", 20, 23], ["ulcerative colitis", "PROBLEM", 66, 84], ["lack antibodies", "PROBLEM", 93, 108], ["Crohn's disease", "PROBLEM", 156, 171], ["IBD", "OBSERVATION", 20, 23], ["ulcerative", "OBSERVATION_MODIFIER", 66, 76], ["colitis", "OBSERVATION", 77, 84]]], ["Another intriguing fact is that smoking (nicotine) seems to be protective for ulcerative colitis but not for Crohn's disease [28] , although the exact mechanisms operative here have not been fully elucidated, nor do we know the possible role that ingested food products play under these circumstances.", [["smoking", "CHEMICAL", 32, 39], ["nicotine", "CHEMICAL", 41, 49], ["ulcerative colitis", "DISEASE", 78, 96], ["Crohn's disease", "DISEASE", 109, 124], ["nicotine", "CHEMICAL", 41, 49], ["nicotine", "SIMPLE_CHEMICAL", 41, 49], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 78, 96], ["ulcerative colitis", "PROBLEM", 78, 96], ["Crohn's disease", "PROBLEM", 109, 124], ["ulcerative", "OBSERVATION_MODIFIER", 78, 88], ["colitis", "OBSERVATION", 89, 96], ["not for", "UNCERTAINTY", 101, 108]]], ["In this regard, within the gut-microbiome-immune network, it has become clear [30] that, after passing through the colonic epithelium and mucosa, microbial metabolites, arising during the processing of ingested food products, can enter and accumulate in the vasculature, where they can elicit a wide range of biologic functions including those rendered by the immune system.", [["gut", "ANATOMY", 27, 30], ["colonic epithelium", "ANATOMY", 115, 133], ["mucosa", "ANATOMY", 138, 144], ["vasculature", "ANATOMY", 258, 269], ["immune system", "ANATOMY", 360, 373], ["gut", "ORGANISM_SUBDIVISION", 27, 30], ["immune network", "MULTI-TISSUE_STRUCTURE", 42, 56], ["colonic epithelium", "TISSUE", 115, 133], ["mucosa", "MULTI-TISSUE_STRUCTURE", 138, 144], ["vasculature", "MULTI-TISSUE_STRUCTURE", 258, 269], ["immune system", "ANATOMICAL_SYSTEM", 360, 373], ["gut", "ANATOMY", 27, 30], ["clear", "OBSERVATION", 72, 77], ["colonic epithelium", "ANATOMY", 115, 133], ["mucosa", "ANATOMY", 138, 144], ["microbial metabolites", "OBSERVATION", 146, 167], ["vasculature", "ANATOMY", 258, 269]]], ["Accordingly, such processes and responses can be seriously affected following the exposure to nicotine.Bacterial and fungal pathogens affected by nicotineIn light of the foregoing, our laboratory began a series of experiments [31] that initially reexamined the effect that nicotineperhaps the most important and potent, pharmacologically active substance in tobaccohas on microbial viability.", [["nicotine", "CHEMICAL", 94, 102], ["nicotine", "CHEMICAL", 146, 154], ["nicotine", "CHEMICAL", 94, 102], ["nicotine", "CHEMICAL", 146, 154], ["nicotine", "SIMPLE_CHEMICAL", 94, 102], ["nicotine", "SIMPLE_CHEMICAL", 146, 154], ["nicotineperhaps", "SIMPLE_CHEMICAL", 273, 288], ["tobaccohas", "SIMPLE_CHEMICAL", 358, 368], ["nicotine", "TREATMENT", 94, 102], ["Bacterial and fungal pathogens", "PROBLEM", 103, 133], ["nicotine", "TREATMENT", 146, 154], ["nicotineperhaps", "TREATMENT", 273, 288], ["fungal pathogens", "OBSERVATION", 117, 133]]], ["We included some microorganisms known to naturally colonize the oral cavity and g.i. tract, as part of the human microbiome, which could impact on the host response to an infection occurring in such locations and/or provide antigenic stimulation/immunization.", [["oral cavity", "ANATOMY", 64, 75], ["g.i. tract", "ANATOMY", 80, 90], ["infection", "DISEASE", 171, 180], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 64, 75], ["g.i. tract", "ORGANISM_SUBDIVISION", 80, 90], ["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["some microorganisms", "PROBLEM", 12, 31], ["an infection", "PROBLEM", 168, 180], ["antigenic stimulation/immunization", "TREATMENT", 224, 258], ["oral cavity", "ANATOMY", 64, 75], ["infection", "OBSERVATION", 171, 180]]], ["Proposed studies, such as these, involving direct exposure of bacteria to nicotine and determining what effect these interactions may have on immunity to infection and the inflammatory response (such as might occur in the bowel wall and periodontal disease) have rarely been done or reported in peer-reviewed publications.", [["bowel wall", "ANATOMY", 222, 232], ["periodontal", "ANATOMY", 237, 248], ["nicotine", "CHEMICAL", 74, 82], ["infection", "DISEASE", 154, 163], ["periodontal disease", "DISEASE", 237, 256], ["nicotine", "CHEMICAL", 74, 82], ["nicotine", "SIMPLE_CHEMICAL", 74, 82], ["bowel wall", "MULTI-TISSUE_STRUCTURE", 222, 232], ["periodontal", "ORGAN", 237, 248], ["Proposed studies", "TEST", 0, 16], ["bacteria", "PROBLEM", 62, 70], ["nicotine", "TREATMENT", 74, 82], ["infection", "PROBLEM", 154, 163], ["the inflammatory response", "PROBLEM", 168, 193], ["periodontal disease", "PROBLEM", 237, 256], ["inflammatory", "OBSERVATION_MODIFIER", 172, 184], ["bowel wall", "ANATOMY", 222, 232], ["periodontal", "ANATOMY", 237, 248]]], ["Yet they should provide new, important and key insights on nicotinemicrobial-host immune system interactions.Bacterial and fungal pathogens affected by nicotineSome of the key details on the procedures that we used along with the resulting findings have been published elsewhere [31] and are summarized as follows.", [["nicotinemicrobial", "SIMPLE_CHEMICAL", 59, 76], ["Bacterial and fungal pathogens", "PROBLEM", 109, 139], ["the procedures", "TREATMENT", 187, 201], ["fungal pathogens", "OBSERVATION", 123, 139]]], ["Diverse groups of bacteria and fungi were mixed separately in vitro with various concentrations of commercially available, purified nicotine.", [["nicotine", "CHEMICAL", 132, 140], ["nicotine", "CHEMICAL", 132, 140], ["nicotine", "SIMPLE_CHEMICAL", 132, 140], ["bacteria", "PROBLEM", 18, 26], ["fungi", "PROBLEM", 31, 36], ["bacteria", "OBSERVATION", 18, 26]]], ["These mixtures were then cultured onto agar plates for 24\u221248 h, and inhibitory activity was evaluated based on measuring colony-forming units.", [["colony", "ANATOMY", 121, 127], ["agar plates", "TEST", 39, 50]]], ["This is a well-accepted and relatively routine method for calculating the number of surviving organisms present in the original test mixtures.", [["surviving organisms", "PROBLEM", 84, 103]]], ["As shown in Fig. 1 , nicotine caused a dose-dependent growth inhibition of a broad spectrum of our test organisms, some of which are known pathogens.", [["nicotine", "CHEMICAL", 21, 29], ["nicotine", "CHEMICAL", 21, 29], ["nicotine", "SIMPLE_CHEMICAL", 21, 29], ["nicotine", "TREATMENT", 21, 29], ["dependent growth inhibition", "PROBLEM", 44, 71], ["our test organisms", "TEST", 95, 113], ["known pathogens", "PROBLEM", 133, 148], ["Fig", "OBSERVATION", 12, 15], ["pathogens", "OBSERVATION", 139, 148]]], ["Equally affected were both gram-positive and gram-negative bacteria, and the fungal organism, Candida albicans.", [["Candida albicans", "ORGANISM", 94, 110], ["Candida albicans", "SPECIES", 94, 110], ["Candida albicans", "SPECIES", 94, 110], ["gram", "TEST", 27, 31], ["gram-negative bacteria", "PROBLEM", 45, 67], ["the fungal organism", "PROBLEM", 73, 92], ["Candida albicans", "PROBLEM", 94, 110], ["negative bacteria", "OBSERVATION", 50, 67], ["fungal organism", "OBSERVATION", 77, 92], ["Candida albicans", "OBSERVATION", 94, 110]]], ["Although not shown here, but published elsewhere [31] nicotine exerted a significant inhibitory effect against another fungal pathogen, Cryptococcus neoformans.", [["nicotine", "CHEMICAL", 54, 62], ["Cryptococcus neoformans", "DISEASE", 136, 159], ["[31] nicotine", "CHEMICAL", 49, 62], ["[31] nicotine", "SIMPLE_CHEMICAL", 49, 62], ["Cryptococcus neoformans", "ORGANISM", 136, 159], ["Cryptococcus neoformans", "SPECIES", 136, 159], ["Cryptococcus neoformans", "SPECIES", 136, 159], ["nicotine", "TREATMENT", 54, 62], ["a significant inhibitory effect", "PROBLEM", 71, 102], ["another fungal pathogen", "PROBLEM", 111, 134], ["Cryptococcus neoformans", "PROBLEM", 136, 159], ["Cryptococcus neoformans", "OBSERVATION", 136, 159]]], ["Collectively, these two opportunistic fungi are frequent indigenous colonizers of the human oral cavity [29] and it has been well established that they are capable of causing superficial and systemic infections primarily in immunocompromised patients, or in people who are being treated with certain antibiotics (especially for C. albicans).", [["oral cavity", "ANATOMY", 92, 103], ["superficial", "ANATOMY", 175, 186], ["opportunistic fungi", "DISEASE", 24, 43], ["infections", "DISEASE", 200, 210], ["human", "ORGANISM", 86, 91], ["oral", "ORGANISM_SUBDIVISION", 92, 96], ["patients", "ORGANISM", 242, 250], ["people", "ORGANISM", 258, 264], ["C. albicans", "ORGANISM", 328, 339], ["human", "SPECIES", 86, 91], ["patients", "SPECIES", 242, 250], ["people", "SPECIES", 258, 264], ["C. albicans", "SPECIES", 328, 339], ["human", "SPECIES", 86, 91], ["C. albicans", "SPECIES", 328, 339], ["these two opportunistic fungi", "PROBLEM", 14, 43], ["superficial and systemic infections", "PROBLEM", 175, 210], ["certain antibiotics", "TREATMENT", 292, 311], ["C. albicans", "PROBLEM", 328, 339], ["opportunistic", "OBSERVATION_MODIFIER", 24, 37], ["fungi", "OBSERVATION", 38, 43], ["frequent", "OBSERVATION_MODIFIER", 48, 56], ["indigenous", "OBSERVATION_MODIFIER", 57, 67], ["colonizers", "OBSERVATION", 68, 78], ["human", "ANATOMY_MODIFIER", 86, 91], ["oral cavity", "ANATOMY", 92, 103], ["superficial", "OBSERVATION_MODIFIER", 175, 186], ["systemic", "OBSERVATION_MODIFIER", 191, 199], ["infections", "OBSERVATION", 200, 210], ["immunocompromised", "OBSERVATION_MODIFIER", 224, 241]]], ["In contrast, Staphylococcus aureus and Mycobacterium phlei were only slightly inhibited following nicotine exposure.", [["nicotine", "CHEMICAL", 98, 106], ["nicotine", "CHEMICAL", 98, 106], ["Staphylococcus aureus", "ORGANISM", 13, 34], ["Mycobacterium phlei", "ORGANISM", 39, 58], ["nicotine", "SIMPLE_CHEMICAL", 98, 106], ["Staphylococcus aureus", "SPECIES", 13, 34], ["Mycobacterium phlei", "SPECIES", 39, 58], ["Staphylococcus aureus", "SPECIES", 13, 34], ["Mycobacterium phlei", "SPECIES", 39, 58], ["Staphylococcus aureus", "PROBLEM", 13, 34], ["Mycobacterium phlei", "PROBLEM", 39, 58], ["nicotine exposure", "TREATMENT", 98, 115], ["Staphylococcus aureus", "OBSERVATION", 13, 34], ["Mycobacterium phlei", "OBSERVATION", 39, 58]]], ["Also significant, along these lines, was our finding that nicotine had strong inhibitory activity against the viridans Streptococci (a member comprising a large portion of the oral resident microflora that have been well documented as a significant cause of bacteremia and infective sub-acute endocarditis).", [["oral", "ANATOMY", 176, 180], ["nicotine", "CHEMICAL", 58, 66], ["bacteremia", "DISEASE", 258, 268], ["infective sub-acute endocarditis", "DISEASE", 273, 305], ["nicotine", "CHEMICAL", 58, 66], ["nicotine", "SIMPLE_CHEMICAL", 58, 66], ["viridans Streptococci", "ORGANISM", 110, 131], ["oral", "ORGANISM_SUBDIVISION", 176, 180], ["nicotine", "TREATMENT", 58, 66], ["the viridans Streptococci", "PROBLEM", 106, 131], ["bacteremia", "PROBLEM", 258, 268], ["infective sub", "PROBLEM", 273, 286], ["acute endocarditis", "PROBLEM", 287, 305], ["significant", "OBSERVATION_MODIFIER", 5, 16], ["viridans Streptococci", "OBSERVATION", 110, 131], ["bacteremia", "OBSERVATION", 258, 268], ["infective", "OBSERVATION_MODIFIER", 273, 282], ["acute", "OBSERVATION_MODIFIER", 287, 292], ["endocarditis", "OBSERVATION", 293, 305]]], ["Such a result could minimize the harmful effects associated with this group of organisms by limiting or preventing their dissemination, under certain conditions, from the mouth to the bloodstream.", [["mouth", "ANATOMY", 171, 176], ["bloodstream", "ANATOMY", 184, 195], ["mouth", "ORGANISM_SUBDIVISION", 171, 176], ["the harmful effects", "PROBLEM", 29, 48], ["mouth", "ANATOMY", 171, 176], ["bloodstream", "ANATOMY", 184, 195]]], ["Levels of inhibition > 50 % occurred when most of the affected organisms were cultured with nicotine at concentrations ranging from 100 to 250 u g/ml.", [["nicotine", "CHEMICAL", 92, 100], ["nicotine", "CHEMICAL", 92, 100], ["nicotine", "SIMPLE_CHEMICAL", 92, 100], ["Levels", "TEST", 0, 6], ["inhibition", "TEST", 10, 20], ["the affected organisms", "PROBLEM", 50, 72], ["nicotine at concentrations", "TREATMENT", 92, 118]]], ["It is noteworthy that these levels of nicotine can be found in vivo [32] , especially in the oral cavity of smokeless tobacco users, thereby making these findings physiologically relevant.ConclusionBased on the foregoing and the results from our limited series of experiments [31] and those of others [7, 8] , the ability of nicotine to limit or interfere with the growth of various human microflora could be considered a significant finding.", [["oral cavity", "ANATOMY", 93, 104], ["nicotine", "CHEMICAL", 38, 46], ["nicotine", "CHEMICAL", 325, 333], ["nicotine", "CHEMICAL", 38, 46], ["nicotine", "CHEMICAL", 325, 333], ["nicotine", "SIMPLE_CHEMICAL", 38, 46], ["oral cavity", "ORGANISM_SUBDIVISION", 93, 104], ["tobacco", "ORGANISM", 118, 125], ["nicotine", "SIMPLE_CHEMICAL", 325, 333], ["human", "ORGANISM", 383, 388], ["human", "SPECIES", 383, 388], ["tobacco", "SPECIES", 118, 125], ["human", "SPECIES", 383, 388], ["nicotine", "TREATMENT", 38, 46], ["nicotine", "TREATMENT", 325, 333], ["the growth of various human microflora", "PROBLEM", 361, 399], ["oral cavity", "ANATOMY", 93, 104]]], ["Such results could have broad range implications and relevance, since a large segment of the human population uses nicotine-containing tobacco products or nicotine alone for therapeutic purposes (withdrawal relief), and very little is known on how such events impact on various metabolic processes, especially those involving the microbiome and the host's immune system.", [["nicotine", "CHEMICAL", 115, 123], ["nicotine", "CHEMICAL", 155, 163], ["nicotine", "CHEMICAL", 115, 123], ["nicotine", "CHEMICAL", 155, 163], ["human", "ORGANISM", 93, 98], ["nicotine", "SIMPLE_CHEMICAL", 115, 123], ["tobacco", "ORGANISM", 135, 142], ["nicotine", "SIMPLE_CHEMICAL", 155, 163], ["immune system", "ANATOMICAL_SYSTEM", 356, 369], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["tobacco", "SPECIES", 135, 142], ["nicotine", "TREATMENT", 115, 123], ["tobacco products", "TREATMENT", 135, 151], ["nicotine", "TREATMENT", 155, 163], ["withdrawal relief", "TREATMENT", 196, 213], ["large", "OBSERVATION_MODIFIER", 72, 77], ["segment", "OBSERVATION_MODIFIER", 78, 85]]], ["A large body of evidence has revealed that IBD is most likely a result of aberrations (dysregulation) of mucosal immune reactivity initiated by one or more yet-to-be determined stimulus and/or etiologic agent(s) possibly involving one or more organisms that colonize the g.i. tract.", [["mucosal", "ANATOMY", 105, 112], ["g.i. tract", "ANATOMY", 271, 281], ["IBD", "DISEASE", 43, 46], ["tract", "ORGANISM_SUBDIVISION", 276, 281], ["IBD", "PROBLEM", 43, 46], ["aberrations (dysregulation", "PROBLEM", 74, 100], ["mucosal immune reactivity", "PROBLEM", 105, 130], ["large", "OBSERVATION_MODIFIER", 2, 7], ["IBD", "OBSERVATION", 43, 46], ["most likely", "UNCERTAINTY", 50, 61], ["aberrations", "OBSERVATION", 74, 85], ["mucosal immune reactivity", "OBSERVATION", 105, 130]]], ["Nicotine exposure, either through the use of gums or lozenges, especially in the oral cavity, where it occurs most often and would interact most intensely and directly with the contents of the oral cavity, could seriously affect or shift the type of species and/or the amount of microflora colonizing the mouth.", [["oral cavity", "ANATOMY", 81, 92], ["oral cavity", "ANATOMY", 193, 204], ["mouth", "ANATOMY", 305, 310], ["Nicotine", "CHEMICAL", 0, 8], ["Nicotine", "CHEMICAL", 0, 8], ["Nicotine", "SIMPLE_CHEMICAL", 0, 8], ["gums", "ORGANISM_SUBDIVISION", 45, 49], ["oral cavity", "ORGANISM_SUBDIVISION", 81, 92], ["oral cavity", "ORGANISM_SUBDIVISION", 193, 204], ["mouth", "ORGANISM_SUBDIVISION", 305, 310], ["Nicotine exposure", "TREATMENT", 0, 17], ["gums", "TREATMENT", 45, 49], ["lozenges", "TREATMENT", 53, 61], ["microflora colonizing the mouth", "PROBLEM", 279, 310], ["oral cavity", "ANATOMY", 81, 92], ["oral cavity", "ANATOMY", 193, 204], ["mouth", "ANATOMY", 305, 310]]], ["Similar effects could manifest themselves in the Organisms were mixed with nicotine in vitro and cultured onto blood agar.", [["blood", "ANATOMY", 111, 116], ["nicotine", "CHEMICAL", 75, 83], ["nicotine", "CHEMICAL", 75, 83], ["nicotine", "SIMPLE_CHEMICAL", 75, 83], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["the Organisms", "PROBLEM", 45, 58], ["nicotine in vitro", "TREATMENT", 75, 92], ["blood agar", "TEST", 111, 121]]], ["After re-incubation, CFU of the number of surviving organisms were counted.", [["re-incubation", "TREATMENT", 6, 19], ["surviving organisms", "PROBLEM", 42, 61], ["number", "OBSERVATION_MODIFIER", 32, 38]]], ["Each data point represents the mean value of 3 replicate experiments.Conclusiong.i. tract and elsewhere following the use of the nicotine dermal patch, which leads to systemic absorption of nicotine.", [["dermal", "ANATOMY", 138, 144], ["nicotine", "CHEMICAL", 129, 137], ["nicotine", "CHEMICAL", 190, 198], ["nicotine", "CHEMICAL", 129, 137], ["nicotine", "CHEMICAL", 190, 198], ["nicotine", "SIMPLE_CHEMICAL", 190, 198], ["the mean value", "TEST", 27, 41], ["the nicotine dermal patch", "TREATMENT", 125, 150], ["systemic absorption of nicotine", "TREATMENT", 167, 198], ["tract", "OBSERVATION", 84, 89]]], ["As a by-product of these events, degradation products of altered or dying organisms could contribute or modify the development of various pathologic processes such as periodontal disease(s) and IBD, as well as enable other microorganisms, including newly acquired pathogens, to proliferate and serve as foci for subsequent infections.", [["periodontal", "ANATOMY", 167, 178], ["foci", "ANATOMY", 303, 307], ["periodontal disease", "DISEASE", 167, 186], ["IBD", "DISEASE", 194, 197], ["infections", "DISEASE", 323, 333], ["these events", "PROBLEM", 19, 31], ["altered or dying organisms", "PROBLEM", 57, 83], ["various pathologic processes", "PROBLEM", 130, 158], ["periodontal disease", "PROBLEM", 167, 186], ["IBD", "PROBLEM", 194, 197], ["enable other microorganisms", "PROBLEM", 210, 237], ["newly acquired pathogens", "PROBLEM", 249, 273], ["subsequent infections", "PROBLEM", 312, 333], ["altered", "OBSERVATION_MODIFIER", 57, 64], ["various", "OBSERVATION_MODIFIER", 130, 137], ["pathologic", "OBSERVATION", 138, 148], ["periodontal", "ANATOMY", 167, 178], ["infections", "OBSERVATION", 323, 333]]], ["On the other hand, nicotine exposure in the oral cavity could have a subtle beneficial effect on the host, by limiting the growth of certain respiratory / enteric or indigenous opportunistic pathogens that enter the body through the oral/ nasal passages either as the result of inhalation of infectious aerosolized particles or via the ingestion of contaminated food products.", [["oral cavity", "ANATOMY", 44, 55], ["respiratory", "ANATOMY", 141, 152], ["body", "ANATOMY", 216, 220], ["oral", "ANATOMY", 233, 237], ["nasal", "ANATOMY", 239, 244], ["nicotine", "CHEMICAL", 19, 27], ["nicotine", "CHEMICAL", 19, 27], ["nicotine", "SIMPLE_CHEMICAL", 19, 27], ["oral cavity", "ORGAN", 44, 55], ["body", "ORGANISM_SUBDIVISION", 216, 220], ["oral", "ORGANISM_SUBDIVISION", 233, 237], ["nicotine exposure in the oral cavity", "PROBLEM", 19, 55], ["a subtle beneficial effect on the host", "PROBLEM", 67, 105], ["certain respiratory / enteric or indigenous opportunistic pathogens", "PROBLEM", 133, 200], ["the oral/ nasal passages", "TREATMENT", 229, 253], ["infectious aerosolized particles", "PROBLEM", 292, 324], ["nicotine exposure", "OBSERVATION", 19, 36], ["oral cavity", "ANATOMY", 44, 55], ["subtle", "OBSERVATION_MODIFIER", 69, 75], ["beneficial", "OBSERVATION_MODIFIER", 76, 86], ["enteric", "ANATOMY", 155, 162], ["nasal", "ANATOMY", 239, 244], ["passages", "OBSERVATION", 245, 253], ["infectious", "OBSERVATION_MODIFIER", 292, 302]]], ["As a follow-up to these provocative findings, future related studies should examine whether nicotine exerts its anti-microbial effects against a much broader range of indigenous microflora than has been studied so far, along with focusing on the molecular biologic mechanisms and host pathologic changes associated with nicotine-mediated killing of the oral and intestinal microflora.Declaration of Competing InterestThe authors have none to declare.", [["oral", "ANATOMY", 353, 357], ["intestinal microflora", "ANATOMY", 362, 383], ["nicotine", "CHEMICAL", 92, 100], ["nicotine", "CHEMICAL", 320, 328], ["nicotine", "CHEMICAL", 92, 100], ["nicotine", "CHEMICAL", 320, 328], ["nicotine", "SIMPLE_CHEMICAL", 92, 100], ["nicotine", "SIMPLE_CHEMICAL", 320, 328], ["oral", "ORGANISM_SUBDIVISION", 353, 357], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 362, 383], ["future related studies", "TEST", 46, 68], ["nicotine", "TREATMENT", 92, 100], ["host pathologic changes", "PROBLEM", 280, 303], ["nicotine", "TREATMENT", 320, 328], ["intestinal microflora", "ANATOMY", 362, 383]]]], "d5bcb5d8c2edd7162e5f0fe6c189662b39eebfbe": [["Despite high sequence similarity between pandemic and seasonal influenza viruses, there is extreme variation in host pathogenicity from one viral strain to the next.", [["pandemic", "DISEASE", 41, 49], ["influenza viruses", "DISEASE", 63, 80], ["seasonal influenza viruses", "ORGANISM", 54, 80], ["seasonal influenza viruses", "SPECIES", 54, 80], ["pandemic", "PROBLEM", 41, 49], ["seasonal influenza viruses", "PROBLEM", 54, 80], ["extreme variation", "PROBLEM", 91, 108], ["host pathogenicity", "PROBLEM", 112, 130], ["one viral strain", "PROBLEM", 136, 152], ["seasonal", "OBSERVATION_MODIFIER", 54, 62], ["influenza viruses", "OBSERVATION", 63, 80], ["extreme", "OBSERVATION_MODIFIER", 91, 98], ["variation", "OBSERVATION_MODIFIER", 99, 108], ["host pathogenicity", "OBSERVATION", 112, 130], ["viral strain", "OBSERVATION", 140, 152]]], ["Identifying the underlying mechanisms of variability in pathogenicity is a critical task for understanding influenza virus infection and effective management of highly pathogenic influenza virus disease.", [["influenza virus infection", "DISEASE", 107, 132], ["influenza virus disease", "DISEASE", 179, 202], ["influenza virus", "ORGANISM", 107, 122], ["influenza virus", "ORGANISM", 179, 194], ["influenza virus", "SPECIES", 107, 122], ["influenza virus", "SPECIES", 179, 194], ["influenza virus", "SPECIES", 107, 122], ["variability in pathogenicity", "PROBLEM", 41, 69], ["understanding influenza virus infection", "PROBLEM", 93, 132], ["effective management", "TREATMENT", 137, 157], ["highly pathogenic influenza virus disease", "PROBLEM", 161, 202], ["variability", "OBSERVATION_MODIFIER", 41, 52], ["pathogenic", "OBSERVATION_MODIFIER", 168, 178], ["influenza virus disease", "OBSERVATION", 179, 202]]], ["We applied a network-based modeling approach to identify critical functions related to influenza virus pathogenicity using large transcriptomic and proteomic datasets from mice infected with six influenza virus strains or mutants.", [["influenza virus", "DISEASE", 195, 210], ["influenza virus", "ORGANISM", 87, 102], ["mice", "ORGANISM", 172, 176], ["influenza virus", "ORGANISM", 195, 210], ["influenza virus", "SPECIES", 87, 102], ["mice", "SPECIES", 172, 176], ["influenza virus", "SPECIES", 195, 210], ["influenza virus", "SPECIES", 87, 102], ["mice", "SPECIES", 172, 176], ["a network-based modeling approach", "TREATMENT", 11, 44], ["critical functions", "PROBLEM", 57, 75], ["influenza virus pathogenicity", "PROBLEM", 87, 116], ["large transcriptomic and proteomic datasets", "PROBLEM", 123, 166], ["mice infected", "PROBLEM", 172, 185], ["six influenza virus strains", "PROBLEM", 191, 218]]], ["Our analysis revealed two pathogenicity-related gene expression clusters; these results were corroborated by matching proteomics data.", [["Our analysis", "TEST", 0, 12], ["two pathogenicity", "PROBLEM", 22, 39], ["gene expression clusters", "PROBLEM", 48, 72], ["two", "OBSERVATION_MODIFIER", 22, 25], ["pathogenicity", "OBSERVATION", 26, 39], ["gene expression clusters", "OBSERVATION", 48, 72]]], ["We also identified parallel downstream processes that were altered during influenza pathogenesis.", [["influenza", "DISEASE", 74, 83], ["parallel downstream processes", "PROBLEM", 19, 48], ["influenza pathogenesis", "PROBLEM", 74, 96], ["downstream processes", "OBSERVATION", 28, 48]]], ["We found that network bottlenecks (nodes that bridge different network regions) were highly enriched in pathogenicity-related genes, while network hubs (highly connected network nodes) were significantly depleted in these genes.", [["network nodes", "ANATOMY", 170, 183], ["network hubs", "MULTI-TISSUE_STRUCTURE", 139, 151], ["network nodes", "MULTI-TISSUE_STRUCTURE", 170, 183], ["pathogenicity-related genes", "DNA", 104, 131], ["network bottlenecks (nodes", "PROBLEM", 14, 40], ["bottlenecks", "OBSERVATION_MODIFIER", 22, 33], ["nodes", "OBSERVATION", 35, 40], ["highly", "OBSERVATION_MODIFIER", 85, 91], ["enriched", "OBSERVATION_MODIFIER", 92, 100]]], ["We confirmed that this trend persisted in a distinct virus: Severe Acute Respiratory Syndrome Coronavirus (SARS).", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 67, 105], ["SARS", "DISEASE", 107, 111], ["Severe Acute Respiratory Syndrome Coronavirus", "SPECIES", 60, 105], ["a distinct virus", "PROBLEM", 42, 58], ["Severe Acute Respiratory Syndrome Coronavirus (SARS)", "PROBLEM", 60, 112], ["Severe", "OBSERVATION_MODIFIER", 60, 66], ["Acute", "OBSERVATION_MODIFIER", 67, 72], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 73, 105]]], ["The role of epidermal growth factor receptor (EGFR) in influenza pathogenesis, one of the bottleneck regulators with corroborating signals across transcript and protein expression data, was tested and validated in additional mouse infection experiments.", [["influenza", "DISEASE", 55, 64], ["infection", "DISEASE", 231, 240], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 12, 44], ["EGFR", "GENE_OR_GENE_PRODUCT", 46, 50], ["mouse", "ORGANISM", 225, 230], ["epidermal growth factor receptor", "PROTEIN", 12, 44], ["EGFR", "PROTEIN", 46, 50], ["mouse", "SPECIES", 225, 230], ["mouse", "SPECIES", 225, 230], ["epidermal growth factor receptor (EGFR) in influenza pathogenesis", "PROBLEM", 12, 77], ["protein expression data", "TEST", 161, 184], ["additional mouse infection experiments", "PROBLEM", 214, 252], ["epidermal", "OBSERVATION_MODIFIER", 12, 21], ["growth", "OBSERVATION_MODIFIER", 22, 28], ["infection", "OBSERVATION", 231, 240]]], ["We demonstrate that EGFR is important during influenza infection, but the role it plays changes for lethal versus non-lethal infections.", [["influenza infection", "DISEASE", 45, 64], ["infections", "DISEASE", 125, 135], ["EGFR", "GENE_OR_GENE_PRODUCT", 20, 24], ["EGFR", "PROTEIN", 20, 24], ["EGFR", "TEST", 20, 24], ["influenza infection", "PROBLEM", 45, 64], ["lethal", "PROBLEM", 100, 106], ["non-lethal infections", "PROBLEM", 114, 135], ["EGFR", "OBSERVATION", 20, 24], ["infections", "OBSERVATION", 125, 135]]], ["Our results show that by using association networks, bottleneck genes that lack hub characteristics can be used to predict a gene's involvement in influenza virus pathogenicity.", [["influenza virus", "ORGANISM", 147, 162], ["bottleneck genes", "DNA", 53, 69], ["influenza virus", "SPECIES", 147, 162], ["influenza virus", "SPECIES", 147, 162], ["a gene's involvement", "PROBLEM", 123, 143], ["influenza virus pathogenicity", "PROBLEM", 147, 176]]], ["We also demonstrate the utility of employing multiple network approaches for analyzing host response data from viral infections.", [["viral infections", "DISEASE", 111, 127], ["viral infections", "PROBLEM", 111, 127], ["viral infections", "OBSERVATION", 111, 127]]]], "PMC7309333": [["IntroductionThe catastrophic coronavirus disease 2019 (COVID-19) pandemic caused by a novel coronavirus referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought the world to a standstill and has afflicted global public health (Abraham et al., 2020; Bhardwaj et al., 2020; Elasnaoui & Chawki, 2020; Paniri et al., 2020; Wu et al., 2020).", [["catastrophic coronavirus disease", "DISEASE", 16, 48], ["COVID-19", "CHEMICAL", 55, 63], ["coronavirus", "DISEASE", 92, 103], ["acute respiratory syndrome coronavirus", "DISEASE", 126, 164], ["SARS-CoV-2", "CHEMICAL", 168, 178], ["coronavirus", "ORGANISM", 29, 40], ["COVID-19", "ORGANISM", 55, 63], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 119, 166], ["SARS-CoV-2", "ORGANISM", 168, 178], ["coronavirus", "SPECIES", 92, 103], ["coronavirus disease 2019 (COVID-19", "SPECIES", 29, 63], ["severe acute respiratory syndrome coronavirus", "SPECIES", 119, 164], ["SARS-CoV-2", "SPECIES", 168, 178], ["The catastrophic coronavirus disease", "PROBLEM", 12, 48], ["COVID", "TEST", 55, 60], ["pandemic", "PROBLEM", 65, 73], ["a novel coronavirus", "PROBLEM", 84, 103], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 119, 164], ["catastrophic coronavirus disease", "OBSERVATION", 16, 48], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["respiratory syndrome", "OBSERVATION", 132, 152]]], ["The virus has infected over six million people and has ruthlessly claimed nearly four hundred thousand lives till date (as per updates on June 2, 2020) (https://www.worldometers.info/coronavirus/).", [["people", "ORGANISM", 40, 46], ["people", "SPECIES", 40, 46], ["virus", "OBSERVATION", 4, 9], ["infected", "OBSERVATION_MODIFIER", 14, 22]]], ["COVID-19 has surpassed the two other coronavirus-related outbreaks associated with severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) that occurred in recent past in terms of the frequency of infected individuals and the number of deaths (Lu et al., 2020), though the overall case-fatality rate remains lower than both SARS and MERS (Wu & McGoogan, 2020).", [["COVID-19", "CHEMICAL", 0, 8], ["coronavirus", "DISEASE", 37, 48], ["acute respiratory syndrome", "DISEASE", 90, 116], ["SARS", "DISEASE", 118, 122], ["Middle East respiratory syndrome", "DISEASE", 132, 164], ["MERS", "DISEASE", 166, 170], ["deaths", "DISEASE", 269, 275], ["SARS", "DISEASE", 357, 361], ["COVID", "TEST", 0, 5], ["severe acute respiratory syndrome", "PROBLEM", 83, 116], ["SARS", "PROBLEM", 118, 122], ["the Middle East respiratory syndrome", "PROBLEM", 128, 164], ["fatality rate", "TEST", 319, 332], ["coronavirus", "OBSERVATION", 37, 48], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116], ["Middle", "ANATOMY_MODIFIER", 132, 138], ["respiratory syndrome", "OBSERVATION", 144, 164], ["infected", "OBSERVATION", 230, 238]]], ["Patients infected with COVID-19 are diagnosed with mild-to-severe respiratory illness and symptoms like high fever, cough, dizziness and shortness of breath which might further advance to pneumonia and acute respiratory distress causing death (Lu et al., 2020; Wu & McGoogan, 2020).IntroductionSARS-CoV-2 is a positive-stranded RNA virus that represents the genus Betacoronovirus and belongs to the family Coronaviridae (Benvenuto et al., 2020; Sarma et al., 2020).", [["respiratory", "ANATOMY", 66, 77], ["respiratory", "ANATOMY", 208, 219], ["respiratory illness", "DISEASE", 66, 85], ["fever", "DISEASE", 109, 114], ["cough", "DISEASE", 116, 121], ["dizziness", "DISEASE", 123, 132], ["shortness of breath", "DISEASE", 137, 156], ["pneumonia", "DISEASE", 188, 197], ["respiratory distress", "DISEASE", 208, 228], ["death", "DISEASE", 237, 242], ["Patients", "ORGANISM", 0, 8], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 282, 304], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 23, 28], ["severe respiratory illness", "PROBLEM", 59, 85], ["symptoms", "PROBLEM", 90, 98], ["high fever", "PROBLEM", 104, 114], ["cough", "PROBLEM", 116, 121], ["dizziness", "PROBLEM", 123, 132], ["shortness of breath", "PROBLEM", 137, 156], ["pneumonia", "PROBLEM", 188, 197], ["acute respiratory distress", "PROBLEM", 202, 228], ["death", "PROBLEM", 237, 242], ["IntroductionSARS", "TEST", 282, 298], ["CoV", "TEST", 299, 302], ["a positive-stranded RNA virus", "PROBLEM", 308, 337], ["infected", "OBSERVATION", 9, 17], ["mild", "OBSERVATION_MODIFIER", 51, 55], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["respiratory", "ANATOMY", 66, 77], ["illness", "OBSERVATION", 78, 85], ["high", "OBSERVATION_MODIFIER", 104, 108], ["fever", "OBSERVATION", 109, 114], ["pneumonia", "OBSERVATION", 188, 197], ["acute", "OBSERVATION_MODIFIER", 202, 207], ["respiratory distress", "OBSERVATION", 208, 228], ["stranded RNA virus", "OBSERVATION", 319, 337], ["genus Betacoronovirus", "OBSERVATION", 358, 379]]], ["The novel coronavirus is significantly distant from SARS-CoV (around 79% identify) and MERS-CoV (around 50% identity) (Lu et al., 2020).", [["SARS", "DISEASE", 52, 56], ["coronavirus", "ORGANISM", 10, 21], ["SARS-CoV", "ORGANISM", 52, 60], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 87, 95], ["SARS-CoV", "SPECIES", 52, 60], ["MERS-CoV", "SPECIES", 87, 95], ["The novel coronavirus", "PROBLEM", 0, 21], ["SARS", "TEST", 52, 56], ["CoV", "TEST", 57, 60], ["coronavirus", "OBSERVATION", 10, 21], ["significantly", "OBSERVATION_MODIFIER", 25, 38], ["distant", "OBSERVATION_MODIFIER", 39, 46]]], ["Despite the novelty of SARS-CoV-2, significant advancements have been made in elucidating the complex genomic features (Wu et al., 2020), understanding the codon usage signatures and evolutionary enigma (Andersen et al., 2020; Tort et al., 2020) and unraveling the riddles of infectivity and epidemiology (Lu et al., 2020; Rothan & Byrareddy, 2020) of the intimidating virus.", [["SARS", "DISEASE", 23, 27], ["SARS-CoV-2", "ORGANISM", 23, 33], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["the intimidating virus", "PROBLEM", 352, 374]]], ["The viral genome encodes several structural and non-structural proteins (nsp) that play crucial roles in attaching the virus to host cellular receptors, regulating viral replication and facilitating subsequent infection (Gupta et al., 2020; Tai et al., 2020; Wu et al., 2020).", [["cellular", "ANATOMY", 133, 141], ["infection", "DISEASE", 210, 219], ["nsp", "GENE_OR_GENE_PRODUCT", 73, 76], ["cellular", "CELL", 133, 141], ["viral genome", "DNA", 4, 16], ["structural and non-structural proteins", "PROTEIN", 33, 71], ["nsp", "PROTEIN", 73, 76], ["host cellular receptors", "PROTEIN", 128, 151], ["The viral genome encodes several structural and non-structural proteins (nsp)", "PROBLEM", 0, 77], ["host cellular receptors", "TREATMENT", 128, 151], ["viral replication", "TREATMENT", 164, 181], ["viral genome", "OBSERVATION", 4, 16], ["several structural", "OBSERVATION_MODIFIER", 25, 43], ["non-structural proteins", "OBSERVATION", 48, 71], ["viral replication", "OBSERVATION", 164, 181], ["infection", "OBSERVATION", 210, 219]]], ["The spike (S) protein is a vital structural protein component that forms prominent spikes on the outer surface of the virus and helps in viral attachment, successful fusion and subsequent entry into the host cells (Elfiky, 2020; Sinha et al., 2020; Tai et al., 2020).", [["outer surface", "ANATOMY", 97, 110], ["cells", "ANATOMY", 208, 213], ["spike (S)", "GENE_OR_GENE_PRODUCT", 4, 13], ["outer surface", "CELLULAR_COMPONENT", 97, 110], ["cells", "CELL", 208, 213], ["spike (S) protein", "PROTEIN", 4, 21], ["structural protein component", "PROTEIN", 33, 61], ["host cells", "CELL_TYPE", 203, 213], ["The spike (S) protein", "TEST", 0, 21], ["a vital structural protein component", "PROBLEM", 25, 61], ["prominent spikes", "PROBLEM", 73, 89], ["the virus", "PROBLEM", 114, 123], ["viral attachment", "PROBLEM", 137, 153], ["successful fusion", "TREATMENT", 155, 172], ["prominent", "OBSERVATION_MODIFIER", 73, 82], ["spikes", "OBSERVATION_MODIFIER", 83, 89], ["virus", "OBSERVATION", 118, 123], ["viral attachment", "OBSERVATION", 137, 153]]], ["The imperative main protease enzyme Mpro (also referred to as 3 C-like protease) of SARS-CoV-2 plays pivotal role in proteolytic cleavage and processing of the large viral polyprotein orf1ab in combination with papain-like proteases and facilitates viral replication (Al-Khafaji et al., 2020; Gyebi et al., 2020; Islam et al., 2020; Jin et al., 2020; Joshi et al., 2020; Khan et al., 2020; Mittal et al., 2020).", [["Mpro", "GENE_OR_GENE_PRODUCT", 36, 40], ["3 C-like protease", "GENE_OR_GENE_PRODUCT", 62, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 84, 94], ["orf1ab", "GENE_OR_GENE_PRODUCT", 184, 190], ["papain", "GENE_OR_GENE_PRODUCT", 211, 217], ["protease enzyme", "PROTEIN", 20, 35], ["Mpro", "PROTEIN", 36, 40], ["3 C-like protease", "PROTEIN", 62, 79], ["large viral polyprotein orf1ab", "PROTEIN", 160, 190], ["papain-like proteases", "PROTEIN", 211, 232], ["SARS-CoV", "SPECIES", 84, 92], ["SARS", "PROBLEM", 84, 88], ["CoV", "TEST", 89, 92], ["proteolytic cleavage", "TREATMENT", 117, 137], ["the large viral polyprotein orf1ab", "TREATMENT", 156, 190], ["papain", "TREATMENT", 211, 217]]], ["Efficient replication and the spread of SARS-CoV-2 in host cells are largely dependent on proper functioning of the RNA-dependent RNA polymerase (RdRp) (Elfiky, 2020; Ziebuhr, 2005).", [["cells", "ANATOMY", 59, 64], ["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["host cells", "CELL", 54, 64], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 116, 144], ["host cells", "CELL_TYPE", 54, 64], ["RNA-dependent RNA polymerase", "PROTEIN", 116, 144], ["RdRp", "PROTEIN", 146, 150], ["SARS-CoV", "SPECIES", 40, 48], ["Efficient replication", "PROBLEM", 0, 21], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["replication", "OBSERVATION", 10, 21], ["spread", "OBSERVATION_MODIFIER", 30, 36], ["host cells", "OBSERVATION", 54, 64], ["dependent", "OBSERVATION_MODIFIER", 77, 86], ["proper functioning", "OBSERVATION_MODIFIER", 90, 108]]], ["Non-structural protein 12 (nsp12), the catalytic subunit of RdRp, mediates viral replication and enhances template binding and processivity in combination with nsp7 and nsp8 (Subissi et al., 2014; Te Velthuis et al., 2010).", [["Non-structural protein 12", "GENE_OR_GENE_PRODUCT", 0, 25], ["nsp12", "GENE_OR_GENE_PRODUCT", 27, 32], ["RdRp", "GENE_OR_GENE_PRODUCT", 60, 64], ["nsp7", "GENE_OR_GENE_PRODUCT", 160, 164], ["nsp8", "GENE_OR_GENE_PRODUCT", 169, 173], ["Non-structural protein 12", "PROTEIN", 0, 25], ["nsp12", "PROTEIN", 27, 32], ["catalytic subunit", "PROTEIN", 39, 56], ["RdRp", "PROTEIN", 60, 64], ["nsp7", "PROTEIN", 160, 164], ["Non-structural protein", "TEST", 0, 22], ["the catalytic subunit of RdRp", "TREATMENT", 35, 64], ["viral replication", "TREATMENT", 75, 92], ["enhances template binding", "PROBLEM", 97, 122], ["nsp7", "TEST", 160, 164], ["viral replication", "OBSERVATION", 75, 92]]], ["The pivotal roles of these viral proteins in the attachment of the virus to host cell receptors and subsequent replication and infection establish them as promising drug and vaccine candidates (Aanouz et al., 2020; Adeoye et al., 2020; Das et al., 2020; Kumar et al., 2020; Lobo-Galo et al., 2020; Mahanta et al., 2020; Pant et al., 2020; Sk et al., 2020; Tai et al., 2020; Yin et al., 2020).", [["cell", "ANATOMY", 81, 85], ["infection", "DISEASE", 127, 136], ["host cell", "CELL", 76, 85], ["viral proteins", "PROTEIN", 27, 41], ["host cell receptors", "PROTEIN", 76, 95], ["these viral proteins", "PROBLEM", 21, 41], ["the virus", "PROBLEM", 63, 72], ["host cell receptors", "TREATMENT", 76, 95], ["subsequent replication", "TREATMENT", 100, 122], ["infection", "PROBLEM", 127, 136], ["viral proteins", "OBSERVATION", 27, 41]]], ["Several methods like drug repurposing (Ciliberto & Cardone, 2020; Elmezayen et al., 2020), administration of convalescent plasma transfusion (Shen et al., 2020) and usage of SARS-CoV and MERS-CoV antibodies (Huang et al., 2020) are presently being employed to combat COVID-19.", [["plasma", "ANATOMY", 122, 128], ["COVID-19", "CHEMICAL", 267, 275], ["plasma", "ORGANISM_SUBSTANCE", 122, 128], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 174, 182], ["MERS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 187, 206], ["SARS-CoV and MERS-CoV antibodies", "PROTEIN", 174, 206], ["SARS-CoV", "SPECIES", 174, 182], ["MERS-CoV", "SPECIES", 187, 195], ["drug repurposing (Ciliberto & Cardone", "TREATMENT", 21, 58], ["convalescent plasma transfusion", "TREATMENT", 109, 140], ["SARS", "PROBLEM", 174, 178], ["COVID", "TEST", 267, 272]]], ["A combination of hydroxychloroquine and azithromycin has been observed to be effective in the treatment of the disease (Gautret et al., 2020).", [["hydroxychloroquine", "CHEMICAL", 17, 35], ["azithromycin", "CHEMICAL", 40, 52], ["hydroxychloroquine", "CHEMICAL", 17, 35], ["azithromycin", "CHEMICAL", 40, 52], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 17, 35], ["azithromycin", "SIMPLE_CHEMICAL", 40, 52], ["hydroxychloroquine", "TREATMENT", 17, 35], ["azithromycin", "TREATMENT", 40, 52], ["the disease", "PROBLEM", 107, 118], ["disease", "OBSERVATION", 111, 118]]], ["Hydroxychloroquine, an anti-malarial drug, facilitates endosomal acidification and blocks viral entry and fusion by inhibiting glycosylation of the host cellular receptors that bind with the viral proteins (Sanders et al., 2020).", [["endosomal", "ANATOMY", 55, 64], ["cellular", "ANATOMY", 153, 161], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["endosomal", "CELLULAR_COMPONENT", 55, 64], ["cellular", "CELL", 153, 161], ["host cellular receptors", "PROTEIN", 148, 171], ["viral proteins", "PROTEIN", 191, 205], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["an anti-malarial drug", "TREATMENT", 20, 41], ["endosomal acidification", "PROBLEM", 55, 78], ["blocks viral entry", "TREATMENT", 83, 101], ["fusion", "TREATMENT", 106, 112], ["the host cellular receptors", "TREATMENT", 144, 171]]], ["Though hydroxychloroquine efficiently arrests viral growth, toxic side effects and concerns over drug poisoning remain the major bottlenecks in using it in COVID-19 therapy (Enmozhi et al., 2020).", [["hydroxychloroquine", "CHEMICAL", 7, 25], ["poisoning", "DISEASE", 102, 111], ["COVID-19", "CHEMICAL", 156, 164], ["hydroxychloroquine", "CHEMICAL", 7, 25], ["COVID-19", "CHEMICAL", 156, 164], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 7, 25], ["hydroxychloroquine", "TREATMENT", 7, 25], ["viral growth", "PROBLEM", 46, 58], ["toxic side effects", "PROBLEM", 60, 78], ["drug poisoning", "PROBLEM", 97, 111]]], ["Drugs like arbidol targeted against the SARS-CoV-2 spike protein (Sanders et al., 2020) and lopinavir and ritonavir targeted against SARS-CoV-2 Mpro (Li et al., 2020) have been reported to be effective against the menacing pathogen.", [["arbidol", "CHEMICAL", 11, 18], ["lopinavir", "CHEMICAL", 92, 101], ["ritonavir", "CHEMICAL", 106, 115], ["arbidol", "CHEMICAL", 11, 18], ["lopinavir", "CHEMICAL", 92, 101], ["ritonavir", "CHEMICAL", 106, 115], ["arbidol", "SIMPLE_CHEMICAL", 11, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 40, 50], ["lopinavir", "SIMPLE_CHEMICAL", 92, 101], ["ritonavir", "SIMPLE_CHEMICAL", 106, 115], ["SARS-CoV-2 Mpro", "ORGANISM", 133, 148], ["SARS-CoV-2 spike protein", "PROTEIN", 40, 64], ["SARS-CoV", "SPECIES", 40, 48], ["SARS-CoV", "SPECIES", 133, 141], ["Drugs", "TREATMENT", 0, 5], ["arbidol", "TREATMENT", 11, 18], ["the SARS", "PROBLEM", 36, 44], ["CoV", "TEST", 45, 48], ["lopinavir", "TREATMENT", 92, 101], ["ritonavir", "TREATMENT", 106, 115], ["SARS", "PROBLEM", 133, 137], ["CoV", "TEST", 138, 141], ["the menacing pathogen", "PROBLEM", 210, 231]]], ["Antiviral drugs like remdesivir and favipiravir that inhibit RdRp activity (Hendaus, 2020; Li et al., 2020) ; Nejadi Babadaei et al., 2020have been observed to arrest SARS-CoV-2 replication and are currently in clinical trials.", [["remdesivir", "CHEMICAL", 21, 31], ["favipiravir", "CHEMICAL", 36, 47], ["remdesivir", "CHEMICAL", 21, 31], ["favipiravir", "CHEMICAL", 36, 47], ["remdesivir", "SIMPLE_CHEMICAL", 21, 31], ["favipiravir", "SIMPLE_CHEMICAL", 36, 47], ["SARS-CoV", "SPECIES", 167, 175], ["Antiviral drugs", "TREATMENT", 0, 15], ["remdesivir", "TREATMENT", 21, 31], ["favipiravir", "TREATMENT", 36, 47]]], ["Despite relentless attempts, researchers and medical practitioners are struggling to limit the rapid transmission and combat the calamitous health hazards posed by SARS-CoV-2 due to the lack of specific effective therapeutics and prophylactics.", [["SARS", "DISEASE", 164, 168], ["SARS-CoV-2", "ORGANISM", 164, 174], ["SARS-CoV", "SPECIES", 164, 172], ["prophylactics", "TREATMENT", 230, 243], ["relentless", "OBSERVATION_MODIFIER", 8, 18]]], ["Though several drugs and vaccines are in clinical trials all over the world, an effective therapeutic remedy specifically targeted to treat and cure COVID-19 is yet to be achieved.IntroductionSince time immemorial, phytochemicals and natural compounds have been employed as medicinal agents towards the effective treatment of grave ailments.", [["several drugs", "TREATMENT", 7, 20], ["vaccines", "TREATMENT", 25, 33], ["an effective therapeutic remedy", "TREATMENT", 77, 108], ["cure COVID", "TREATMENT", 144, 154], ["natural compounds", "TREATMENT", 234, 251], ["medicinal agents", "TREATMENT", 274, 290], ["grave ailments", "PROBLEM", 326, 340], ["grave ailments", "OBSERVATION", 326, 340]]], ["In the quest of natural therapeutic remedy against COVID-19 several studies have been designed to explore the inhibitory prospects of phytochemicals from various important and conventionally used medicinal plants and herbs all over the world (Boopathi et al., 2020).", [["natural therapeutic remedy", "TREATMENT", 16, 42], ["COVID", "TEST", 51, 56], ["several studies", "TEST", 60, 75], ["medicinal plants", "TREATMENT", 196, 212], ["herbs", "TREATMENT", 217, 222]]], ["Clerodendrum, a perennial shrub and a member of Lamiaceae family, is prevalent in the tropical regions of Asia including India, Myanmar, Bangladesh, Malayasia, Indonesia, Thailand, Bhutan, Nepal and also in temperate Tibet (Chathuranga et al., 2019).", [["Clerodendrum", "CHEMICAL", 0, 12], ["Clerodendrum", "SIMPLE_CHEMICAL", 0, 12], ["perennial shrub", "OBSERVATION", 16, 31], ["tropical", "ANATOMY_MODIFIER", 86, 94]]], ["Various medicinally important species of Clerodendrum are frequently used to treat respiratory ailments like common cold, bronchitis and pneumonia (Chathuranga et al., 2019; Patel et al., 2014).", [["respiratory", "ANATOMY", 83, 94], ["Clerodendrum", "CHEMICAL", 41, 53], ["respiratory ailments", "DISEASE", 83, 103], ["bronchitis", "DISEASE", 122, 132], ["pneumonia", "DISEASE", 137, 146], ["Clerodendrum", "SIMPLE_CHEMICAL", 41, 53], ["Clerodendrum", "TREATMENT", 41, 53], ["respiratory ailments", "PROBLEM", 83, 103], ["common cold", "PROBLEM", 109, 120], ["bronchitis", "PROBLEM", 122, 132], ["pneumonia", "PROBLEM", 137, 146], ["bronchitis", "OBSERVATION", 122, 132], ["pneumonia", "OBSERVATION", 137, 146]]], ["A crude extract of Clerodendrum trichotomum has been reported to actively inhibit Respiratory syncytial virus (RSV) without any cytotoxic effects towards normal tissues (Chathuranga et al., 2019).IntroductionConsidering the fact that Clerodendrum spp. often finds widespread applications in treating respiratory disorders (Chathuranga et al., 2019; Patel et al., 2014), an in house repertoire of the phytochemicals obtained from GC-MS analysis of twelve Clerodendrum species were assessed to explore their inhibitory prospects against the imperative spike, Mpro and RdRp proteins of SARS-CoV-2 employing an in silico molecular interaction-based approach.", [["extract", "ANATOMY", 8, 15], ["tissues", "ANATOMY", 161, 168], ["respiratory", "ANATOMY", 300, 311], ["extract of Clerodendrum trichotomum", "CHEMICAL", 8, 43], ["Respiratory syncytial virus", "DISEASE", 82, 109], ["respiratory disorders", "DISEASE", 300, 321], ["Clerodendrum trichotomum", "ORGANISM", 19, 43], ["Respiratory syncytial virus", "ORGANISM", 82, 109], ["RSV", "ORGANISM", 111, 114], ["normal tissues", "TISSUE", 154, 168], ["Clerodendrum spp", "ORGANISM", 234, 250], ["Mpro", "GENE_OR_GENE_PRODUCT", 557, 561], ["SARS-CoV-2", "ORGANISM", 583, 593], ["imperative spike, Mpro and RdRp proteins", "PROTEIN", 539, 579], ["Clerodendrum trichotomum", "SPECIES", 19, 43], ["Respiratory syncytial virus", "SPECIES", 82, 109], ["Clerodendrum trichotomum", "SPECIES", 19, 43], ["Respiratory syncytial virus", "SPECIES", 82, 109], ["RSV", "SPECIES", 111, 114], ["SARS-CoV", "SPECIES", 583, 591], ["A crude extract of Clerodendrum trichotomum", "PROBLEM", 0, 43], ["Respiratory syncytial virus", "PROBLEM", 82, 109], ["any cytotoxic effects", "PROBLEM", 124, 145], ["Clerodendrum spp", "PROBLEM", 234, 250], ["treating respiratory disorders", "PROBLEM", 291, 321], ["GC-MS analysis", "TEST", 429, 443], ["twelve Clerodendrum species", "PROBLEM", 447, 474], ["the imperative spike", "PROBLEM", 535, 555], ["Mpro", "TREATMENT", 557, 561], ["SARS", "PROBLEM", 583, 587], ["CoV", "TEST", 588, 591], ["Respiratory syncytial virus", "OBSERVATION", 82, 109], ["widespread", "OBSERVATION_MODIFIER", 264, 274], ["respiratory", "ANATOMY", 300, 311]]], ["Present work also involves a comprehensive investigation of the physicochemical features of the screened phytocompounds and their accordance with the general rules of drug-likeness viz., Lipinski\u2019s rule of five (RO5) and Veber\u2019s rule, with a purpose to assess their potential drug-likeness.Sample collection ::: Materials and methodsThe leaves of twelve species of Clerodendrum were collected during 2019 (Table S1, Supplementary material) from different localities in North Bengal (Garden of the medicinal plants of Department of Botany, University of North Bengal and Jalpaiguri) and roadside sites from Azra, Guwahati, Assam.", [["leaves", "ANATOMY", 337, 343], ["Clerodendrum", "ORGANISM", 365, 377], ["twelve species of Clerodendrum", "PROBLEM", 347, 377], ["Jalpaiguri", "TREATMENT", 570, 580], ["Azra", "TREATMENT", 606, 610]]], ["(Mumbai, India), Merck (Mumbai, India) and Sigma-Aldrich (USA).", [["Sigma-Aldrich", "ORGANISM", 43, 56]]], ["Milli-Q ultrapure water from the departmental facility was used in all the experiments.", [["Milli-Q ultrapure water", "TREATMENT", 0, 23]]], ["All the chemicals were of analytical grade.Preparation of plant extracts ::: Materials and methodsFresh and disease free leaves of selected plants were washed twice with double distilled water, shade dried at room temperature for 21 days and pulverized into fine powder by using a mechanical grinder.", [["extracts", "ANATOMY", 64, 72], ["extracts", "ORGANISM_SUBSTANCE", 64, 72], ["Materials", "TREATMENT", 77, 86], ["disease", "PROBLEM", 108, 115], ["selected plants", "TREATMENT", 131, 146], ["double distilled water", "TREATMENT", 170, 192], ["a mechanical grinder", "TREATMENT", 279, 299]]], ["Powdered leaves of selected plants (10 g each) were extracted in a Soxhlet apparatus using absolute methanol (the ratio of plant material to solvent was 1:10 m/v) for 6-7 h.", [["leaves", "ANATOMY", 9, 15], ["methanol", "CHEMICAL", 100, 108], ["methanol", "CHEMICAL", 100, 108], ["methanol", "SIMPLE_CHEMICAL", 100, 108], ["a Soxhlet apparatus", "TREATMENT", 65, 84], ["absolute methanol (the ratio of plant material to solvent", "TREATMENT", 91, 148], ["leaves", "OBSERVATION_MODIFIER", 9, 15]]], ["The extracts were then concentrated under reduced pressure and controlled temperature (40\u00b0-50 \u00b0C) using a rotary evaporator (Buchi Rotavapor R-3, Switzerland).", [["extracts", "ANATOMY", 4, 12], ["extracts", "ORGANISM_SUBSTANCE", 4, 12], ["The extracts", "TREATMENT", 0, 12], ["controlled temperature", "TEST", 63, 85], ["a rotary evaporator (Buchi Rotavapor R", "TREATMENT", 104, 142], ["pressure", "OBSERVATION_MODIFIER", 50, 58]]], ["The extracts were further lyophilized using an Eyela Freeze Dryer (FDU-506, USA) to obtain dry powder and stored at 4 \u00b0C until further use.Gas chromatography-mass spectrometry (GC-MS) analysis ::: Materials and methodsAll the lyophilized methanolic extracts were centrifuged at 12,000 rpm for 15 min.", [["extracts", "ANATOMY", 4, 12], ["extracts", "ANATOMY", 249, 257], ["FDU-506", "CHEMICAL", 67, 74], ["extracts", "ORGANISM_SUBSTANCE", 4, 12], ["methanolic extracts", "ORGANISM_SUBSTANCE", 238, 257], ["The extracts", "TREATMENT", 0, 12], ["an Eyela Freeze Dryer", "TREATMENT", 44, 65], ["dry powder", "TREATMENT", 91, 101], ["Gas chromatography", "TEST", 139, 157], ["mass spectrometry", "TEST", 158, 175], ["All the lyophilized methanolic extracts", "TREATMENT", 218, 257], ["lyophilized", "OBSERVATION_MODIFIER", 226, 237], ["methanolic extracts", "OBSERVATION", 238, 257]]], ["Clear supernatants thus, obtained were utilized for GC-MS analysis to identify the different phytochemical compounds.", [["supernatants", "ANATOMY", 6, 18], ["GC-MS analysis", "TEST", 52, 66], ["phytochemical compounds", "OBSERVATION", 93, 116]]], ["Thermo Scientific make \u2018Trace 1300\u2019 GC, attached to a TG-5MS column (30 m \u00d7 0.25 mm \u00d7 0.25 \u03bcm) and equipped with ISQ-QD (Thermo Scientific) single quadrupole mass analyzer conditioned at ion trap 230 \u00b0C, transfer line 290 \u00b0C, electron energy of 70 eV (vacuum pressure- 2.21e-0.5 Torr) was employed for the present study (Kar et al., 2016).", [["GC", "TEST", 36, 38], ["a TG-5MS column", "TREATMENT", 52, 67], ["electron energy", "TEST", 226, 241], ["vacuum pressure", "TEST", 252, 267]]], ["One microlitre of the sample was injected through a Thermo Scientific AI-1310 auto-sampler in splitless mode (split flow 50 ml/min) with a splitless time of 0.80 min.", [["sample", "ANATOMY", 22, 28], ["AI-1310", "CHEMICAL", 70, 77], ["auto-sampler in splitless mode", "TREATMENT", 78, 108]]], ["Helium was selected as the carrier gas with a constant flow of 1 ml/min.Gas chromatography-mass spectrometry (GC-MS) analysis ::: Materials and methodsAll samples were run thrice to minimize the error and the results were plotted only with the compounds identified in all three runs.", [["samples", "ANATOMY", 155, 162], ["Helium", "CHEMICAL", 0, 6], ["Helium", "CHEMICAL", 0, 6], ["Helium", "TREATMENT", 0, 6], ["the carrier gas", "TEST", 23, 38], ["a constant flow", "TREATMENT", 44, 59], ["Gas chromatography", "TEST", 72, 90], ["mass spectrometry", "TEST", 91, 108], ["All samples", "TEST", 151, 162], ["the error", "TEST", 191, 200]]], ["The essential compounds were identified by their retention times and mass fragmentation patterns using the reference of parent compound using MS interpreter Version 2.0 and also by matching with the reference database of National Institute of Standards and Technology (NIST) with a MS library version 2011.", [["mass fragmentation patterns", "PROBLEM", 69, 96], ["essential", "OBSERVATION_MODIFIER", 4, 13], ["compounds", "OBSERVATION", 14, 23]]], ["No external standards were used in this study.Retrieval and refinement of protein and ligand structures ::: Materials and methodsThe most prominent and active compounds present in the selected species of Clerodendrum (detected through GC-MS analysis) were subjected to robust molecular docking analysis against the imperative SARS-CoV-2 proteins that currently serve as promising targets for effective drug development namely, the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, SARS-CoV-2 main protease enzyme Mpro and SARS-CoV-2 RdRp (Tai et al., 2020).", [["Clerodendrum", "CHEMICAL", 204, 216], ["Clerodendrum", "SIMPLE_CHEMICAL", 204, 216], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 468, 478], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 494, 504], ["Mpro", "GENE_OR_GENE_PRODUCT", 526, 530], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 535, 545], ["SARS-CoV-2 proteins", "PROTEIN", 326, 345], ["receptor-binding domain", "PROTEIN", 431, 454], ["RBD", "PROTEIN", 456, 459], ["SARS-CoV-2 spike protein", "PROTEIN", 468, 492], ["SARS-CoV-2 main protease enzyme", "PROTEIN", 494, 525], ["Mpro", "PROTEIN", 526, 530], ["SARS-CoV-2 RdRp", "PROTEIN", 535, 550], ["external standards", "TREATMENT", 3, 21], ["this study", "TEST", 35, 45], ["Retrieval", "TREATMENT", 46, 55], ["GC-MS analysis", "TEST", 235, 249], ["the imperative SARS", "PROBLEM", 311, 330], ["CoV-2 proteins", "TREATMENT", 331, 345], ["the SARS", "TEST", 464, 472], ["CoV", "TEST", 473, 476], ["spike protein", "TEST", 479, 492], ["SARS", "TEST", 494, 498], ["CoV", "TEST", 499, 502], ["protease enzyme", "TEST", 510, 525], ["SARS", "TEST", 535, 539], ["CoV", "TEST", 540, 543], ["external standards", "OBSERVATION", 3, 21], ["most prominent", "OBSERVATION_MODIFIER", 133, 147], ["active", "OBSERVATION_MODIFIER", 152, 158], ["compounds", "OBSERVATION", 159, 168]]], ["The high-resolution X-ray diffraction crystal structures of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein (PDB ID: 6LZG Chain B; 2.50 \u00c5 resolution) (Wang et al., 2020), SARS-CoV-2 main protease enzyme Mpro (PDB ID: 6LU7 Chain A; 2.16 \u00c5 resolution) (Jin et al., 2020) and SARS-CoV-2 RdRp (PDB ID: 7BV2 Chain A; 2.50 \u00c5 resolution) were retrieved from PDB (Yin et al., 2020).", [["receptor-binding domain", "PROTEIN", 64, 87], ["RBD", "PROTEIN", 89, 92], ["SARS-CoV-2 spike protein", "PROTEIN", 101, 125], ["PDB ID", "PROTEIN", 127, 133], ["6LZG Chain B", "PROTEIN", 135, 147], ["SARS-CoV-2 main protease enzyme", "PROTEIN", 189, 220], ["Mpro", "PROTEIN", 221, 225], ["RdRp", "PROTEIN", 302, 306], ["the SARS", "TEST", 97, 105], ["CoV", "TEST", 106, 109], ["spike protein", "TEST", 112, 125], ["SARS", "TEST", 189, 193], ["CoV", "TEST", 194, 197], ["SARS", "TEST", 291, 295], ["CoV", "TEST", 296, 299], ["high", "OBSERVATION_MODIFIER", 4, 8], ["PDB", "ANATOMY", 369, 372]]], ["The inhibitor and water molecules were removed from the PDB files prior to analysis.", [["The inhibitor and water molecules", "TREATMENT", 0, 33], ["analysis", "TEST", 75, 83], ["PDB", "ANATOMY", 56, 59]]], ["Polar hydrogen atoms and Kollman charges were added to the corresponding PDB files using AutoDock tools.", [["hydrogen atoms", "CHEMICAL", 6, 20], ["hydrogen", "CHEMICAL", 6, 14], ["Polar hydrogen atoms", "SIMPLE_CHEMICAL", 0, 20], ["Kollman", "SIMPLE_CHEMICAL", 25, 32], ["Polar hydrogen atoms", "TREATMENT", 0, 20], ["Kollman charges", "TREATMENT", 25, 40], ["AutoDock tools", "TEST", 89, 103], ["hydrogen atoms", "OBSERVATION", 6, 20], ["Kollman charges", "OBSERVATION", 25, 40]]], ["The structures of the concerned phytocompounds were retrieved from NCBI PubChem (https://pubchem.ncbi.nlm.nih.gov/) and respective three-dimensional structures were generated through the Open Babel software (O\u2019Boyle et al., 2011).", [["phytocompounds", "SIMPLE_CHEMICAL", 32, 46], ["NCBI PubChem", "TEST", 67, 79]]], ["Gromos 96 force field was applied for the process of energy minimization.", [["energy minimization", "TREATMENT", 53, 72], ["energy minimization", "OBSERVATION", 53, 72]]], ["Gasteiger charges were added to the corresponding ligand structures using AutoDock tools.Molecular docking ::: Materials and methodsMolecular docking was achieved using the AutoDock Vina software (Naidoo et al., 2020; Trott & Olson, 2010).", [["Gasteiger", "SIMPLE_CHEMICAL", 0, 9], ["Gasteiger charges", "TREATMENT", 0, 17], ["AutoDock tools", "TEST", 74, 88]]], ["Thorough information about the active site residues of the RBD of SARS-CoV-2 spike, SARS-CoV-2 Mpro and SARS-CoV-2 RdRp proteins was obtained from recent reports on their structure and interaction/inhibition binding pockets (Andersen et al., 2020; Jin et al., 2020; Wang et al., 2020; Yin et al., 2020).", [["SARS", "DISEASE", 66, 70], ["SARS-CoV-2 Mpro", "ORGANISM", 84, 99], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["RBD", "PROTEIN", 59, 62], ["SARS-CoV-2 spike, SARS-CoV-2 Mpro and SARS-CoV-2 RdRp proteins", "PROTEIN", 66, 128], ["the active site residues", "PROBLEM", 27, 51], ["the RBD of SARS", "PROBLEM", 55, 70], ["CoV", "TEST", 71, 74], ["spike", "PROBLEM", 77, 82], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["SARS", "PROBLEM", 104, 108], ["CoV", "TEST", 109, 112], ["RdRp proteins", "TEST", 115, 128]]], ["The ligands were docked at the active binding pockets of the concerned proteins employing a grid-based docking method opting a rigid protein receptor and flexible ligand docking protocol (Naidoo et al., 2020).", [["rigid protein receptor", "PROTEIN", 127, 149], ["a grid", "TREATMENT", 90, 96], ["a rigid protein receptor", "TREATMENT", 125, 149], ["flexible ligand docking protocol", "TREATMENT", 154, 186], ["active", "OBSERVATION_MODIFIER", 31, 37], ["binding pockets", "OBSERVATION", 38, 53]]], ["Grid boxes of coordinates 30, 30 and 30 in x, y and z dimensions involving the active site residues were generated to carry out molecular docking at the binding pockets of the viral proteins (Naidoo et al., 2020).", [["Grid boxes", "DNA", 0, 10], ["viral proteins", "PROTEIN", 176, 190], ["the active site residues", "PROBLEM", 75, 99], ["active", "OBSERVATION_MODIFIER", 79, 85], ["viral proteins", "OBSERVATION", 176, 190]]], ["The DINC server was used to further validate the results of AutoDock Vina (Antunes et al., 2017).", [["DINC server", "DNA", 4, 15]]], ["Ligand-receptor complexes with the lowest binding scores and RMSD < 2.0 \u00c5 (Naidoo et al., 2020) were used for robust interaction profiling employing the PyMol software (version 1.7.4) and the Protein-Ligand Interaction Profiler (PLIP) web-server (Salentin et al., 2015).", [["Ligand-receptor complexes", "PROTEIN", 0, 25], ["RMSD", "TEST", 61, 65]]], ["The compounds displaying binding energy scores \u2264 \u22127.0 kcal/mol were selected for the next phases of analysis (Naidoo et al., 2020).Assessment of physicochemical features and potential toxicity of the phytocompounds ::: Materials and methodsPhysicochemical features of the selected phytocompounds were thoroughly estimated using the SwissADME server and the results were validated with the pkCSM server (Daina et al., 2017; Pires et al., 2015).", [["toxicity", "DISEASE", 184, 192], ["binding energy scores", "TEST", 25, 46]]], ["Pan-Assay Interference Structures (PAINS) medicinal chemistry analysis was performed employing the SwissADME and FAF-Drugs4 (Lagorce et al., 2017) servers.", [["Interference Structures (PAINS", "PROBLEM", 10, 40], ["medicinal chemistry analysis", "TEST", 42, 70], ["FAF", "TEST", 113, 116]]], ["Toxicity parameters like mutagenicity (AMES mutagenesis) and cytotoxicity of the phytochemicals were assessed using the ProTox-II web-server (Banerjee et al., 2018) and validated with the vNN-ADMET server (Schyman et al., 2017).Prime MM-GBSA (molecular mechanics-generalized born surface area) calculation ::: Materials and methodsMolecular mechanics-generalized Born surface area (MM-GBSA) was used to estimate the free energies of binding (\u0394Gbind) of the selected protein-ligand complexes employing the default parameters of the Prime MM-GBSA modules (Vijayakumar et al., 2014) implemented in the Schr\u00f6dinger software.", [["surface", "ANATOMY", 280, 287], ["Toxicity", "DISEASE", 0, 8], ["protein-ligand complexes", "PROTEIN", 466, 490], ["Toxicity parameters", "TEST", 0, 19], ["AMES mutagenesis", "TEST", 39, 55], ["cytotoxicity of the phytochemicals", "PROBLEM", 61, 95], ["GBSA (molecular mechanics", "PROBLEM", 237, 262], ["methodsMolecular mechanics", "TEST", 324, 350], ["generalized Born surface area", "PROBLEM", 351, 380], ["GBSA modules", "PROBLEM", 540, 552], ["generalized", "OBSERVATION_MODIFIER", 351, 362]]], ["Prime MMGBSA is an approach that uses the optimized potential for liquid simulations (OPLS) force field in combination with molecular mechanics energies (EMM), surface generalized Born (SGB) solvation model for polar solvation (GSGB) and a non-polar solvation term (GNP) for the calculation purpose (Al-Khafaji et al., 2020; Mittal et al., 2020; Sarma et al., 2020).", [["liquid simulations (OPLS) force field", "TREATMENT", 66, 103], ["surface generalized Born (SGB) solvation model", "TREATMENT", 160, 206], ["polar solvation", "PROBLEM", 211, 226], ["a non-polar solvation term (GNP)", "TREATMENT", 238, 270], ["the calculation purpose", "TEST", 275, 298]]], ["The total free energy of binding of each concerned protein-ligand complex was calculated as:\u0394Gbind = \u0394Gcomplex \u2212 (\u0394Gprotein + \u0394Gligand)", [["protein-ligand complex", "PROTEIN", 51, 73], ["\u0394Gcomplex", "PROTEIN", 101, 110], ["\u0394Gprotein", "PROTEIN", 114, 123], ["\u0394Gligand", "PROTEIN", 126, 134], ["\u0394Gbind", "TEST", 92, 98], ["\u0394Gcomplex", "TEST", 101, 110]]]], "PMC7300878": [["The coronavirus disease 2019 (COVID\u201019) has become a serious pandemic.", [["coronavirus disease", "DISEASE", 4, 23], ["COVID\u201019", "CHEMICAL", 30, 38], ["The coronavirus disease", "PROBLEM", 0, 23], ["COVID", "TEST", 30, 35], ["a serious pandemic", "PROBLEM", 51, 69], ["coronavirus disease", "OBSERVATION", 4, 23], ["serious", "OBSERVATION_MODIFIER", 53, 60], ["pandemic", "OBSERVATION", 61, 69]]], ["According to a report from Wuhan, China, 40 (29%) health professionals were among the first 138 patients to be consecutively hospitalized.1The reported symptoms of COVID\u201019 included cough (67.8%), fever (43.8%), increased sputum production (33.7%), sore throat (13.9%), and nasal congestion (4.8%).2Some patients had only hyposmia and dysgeusia as their initial symptoms.", [["sputum", "ANATOMY", 222, 228], ["nasal", "ANATOMY", 274, 279], ["COVID", "DISEASE", 164, 169], ["cough", "DISEASE", 182, 187], ["fever", "DISEASE", 197, 202], ["sore throat", "DISEASE", 249, 260], ["nasal congestion", "DISEASE", 274, 290], ["hyposmia", "DISEASE", 322, 330], ["dysgeusia", "DISEASE", 335, 344], ["patients", "ORGANISM", 96, 104], ["nasal", "ORGAN", 274, 279], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 304, 312], ["COVID", "TEST", 164, 169], ["cough", "PROBLEM", 182, 187], ["fever", "PROBLEM", 197, 202], ["increased sputum production", "PROBLEM", 212, 239], ["sore throat", "PROBLEM", 249, 260], ["nasal congestion", "PROBLEM", 274, 290], ["hyposmia", "PROBLEM", 322, 330], ["dysgeusia", "PROBLEM", 335, 344], ["their initial symptoms", "PROBLEM", 348, 370], ["increased", "OBSERVATION_MODIFIER", 212, 221], ["sputum", "OBSERVATION", 222, 228], ["sore throat", "ANATOMY", 249, 260], ["nasal", "ANATOMY", 274, 279], ["congestion", "OBSERVATION", 280, 290], ["hyposmia", "OBSERVATION", 322, 330]]], ["In particular, health care workers, such as otolaryngologists, who work on upper aerodigestive tract diseases, have the highest risk of contracting COVID\u201019.", [["upper aerodigestive tract", "ANATOMY", 75, 100], ["upper aerodigestive tract diseases", "DISEASE", 75, 109], ["COVID", "DISEASE", 148, 153], ["upper aerodigestive tract", "ORGANISM_SUBDIVISION", 75, 100], ["upper aerodigestive tract diseases", "PROBLEM", 75, 109], ["upper", "ANATOMY_MODIFIER", 75, 80], ["aerodigestive tract", "ANATOMY", 81, 100]]], ["Specifically, the first physicians to die from COVID\u201019 in Wuhan and from severe acute respiratory syndrome (SARS) in Hong Kong pandemic were otolaryngologists.3", [["acute respiratory syndrome", "DISEASE", 81, 107], ["SARS", "DISEASE", 109, 113], ["severe acute respiratory syndrome", "PROBLEM", 74, 107], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["respiratory syndrome", "OBSERVATION", 87, 107]]]], "3250280b986d85921e58d17218a11f19293984db": [["IntroductionInfectious diseases are still among the major causes of morbidity and mortality worldwide.", [["IntroductionInfectious diseases", "DISEASE", 0, 31], ["IntroductionInfectious diseases", "PROBLEM", 0, 31], ["morbidity", "PROBLEM", 68, 77], ["morbidity", "OBSERVATION", 68, 77]]], ["Current estimates are that each year -mainly in developing countries -500 million people become ill and more than 1 million die from malaria; 2 million of the 33 million people living with human immunodeficiency virus (HIV) infection die of acquired immune deficiency syndrome (AIDS); and 1.7 million of the 14 million with active tuberculosis (TB) die from it (WHO 2000 (WHO , 2007 (WHO , 2009 ).", [["malaria", "DISEASE", 133, 140], ["human immunodeficiency virus (HIV) infection", "DISEASE", 189, 233], ["acquired immune deficiency syndrome", "DISEASE", 241, 276], ["AIDS", "DISEASE", 278, 282], ["tuberculosis", "DISEASE", 331, 343], ["TB", "DISEASE", 345, 347], ["people", "ORGANISM", 82, 88], ["people", "ORGANISM", 170, 176], ["human immunodeficiency virus", "ORGANISM", 189, 217], ["people", "SPECIES", 82, 88], ["people", "SPECIES", 170, 176], ["human immunodeficiency virus (HIV", "SPECIES", 189, 222], ["human immunodeficiency virus", "SPECIES", 189, 217], ["HIV", "SPECIES", 219, 222], ["malaria", "PROBLEM", 133, 140], ["human immunodeficiency virus", "PROBLEM", 189, 217], ["HIV) infection", "PROBLEM", 219, 233], ["acquired immune deficiency syndrome", "PROBLEM", 241, 276], ["active tuberculosis", "PROBLEM", 324, 343], ["malaria", "OBSERVATION", 133, 140], ["immune deficiency", "OBSERVATION", 250, 267], ["active", "OBSERVATION_MODIFIER", 324, 330], ["tuberculosis", "OBSERVATION", 331, 343]]], ["Millions of children, particularly, die each year from respiratory and diarrheal diseases, the rates of which are largely determined by political, socioeconomic and environmental factors.", [["respiratory", "ANATOMY", 55, 66], ["respiratory and diarrheal diseases", "DISEASE", 55, 89], ["children", "ORGANISM", 12, 20], ["children", "SPECIES", 12, 20], ["respiratory and diarrheal diseases", "PROBLEM", 55, 89], ["respiratory", "ANATOMY", 55, 66], ["diarrheal diseases", "OBSERVATION", 71, 89]]], ["Although there has been a progress in the control of vaccine preventable diseases in developing countries, vaccines for malaria, TB and HIV/ AIDS remain elusive and increasing antimicrobial resistance makes treatment difficult, even when it is available.IntroductionIn industrialized countries, food-borne, respiratory and healthcare associated infections (HAIs) cause significant excess morbidity, mortality and healthcare costs.", [["malaria", "DISEASE", 120, 127], ["TB", "DISEASE", 129, 131], ["HIV/ AIDS", "DISEASE", 136, 145], ["respiratory and healthcare associated infections", "DISEASE", 307, 355], ["HAIs", "DISEASE", 357, 361], ["HIV", "SPECIES", 136, 139], ["HIV", "SPECIES", 136, 139], ["vaccine preventable diseases", "PROBLEM", 53, 81], ["vaccines", "TREATMENT", 107, 115], ["malaria", "PROBLEM", 120, 127], ["TB", "PROBLEM", 129, 131], ["HIV/ AIDS", "PROBLEM", 136, 145], ["increasing antimicrobial resistance", "TREATMENT", 165, 200], ["treatment", "TREATMENT", 207, 216], ["respiratory and healthcare associated infections", "PROBLEM", 307, 355], ["significant excess morbidity", "PROBLEM", 369, 397], ["antimicrobial resistance", "OBSERVATION", 176, 200]]], ["In the USA each year, an estimated 1.7 million HAIs cause ~100,000 deaths; 76 million food-borne diseases lead to 5,000 deaths.", [["HAIs", "DISEASE", 47, 51], ["deaths", "DISEASE", 67, 73], ["food-borne diseases", "DISEASE", 86, 105], ["deaths", "DISEASE", 120, 126], ["borne diseases", "PROBLEM", 91, 105]]], ["Many of these infections and deaths could be prevented if evidence-based control measures were properly implemented (Mead et al. 1999; Klevens et al. 2007) .", [["infections", "DISEASE", 14, 24], ["deaths", "DISEASE", 29, 35], ["these infections", "PROBLEM", 8, 24], ["infections", "OBSERVATION", 14, 24]]], ["Clearly \"smarter\" strategies are needed to control communicable diseases.IntroductionModern technology has enabled large scale screening for human genomic markers of susceptibility or resistance to infection and comparative studies of microbial genomes and is providing new knowledge about relationships between humans and disease-causing microbes.", [["infection", "DISEASE", 198, 207], ["human", "ORGANISM", 141, 146], ["humans", "ORGANISM", 312, 318], ["human", "SPECIES", 141, 146], ["humans", "SPECIES", 312, 318], ["human", "SPECIES", 141, 146], ["humans", "SPECIES", 312, 318], ["communicable diseases", "PROBLEM", 51, 72], ["large scale screening", "TEST", 115, 136], ["susceptibility", "PROBLEM", 166, 180], ["resistance to infection", "PROBLEM", 184, 207], ["comparative studies", "TEST", 212, 231], ["disease", "PROBLEM", 323, 330], ["microbes", "PROBLEM", 339, 347], ["infection", "OBSERVATION", 198, 207], ["disease", "OBSERVATION", 323, 330]]], ["This knowledge will reveal new targets for vaccines, antimicrobial agents, diagnostics and disease surveillance, which can be exploited to improve disease prevention, control and management.IntroductionBecause infectious (or communicable) diseases affect communities -rather than merely independent individuals -new strategies to control and prevent infection involve complex relationships within and between populations.", [["infectious (or communicable) diseases", "DISEASE", 210, 247], ["infection", "DISEASE", 350, 359], ["vaccines", "TREATMENT", 43, 51], ["antimicrobial agents", "TREATMENT", 53, 73], ["disease surveillance", "TEST", 91, 111], ["disease prevention", "TREATMENT", 147, 165], ["management", "TREATMENT", 179, 189], ["diseases affect communities", "PROBLEM", 239, 266], ["infection", "PROBLEM", 350, 359], ["infection", "OBSERVATION", 350, 359]]], ["The disproportionate burden of communicable diseases among the most disadvantaged populations provides a challenge for new technology to improve disease prevention and control where conventional strategies have failed.Infectious Diseases EthicsThe emergence of the discipline of human bioethics in the 1950s and 1960s coincided with a prevalent (but, with hindsight, unwarranted and dangerous) belief that the problems of infectious diseases had been solved by sanitation, immunization and antibiotic therapy.", [["communicable diseases", "DISEASE", 31, 52], ["Infectious Diseases", "DISEASE", 218, 237], ["infectious diseases", "DISEASE", 422, 441], ["human", "ORGANISM", 279, 284], ["human", "SPECIES", 279, 284], ["human", "SPECIES", 279, 284], ["communicable diseases", "PROBLEM", 31, 52], ["new technology", "TREATMENT", 119, 133], ["disease prevention", "TREATMENT", 145, 163], ["conventional strategies", "TREATMENT", 182, 205], ["infectious diseases", "PROBLEM", 422, 441], ["immunization", "TREATMENT", 473, 485], ["antibiotic therapy", "TREATMENT", 490, 508], ["disproportionate", "OBSERVATION_MODIFIER", 4, 20], ["burden", "OBSERVATION_MODIFIER", 21, 27], ["communicable diseases", "OBSERVATION", 31, 52]]], ["The much-quoted pronouncement that \"it is time to close the book on infectious disease\" is usually attributed to former US Surgeon General William Stewart.", [["infectious disease", "DISEASE", 68, 86]]], ["Although there appears to be no evidence that he ever actually said this, \"the sentiment was certainly widely shared\" at the time (Sassetti and Rubin 2007) .", [["appears to be no evidence", "UNCERTAINTY", 15, 40]]], ["This widespread complacency remained largely unchallenged throughout most of the twentieth century.", [["widespread", "OBSERVATION_MODIFIER", 5, 15], ["complacency", "OBSERVATION", 16, 27], ["largely", "OBSERVATION_MODIFIER", 37, 44], ["unchallenged", "OBSERVATION", 45, 57]]], ["It was dispelled by the unfolding of HIV pandemic and the plethora of other emerging and re-emerging infectious diseases that followed (or in some cases preceded) it, but it had already contributed to the gross neglect of infectious diseases by bioethicists (Smith et al. 2004; Francis et al. 2005; Selgelid and Selgelid 2005) .", [["HIV pandemic", "DISEASE", 37, 49], ["infectious diseases", "DISEASE", 101, 120], ["infectious diseases", "DISEASE", 222, 241], ["HIV", "SPECIES", 37, 40], ["HIV pandemic", "PROBLEM", 37, 49], ["re-emerging infectious diseases", "PROBLEM", 89, 120], ["the gross neglect of infectious diseases", "PROBLEM", 201, 241], ["infectious", "OBSERVATION", 101, 111], ["gross", "OBSERVATION_MODIFIER", 205, 210], ["neglect", "OBSERVATION", 211, 218], ["infectious", "OBSERVATION", 222, 232]]], ["AIDS was a rare exception, but many of the ethical issues it raised -confidentiality, discrimination, patients' rights and sexual freedom -were not specifically related to its status as an infectious disease.Infectious Diseases EthicsBelatedly, this neglect is now being addressed; infectious diseases have at last come to the attention of bioethicists.", [["AIDS", "DISEASE", 0, 4], ["infectious disease", "DISEASE", 189, 207], ["Infectious Diseases EthicsBelatedly", "DISEASE", 208, 243], ["infectious diseases", "DISEASE", 282, 301], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["the ethical issues", "PROBLEM", 39, 57], ["an infectious disease", "PROBLEM", 186, 207], ["this neglect", "PROBLEM", 245, 257], ["infectious", "OBSERVATION", 189, 199]]], ["During the twenty-first century, public health ethics has become a rapidly growing sub-discipline of bioethics, and much of the public health ethics literature has focused on infectious disease in particular.", [["infectious disease", "DISEASE", 175, 193], ["infectious disease", "PROBLEM", 175, 193], ["infectious", "OBSERVATION", 175, 185]]], ["In addition to AIDS, attention has especially focused on severe acquired respiratory syndrome (SARS), pandemic influenza planning and issues related to bioterrorism (Reid 2005; Thompson et al. 2006; Miller et al. 2007 ).", [["AIDS", "DISEASE", 15, 19], ["respiratory syndrome", "DISEASE", 73, 93], ["SARS", "DISEASE", 95, 99], ["influenza", "DISEASE", 111, 120], ["AIDS", "PROBLEM", 15, 19], ["severe acquired respiratory syndrome", "PROBLEM", 57, 93], ["pandemic influenza planning", "TREATMENT", 102, 129], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["respiratory syndrome", "OBSERVATION", 73, 93]]], ["There has also been debate about the ethics of issues such as: intellectual property rights, relating to antimicrobial agents and their implications for the access to essential treatment of infectious diseases (Gupta et al. 2005) and the relationship between marketing of antimicrobials and the emergence of antibiotic resistance (Selgelid 2007) .Infectious Diseases EthicsAlthough infectious diseases are no longer the most common cause of death worldwide, they are still major contributors to illness, loss of productivity and premature death in developing countries and among poor and disadvantaged people everywhere, despite the long history of successful prevention and control.", [["infectious diseases", "DISEASE", 190, 209], ["infectious diseases", "DISEASE", 382, 401], ["death", "DISEASE", 441, 446], ["illness", "DISEASE", 495, 502], ["premature death", "DISEASE", 529, 544], ["people", "ORGANISM", 602, 608], ["people", "SPECIES", 602, 608], ["antimicrobial agents", "TREATMENT", 105, 125], ["infectious diseases", "PROBLEM", 190, 209], ["antimicrobials", "TREATMENT", 272, 286], ["antibiotic resistance", "TREATMENT", 308, 329], ["illness", "PROBLEM", 495, 502], ["loss of productivity", "PROBLEM", 504, 524], ["premature death", "PROBLEM", 529, 544], ["infectious", "OBSERVATION", 190, 200], ["no longer", "UNCERTAINTY", 406, 415]]], ["Communicable diseases have implications far beyond their effects on individual sufferers and their immediate families.", [["Communicable diseases", "DISEASE", 0, 21], ["Communicable diseases", "PROBLEM", 0, 21]]], ["Because they can be rapidly fatal in previously healthy people and their spread is often unpredictable and indiscriminate, they can cause fear, panic, social disruption, political overreaction and victimization, out of proportion to the actual disease burden or risk (Smith et al. 2004) .", [["panic", "DISEASE", 144, 149], ["people", "ORGANISM", 56, 62], ["people", "SPECIES", 56, 62], ["panic", "PROBLEM", 144, 149], ["social disruption", "PROBLEM", 151, 168], ["political overreaction", "PROBLEM", 170, 192], ["victimization", "PROBLEM", 197, 210], ["the actual disease burden", "PROBLEM", 233, 258]]], ["The explosive, but relatively shortlived, spread and high mortality of SARS in 2003 led to international socioeconomic repercussions affecting tourism, trade and international relations and costing billions of dollars.", [["SARS", "DISEASE", 71, 75], ["SARS", "PROBLEM", 71, 75], ["explosive", "OBSERVATION_MODIFIER", 4, 13]]], ["Disproportionate responses are often exacerbated by the florid language used by media and politicians, with analogies to terrorism or war (\"flesh-eating\"; \"silent killer\"; \"superbug\"; \"plague\"; \"attack\"; \"struck down\").", [["flesh", "ORGANISM_SUBDIVISION", 140, 145], ["Disproportionate responses", "PROBLEM", 0, 26], ["the florid language", "PROBLEM", 52, 71]]], ["The fact that many communicable diseases are preventable or can be successfully treated can provoke recriminations against individuals or institutions, which are perceived to have failed.Infectious Diseases EthicsInfectious disease ethics occupies a position between the individualistic perspective of conventional bioethics and the traditionally more collective approach of public health and incorporates elements of both.", [["communicable diseases", "DISEASE", 19, 40], ["Diseases EthicsInfectious disease", "DISEASE", 198, 231], ["many communicable diseases", "PROBLEM", 14, 40], ["many", "OBSERVATION_MODIFIER", 14, 18], ["communicable", "OBSERVATION_MODIFIER", 19, 31], ["diseases", "OBSERVATION", 32, 40]]], ["The former emphasizes the right of individuals to make decisions about their health, based on their own interests or preferences (autonomy), limited only by the potential of those decisions to harm others (the harm principle).", [["right", "ANATOMY_MODIFIER", 26, 31]]], ["The latter is based on utilitarian principles, whereby decisions are determined by the best overall outcomes (in terms of aggregate and/ or average human well-being), even if some individuals may be disadvantaged as a result.", [["human", "ORGANISM", 148, 153], ["individuals", "ORGANISM", 180, 191], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153]]], ["Recently, Margaret Battin and colleagues have suggested a new approachthat ethical decision-making about infectious diseases should take place behind a Rawlsian \"veil of ignorance\", a concept developed as the basis for making fair decisions about distributive justice (Battin et al. 2009; Rawls 1971) .", [["infectious diseases", "DISEASE", 105, 124], ["infectious diseases", "PROBLEM", 105, 124]]], ["They propose that patients with infectious diseases -and indeed anyone -can be seen, actually or potentially, as both a victim and a vector of infection (Battin et al. 2009 ).", [["infectious diseases", "DISEASE", 32, 51], ["infection", "DISEASE", 143, 152], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["infectious diseases", "PROBLEM", 32, 51], ["infection", "PROBLEM", 143, 152], ["infection", "OBSERVATION", 143, 152]]], ["Behind the \"veil of ignorance\", the decision-maker does not know her actual status -victim and/or vector -but acknowledges that she could be, or could become, either.Infectious Diseases EthicsInfection affects communities, not just individuals; everyone is both part of a human social network and host to billions of micro-organisms which can spread from person to person.", [["Diseases EthicsInfection", "DISEASE", 177, 201], ["human", "ORGANISM", 272, 277], ["social network", "MULTI-TISSUE_STRUCTURE", 278, 292], ["human", "SPECIES", 272, 277], ["person", "SPECIES", 355, 361], ["person", "SPECIES", 365, 371], ["human", "SPECIES", 272, 277], ["micro-organisms", "PROBLEM", 317, 332]]], ["Most of these microbes are benign or even essential to health, but a minority are potentially harmful to people carrying them or to others with whom they interact.", [["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111], ["microbes", "OBSERVATION", 14, 22], ["benign", "OBSERVATION", 27, 33]]], ["Levels of susceptibility to infection vary between individuals, as determined by, inter alia, where and how they live, their age, underlying health, nutritional status, life-style choices and genetic makeup and the measures they take to protect themselves, such as immunization.", [["infection", "DISEASE", 28, 37], ["susceptibility to infection", "PROBLEM", 10, 37], ["life-style choices", "TREATMENT", 169, 187], ["genetic makeup", "TREATMENT", 192, 206], ["immunization", "TREATMENT", 265, 277], ["infection", "OBSERVATION", 28, 37]]], ["No one can be reliably protected from infections due to respiratory viruses, food-borne bacteria or pathogens spread by mosquitoes.", [["infections", "DISEASE", 38, 48], ["respiratory viruses", "DISEASE", 56, 75], ["infections", "PROBLEM", 38, 48], ["respiratory viruses", "PROBLEM", 56, 75], ["borne bacteria", "PROBLEM", 82, 96], ["pathogens", "PROBLEM", 100, 109], ["infections", "OBSERVATION", 38, 48], ["respiratory", "ANATOMY", 56, 67], ["viruses", "OBSERVATION", 68, 75]]], ["Like the patient with fever and cough or diarrhea, each of us is a potential victim and a potential vector.", [["fever", "DISEASE", 22, 27], ["cough", "DISEASE", 32, 37], ["diarrhea", "DISEASE", 41, 49], ["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["fever", "PROBLEM", 22, 27], ["cough", "PROBLEM", 32, 37], ["diarrhea", "PROBLEM", 41, 49], ["fever", "OBSERVATION", 22, 27], ["cough", "OBSERVATION", 32, 37], ["diarrhea", "OBSERVATION", 41, 49]]], ["Ethical infectious disease policy will respect the interests of both patients with infections -who want care and protection, without discriminationand of the rest of the community who seek protection from infection.", [["infectious disease", "DISEASE", 8, 26], ["infections", "DISEASE", 83, 93], ["infection", "DISEASE", 205, 214], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["infections", "PROBLEM", 83, 93], ["protection", "TREATMENT", 113, 123], ["infection", "PROBLEM", 205, 214], ["infectious", "OBSERVATION", 8, 18], ["infection", "OBSERVATION", 205, 214]]], ["The latter include not only apparently healthy individuals, some of whom are unwitting carriers of potentially dangerous pathogens, but also people at increased risk of infection, because of underlying disease or genetic predisposition.Infectious Diseases EthicsIn this chapter we explore how recent advances in microbial and/or human genomics and modern information technology can improve our understanding of communicable diseases and provide better strategies to manage, prevent and control them.", [["infection", "DISEASE", 169, 178], ["people", "ORGANISM", 141, 147], ["human", "ORGANISM", 329, 334], ["people", "SPECIES", 141, 147], ["human", "SPECIES", 329, 334], ["human", "SPECIES", 329, 334], ["dangerous pathogens", "PROBLEM", 111, 130], ["infection", "PROBLEM", 169, 178], ["underlying disease", "PROBLEM", 191, 209], ["genetic predisposition", "PROBLEM", 213, 235], ["communicable diseases", "PROBLEM", 411, 432], ["infection", "OBSERVATION", 169, 178], ["disease", "OBSERVATION", 202, 209]]], ["Some ethical issues, such as those relating to research in developing countries or human genomics, are neither new nor specific to communicable diseases and have been debated at length.", [["communicable diseases", "DISEASE", 131, 152], ["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["Some ethical issues", "PROBLEM", 0, 19]]], ["Others, which arise from application of new microbial diagnostics and pathogen profiling, enhanced communicable disease surveillance and informatics, have been explored less extensively, if at all.", [["new microbial diagnostics", "TEST", 40, 65], ["pathogen profiling", "TEST", 70, 88], ["enhanced communicable disease surveillance", "PROBLEM", 90, 132]]], ["We examine issues such as informed consent, privacy and confidentiality, autonomy, resource allocation, quality control, compliance with evidence-based practice and disease surveillance, prevention and control, in these contexts, from behind a \"veil of ignorance,\" by assuming that anyone could be victim or vector of infection.Genetics and Disease SusceptibilityIt is well established that susceptibility to infection varies between individuals and that a component of this variation is inherited (Cooke and Hill 2001) .", [["infection", "DISEASE", 318, 327], ["infection", "DISEASE", 409, 418], ["disease surveillance", "TEST", 165, 185], ["infection", "PROBLEM", 318, 327], ["susceptibility to infection", "PROBLEM", 391, 418], ["infection", "OBSERVATION", 318, 327], ["infection", "OBSERVATION", 409, 418], ["component", "OBSERVATION_MODIFIER", 457, 466]]], ["For example, malaria parasites are known to have contributed, over millennia, to the evolution of the human genome, by selecting gene mutations, such as those causing sickle cell disease and glucose-6-phosphate deficiency (G6PD) that enhance survival of heterozygous carriers living in malaria-endemic areas (Daily et al. 2008) .", [["sickle cell", "ANATOMY", 167, 178], ["malaria parasites", "DISEASE", 13, 30], ["sickle cell disease", "DISEASE", 167, 186], ["glucose-6-phosphate", "CHEMICAL", 191, 210], ["malaria-endemic areas", "DISEASE", 286, 307], ["glucose-6-phosphate", "CHEMICAL", 191, 210], ["human", "ORGANISM", 102, 107], ["sickle cell", "CELL", 167, 178], ["glucose-6-phosphate", "GENE_OR_GENE_PRODUCT", 191, 210], ["G6PD", "GENE_OR_GENE_PRODUCT", 223, 227], ["human genome", "DNA", 102, 114], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["malaria parasites", "PROBLEM", 13, 30], ["the human genome", "PROBLEM", 98, 114], ["selecting gene mutations", "PROBLEM", 119, 143], ["sickle cell disease", "PROBLEM", 167, 186], ["glucose", "TEST", 191, 198], ["phosphate deficiency (G6PD)", "PROBLEM", 201, 228], ["heterozygous carriers", "PROBLEM", 254, 275], ["malaria", "OBSERVATION", 13, 20], ["human genome", "OBSERVATION", 102, 114], ["sickle cell disease", "OBSERVATION", 167, 186], ["endemic", "OBSERVATION_MODIFIER", 294, 301]]], ["Differences in susceptibility to malaria and TB have been recognized between different but closely related ethnic groups (Modiano et al. 1996) ; and large epidemiological, twin and genetic studies have provided insights into the hereditable proportions of susceptibility or resistance to a number of infectious diseases.", [["malaria", "DISEASE", 33, 40], ["TB", "DISEASE", 45, 47], ["infectious diseases", "DISEASE", 300, 319], ["malaria", "PROBLEM", 33, 40], ["TB", "PROBLEM", 45, 47], ["genetic studies", "TEST", 181, 196], ["infectious diseases", "PROBLEM", 300, 319], ["malaria", "OBSERVATION", 33, 40], ["TB", "OBSERVATION", 45, 47], ["large", "OBSERVATION_MODIFIER", 149, 154], ["infectious", "OBSERVATION", 300, 310]]], ["There are well documented associations between certain human leukocyte antigen (HLA) genes and susceptibility to severe malaria, rapid progression of HIV infection to AIDS, development of overt TB disease or leprosy and hepatitis B carriage (Cooke and Hill 2001) .", [["malaria", "DISEASE", 120, 127], ["HIV infection", "DISEASE", 150, 163], ["AIDS", "DISEASE", 167, 171], ["TB disease", "DISEASE", 194, 204], ["leprosy", "DISEASE", 208, 215], ["hepatitis B", "DISEASE", 220, 231], ["human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 55, 78], ["HLA", "GENE_OR_GENE_PRODUCT", 80, 83], ["HIV", "ORGANISM", 150, 153], ["hepatitis B", "ORGANISM", 220, 231], ["human leukocyte antigen (HLA) genes", "DNA", 55, 90], ["human", "SPECIES", 55, 60], ["HIV", "SPECIES", 150, 153], ["human", "SPECIES", 55, 60], ["HIV", "SPECIES", 150, 153], ["certain human leukocyte antigen (HLA) genes", "PROBLEM", 47, 90], ["susceptibility to severe malaria", "PROBLEM", 95, 127], ["HIV infection", "PROBLEM", 150, 163], ["AIDS", "PROBLEM", 167, 171], ["overt TB disease", "PROBLEM", 188, 204], ["leprosy", "PROBLEM", 208, 215], ["well documented", "OBSERVATION_MODIFIER", 10, 25], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["malaria", "OBSERVATION", 120, 127], ["rapid", "OBSERVATION_MODIFIER", 129, 134], ["progression", "OBSERVATION_MODIFIER", 135, 146], ["HIV", "OBSERVATION_MODIFIER", 150, 153], ["infection", "OBSERVATION", 154, 163], ["overt", "OBSERVATION_MODIFIER", 188, 193], ["TB disease", "OBSERVATION", 194, 204], ["leprosy", "OBSERVATION", 208, 215]]], ["However, HLA genes account for only a small component of genetic susceptibility to infection, which (like many other types of disease) is apparently determined by interactions between many different genes, acquired characteristics (e.g., nutrition, previous exposure) and environmental factors.Genetics and Disease SusceptibilitySequencing of the human genome and advances in metagenomics have provided opportunities to search more broadly for genetic traits that contribute to infectious disease susceptibility and host-pathogen interactions that can be targeted by new vaccines or drugs.", [["infection", "DISEASE", 83, 92], ["HLA", "GENE_OR_GENE_PRODUCT", 9, 12], ["human", "ORGANISM", 347, 352], ["HLA genes", "DNA", 9, 18], ["human genome", "DNA", 347, 359], ["human", "SPECIES", 347, 352], ["human", "SPECIES", 347, 352], ["genetic susceptibility to infection", "PROBLEM", 57, 92], ["disease", "PROBLEM", 126, 133], ["the human genome", "TREATMENT", 343, 359], ["genetic traits", "PROBLEM", 444, 458], ["infectious disease susceptibility", "PROBLEM", 478, 511], ["host-pathogen interactions", "PROBLEM", 516, 542], ["drugs", "TREATMENT", 583, 588], ["small", "OBSERVATION_MODIFIER", 38, 43], ["component", "OBSERVATION_MODIFIER", 44, 53], ["genetic susceptibility", "OBSERVATION", 57, 79], ["infection", "OBSERVATION", 83, 92], ["disease", "OBSERVATION", 126, 133], ["human genome", "OBSERVATION", 347, 359], ["infectious", "OBSERVATION_MODIFIER", 478, 488]]], ["Genome-wide mapping and analysis of hundreds of polymorphic markers in family groups and matched case/control studies of diseases of interest are currently underway.", [["wide mapping", "TEST", 7, 19], ["diseases", "PROBLEM", 121, 129]]], ["The aim is to identify genomic regions linked to communicable disease risk.", [["communicable disease", "DISEASE", 49, 69], ["genomic regions", "DNA", 23, 38], ["communicable disease risk", "PROBLEM", 49, 74]]], ["These studies are difficult, because the diseases most suited to this type of investigation are most common in the poorest countries with limited health (and research) infrastructure and whose residents are understandably wary of possible exploitation by researchers from rich countries (Cooke and Hill 2001The Malaria Genomic Epidemiology NetworkThe MalariaGEN project illustrates some of the ethical challenges involved in human genomics research.", [["human", "ORGANISM", 425, 430], ["human", "SPECIES", 425, 430], ["human", "SPECIES", 425, 430], ["These studies", "TEST", 0, 13], ["the diseases", "PROBLEM", 37, 49], ["The MalariaGEN project", "TREATMENT", 347, 369]]], ["It was established in 2005, with joint funding from the Gates Foundation and the Wellcome Trust.", [["joint funding", "TREATMENT", 33, 46], ["joint", "ANATOMY", 33, 38]]], ["Members of this network of independent investigators contribute to a central DNA repository and to databases of core phenotypic data.", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["a central DNA repository", "PROBLEM", 67, 91], ["core phenotypic data", "TEST", 112, 132]]], ["One of the goals of MalariaGEN is to determine why only a small proportion of children develop life-threatening malaria, in communities where all children are repeatedly infected with the malaria parasite, Plasmodium falciparum.", [["malaria", "DISEASE", 112, 119], ["malaria parasite", "DISEASE", 188, 204], ["Plasmodium falciparum", "DISEASE", 206, 227], ["children", "ORGANISM", 78, 86], ["children", "ORGANISM", 146, 154], ["Plasmodium falciparum", "ORGANISM", 206, 227], ["children", "SPECIES", 78, 86], ["children", "SPECIES", 146, 154], ["Plasmodium falciparum", "SPECIES", 206, 227], ["Plasmodium falciparum", "SPECIES", 206, 227], ["threatening malaria", "PROBLEM", 100, 119], ["the malaria parasite", "PROBLEM", 184, 204], ["Plasmodium falciparum", "PROBLEM", 206, 227], ["malaria", "OBSERVATION", 112, 119], ["Plasmodium falciparum", "OBSERVATION", 206, 227]]], ["Researchers are using the technique of genome-wide association (GWA) analysis, which involves mapping half a million or more single nucleotide polymorphisms (SNPs) in thousands of individuals -without the need for whole genome sequencing -to identify sequence variants that correlate with disease risk, using statistical inferences based on common patterns.The Malaria Genomic Epidemiology NetworkThe study has the potential to benefit millions of children but involves the complex methodological, social and ethical challenges which are common to any clinical research in developing countries or human genomics research anywhere.", [["children", "ORGANISM", 448, 456], ["human", "ORGANISM", 597, 602], ["children", "SPECIES", 448, 456], ["human", "SPECIES", 597, 602], ["human", "SPECIES", 597, 602], ["more single nucleotide polymorphisms (SNPs)", "PROBLEM", 120, 163], ["whole genome sequencing", "TEST", 214, 237], ["disease risk", "PROBLEM", 289, 301], ["The study", "TEST", 397, 406], ["Malaria", "OBSERVATION", 361, 368]]], ["The involvement of numerous independent investigators, in rich and poor countries, from disciplines as varied as clinical and community medicine to state-of-the-art genomics and bioinformatics, requires a balance between standardization and uniformity of practice, on the one hand, and the need for sensitivity to diverse cultural settings, on the other (The Malaria Genomic Epidemiology Network 2008).The Malaria Genomic Epidemiology NetworkInformed consent and privacy.", [["numerous", "OBSERVATION_MODIFIER", 19, 27], ["Malaria", "OBSERVATION", 406, 413]]], ["Children with severe malaria often die within hours of the admission to hospital.", [["malaria", "DISEASE", 21, 28], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["severe malaria", "PROBLEM", 14, 28], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["malaria", "OBSERVATION", 21, 28]]], ["This raises logistical issues of recruiting subjects, classifying clinical phenotypes correctly and collecting specimens for genetic studies, without compromising medical care in the resource-poor settings where most cases occur.", [["specimens", "ANATOMY", 111, 120], ["collecting specimens", "TEST", 100, 120], ["genetic studies", "TEST", 125, 140]]], ["Language and cultural barriers complicate effective communication with the parents of potential research participants.", [["participants", "SPECIES", 105, 117]]], ["Guidelines for obtaining informed consent, without creating undue anxiety, are being developed and carefully evaluated by MalariaGEN researchers, in collaboration with local communities.The Malaria Genomic Epidemiology NetworkActual and perceived protection of the anonymity of research participants and their communities is critical to the development of trust between researchers and participants.", [["anxiety", "DISEASE", 66, 73], ["participants", "SPECIES", 287, 299], ["participants", "SPECIES", 386, 398], ["creating undue anxiety", "PROBLEM", 51, 73], ["Malaria", "OBSERVATION", 190, 197]]], ["In the MalariaGEN project, local databases which contain both phenotypic and genotypic data are designed to comply with appropriate ethical guidelines to ensure data security.", [["local databases", "TEST", 27, 42]]], ["A data access committee oversees researchers' access to individual genomic data.", [["individual genomic data", "TEST", 56, 79]]], ["Qualitative research is underway to identify the concerns, of community members and other stakeholders, about the collection and use of ethnicity data in relation to genomic epidemiology, which could result in stigmatization if misused.", [["ethnicity data", "TEST", 136, 150]]], ["Although it is commonly claimed that the use of de-identified data cannot harm research subjects, this is not necessarily so; research findings can sometimes lead to the development of policies or behaviors that are harmful to (e.g., ethnic) groups of which the subject is a member.", [["not necessarily", "UNCERTAINTY", 106, 121]]], ["Guidelines are essential for the publication and release of ethnicity data to provide maximum scientific benefit while respecting and protecting the interests of participants and their communities.The Malaria Genomic Epidemiology NetworkOwnership of data and intellectual property.", [["participants", "SPECIES", 162, 174], ["Malaria", "OBSERVATION", 201, 208]]], ["There is often institutional pressure on researchers to patent any discoveries with the potential for commercial development.", [["pressure", "OBSERVATION_MODIFIER", 29, 37], ["patent", "OBSERVATION", 56, 62]]], ["The principle agreed by MalariaGEN is that intellectual property protection will be sought only if it will facilitate the translation of research results into affordable health benefits for the populations most in need.", [["intellectual property protection", "TREATMENT", 43, 75], ["the populations", "PROBLEM", 190, 205]]], ["Any resulting financial gains will be returned to the participating communities.The Human Microbiome ProjectThe Human Microbiome project ) is another multicenter program, which entails familiar ethical, legal, and social challenges in a novel setting.", [["Human", "ORGANISM", 84, 89], ["Human", "ORGANISM", 112, 117], ["Human", "SPECIES", 84, 89], ["Human", "SPECIES", 112, 117]]], ["It is an investigation of the relationship between humans and microbial societies that inhabit all body surfaces and play a vital role in human health.", [["body surfaces", "ANATOMY", 99, 112], ["humans", "ORGANISM", 51, 57], ["body surfaces", "TISSUE", 99, 112], ["human", "ORGANISM", 138, 143], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 138, 143], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 138, 143], ["microbial societies", "TREATMENT", 62, 81]]], ["It will establish a database of microbial DNA and RNA, based on sampling of 15-18 mucosal and skin sites from about 250 healthy individuals aged between 18 and 40 years of age, about half of whom will provide a follow-up set of samples within 12 months.", [["mucosal", "ANATOMY", 82, 89], ["skin sites", "ANATOMY", 94, 104], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["mucosal", "TISSUE", 82, 89], ["skin sites", "MULTI-TISSUE_STRUCTURE", 94, 104], ["microbial DNA", "DNA", 32, 45], ["microbial DNA and RNA", "PROBLEM", 32, 53], ["sampling", "TEST", 64, 72], ["skin", "ANATOMY", 94, 98]]], ["Blood will be collected and stored for human genome and immune response investigation from a subset of around 10 participants.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["human", "ORGANISM", 39, 44], ["human genome", "DNA", 39, 51], ["human", "SPECIES", 39, 44], ["participants", "SPECIES", 113, 125], ["human", "SPECIES", 39, 44], ["Blood", "TEST", 0, 5], ["immune response investigation", "TEST", 56, 85]]], ["Extensive demographic and medical historical data will be collected.The Human Microbiome ProjectInformed consent, respect for autonomy, and communication.", [["Human", "ORGANISM", 72, 77], ["Human", "SPECIES", 72, 77], ["medical historical data", "TEST", 26, 49]]], ["Disclosure of the possible risks involved in providing samples for this project is difficult because of the current dearth of knowledge about the human microbiome and what future research questions may arise from linking microbial with human genomic data.", [["human", "ORGANISM", 146, 151], ["human", "ORGANISM", 236, 241], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 236, 241]]], ["As in other areas of research involving biobanking, there is controversy as to whether participants should be asked to give consent only for specific investigations already planned or blanket consent for future research.", [["participants", "SPECIES", 87, 99], ["specific investigations", "TEST", 141, 164], ["blanket consent", "TREATMENT", 184, 199]]], ["It has been argued, however, that requesting general consent is acceptable so long as participants are well informed about the uncertainties, and there is a strong governance structure to protect the privacy of participants and ensure that future research is consistent with their expectations (Caulfield et al. 2008 ).", [["participants", "SPECIES", 86, 98], ["participants", "SPECIES", 211, 223]]], ["This would generally involve the appointment of an independent multidisciplinary monitoring body, including lay representatives, to promote public trust and ensure respect for participants' autonomy; therefore, blanket consent would be limited to future research approved by this body.The Human Microbiome ProjectIt is likely that analysis of the preliminary results of this project will identify characteristics of individual microbiomes, which could affect the health of the participant (e.g., risk of obesity or type 2 diabetes or changes due to medical interventions, such as antibiotic therapy).", [["body", "ANATOMY", 92, 96], ["body", "ANATOMY", 280, 284], ["obesity", "DISEASE", 504, 511], ["type 2 diabetes", "DISEASE", 515, 530], ["body", "ORGANISM_SUBDIVISION", 92, 96], ["body", "ORGANISM_SUBDIVISION", 280, 284], ["Human", "ORGANISM", 289, 294], ["participants", "SPECIES", 176, 188], ["Human", "SPECIES", 289, 294], ["participant", "SPECIES", 477, 488], ["blanket consent", "TREATMENT", 211, 226], ["The Human Microbiome ProjectIt", "TREATMENT", 285, 315], ["individual microbiomes", "PROBLEM", 416, 438], ["obesity", "PROBLEM", 504, 511], ["type 2 diabetes", "PROBLEM", 515, 530], ["medical interventions", "TREATMENT", 549, 570], ["antibiotic therapy", "TREATMENT", 580, 598]]], ["The point at which information, which could affect lifestyle or medical decisions, should be shared with participants or their physicians will be controversial.", [["participants", "SPECIES", 105, 117]]], ["The study will almost certainly identify healthy individuals who are infected or colonized with potential pathogens that could cause future disease, under circumstances which are currently unpredictable and likely to vary between individuals.", [["The study", "TEST", 0, 9], ["infected", "PROBLEM", 69, 77], ["potential pathogens", "PROBLEM", 96, 115], ["future disease", "PROBLEM", 133, 147]]], ["Should participants be told that they are potential victims or vectors if the level of risk is unknown?", [["participants", "SPECIES", 7, 19]]], ["Researchers are unlikely to be qualified to manage potential clinical issues; at what stage should a medical practitioner be consulted, if at all?The Human Microbiome ProjectThe answers will depend on the validity and clinical significance of the findings and whether the participant has expressed a desire to know the results.", [["Human", "ORGANISM", 150, 155], ["Human", "SPECIES", 150, 155], ["participant", "SPECIES", 272, 283], ["potential clinical issues", "PROBLEM", 51, 76]]], ["For example, identifying nasal colonization with Staphylococcus aureus would require a different response from the discovery that the participant has asymptomatic genital infection with a sexually transmissible pathogen, which is a potential risk to others.", [["nasal", "ANATOMY", 25, 30], ["genital", "ANATOMY", 163, 170], ["Staphylococcus aureus", "DISEASE", 49, 70], ["genital infection", "DISEASE", 163, 180], ["sexually transmissible pathogen", "DISEASE", 188, 219], ["nasal", "ORGANISM_SUBDIVISION", 25, 30], ["Staphylococcus aureus", "ORGANISM", 49, 70], ["genital", "ORGANISM_SUBDIVISION", 163, 170], ["Staphylococcus aureus", "SPECIES", 49, 70], ["participant", "SPECIES", 134, 145], ["Staphylococcus aureus", "SPECIES", 49, 70], ["nasal colonization", "PROBLEM", 25, 43], ["Staphylococcus aureus", "PROBLEM", 49, 70], ["asymptomatic genital infection", "PROBLEM", 150, 180], ["a sexually transmissible pathogen", "PROBLEM", 186, 219], ["nasal", "ANATOMY", 25, 30], ["colonization", "OBSERVATION", 31, 43], ["Staphylococcus aureus", "OBSERVATION", 49, 70], ["asymptomatic", "OBSERVATION_MODIFIER", 150, 162], ["genital", "ANATOMY", 163, 170], ["infection", "OBSERVATION", 171, 180]]], ["If there were no apparent risk (e.g., of infection) to others, the participant's \"desire to know\" may be a key consideration.", [["infection", "DISEASE", 41, 50], ["participant", "SPECIES", 67, 78], ["infection", "PROBLEM", 41, 50], ["no apparent", "UNCERTAINTY", 14, 25], ["infection", "OBSERVATION", 41, 50]]], ["For this kind of research, discussion and negotiation on details regarding disclosure of findings to the subject and/or others should arguably become a more important part of the informed consent process.The Human Microbiome ProjectData confidentiality and security.", [["Human", "ORGANISM", 208, 213], ["Human", "SPECIES", 208, 213]]], ["For the human microbiome project, microbial DNA sequence data will be coded and released into publicly accessible databases, but clinical information and individual human DNA data will be coded and stored in controlled-access databases for later correlation with microbial data.", [["human", "ORGANISM", 8, 13], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["human", "ORGANISM", 165, 170], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["microbial DNA sequence", "DNA", 34, 56], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 165, 170], ["microbial DNA sequence data", "TEST", 34, 61], ["individual human DNA data", "TEST", 154, 179], ["microbial data", "TEST", 263, 277]]], ["Only aggregate human genomic data will be released into public databases.", [["human", "ORGANISM", 15, 20], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20]]], ["Whether, how, and by whom data are linked remain controversial because of the existing uncertainty about the extent to which microbial data can reveal individual identity and could be used to stigmatize individuals or groups.", [["microbial data", "TEST", 125, 139]]], ["These are among the risks that will be discussed with participants when seeking informed consent.The Human Microbiome ProjectRepresentativeness and justice.", [["Human", "ORGANISM", 101, 106], ["participants", "SPECIES", 54, 66], ["Human", "SPECIES", 101, 106]]], ["The human microbiome project excludes children and older adults, to ensure that interpretation is not complicated by metabolic changes related to growth, puberty, or aging.", [["human", "ORGANISM", 4, 9], ["children", "ORGANISM", 38, 46], ["human", "SPECIES", 4, 9], ["children", "SPECIES", 38, 46], ["human", "SPECIES", 4, 9]]], ["However, subjects are chosen to include as many racial and ethnic groups as possible even though this could risk identifying false associations due to unrecognized confounding factors.", [["unrecognized confounding factors", "PROBLEM", 151, 183]]], ["While these problems are often unavoidable, they must be recognized and accounted for in the data analysis and conclusions.Application of Pathogenomics and Informatics Research to Communicable Disease Diagnostics and PreventionOver the past half-century or so, the natural histories of many human infectious diseases have changed, often fundamentally and often as a result of deliberate or unwitting human intervention.", [["Communicable Disease", "DISEASE", 180, 200], ["infectious diseases", "DISEASE", 297, 316], ["human", "ORGANISM", 291, 296], ["human", "ORGANISM", 400, 405], ["human", "SPECIES", 291, 296], ["human", "SPECIES", 400, 405], ["human", "SPECIES", 291, 296], ["human", "SPECIES", 400, 405], ["the data analysis", "TEST", 89, 106], ["Pathogenomics", "TREATMENT", 138, 151], ["many human infectious diseases", "PROBLEM", 286, 316], ["human intervention", "TREATMENT", 400, 418], ["infectious", "OBSERVATION", 297, 307]]], ["For example, immunization has (actually or almost) eliminated a few (smallpox, polio, and measles) and has controlled many other diseases (diphtheria, rubella, tetanus, hepatitis B).", [["polio", "DISEASE", 79, 84], ["measles", "DISEASE", 90, 97], ["diphtheria, rubella, tetanus, hepatitis B", "DISEASE", 139, 180], ["hepatitis B", "ORGANISM", 169, 180], ["immunization", "TREATMENT", 13, 25], ["polio", "PROBLEM", 79, 84], ["measles", "PROBLEM", 90, 97], ["many other diseases", "PROBLEM", 118, 137], ["diphtheria", "PROBLEM", 139, 149], ["rubella", "PROBLEM", 151, 158], ["tetanus", "PROBLEM", 160, 167], ["hepatitis B", "PROBLEM", 169, 180]]], ["However, although vaccines are available, they have been less successful in controlling some diseases (e.g., pertussis, TB, influenza), and immunization remains elusive for many (e.g., most respiratory and diarrheal diseases, malaria, and HIV infection).", [["respiratory", "ANATOMY", 190, 201], ["pertussis", "DISEASE", 109, 118], ["TB", "DISEASE", 120, 122], ["influenza", "DISEASE", 124, 133], ["respiratory and diarrheal diseases", "DISEASE", 190, 224], ["malaria", "DISEASE", 226, 233], ["HIV infection", "DISEASE", 239, 252], ["HIV", "SPECIES", 239, 242], ["HIV", "SPECIES", 239, 242], ["vaccines", "TREATMENT", 18, 26], ["some diseases", "PROBLEM", 88, 101], ["pertussis", "PROBLEM", 109, 118], ["TB", "PROBLEM", 120, 122], ["influenza", "PROBLEM", 124, 133], ["immunization", "TREATMENT", 140, 152], ["most respiratory and diarrheal diseases", "PROBLEM", 185, 224], ["malaria", "PROBLEM", 226, 233], ["HIV infection", "PROBLEM", 239, 252], ["diarrheal diseases", "OBSERVATION", 206, 224]]], ["Antimicrobial agents are available for the treatment of many types of infection but, with few exceptions, their efficacy has been compromised by the development of resistance in target pathogens.", [["infection", "DISEASE", 70, 79], ["Antimicrobial agents", "TREATMENT", 0, 20], ["the treatment", "TREATMENT", 39, 52], ["infection", "PROBLEM", 70, 79], ["resistance in target pathogens", "PROBLEM", 164, 194], ["infection", "OBSERVATION", 70, 79]]], ["On the other hand, changes in land and water use, agriculture, animal husbandry, transportation, climate, or lifestyle, as well as increasing numbers of people who are immunocompromised because of AIDS or immunosuppressive drug therapy, have led to the emergence of new and opportunistic human pathogens which were once regarded -if they were recognized at all -as animal, rather than human, pathogens or as harmless commensals.Application of Pathogenomics and Informatics Research to Communicable Disease Diagnostics and PreventionRecently, studies of microbial genomes have helped explain many of these phenomena at the molecular level and have led to changes in anthropocentric concepts of pathogens and commensals.", [["AIDS", "DISEASE", 197, 201], ["people", "ORGANISM", 153, 159], ["human", "ORGANISM", 288, 293], ["human", "ORGANISM", 385, 390], ["people", "SPECIES", 153, 159], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 385, 390], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 385, 390], ["immunocompromised", "PROBLEM", 168, 185], ["AIDS", "PROBLEM", 197, 201], ["immunosuppressive drug therapy", "TREATMENT", 205, 235], ["opportunistic human pathogens", "PROBLEM", 274, 303], ["microbial genomes", "PROBLEM", 553, 570], ["these phenomena", "PROBLEM", 599, 614], ["pathogens", "PROBLEM", 693, 702]]], ["In future, they will reveal new ways to protect humans from illness and death by identifying new targets for antimicrobial agents or vaccines.", [["illness", "DISEASE", 60, 67], ["death", "DISEASE", 72, 77], ["humans", "ORGANISM", 48, 54], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54], ["illness", "PROBLEM", 60, 67], ["death", "PROBLEM", 72, 77], ["antimicrobial agents", "TREATMENT", 109, 129], ["vaccines", "TREATMENT", 133, 141]]], ["At least one genome (and often several) of all significant human pathogens has now been fully sequenced.", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["all significant human pathogens", "PROBLEM", 43, 74], ["one", "OBSERVATION_MODIFIER", 9, 12], ["genome", "OBSERVATION", 13, 19], ["pathogens", "OBSERVATION", 65, 74]]], ["Comparison of genomes of different strains of the same and related species can provide extensive information about microbial evolution and the relative importance of different types of genetic variation (e.g., mutation, insertion, deletion, duplication, recombination, or lateral transfer) and how they occur.", [["different strains", "PROBLEM", 25, 42], ["mutation, insertion, deletion", "TREATMENT", 210, 239], ["duplication", "TREATMENT", 241, 252], ["different strains", "OBSERVATION_MODIFIER", 25, 42]]], ["We now know that many of the genes that determine virulence or antibiotic resistance are transferred on mobile genetic elements (plasmids, bacteriophages, transposons, pathogenicity islands) between different strains or species; this can dramatically amplify the effects of selection pressures (see Chap.", [["plasmids", "ANATOMY", 129, 137], ["mobile genetic elements", "DNA", 104, 127], ["plasmids", "DNA", 129, 137], ["bacteriophages", "DNA", 139, 153], ["transposons", "DNA", 155, 166], ["virulence", "PROBLEM", 50, 59], ["antibiotic resistance", "TREATMENT", 63, 84], ["mobile genetic elements (plasmids", "TREATMENT", 104, 137], ["bacteriophages", "PROBLEM", 139, 153], ["pathogenicity islands)", "PROBLEM", 168, 190], ["different strains or species", "PROBLEM", 199, 227], ["selection pressures", "TEST", 274, 293]]], ["These mobile elements can be exploited in the development of diagnostic and surveillance tools, but they also complicate the interpretation of test results and attempts to control disease transmission.Diagnostics and Antibiotic Resistance: Ethical ImplicationsIncreasingly sophisticated \"smart\" diagnostics, which are currently under development, will potentially allow more sensitive and specific pathogen detection and profiling (Sintchenko et al. 2007 ) which could significantly improve communicable disease diagnosis, management, and control.", [["surveillance tools", "TEST", 76, 94], ["test results", "TEST", 143, 155], ["disease transmission", "PROBLEM", 180, 200], ["specific pathogen detection", "TEST", 389, 416]]], ["If their benefits are to be fully realized, the predictive values of new tests (i.e., the ability to predict whether or not the patient has the infection which the test is intended to diagnose) must be thoroughly evaluated, with reference to clinical outcomes not just through comparisons with existing diagnostic methods.", [["infection", "DISEASE", 144, 153], ["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["new tests", "TEST", 69, 78], ["the infection", "PROBLEM", 140, 153], ["infection", "OBSERVATION", 144, 153]]], ["Moreover, the evaluation should not end with their introduction into routine practice.", [["the evaluation", "TEST", 10, 24], ["routine practice", "TREATMENT", 69, 85]]], ["Currently, the microbiology laboratory's task is to identify a relevant pathogen in a clinical specimen and report it, with an antibiotic susceptibility profile, if appropriate.", [["specimen", "ANATOMY", 95, 103], ["the microbiology laboratory's task", "TEST", 11, 45], ["a relevant pathogen", "PROBLEM", 61, 80], ["an antibiotic susceptibility profile", "TEST", 124, 160]]], ["Conventional diagnostic methods are relatively slow, and the interpretation of results is often subjective.", [["Conventional diagnostic methods", "TEST", 0, 31]]], ["For example, whether or not a pathogen is identified and reported in a culture from a site with normal flora may depend on the skill and experience of the laboratory scientist.", [["a pathogen", "PROBLEM", 28, 38], ["a culture", "TEST", 69, 78], ["pathogen", "OBSERVATION", 30, 38], ["flora", "OBSERVATION", 103, 108]]], ["The interpretation of the result depends on clinical information, which is often not available to the scientist, and technical information which may not be available to the clinician -such as the type and quality of specimen, diagnostic method used, and the pathogen strain.", [["specimen", "ANATOMY", 216, 224], ["diagnostic method", "TEST", 226, 243], ["the pathogen strain", "PROBLEM", 254, 273]]], ["The clinician's interpretation of the result will often determine the antibiotic choice, but if this is inappropriate, the outcome may be compromised (Khatib et al. 2006; Chapman et al. 2008) .Diagnostics and Antibiotic Resistance: Ethical ImplicationsIn the near future (and to some extent already), multiplexed nucleic acid detection (NAD) systems, which target 10s, 100s, or even 1,000s of highly specific nucleic acid sequences, will identify, in virtually real-time, any of a large number of possible pathogens relevant to the site of the specimen or the clinical syndrome.", [["specimen", "ANATOMY", 544, 552], ["nucleic acid", "CHEMICAL", 313, 325], ["NAD", "CHEMICAL", 337, 340], ["nucleic acid", "CHEMICAL", 409, 421], ["the antibiotic choice", "TREATMENT", 66, 87], ["multiplexed nucleic acid detection", "TEST", 301, 335], ["highly specific nucleic acid sequences", "PROBLEM", 393, 431], ["pathogens", "PROBLEM", 506, 515], ["the clinical syndrome", "PROBLEM", 556, 577], ["large", "OBSERVATION_MODIFIER", 481, 486]]], ["At the same time, they will also determine whether the pathogen identified carries specific virulence determinants or antibiotic resistance genes and/or whether its profile is similar to those of pathogens isolated from other people (a cluster of infections) (see Sect.", [["infections", "DISEASE", 247, 257], ["people", "ORGANISM", 226, 232], ["antibiotic resistance genes", "DNA", 118, 145], ["people", "SPECIES", 226, 232], ["the pathogen", "PROBLEM", 51, 63], ["antibiotic resistance genes", "PROBLEM", 118, 145], ["pathogens", "PROBLEM", 196, 205], ["infections", "PROBLEM", 247, 257], ["infections", "OBSERVATION", 247, 257]]], ["New or unusual pathogens can be included in these systems at little or no extra cost, which will save time by identifying less common or less obvious pathogens sooner than is currently possible.Diagnostics and Antibiotic Resistance: Ethical ImplicationsIn a clinical research setting, the ability to study the prevalence and clinical associations of many different species or genetic markers simultaneously will provide new knowledge about the etiology, epidemiology, and pathogenesis of infectious disease syndromes and interactions between species.", [["infectious disease syndromes", "DISEASE", 488, 516], ["New or unusual pathogens", "PROBLEM", 0, 24], ["Ethical Implications", "TREATMENT", 233, 253], ["many different species", "PROBLEM", 350, 372], ["infectious disease syndromes", "PROBLEM", 488, 516], ["unusual", "OBSERVATION_MODIFIER", 7, 14], ["pathogens", "OBSERVATION", 15, 24], ["less obvious", "OBSERVATION_MODIFIER", 137, 149], ["pathogens", "OBSERVATION", 150, 159], ["infectious", "OBSERVATION", 488, 498]]], ["Multiplexed NAD systems will allow inclusion of species which are usually harmless commensals but occasionally are potential pathogens, copathogens or opportunists (Wang et al. 2008; Masue et al. 2007; Mckechnie et al. 2009 ).", [["NAD", "CHEMICAL", 12, 15], ["NAD", "CHEMICAL", 12, 15], ["NAD", "SIMPLE_CHEMICAL", 12, 15], ["Multiplexed NAD systems", "PROBLEM", 0, 23], ["species", "PROBLEM", 48, 55]]], ["With appropriate analysis of clinical, epidemiological, and microbial data, this will help define their role and the circumstances, if any, in which they cause disease.Diagnostics and Antibiotic Resistance: Ethical ImplicationsProperly designed clinical research studies (currently, a rarity in diagnostic microbiology) will clarify the circumstances in which the detection of virulence or antibiotic resistance markers in mixed flora is significant (Table 20 .1).", [["disease", "PROBLEM", 160, 167], ["clinical research studies", "TEST", 245, 270], ["virulence", "PROBLEM", 377, 386], ["antibiotic resistance markers", "TEST", 390, 419], ["mixed flora", "PROBLEM", 423, 434], ["disease", "OBSERVATION", 160, 167]]], ["For example, genes that encode resistance to newer b-lactamase and carbapenem antibiotics or vancomycin are often carried in commensal gut flora, but can be transferred to virulent Gram negative bacilli (such as Enterobacteriaceae) or enterococci, respectively, under selection pressure from antibiotic therapy (Chapman et al. 2008; Iredell et al. 2006) .", [["gut flora", "ANATOMY", 135, 144], ["b-lactamase", "CHEMICAL", 51, 62], ["carbapenem", "CHEMICAL", 67, 77], ["vancomycin", "CHEMICAL", 93, 103], ["carbapenem", "CHEMICAL", 67, 77], ["vancomycin", "CHEMICAL", 93, 103], ["b-lactamase", "GENE_OR_GENE_PRODUCT", 51, 62], ["carbapenem antibiotics", "SIMPLE_CHEMICAL", 67, 89], ["vancomycin", "SIMPLE_CHEMICAL", 93, 103], ["gut flora", "PATHOLOGICAL_FORMATION", 135, 144], ["Gram", "GENE_OR_GENE_PRODUCT", 181, 185], ["newer b-lactamase", "TREATMENT", 45, 62], ["carbapenem antibiotics", "TREATMENT", 67, 89], ["vancomycin", "TREATMENT", 93, 103], ["commensal gut flora", "PROBLEM", 125, 144], ["virulent Gram negative bacilli", "PROBLEM", 172, 202], ["Enterobacteriaceae", "PROBLEM", 212, 230], ["enterococci", "PROBLEM", 235, 246], ["antibiotic therapy", "TREATMENT", 292, 310], ["enterococci", "OBSERVATION", 235, 246]]], ["Multiresistant Enterobacteriaceae or vancomycin resistant enterococci (VRE) are much more likely SCCmec is the staphylococcal cassette chromosome (a mobile genetic element), which carries the methicillin resistance gene mecA than commensal or environmental bacteria to cause disease or spread to other patients and are more difficult to treat than their antibiotic susceptible counterparts.", [["Enterobacteriaceae", "CHEMICAL", 15, 33], ["vancomycin", "CHEMICAL", 37, 47], ["methicillin", "CHEMICAL", 192, 203], ["vancomycin", "CHEMICAL", 37, 47], ["methicillin", "CHEMICAL", 192, 203], ["vancomycin resistant enterococci", "GENE_OR_GENE_PRODUCT", 37, 69], ["VRE", "CANCER", 71, 74], ["chromosome", "CELLULAR_COMPONENT", 135, 145], ["mecA", "GENE_OR_GENE_PRODUCT", 220, 224], ["patients", "ORGANISM", 302, 310], ["SCCmec", "DNA", 97, 103], ["staphylococcal cassette chromosome", "DNA", 111, 145], ["mobile genetic element", "DNA", 149, 171], ["methicillin resistance gene mecA", "DNA", 192, 224], ["patients", "SPECIES", 302, 310], ["Multiresistant Enterobacteriaceae", "PROBLEM", 0, 33], ["vancomycin resistant enterococci", "PROBLEM", 37, 69], ["VRE", "PROBLEM", 71, 74], ["SCCmec", "PROBLEM", 97, 103], ["the staphylococcal cassette chromosome", "PROBLEM", 107, 145], ["the methicillin resistance gene mecA", "PROBLEM", 188, 224], ["environmental bacteria", "PROBLEM", 243, 265], ["disease", "PROBLEM", 275, 282], ["their antibiotic susceptible counterparts", "TREATMENT", 348, 389], ["Enterobacteriaceae", "OBSERVATION", 15, 33], ["vancomycin resistant enterococci", "OBSERVATION", 37, 69], ["methicillin resistance", "OBSERVATION", 192, 214]]], ["However, even after careful evaluation, in a research setting, there are pitfalls in the translation of new diagnostic methods into practice.", [["careful evaluation", "TEST", 20, 38], ["new", "OBSERVATION_MODIFIER", 104, 107]]], ["Faster and more sensitive methods will provide more information, more timely and reproducible results and detection of a broader range of pathogens than conventional methods; they may uncover new infectious disease syndromes or identify previously unrecognized carriers.", [["infectious disease syndromes", "DISEASE", 196, 224], ["new infectious disease syndromes", "PROBLEM", 192, 224], ["new", "OBSERVATION_MODIFIER", 192, 195], ["infectious", "OBSERVATION", 196, 206]]], ["Confirmation that a new (and usually more expensive) assay will improve clinical outcomes requires ongoing prospective analysis of reliability and cost-effectiveness, which is difficult in a diagnostic laboratory setting.", [["new", "OBSERVATION_MODIFIER", 20, 23]]], ["However, without it, the use of new assays could lead to unnecessary therapy or medicalization of \"normal\" conditions.", [["new assays", "TEST", 32, 42], ["unnecessary therapy", "TREATMENT", 57, 76]]], ["For example, screening patients for carriage of multiresistant organisms, such as methicillin resistant Staphylococcus aureus (MRSA) using rapid NAD methods, can improve hospital infection control by allowing more timely and appropriate isolation of patients and can guide appropriate antibiotic therapy.", [["methicillin", "CHEMICAL", 82, 93], ["Staphylococcus aureus", "DISEASE", 104, 125], ["NAD", "CHEMICAL", 145, 148], ["infection", "DISEASE", 179, 188], ["methicillin", "CHEMICAL", 82, 93], ["NAD", "CHEMICAL", 145, 148], ["patients", "ORGANISM", 23, 31], ["methicillin resistant Staphylococcus aureus", "ORGANISM", 82, 125], ["MRSA", "CANCER", 127, 131], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 23, 31], ["Staphylococcus aureus", "SPECIES", 104, 125], ["MRSA", "SPECIES", 127, 131], ["patients", "SPECIES", 250, 258], ["Staphylococcus aureus", "SPECIES", 104, 125], ["MRSA", "SPECIES", 127, 131], ["screening", "TEST", 13, 22], ["carriage", "PROBLEM", 36, 44], ["multiresistant organisms", "PROBLEM", 48, 72], ["methicillin resistant Staphylococcus aureus", "PROBLEM", 82, 125], ["MRSA", "PROBLEM", 127, 131], ["rapid NAD methods", "TREATMENT", 139, 156], ["hospital infection control", "TREATMENT", 170, 196], ["appropriate antibiotic therapy", "TREATMENT", 273, 303]]], ["However, the sensitivity and specificity of some NAD methods differ from those of conventional methods, leading to potentially adverse consequences.", [["NAD", "CHEMICAL", 49, 52], ["NAD", "CHEMICAL", 49, 52], ["NAD", "SIMPLE_CHEMICAL", 49, 52], ["the sensitivity", "TEST", 9, 24], ["some NAD methods", "PROBLEM", 44, 60], ["conventional methods", "TEST", 82, 102], ["potentially adverse consequences", "PROBLEM", 115, 147]]], ["Failure to identify some carriers (Thomas et al. 2008 ) will increase the risk of transmission to other patients.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["Failure", "PROBLEM", 0, 7]]], ["On the other hand if NAD assays identify more carriers than conventional methods, it can be difficult to distinguish increased sensitivity from false positive results.", [["NAD", "CHEMICAL", 21, 24], ["NAD", "CHEMICAL", 21, 24], ["NAD", "SIMPLE_CHEMICAL", 21, 24], ["NAD assays", "TEST", 21, 31], ["increased sensitivity", "PROBLEM", 117, 138], ["false positive results", "PROBLEM", 144, 166]]], ["Either way, it will mean that more patients will be isolated, possibly unnecessarily (Humphreys 2008) , which is costly, can adversely affect clinical care (Stelfox et al. 2003 ) and may cause unnecessary anxiety.Diagnostics and Antibiotic Resistance: Ethical ImplicationsThese uncertainties emphasize the importance of not only carefully evaluating the performance characteristics of a new test, but also of defining its purpose and clinical impact.", [["anxiety", "DISEASE", 205, 212], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["unnecessary anxiety", "PROBLEM", 193, 212], ["Ethical Implications", "TREATMENT", 252, 272], ["a new test", "TEST", 385, 395]]], ["Is it performed for the benefit of the patient on whom it is performed or for the benefit of other patients?", [["patient", "ORGANISM", 39, 46], ["patients", "ORGANISM", 99, 107], ["patient", "SPECIES", 39, 46], ["patients", "SPECIES", 99, 107]]], ["While benefits to other patients may justify screening and isolation of patients who are colonized with multiresistant organisms, the degree of benefit, cost-effectiveness, and possible alternative strategies to achieve similar results must be assessed (Jeyaratnam et al. 2008; Wenzel et al. 2008; Buhlmann et al. 2008) .", [["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 72, 80], ["screening", "TEST", 45, 54], ["multiresistant organisms", "PROBLEM", 104, 128], ["alternative strategies", "TREATMENT", 186, 208]]], ["A key question in public health (and infection control) ethics is: how great must the expected danger to public health (or to hospital patients) be to justify involuntary isolation of an individual who is a potential source of danger?", [["infection", "DISEASE", 37, 46], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143]]], ["Assuming that the appropriate metric of danger to public health is the \"disabilityadjusted life year\" (DALY), for how many DALYs (x) would confinement of a person (e.g., a carrier of MRSA) for time t be justified, assuming that the free movement of that person could be expected, on average, to result in x or more DALYs?Diagnostics and Antibiotic Resistance: Ethical ImplicationsThe effects of changes in test turn-around times, reliability and predictive values, on patient care should be critically assessed, as new diagnostic methods are introduced.", [["patient", "ORGANISM", 468, 475], ["person", "SPECIES", 156, 162], ["MRSA", "SPECIES", 183, 187], ["person", "SPECIES", 254, 260], ["patient", "SPECIES", 468, 475], ["MRSA", "PROBLEM", 183, 187], ["Ethical Implications", "TREATMENT", 360, 380], ["test turn", "TEST", 406, 415], ["predictive values", "TEST", 446, 463]]], ["As part of this assessment, the point at which clinical research -with its ethical safeguards such as the informed consent of subjects -merges into routine practice will need to be defined.", [["this assessment", "TEST", 11, 26], ["routine practice", "TREATMENT", 148, 164]]], ["We need to develop standards for interpretation and reporting of the results of new diagnostic tests, in consultation with clinicians, to improve consistency.", [["new diagnostic tests", "TEST", 80, 100]]], ["At present, introduction of new diagnostic and screening methods generally occurs independently in individual laboratories; test evaluation is often limited to comparison with existing methods and continued satisfactory performance in quality assurance programs, as required by accreditation bodies.", [["screening methods", "TEST", 47, 64], ["test evaluation", "TEST", 124, 139], ["existing methods", "TEST", 176, 192]]], ["Differences between methods used by different accredited laboratories suggest that some are \"better\" than others, but this information is not readily accessible to clinicians or patients and the criteria on which choices are based are often poorly defined.", [["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186]]], ["New tests are usually more expensive that conventional methods.", [["New tests", "TEST", 0, 9]]], ["It is usually assumed -and often true -that any increased costs are justified by better patient outcomes and savings elsewhere, but formal cost-effectiveness studies that are needed to confirm this are rarely done.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["any increased costs", "PROBLEM", 44, 63], ["formal cost-effectiveness studies", "TEST", 132, 165], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["costs", "OBSERVATION", 58, 63]]], ["Even if extensive evaluation demonstrates that a new method can improve patient outcomes and/or reduce costs, introduction of the test is often prevented or delayed because of the difficulty of transferring costs (and savings) between cost centers.Diagnostics and Antibiotic Resistance: Ethical ImplicationsIn summary: the widespread application of the new science of pathogenomics to infectious diseases diagnosis -with appropriate prospective evaluation of the clinical impact -should not only improve outcomes, but also provide a better understanding of many aspects of human infection and disease such as:Diagnostics and Antibiotic Resistance: Ethical ImplicationsThe spectrum of diseases caused by known pathogens \u2022Diagnostics and Antibiotic Resistance: Ethical ImplicationsThe possible infectious etiology of diseases of unknown cause \u2022Diagnostics and Antibiotic Resistance: Ethical ImplicationsThe ecology of human microflora and factors that affect them \u2022 The incidence and significance of colonization with different strains of known \u2022 pathogens and of carriage, by commensals or opportunistic pathogens, of virulence or antibiotic resistance genes Potential interactions that may affect virulence, simultaneous carriage of combi-\u2022 nations of pathogens, and/or commensal species The routes and mechanisms of transmission of pathogens between people and of \u2022 genes between different microbial strains or speciesStrain Typing for Pathogen TrackingSurveillance is essential for disease control.", [["infectious diseases", "DISEASE", 385, 404], ["infection", "DISEASE", 579, 588], ["patient", "ORGANISM", 72, 79], ["human", "ORGANISM", 573, 578], ["human", "ORGANISM", 916, 921], ["people", "ORGANISM", 1351, 1357], ["patient", "SPECIES", 72, 79], ["human", "SPECIES", 573, 578], ["human", "SPECIES", 916, 921], ["people", "SPECIES", 1351, 1357], ["human", "SPECIES", 573, 578], ["human", "SPECIES", 916, 921], ["extensive evaluation", "TEST", 8, 28], ["a new method", "TREATMENT", 47, 59], ["the test", "TEST", 126, 134], ["Ethical Implications", "TREATMENT", 287, 307], ["appropriate prospective evaluation", "TEST", 421, 455], ["human infection", "PROBLEM", 573, 588], ["disease", "PROBLEM", 593, 600], ["diseases", "PROBLEM", 684, 692], ["known pathogens", "PROBLEM", 703, 718], ["Antibiotic Resistance", "TREATMENT", 736, 757], ["diseases", "PROBLEM", 815, 823], ["human microflora", "TREATMENT", 916, 932], ["colonization", "PROBLEM", 998, 1010], ["known \u2022 pathogens", "PROBLEM", 1037, 1054], ["carriage", "PROBLEM", 1062, 1070], ["opportunistic pathogens", "PROBLEM", 1089, 1112], ["virulence", "PROBLEM", 1117, 1126], ["antibiotic resistance genes", "TREATMENT", 1130, 1157], ["pathogens", "PROBLEM", 1252, 1261], ["commensal species", "PROBLEM", 1270, 1287], ["pathogens", "PROBLEM", 1333, 1342], ["different microbial strains", "PROBLEM", 1381, 1408], ["speciesStrain Typing", "PROBLEM", 1412, 1432], ["disease control", "TREATMENT", 1484, 1499], ["new", "OBSERVATION_MODIFIER", 49, 52], ["infection", "OBSERVATION", 579, 588], ["possible", "UNCERTAINTY", 783, 791], ["infectious", "OBSERVATION_MODIFIER", 792, 802], ["colonization", "OBSERVATION", 998, 1010]]], ["It has been described as \"the eyes of public health\" (Fairchild et al. 2008) .", [["eyes", "ANATOMY", 30, 34], ["eyes", "ORGAN", 30, 34]]], ["Although laboratory-confirmed cases of infectious diseases represent a small minority of notified cases (and an even smaller proportion of all cases), laboratory notification is more specific, reliable, and consistent than clinician notification.", [["infectious diseases", "DISEASE", 39, 58], ["infectious diseases", "PROBLEM", 39, 58], ["infectious", "OBSERVATION", 39, 49], ["small", "OBSERVATION_MODIFIER", 71, 76]]], ["For many notifiable infectious diseases, simple species identification of the pathogen is inadequate and strain typing is required to monitor trends or to investigate outbreaks.", [["infectious diseases", "DISEASE", 20, 39], ["many notifiable infectious diseases", "PROBLEM", 4, 39], ["simple species", "PROBLEM", 41, 55], ["the pathogen", "PROBLEM", 74, 86], ["strain typing", "TEST", 105, 118], ["infectious", "OBSERVATION", 20, 30]]], ["However, until recently, the efficacy of surveillance has been limited by the fact that conventional strain typing methods are relatively slow, insensitive, and often performed only by specialized public health laboratories.", [["surveillance", "TEST", 41, 53], ["conventional strain typing methods", "TEST", 88, 122]]], ["Recent developments in microbial genomics have led to the development of faster and more discriminatory methods (see Chap.", [["microbial genomics", "OBSERVATION", 23, 41]]], ["2, 4, and 17), but their introduction has been limited and haphazard, in part because of inadequate recognition of the importance of improved strain typing methods, for disease control.Strain Typing for Pathogen TrackingDelays of 2-3 weeks, in obtaining strain typing results mean that recognition of outbreaks is delayed and subsequent investigation of the cause is compromised.", [["improved strain typing methods", "TREATMENT", 133, 163], ["disease control", "TREATMENT", 169, 184], ["Strain Typing", "TEST", 185, 198], ["Pathogen", "PROBLEM", 203, 211], ["strain typing", "TEST", 254, 267], ["compromised", "OBSERVATION", 367, 378]]], ["For example, in cases of food-borne disease, it may be impossible to identify a common food source, because victims cannot remember what they ate weeks before.", [["food-borne disease", "DISEASE", 25, 43], ["food-borne disease", "PROBLEM", 25, 43], ["borne disease", "OBSERVATION", 30, 43]]], ["Outbreaks involving large geographic areas, which are investigated in different jurisdictions and laboratories, may only be recognized after very large numbers of people have been affected, if at all.Strain Typing for Pathogen TrackingIn the early stages of the 2009 \"swine flu\" outbreak, there was no rapid strain typing method to distinguish the novel influenza H1N1 strain from other circulating H1N1 seasonal influenza A strains.", [["swine flu", "DISEASE", 268, 277], ["influenza H1N1", "DISEASE", 354, 368], ["people", "ORGANISM", 163, 169], ["influenza H1N1", "ORGANISM", 354, 368], ["H1N1", "ORGANISM", 399, 403], ["seasonal influenza A", "ORGANISM", 404, 424], ["people", "SPECIES", 163, 169], ["swine", "SPECIES", 268, 273], ["influenza H1N1", "SPECIES", 354, 368], ["H1N1 seasonal influenza", "SPECIES", 399, 422], ["Outbreaks", "PROBLEM", 0, 9], ["large geographic areas", "PROBLEM", 20, 42], ["Strain Typing", "TEST", 200, 213], ["Pathogen", "PROBLEM", 218, 226], ["rapid strain typing method", "PROBLEM", 302, 328], ["the novel influenza H1N1 strain", "PROBLEM", 344, 375], ["other circulating H1N1 seasonal influenza A strains", "PROBLEM", 381, 432], ["large", "OBSERVATION_MODIFIER", 20, 25], ["geographic", "OBSERVATION_MODIFIER", 26, 36], ["areas", "OBSERVATION", 37, 42], ["influenza", "OBSERVATION", 354, 363]]], ["This meant that many recent travelers to Mexico, where the outbreak began, or to the USA or Canada, where human-tohuman transmission was reported early, were isolated for many days, awaiting results from the few reference laboratories able to identify the strain (initially, only after it was isolated in cell culture).", [["cell", "ANATOMY", 305, 309], ["human", "ORGANISM", 106, 111], ["cell", "CELL", 305, 309], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["the strain", "PROBLEM", 252, 262], ["cell culture", "TEST", 305, 317]]], ["However, sequences of several relevant antigen genes (hemagglutinin [H], neuraminidase [N] , and polymerase [P]), from \"swine flu\" H1N1 strains isolated in different parts of the world, were published (http:// www.ncbi.nlm.nih.gov/genomes/FLU/SwineFlu.html) within a very short period.", [["hemagglutinin [H]", "GENE_OR_GENE_PRODUCT", 54, 71], ["neuraminidase [N]", "GENE_OR_GENE_PRODUCT", 73, 90], ["swine flu\" H1N1 strains", "ORGANISM", 120, 143], ["antigen genes", "DNA", 39, 52], ["hemagglutinin [H]", "PROTEIN", 54, 71], ["neuraminidase", "PROTEIN", 73, 86], ["swine", "SPECIES", 120, 125], ["swine flu\" H1N1", "SPECIES", 120, 135], ["hemagglutinin", "TEST", 54, 67], ["neuraminidase", "TEST", 73, 86], ["polymerase", "TEST", 97, 107], ["H1N1 strains", "PROBLEM", 131, 143]]], ["This meant that culture-independent strain identification and typing methods soon became available to diagnostic laboratories around the world and played an important role in subsequent surveillance and control.Strain Typing for Pathogen TrackingThe availability of culture-independent diagnostic and strain typing systems for many pathogens of public health importance will make it possible for diagnostic laboratories to simultaneously identify relevant pathogenic species and their strain profiles, in a single assay, and report the results to public health authorities, within hours.", [["culture", "TEST", 16, 23], ["typing methods", "TEST", 62, 76], ["Strain Typing", "TEST", 211, 224], ["Pathogen", "PROBLEM", 229, 237], ["culture", "TEST", 266, 273], ["strain typing systems", "TEST", 301, 322], ["diagnostic laboratories", "TEST", 396, 419], ["relevant pathogenic species", "PROBLEM", 447, 474]]], ["Faster recognition and investigation of outbreaks will limit the number of cases and reduce the risk of new outbreaks.", [["outbreaks", "PROBLEM", 40, 49], ["new outbreaks", "PROBLEM", 104, 117], ["new", "OBSERVATION_MODIFIER", 104, 107], ["outbreaks", "OBSERVATION", 108, 117]]], ["Some rapid strain typing methods are already available and in use.", [["Some rapid strain typing methods", "PROBLEM", 0, 32], ["rapid", "OBSERVATION_MODIFIER", 5, 10], ["strain", "OBSERVATION_MODIFIER", 11, 17]]], ["However, like diagnostic methods, new strain typing methods need to be carefully evaluated to ensure that their use translates into better public health outcomes.", [["new strain typing methods", "TREATMENT", 34, 59]]], ["Unfortunately, the variety of different methods, the speed with which they are already being introduced, and limited funding for surveillance studies make prospective evaluation of risks, costs, and benefits, difficult.", [["surveillance studies", "TEST", 129, 149], ["prospective evaluation", "TEST", 155, 177], ["variety", "OBSERVATION_MODIFIER", 19, 26]]], ["In addition, prospective evaluation will be impracticable without easy access to patient demographic, clinical, and outcome data and will be impracticable without sophisticated informatics tools to analyze these data.Health Information SystemsRapid advances in medical science and therapeutics and increasing specialization have increased the demand for more accessible diagnostic, epidemiological, and therapeutic information, interpretive reporting of diagnostic test results, and clinical decision support systems.", [["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["prospective evaluation", "TEST", 13, 35], ["these data", "TEST", 206, 216], ["therapeutics", "TREATMENT", 281, 293], ["diagnostic test", "TEST", 454, 469]]], ["Electronic patient records (EPRs), networked with relevant clinical databases and information systems, are a logical response to these needs and are predicted to improve the quality, efficiency, safety. and reduce the cost of healthcare (Hillestad et al. 2005) .", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18]]], ["They could also significantly improve disease surveillance and control (Friedman 2006; Chaudhry et al. 2006 ) and population health.Health Information SystemsLinking clinical data from EPRs with microbiological results will enhance and personalize clinical decision support, e.g., for antibiotic prescribing (Sintchenko et al. 2008; Thursky et al. 2007) .", [["disease surveillance", "TEST", 38, 58], ["antibiotic prescribing", "TREATMENT", 285, 307]]], ["Linking clinical information with strain typing data will allow comparison of strains from different patients, in order to identify linked cases or outbreaks and to define their limits in space and time, much more rapidly than is currently possible (Gallego et al. 2009 ).", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["strain typing data", "TEST", 34, 52], ["strains", "PROBLEM", 78, 85]]], ["Prospective surveillance of aggregated clinical, diagnostic, pathogen profile, and outcome data will help identify previously unrecognized risk factors or microbial strains which are associated with more severe disease or adverse outcomes.", [["diagnostic, pathogen profile", "TEST", 49, 77], ["outcome data", "TEST", 83, 95], ["microbial strains", "PROBLEM", 155, 172], ["more severe disease", "PROBLEM", 199, 218], ["adverse outcomes", "PROBLEM", 222, 238], ["severe", "OBSERVATION_MODIFIER", 204, 210], ["disease", "OBSERVATION", 211, 218]]], ["They will provide a basis for risk assessment tools to alert public health or infection control practitioners to the need for quarantine or investigation of contacts.", [["infection", "DISEASE", 78, 87], ["risk assessment", "TEST", 30, 45], ["infection control practitioners", "TREATMENT", 78, 109], ["quarantine", "TREATMENT", 126, 136]]], ["The elements of an integrated clinical and public health information system may include:Health Information SystemsOn-line laboratory test order entry and reporting systems \u2022 Rapid, microbiological diagnosis and strain typing \u2022 Access to components of individual EPRs, including demographics and relevant \u2022 medical history (e.g., medical or environmental risk factors, presenting complaint, and laboratory test results) Data mining/analysis software that can identify and interpret epidemiological \u2022 links Risk assessment and decision support systems to guide public health or infection \u2022 control action Online prescribing and decision support to guide antibiotic therapy, if required, \u2022 based on laboratory results and clinical historyPractical ApplicationImagine this (future) scenario (only some components of which are currently plausible or -some would argue -even desirable):Practical ApplicationA patient presents with symptoms of an infectious disease; the doctor records \u2022 the clinical findings in the EPR and orders diagnostic tests online.", [["infection", "DISEASE", 576, 585], ["infectious disease", "DISEASE", 940, 958], ["patient", "ORGANISM", 903, 910], ["patient", "SPECIES", 903, 910], ["strain typing", "TEST", 211, 224], ["laboratory test results", "TEST", 394, 417], ["Data mining", "TEST", 419, 430], ["Risk assessment", "TEST", 505, 520], ["infection", "PROBLEM", 576, 585], ["antibiotic therapy", "TREATMENT", 652, 670], ["Practical ApplicationImagine", "TREATMENT", 735, 763], ["symptoms", "PROBLEM", 925, 933], ["an infectious disease", "PROBLEM", 937, 958], ["diagnostic tests", "TEST", 1025, 1041], ["infectious", "OBSERVATION", 940, 950]]], ["An informatics program with appropriate scanning software will scan the EPR \u2022 for relevant demographic and medical risk factors and may prompt the doctor to seek additional information (e.g., about recent travel, diet, or contacts).", [["appropriate scanning software", "TEST", 28, 57]]], ["The program will analyze the clinical data, provide a differential diagnosis and \u2022 a list of appropriate laboratory tests, and recommend empirical antibiotic therapy, if indicated, based on therapeutic guidelines, local susceptibility data and the medical history.", [["appropriate laboratory tests", "TEST", 93, 121], ["empirical antibiotic therapy", "TREATMENT", 137, 165], ["therapeutic guidelines", "TREATMENT", 190, 212], ["local susceptibility data", "TEST", 214, 239]]], ["(Artificial intelligence systems capable of making diagnostic and management decisions are still largely aspirational).", [["Artificial intelligence systems", "TREATMENT", 1, 32]]], ["A pharmacy information system will establish that the drug dose is correct and \u2022 will check for possible interactions with other current medications before the drug is dispensed and ready for the patient to collect, along with a personalized information sheet about precautions and potential adverse side-effects.", [["patient", "ORGANISM", 196, 203], ["patient", "SPECIES", 196, 203], ["the drug dose", "TREATMENT", 50, 63], ["other current medications", "TREATMENT", 123, 148], ["precautions", "TREATMENT", 266, 277], ["potential adverse side-effects", "PROBLEM", 282, 312]]], ["The laboratory request form and a list of specimens required will be available \u2022 when the patient arrives at the specimen collection center; specimens will be delivered to the laboratory and processed rapidly.", [["specimens", "ANATOMY", 42, 51], ["specimens", "ANATOMY", 141, 150], ["specimens", "CANCER", 42, 51], ["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97]]], ["If a relevant pathogen is identified, appropriate strain typing and/or antibiotic \u2022 susceptibility testing will be performed.", [["a relevant pathogen", "PROBLEM", 3, 22], ["appropriate strain typing", "TEST", 38, 63], ["antibiotic \u2022 susceptibility testing", "TEST", 71, 106]]], ["The treating doctor's report may include a modified recommendation for treat-\u2022 ment (e.g., a different antibiotic, based on the pathogen susceptibility or a recommendation to discontinue treatment); in some cases, a warning of potential complications (based on patient and pathogen profiles) will be added.", [["patient", "ORGANISM", 261, 268], ["patient", "SPECIES", 261, 268], ["treat-\u2022 ment", "TREATMENT", 71, 83], ["a different antibiotic", "TREATMENT", 91, 113], ["treatment", "TREATMENT", 187, 196], ["potential complications", "PROBLEM", 227, 250]]], ["If the infection is notifiable a second report will be sent, automatically, to the \u2022 relevant public health authority.", [["infection", "DISEASE", 7, 16], ["the infection", "PROBLEM", 3, 16], ["infection", "OBSERVATION", 7, 16]]], ["The strain profile will be compared with those of other strains in a database linked to similar laboratory databases within the same jurisdiction, country or, potentially, internationally.", [["The strain profile", "TEST", 0, 18], ["other strains", "PROBLEM", 50, 63]]], ["This analysis will identify outbreaks and monitor the geographic and temporal \u2022 distribution of different strains in different populations, which may provide early warning of the emergence of new strains or detect potential vaccine failures.", [["This analysis", "TEST", 0, 13], ["outbreaks", "PROBLEM", 28, 37], ["different strains", "PROBLEM", 96, 113], ["new strains", "PROBLEM", 192, 203], ["potential vaccine failures", "PROBLEM", 214, 240], ["different strains", "OBSERVATION", 96, 113]]], ["Spatial and temporal parameters for the detection of outbreaks due to the same strain will be modifiable to account for varying geographic areas or time periods from a few days to months or years.", [["outbreaks", "PROBLEM", 53, 62], ["the same strain", "PROBLEM", 70, 85], ["varying geographic areas", "PROBLEM", 120, 144]]], ["If an outbreak is identified, the report may also list other individuals infected \u2022 with the same pathogen strain and any relevant medical or epidemiological risk factors (recorded in their EPRs) and suggest appropriate public health action or a possible common source or index case.Practical ApplicationThe use of integrated clinical and laboratory systems and informatics tools, linked to decision support systems, with continuous analysis and feedback of epidemiological, clinical, outcome and other data, could improve our understanding of disease epidemiology.", [["the same pathogen strain", "PROBLEM", 89, 113], ["epidemiological risk factors", "PROBLEM", 142, 170], ["laboratory systems", "TEST", 339, 357], ["informatics tools", "TEST", 362, 379], ["continuous analysis", "TEST", 422, 441], ["outbreak", "OBSERVATION", 6, 14]]], ["It would enable assessment and improvement of the predictive accuracy (likelihood ratios) of diagnostic and pathogen profiling methods and the efficacy and cost-effectiveness of treatment and preventive interventions; it should improve clinical outcomes.", [["enable assessment", "TEST", 9, 26], ["the predictive accuracy", "TEST", 46, 69], ["pathogen profiling methods", "TEST", 108, 134], ["treatment", "TREATMENT", 178, 187], ["preventive interventions", "TREATMENT", 192, 216]]], ["Nevertheless, as with other novel health management systems, if there is inadequate validation or precautions against inappropriate use, it could lead to unnecessary anxiety, the stigmatization of infected patients, unwarranted infringement of liberty (if coercive public health restrictions are inappropriately applied) and increased healthcare costs.Electronic Patient RecordsEPRs are computerized medical records, which allow storage, easy retrieval, searching, and sharing of different types of medical and non-medical data (including laboratory results).", [["anxiety", "DISEASE", 166, 173], ["infected", "DISEASE", 197, 205], ["patients", "ORGANISM", 206, 214], ["patients", "SPECIES", 206, 214], ["Patient", "SPECIES", 363, 370], ["precautions", "TREATMENT", 98, 109], ["unnecessary anxiety", "PROBLEM", 154, 173], ["coercive public health restrictions", "TREATMENT", 256, 291], ["infected", "OBSERVATION_MODIFIER", 197, 205]]], ["Many different EPR systems have been described but are still in limited use in hospitals and healthcare systems.", [["Many different EPR systems", "PROBLEM", 0, 26]]], ["A report commissioned by the Rand Corporation, in 2005, suggested that the introduction of EPRs could save >$US 80 billion in healthcare costs in the USA (Hillestad et al. 2005) .", [["EPRs", "TREATMENT", 91, 95]]], ["However, this has been recently disputed by physicians from Harvard Medical School hospitals -where EPRs have been in use for many years -who claimed that, despite some real benefits of EPRs, the projected cost-savings and quality improvement were exaggerated (Groopman and Jartzband 2009) .", [["EPRs", "TREATMENT", 186, 190]]], ["They expressed concern about the potential use of EPRs to gather evidence about costs, which could be used to limit the use of expensive medical or surgical interventions, and warned against the introduction of expensive technology without rigorous evaluation and evidence.Electronic Patient RecordsThere has been very little analysis of the potential improvement in disease surveillance by the use of EPR data (and, to our knowledge, none specifically related to communicable disease control).", [["EPRs", "TREATMENT", 50, 54], ["expensive medical", "TREATMENT", 127, 144], ["surgical interventions", "TREATMENT", 148, 170], ["rigorous evaluation", "TEST", 240, 259], ["disease surveillance", "TEST", 367, 387], ["EPR data", "TEST", 402, 410], ["communicable disease control", "TREATMENT", 464, 492], ["improvement", "OBSERVATION_MODIFIER", 352, 363], ["disease", "OBSERVATION", 367, 374]]], ["In paper-based medical systems, \"privacy is protected by chaos\" (Rothstein 2008) , records are fragmented and often difficult to compile or locate.", [["fragmented", "OBSERVATION", 95, 105]]], ["EPRs can facilitate the optimal use (mining, analysis, linkage) of data to improve health outcomes and save lives.", [["EPRs", "TREATMENT", 0, 4]]], ["Patients will be reluctant to disclose intimate information, no matter what the potential public benefit, if they fear that it could be used to their disadvantage by government officials, employers or insurance companies.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Safeguards based on sound ethical principles will be needed to protect privacy and to prevent harm or disadvantage to individuals while promoting public health and gaining optimal benefit from limited public health resources.Electronic Patient RecordsDespite increasing concern and legislation relating to the privacy of personal information (e.g., in Australia, the Federal Privacy Act, 1988 -http://www.austlii. edu.au/au/legis/cth/consol_act/pa1988108/), health information is generally treated as a separate category of personal information (e.g., New South Wales [NSW] Health Records and Information Privacy Act, 2002 -http://www.lawlink.nsw.gov. au/lawlink/privacynsw/ll_pnsw.nsf/pages/PNSW_03_hripact) .", [["lawlink", "PROTEIN", 655, 662], ["privacynsw", "PROTEIN", 663, 673], ["/ll_pnsw.nsf", "PROTEIN", 673, 685], ["/PNSW_03_hripact", "PROTEIN", 691, 707], ["edu.au/au/legis/cth/consol_act/pa1988108", "SPECIES", 414, 454], ["au/lawlink/privacynsw/ll_pnsw.nsf/pages/PNSW_03_hripact", "SPECIES", 652, 707], ["Safeguards", "TREATMENT", 0, 10], ["sound ethical principles", "TREATMENT", 20, 44]]], ["If the use of health information for disease surveillance were to be expanded, there would be certain requirements for the protection of privacy, such as: Development of ethical standards for the development, implementation, evalua-\u2022 tion and modification of bioinformatics software programs for the storage and analysis of patient data (Gotterbarn and Rogerson 2006) Publicly debated, transparent and binding software and hardware standards to \u2022 protect privacy, confidentiality, integrity and security of data Clearly defined principles governing access to identified data for the purposes of \u2022 disease surveillance or research, including by whom and under what circumstances access is allowed, how it will be monitored and under what circumstances the individual must either give consent or be informed that their record has been accessed Breaches of privacy may be objective (i.e., resulting in fraud or denial of a service or of freedom) or subjective (i.e. resulting in second or third parties having access to intimate information, which may cause distress, without objective harm).", [["patient", "ORGANISM", 324, 331], ["patient", "SPECIES", 324, 331], ["disease surveillance", "TEST", 37, 57], ["hardware standards", "TREATMENT", 423, 441], ["\u2022 disease surveillance", "PROBLEM", 595, 617], ["distress", "PROBLEM", 1055, 1063]]], ["These different consequences may need to be considered differently in assessing the risks associated with the use of EPRs.", [["EPRs", "TREATMENT", 117, 121]]], ["However, informed consent for the selective release of medical records (McKinney et al. 2005) would be difficult to obtain and is unlikely to be practicable if data are to be accessible in an emergency or for disease control purposes.", [["disease control purposes", "TREATMENT", 209, 233]]], ["A number of standards exist already, including some designed to protect confidentiality of data transferred across national borders in compliance with international health-related applications e.g., International Organization for Standardization (ISO) 22857:2004 (Kalra and Ingram 2006) .Communicable Disease Notification and SurveillanceEven for communicable disease surveillance, some data can be de-identified and used to monitor trends in disease rates, to identify risk factors and to assess the effectiveness of public health interventions.", [["communicable disease", "DISEASE", 347, 367], ["communicable disease surveillance", "TEST", 347, 380], ["disease rates", "TEST", 443, 456], ["risk factors", "PROBLEM", 470, 482], ["public health interventions", "TREATMENT", 518, 545]]], ["However, communicable disease surveillance often requires individual patient identification to allow contact tracing, outbreak investigation and the implementation of appropriate control measures and to determine the outcomes.", [["communicable disease", "DISEASE", 9, 29], ["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["communicable disease surveillance", "PROBLEM", 9, 42], ["contact tracing", "TEST", 101, 116], ["outbreak investigation", "TEST", 118, 140], ["appropriate control measures", "TREATMENT", 167, 195]]], ["In practice, there is little public opposition to the notification of identifiable, personal information to health authorities for communicable disease surveillance, which is accepted as necessary in the public interest.", [["communicable disease surveillance", "PROBLEM", 131, 164], ["little", "OBSERVATION_MODIFIER", 22, 28], ["public opposition", "OBSERVATION", 29, 46]]], ["However, this may be, in part, because current communicable disease surveillance systems are generally slow, insensitive, and nonspecific.", [["current communicable disease surveillance systems", "PROBLEM", 39, 88], ["may be", "UNCERTAINTY", 14, 20], ["nonspecific", "OBSERVATION_MODIFIER", 126, 137]]], ["They are relatively ineffective in detecting, preventing, or interrupting disease outbreaks (Eng and Eng 2004) but also difficult for unauthorized individuals to access and use inappropriately.", [["interrupting disease outbreaks", "PROBLEM", 61, 91], ["ineffective", "OBSERVATION_MODIFIER", 20, 31]]], ["The type of future networked EPRs and databases envisaged in the scenario above will be more effective than conventional systems, but potentially more at risk of abuse, with more serious consequences.Communicable Disease Notification and SurveillanceProtection of genetic or infectious diseases data is necessary to prevent objective breaches of privacy, such as harassment or stigmatization, which could lead to denial of insurance or jobs.", [["infectious diseases", "DISEASE", 275, 294], ["Communicable Disease", "PROBLEM", 200, 220], ["infectious diseases data", "PROBLEM", 275, 299]]], ["However, improvements in disease control, based on efficient surveillance across large populations could not be achieved if large numbers of people refused to participate because of fear that results could be misused.", [["people", "ORGANISM", 141, 147], ["people", "SPECIES", 141, 147], ["disease control", "TREATMENT", 25, 40], ["disease", "OBSERVATION", 25, 32]]], ["EPR networks could, paradoxically, protect privacy more effectively, by allowing limits to be imposed on the scope of data that could be accessed.", [["EPR networks", "TREATMENT", 0, 12]]], ["Scanning software could be programmed to select only information relevant to a specific purpose, using 'contextual access criteria' -software algorithms which specify that, for an enquiry of type X, only data A, B, and C are needed.Communicable Disease Notification and SurveillanceNetworking of EPRs and other information systems raises new issues relating to informed consent.", [["B", "GENE_OR_GENE_PRODUCT", 212, 213], ["Scanning software", "TEST", 0, 17], ["software algorithms", "TEST", 133, 152], ["new issues", "PROBLEM", 338, 348]]], ["For effective disease surveillance, all patient records would need to be accessible to data scanning software.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["effective disease surveillance", "PROBLEM", 4, 34], ["scanning software", "TEST", 92, 109]]], ["Informed consent for individual investigations or routine surveillance would be impracticable.", [["individual investigations", "TEST", 21, 46], ["routine surveillance", "TEST", 50, 70]]], ["It will, therefore, be important that the implementation of electronic health data management systems and their use for disease surveillance be preceded and accompanied by adequate information, public debate, transparency and appropriate safeguards.The Use of New Laboratory DataNetworking laboratory information systems.", [["electronic health data management systems", "TREATMENT", 60, 101], ["disease surveillance", "TEST", 120, 140]]], ["The use of laboratory data for electronic disease surveillance would require that laboratory results from different laboratories mean the same thing.", [["laboratory data", "TEST", 11, 26], ["electronic disease surveillance", "TEST", 31, 62]]], ["While this may seem obvious, existing differences in result interpretation, predictive values of different methods and lack of consensus on optimal methods, mean that considerable harmonization of laboratory practices will be required.", [["optimal methods", "TEST", 140, 155], ["laboratory practices", "TREATMENT", 197, 217]]], ["Different laboratory management structures, funding sources, referral patterns, and accountabilities between private and public laboratories or between primarily diagnostic and reference/public health laboratories will make this difficult, but not impossible.The Use of New Laboratory DataLaboratory staff and directors are often reluctant to share details of tests numbers or methods, quality assurance programs are generally conducted anonymously, and accreditation authorities are required to maintain strict confidentiality, in relation to procedures (including any deficiencies) within individual laboratories.", [["any deficiencies", "PROBLEM", 566, 582]]], ["Clearly, issues of trust, commercial confidentiality and quality assurance will need to be addressed at the same time, as details of, laboratory testing methods and interpretation and compatibility of different types of information system.The Use of New Laboratory DataThe ability to generate personalized interpretive laboratory reports based on demographic and clinical data in the EPR would assist clinicians who are often unfamiliar with rapidly changing laboratory methods and their interpretation.", [["laboratory testing methods", "TEST", 134, 160]]], ["The ability of the laboratory information system to rapidly identify a possible outbreak, by identifying clusters of microbial isolates with similar genetic profiles could significantly reduce the size and impact of communicable disease outbreaks.", [["outbreak", "PROBLEM", 80, 88], ["microbial isolates", "PROBLEM", 117, 135], ["communicable disease outbreaks", "PROBLEM", 216, 246], ["size", "OBSERVATION_MODIFIER", 197, 201], ["communicable disease", "OBSERVATION", 216, 236]]], ["Personalized, targeted decision support can potentially reduce inappropriate antibiotic use, healthcare costs (Sintchenko et al. 2005) , the emergence of drug resistance and adverse drug effects.The Use of New Laboratory DataThe use of laboratory data for clinical quality and safety.", [["drug resistance", "TREATMENT", 154, 169], ["adverse drug effects", "PROBLEM", 174, 194], ["laboratory data", "TEST", 236, 251], ["drug resistance", "OBSERVATION", 154, 169]]], ["Laboratory information systems can be used by health authorities to monitor the quality of patient care in individual hospitals (Fairweather and Rogerson 2001) by gathering statistics about infections which develop after a patient's admission to hospital -such as S. aureus or specifically MRSA blood stream infections.", [["blood", "ANATOMY", 295, 300], ["infections", "DISEASE", 190, 200], ["MRSA blood stream infections", "DISEASE", 290, 318], ["patient", "ORGANISM", 91, 98], ["patient", "ORGANISM", 223, 230], ["S. aureus", "ORGANISM", 264, 273], ["MRSA", "ORGANISM", 290, 294], ["blood", "ORGANISM_SUBSTANCE", 295, 300], ["patient", "SPECIES", 91, 98], ["patient", "SPECIES", 223, 230], ["S. aureus", "SPECIES", 264, 273], ["MRSA", "SPECIES", 290, 294], ["S. aureus", "SPECIES", 264, 273], ["MRSA", "SPECIES", 290, 294], ["infections", "PROBLEM", 190, 200], ["S. aureus", "PROBLEM", 264, 273], ["MRSA blood stream infections", "PROBLEM", 290, 318], ["aureus", "OBSERVATION", 267, 273]]], ["This has benefits for both potential patients and the general public who arguably have a right to information about the quality of care in hospitals to which they may be admitted in future.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45]]], ["In some countries, data related to HAIs are publicly reported, and the occurrence of cases judged to be preventable may incur penalties.", [["HAIs", "DISEASE", 35, 39], ["HAIs", "PROBLEM", 35, 39]]], ["For example, the Centers for Medicare and Medicaid Services (CMS) in the USA have recently announced that they will no longer reimburse healthcare facilities for costs related to certain HAIs that could have reasonably been prevented through the use of evidence-based guidelines (http://www.idsociety.org/newsArticle.aspx?id = 6,852).The Use of New Laboratory DataMany health professionals and administrators are concerned about financial penalties for \"preventable\" infections and about possible misinterpretation of publicly reported HAI rates because of differences in case-mix and reporting systems (Stone et al. 2005 ) between hospitals.", [["HAIs", "DISEASE", 187, 191], ["infections", "DISEASE", 467, 477], ["certain HAIs", "PROBLEM", 179, 191], ["preventable\" infections", "PROBLEM", 454, 477]]], ["Some commentators fear that hospitals may refuse to care for high-risk patients who are more likely to develop infections.", [["infections", "DISEASE", 111, 121], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["infections", "PROBLEM", 111, 121], ["infections", "OBSERVATION", 111, 121]]], ["However, electronic reporting and data scanning software have the potential to analyze individual patient risk factors and adjust incidence data according to the differences in case mix between different types of hospital.The Use of New Laboratory DataLike most other applications, the use of surveillance data for quality assurance has the potential to improve patient care and the performance and accountability of individual clinicians and healthcare organizations, but there is, also the potential for misuse, breaches of confidentiality and data security not only for patients, but also for professionals, who are usually very wary of any type of performance monitoring.Surveillance Ethics: A New ParadigmAdvances in surveillance technologies raise the need for the development of frameworks and guidelines for surveillance ethics.", [["patient", "ORGANISM", 98, 105], ["patient", "ORGANISM", 362, 369], ["patients", "ORGANISM", 573, 581], ["patient", "SPECIES", 98, 105], ["patient", "SPECIES", 362, 369], ["patients", "SPECIES", 573, 581], ["data scanning software", "TEST", 34, 56], ["individual patient risk factors", "PROBLEM", 87, 118], ["incidence data", "TEST", 130, 144], ["surveillance data", "TEST", 293, 310], ["performance monitoring", "TEST", 652, 674], ["surveillance technologies", "TREATMENT", 722, 747]]], ["Research ethics has traditionally been a central theme of bioethics discourse, for which monitoring guidelines and procedures are well established in health and research institutions, but the ethics of disease surveillance is a relatively unexplored area in need of debate.", [["procedures", "TREATMENT", 115, 125], ["disease surveillance", "TEST", 202, 222]]], ["In theory, these may be the questions of definition and semantics, but there are currently major differences, which may or may not be justified, in the way these two areas are perceived by practitioners and funding bodies.", [["may not be", "UNCERTAINTY", 123, 133]]], ["From an ethical perspective, the key question is whether there are morally relevant differences between research and surveillance such that the ethical requirements for the former should not also apply to the latter.", [["surveillance", "TEST", 117, 129]]], ["Given that research and surveillance are similar insofar as both aim to generate information to promote health outcomes, the crucial questions are whether, why and how much, if at all, ethical requirements for disease surveillance should be less stringent than those of biomedical research.", [["disease surveillance", "TEST", 210, 230]]]], "d1293cbb27aa58d9b629c26b3f413690701afc7f": [["We have given two articles published recently in Science of the Total Environment by Mandal and Pal (2020) and Zambrano-Monserrate et al. (2020) a thorough reading.", [["Zambrano", "TREATMENT", 111, 119]]], ["Both articles present a significant association between the novel Coronavirus (COVID-19) social distancing policies and improvement in environmental quality such as air pollution, land surface temperature, and noise.", [["surface", "ANATOMY", 185, 192], ["the novel Coronavirus", "PROBLEM", 56, 77], ["social distancing policies", "TREATMENT", 89, 115], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["improvement", "OBSERVATION_MODIFIER", 120, 131]]], ["Both articles present good research, complemented by detailed explanations and displays, yet we have a few concerns that affect the interpretation and meaning of the results.", [["good", "OBSERVATION_MODIFIER", 22, 26]]]], "61f28c2619954ac3b4ae1b41f9dad830d44d35b9": [["Members of the Dhori virus serogroup are as yet unclassified tick transmitted viruses that share structural and genetic properties with the Orthomyxoviridae (Clerx et al., 1983) .", [["Dhori virus serogroup", "ORGANISM", 15, 36], ["Dhori virus serogroup", "SPECIES", 15, 36], ["Dhori virus", "SPECIES", 15, 26], ["the Dhori virus serogroup", "PROBLEM", 11, 36]]], ["Dhori viruses have been isolated from a variety of tick and vertebrate species (Anderson and Casals, 1973; Filipe and Casals, 1979; Karabat-SOS, 1985; Williams et a/., 1973) .", [["Dhori viruses", "ORGANISM", 0, 13], ["Dhori viruses", "SPECIES", 0, 13], ["Dhori viruses", "PROBLEM", 0, 13]]], ["The genome of the virus consists of seven unique segments of singlestranded RNA with a total size of approximately 1 1.9 kb.", [["singlestranded RNA", "RNA", 61, 79], ["the virus", "PROBLEM", 14, 23], ["virus", "OBSERVATION", 18, 23], ["seven", "OBSERVATION_MODIFIER", 36, 41], ["unique", "OBSERVATION_MODIFIER", 42, 48], ["segments", "OBSERVATION_MODIFIER", 49, 57], ["singlestranded RNA", "OBSERVATION", 61, 79], ["total", "OBSERVATION_MODIFIER", 87, 92], ["size", "OBSERVATION_MODIFIER", 93, 97]]], ["The viral RNAs have been shown to encode information in the negative-sense (Clerx et al., 1983; Fuller et al., 1987; Freedman-Faulstich and Fuller, 1990) and it was previously shown that the Dhori nucleoprotein (encoded by RNA segment 5) shares conserved amino acid sequences with the influenza A, B, and C virus nucleoproteins (Fuller et al., 1987) .", [["amino acid", "CHEMICAL", 255, 265], ["amino acid", "CHEMICAL", 255, 265], ["Dhori nucleoprotein", "GENE_OR_GENE_PRODUCT", 191, 210], ["RNA segment 5", "GENE_OR_GENE_PRODUCT", 223, 236], ["amino acid", "AMINO_ACID", 255, 265], ["influenza A", "ORGANISM", 285, 296], ["B", "GENE_OR_GENE_PRODUCT", 298, 299], ["C virus", "ORGANISM", 305, 312], ["viral RNAs", "RNA", 4, 14], ["Dhori nucleoprotein", "PROTEIN", 191, 210], ["RNA segment 5", "DNA", 223, 236], ["The viral RNAs", "PROBLEM", 0, 14], ["Freedman", "TEST", 117, 125], ["the Dhori nucleoprotein", "PROBLEM", 187, 210], ["amino acid sequences", "TEST", 255, 275], ["the influenza A", "PROBLEM", 281, 296], ["C virus nucleoproteins", "PROBLEM", 305, 327], ["viral RNAs", "OBSERVATION", 4, 14]]], ["The sequence of RNA segment 4 encodes the single envelope protein of Dhori virus (Freedman-Faulstich and Fuller, 1990) .", [["RNA segment 4", "GENE_OR_GENE_PRODUCT", 16, 29], ["Dhori virus", "ORGANISM", 69, 80], ["RNA segment 4", "DNA", 16, 29], ["envelope protein", "PROTEIN", 49, 65], ["Dhori virus", "SPECIES", 69, 80], ["Dhori virus", "PROBLEM", 69, 80], ["Dhori virus", "OBSERVATION", 69, 80]]], ["The envelope protein does not share sequence identity with any orthomyxovirus envelope protein.", [["envelope protein", "PROTEIN", 4, 20], ["orthomyxovirus envelope protein", "PROTEIN", 63, 94], ["any orthomyxovirus envelope protein", "PROBLEM", 59, 94]]], ["We have also determined the nucleotide sequence of the Dhori segment 6 RNA and this segment most likely encodes the viral matrix protein (unpublished data).", [["nucleotide", "CHEMICAL", 28, 38], ["nucleotide", "CHEMICAL", 28, 38], ["Dhori segment 6 RNA", "RNA", 55, 74], ["viral matrix protein", "PROTEIN", 116, 136], ["the nucleotide sequence", "TEST", 24, 47], ["the viral matrix protein", "PROBLEM", 112, 136], ["most likely", "UNCERTAINTY", 92, 103], ["viral matrix", "OBSERVATION", 116, 128]]], ["The 3'and 5' nontranslated ends of RNA segments 4, 5, and 6 are very similar to the conserved ends of the genes of the recognized members of the Orthomyxoviridae (Clerx et ' To whom correspondence and requests for reprints should be addressed. a/., Fuller et a/., 1987; Freedman-Faulstich and Fuller, 1990) and segment 3 of Thogoto virus (Staunton et al., 1989) .", [["3'", "CELLULAR_COMPONENT", 4, 6], ["5", "GENE_OR_GENE_PRODUCT", 51, 52], ["6", "GENE_OR_GENE_PRODUCT", 58, 59], ["Thogoto virus", "ORGANISM", 324, 337], ["3'and 5' nontranslated ends", "DNA", 4, 31], ["RNA segments 4, 5, and 6", "DNA", 35, 59], ["Thogoto virus", "SPECIES", 324, 337], ["Freedman", "TEST", 270, 278], ["Thogoto virus", "PROBLEM", 324, 337], ["RNA", "ANATOMY_MODIFIER", 35, 38], ["segments 4", "ANATOMY_MODIFIER", 39, 49]]]], "b0307999b066cba2f0ee328555fec63470b83f6f": [["BackgroundIn terms of general pathology, inflammation is one of the adaptive responses to various injuries including physical, chemical, and biological factors.", [["inflammation", "DISEASE", 41, 53], ["injuries", "DISEASE", 98, 106], ["general pathology", "PROBLEM", 22, 39], ["inflammation", "PROBLEM", 41, 53], ["various injuries", "PROBLEM", 90, 106], ["pathology", "OBSERVATION", 30, 39], ["inflammation", "OBSERVATION", 41, 53]]], ["The Roman encyclopedist A. Cornelius Celsus described four cardinal signs of inflammation in one concise sentence: \"Now the signs of an inflammation are four: redness (rubour) and swelling (tumour), with heat (calour) and pain (dolour)\" [1] .", [["tumour", "ANATOMY", 190, 196], ["inflammation", "DISEASE", 77, 89], ["inflammation", "DISEASE", 136, 148], ["redness", "DISEASE", 159, 166], ["swelling", "DISEASE", 180, 188], ["tumour", "DISEASE", 190, 196], ["pain", "DISEASE", 222, 226], ["tumour", "CANCER", 190, 196], ["inflammation", "PROBLEM", 77, 89], ["an inflammation", "PROBLEM", 133, 148], ["redness (rubour)", "PROBLEM", 159, 175], ["swelling (tumour)", "PROBLEM", 180, 197], ["heat (calour)", "TREATMENT", 204, 217], ["pain", "PROBLEM", 222, 226], ["inflammation", "OBSERVATION", 77, 89], ["inflammation", "OBSERVATION", 136, 148], ["redness", "OBSERVATION", 159, 166], ["swelling", "OBSERVATION", 180, 188]]], ["The classical signs of inflammation are considered to be related to cells and tissues responding to pathological cell injury caused by internal stimuli, including damage-associated products and metabolites, and external stimuli, including bacteria and viruses [3] [4] [5] [6] .BackgroundThe host bears the receptors that facilitate recognition of these damage-associated molecular patterns (DAMPs) and/ or pathogen-associated molecular patterns (PAMPs) that are not host-derived.", [["cells", "ANATOMY", 68, 73], ["tissues", "ANATOMY", 78, 85], ["cell", "ANATOMY", 113, 117], ["inflammation", "DISEASE", 23, 35], ["cells", "CELL", 68, 73], ["tissues", "TISSUE", 78, 85], ["cell", "CELL", 113, 117], ["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 260, 275], ["DAMPs", "GENE_OR_GENE_PRODUCT", 391, 396], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 406, 444], ["PAMPs", "GENE_OR_GENE_PRODUCT", 446, 451], ["DAMPs", "PROTEIN", 391, 396], ["pathogen-associated molecular patterns", "PROTEIN", 406, 444], ["PAMPs", "PROTEIN", 446, 451], ["inflammation", "PROBLEM", 23, 35], ["cells and tissues", "PROBLEM", 68, 85], ["pathological cell injury", "PROBLEM", 100, 124], ["internal stimuli", "TEST", 135, 151], ["damage-associated products and metabolites", "PROBLEM", 163, 205], ["external stimuli", "TEST", 211, 227], ["bacteria and viruses", "PROBLEM", 239, 259], ["these damage", "PROBLEM", 347, 359], ["pathogen", "PROBLEM", 406, 414], ["inflammation", "OBSERVATION", 23, 35], ["pathological cell injury", "OBSERVATION", 100, 124], ["internal stimuli", "OBSERVATION", 135, 151]]], ["These receptors are termed pattern recognition receptors (PRRs) [7] .", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 27, 56], ["pattern recognition receptors", "PROTEIN", 27, 56], ["PRRs", "PROTEIN", 58, 62]]], ["PRRs directly or indirectly detect infection and/or noxious chemicals, resulting in inflammation that is coupled with the induction of immune responses and a tissue reparative component [8] .", [["tissue", "ANATOMY", 158, 164], ["infection", "DISEASE", 35, 44], ["inflammation", "DISEASE", 84, 96], ["PRRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissue", "TISSUE", 158, 164], ["PRRs", "PROTEIN", 0, 4], ["PRRs", "PROBLEM", 0, 4], ["infection", "PROBLEM", 35, 44], ["noxious chemicals", "PROBLEM", 52, 69], ["inflammation", "PROBLEM", 84, 96], ["immune responses", "PROBLEM", 135, 151], ["a tissue reparative component", "PROBLEM", 156, 185], ["infection", "OBSERVATION", 35, 44], ["inflammation", "OBSERVATION", 84, 96]]], ["The signal transduction triggered by these PRRs leads to the acute inflammatory mediator expressions that regulate the elimination of pathogens and infected cells [9, 10] .BackgroundThere are several known PRRs: Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), and C-type lectin receptors (CLRs).", [["cells", "ANATOMY", 157, 162], ["PRRs", "GENE_OR_GENE_PRODUCT", 43, 47], ["cells", "CELL", 157, 162], ["PRRs", "GENE_OR_GENE_PRODUCT", 206, 210], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 212, 231], ["TLRs", "GENE_OR_GENE_PRODUCT", 233, 237], ["RIG-I-like receptors", "GENE_OR_GENE_PRODUCT", 240, 260], ["RLRs", "GENE_OR_GENE_PRODUCT", 262, 266], ["NOD-like receptors", "GENE_OR_GENE_PRODUCT", 269, 287], ["NLRs", "GENE_OR_GENE_PRODUCT", 289, 293], ["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 300, 323], ["CLRs", "GENE_OR_GENE_PRODUCT", 325, 329], ["PRRs", "PROTEIN", 43, 47], ["infected cells", "CELL_TYPE", 148, 162], ["PRRs", "PROTEIN", 206, 210], ["Toll-like receptors", "PROTEIN", 212, 231], ["TLRs", "PROTEIN", 233, 237], ["RIG-I-like receptors", "PROTEIN", 240, 260], ["RLRs", "PROTEIN", 262, 266], ["NOD-like receptors", "PROTEIN", 269, 287], ["NLRs", "PROTEIN", 289, 293], ["C-type lectin receptors", "PROTEIN", 300, 323], ["CLRs", "PROTEIN", 325, 329], ["the acute inflammatory mediator expressions", "PROBLEM", 57, 100], ["pathogens", "PROBLEM", 134, 143], ["infected cells", "PROBLEM", 148, 162], ["RIG-I-like receptors", "PROBLEM", 240, 260], ["RLRs", "TEST", 262, 266], ["NOD", "TEST", 269, 272], ["NLRs", "TEST", 289, 293], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["inflammatory", "OBSERVATION", 67, 79]]], ["The majority of NOD-like receptors such as NLRP1, NLRP3, NLRC4, NLRP6, and NLRP12 can interact with apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC) and caspase-1, and the resulting complex is a sensor of cell injury called \"inflammasome\", an interleukin (IL)-1\u03b2-processing platform that plays a crucial role in IL-1\u03b2 maturation and secretion from cells.", [["cell", "ANATOMY", 242, 246], ["cells", "ANATOMY", 385, 390], ["NOD-like receptors", "GENE_OR_GENE_PRODUCT", 16, 34], ["NLRP1", "GENE_OR_GENE_PRODUCT", 43, 48], ["NLRP3", "GENE_OR_GENE_PRODUCT", 50, 55], ["NLRC4", "GENE_OR_GENE_PRODUCT", 57, 62], ["NLRP6", "GENE_OR_GENE_PRODUCT", 64, 69], ["NLRP12", "GENE_OR_GENE_PRODUCT", 75, 81], ["apoptosis-associated speck-like protein", "GENE_OR_GENE_PRODUCT", 100, 139], ["caspase-recruitment domain", "GENE_OR_GENE_PRODUCT", 153, 179], ["ASC", "GENE_OR_GENE_PRODUCT", 181, 184], ["caspase-1", "GENE_OR_GENE_PRODUCT", 190, 199], ["cell", "CELL", 242, 246], ["interleukin (IL)-1\u03b2", "GENE_OR_GENE_PRODUCT", 280, 299], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 349, 354], ["cells", "CELL", 385, 390], ["NOD-like receptors", "PROTEIN", 16, 34], ["NLRP1", "PROTEIN", 43, 48], ["NLRP3", "PROTEIN", 50, 55], ["NLRC4", "PROTEIN", 57, 62], ["NLRP6", "PROTEIN", 64, 69], ["NLRP12", "PROTEIN", 75, 81], ["apoptosis-associated speck-like protein", "PROTEIN", 100, 139], ["caspase-recruitment domain", "PROTEIN", 153, 179], ["ASC", "PROTEIN", 181, 184], ["caspase-1", "PROTEIN", 190, 199], ["interleukin (IL)-1\u03b2", "PROTEIN", 280, 299], ["NOD-like receptors", "PROBLEM", 16, 34], ["NLRP1", "TEST", 43, 48], ["NLRP3", "TREATMENT", 50, 55], ["NLRC4", "TREATMENT", 57, 62], ["NLRP6", "TREATMENT", 64, 69], ["NLRP12", "TREATMENT", 75, 81], ["apoptosis", "TEST", 100, 109], ["speck", "TEST", 121, 126], ["a caspase", "TREATMENT", 151, 160], ["caspase", "TEST", 190, 197], ["cell injury", "PROBLEM", 242, 253], ["inflammasome", "PROBLEM", 262, 274], ["an interleukin (IL)", "TREATMENT", 277, 296], ["secretion from cells", "PROBLEM", 370, 390], ["cell injury", "OBSERVATION", 242, 253]]], ["Other pyrin-domain (PYD)-containing proteins such as AIM2, IFI-16, and pyrin are also known to form inflammasomes.", [["pyrin", "GENE_OR_GENE_PRODUCT", 6, 11], ["PYD", "GENE_OR_GENE_PRODUCT", 20, 23], ["AIM2", "GENE_OR_GENE_PRODUCT", 53, 57], ["IFI-16", "GENE_OR_GENE_PRODUCT", 59, 65], ["pyrin", "GENE_OR_GENE_PRODUCT", 71, 76], ["pyrin-domain (PYD)-containing proteins", "PROTEIN", 6, 44], ["AIM2", "PROTEIN", 53, 57], ["IFI-16", "PROTEIN", 59, 65], ["pyrin", "PROTEIN", 71, 76], ["inflammasomes", "PROTEIN", 100, 113], ["Other pyrin-domain (PYD)", "TREATMENT", 0, 24], ["proteins", "TREATMENT", 36, 44], ["AIM2", "TEST", 53, 57], ["IFI", "TEST", 59, 62], ["pyrin", "TREATMENT", 71, 76]]], ["Among them, NLRP3 inflammasomes monitor membrane integrity and pore-forming toxins, crystals, and many other noxious stimuli and are involved in IL-1\u03b2 processing and maturation [11] [12] [13] [14] .", [["membrane", "ANATOMY", 40, 48], ["pore", "ANATOMY", 63, 67], ["NLRP3", "GENE_OR_GENE_PRODUCT", 12, 17], ["membrane", "CELLULAR_COMPONENT", 40, 48], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 145, 150], ["[11] [12] [13] [14]", "SIMPLE_CHEMICAL", 177, 196], ["NLRP3 inflammasomes", "PROTEIN", 12, 31], ["IL", "PROTEIN", 145, 147], ["NLRP3 inflammasomes", "TEST", 12, 31], ["membrane integrity", "TEST", 40, 58], ["pore-forming toxins", "TEST", 63, 82], ["crystals", "TEST", 84, 92], ["noxious stimuli", "TEST", 109, 124]]], ["It is now widely accepted that an inflammatory response is the extreme end of a spectrum that ranges from a homeostatic state of inflammation to a stress response and finally inflammation [8, 15] .", [["inflammation", "DISEASE", 129, 141], ["inflammation", "DISEASE", 175, 187], ["an inflammatory response", "PROBLEM", 31, 55], ["inflammation", "PROBLEM", 129, 141], ["a stress response", "PROBLEM", 145, 162], ["finally inflammation", "PROBLEM", 167, 187], ["inflammatory", "OBSERVATION", 34, 46], ["inflammation", "OBSERVATION", 129, 141]]], ["The homeostatic state of inflammation, which is not inflammation from the perspective of general pathology, was suggested to be maintained by PRRs expressed in stromal and/or immune cells, detecting endogenous ligands in parenchymal cells and/or pathogens, leading to chronic inflammatory responses ranging from the basal homeostatic state to disease-causing inflammation [15, 16] .", [["stromal", "ANATOMY", 160, 167], ["immune cells", "ANATOMY", 175, 187], ["parenchymal cells", "ANATOMY", 221, 238], ["inflammation", "DISEASE", 25, 37], ["inflammation", "DISEASE", 52, 64], ["inflammation", "DISEASE", 359, 371], ["PRRs", "GENE_OR_GENE_PRODUCT", 142, 146], ["stromal", "CELL", 160, 167], ["immune cells", "CELL", 175, 187], ["parenchymal cells", "CELL", 221, 238], ["PRRs", "PROTEIN", 142, 146], ["stromal and/or immune cells", "CELL_TYPE", 160, 187], ["parenchymal cells", "CELL_TYPE", 221, 238], ["inflammation", "PROBLEM", 25, 37], ["inflammation", "PROBLEM", 52, 64], ["stromal and/or immune cells", "PROBLEM", 160, 187], ["endogenous ligands in parenchymal cells", "PROBLEM", 199, 238], ["pathogens", "PROBLEM", 246, 255], ["chronic inflammatory responses", "PROBLEM", 268, 298], ["disease", "PROBLEM", 343, 350], ["inflammation", "PROBLEM", 359, 371], ["inflammation", "OBSERVATION", 25, 37], ["not", "UNCERTAINTY", 48, 51], ["inflammation", "OBSERVATION", 52, 64], ["endogenous ligands", "OBSERVATION", 199, 217], ["parenchymal cells", "OBSERVATION", 221, 238], ["chronic", "OBSERVATION_MODIFIER", 268, 275], ["inflammatory", "OBSERVATION", 276, 288], ["basal", "ANATOMY_MODIFIER", 316, 321], ["homeostatic state", "OBSERVATION", 322, 339], ["inflammation", "OBSERVATION_MODIFIER", 359, 371]]], ["In addition to several forms of inflammation including classical inflammation, homeostatic inflammation, a distinct nomenclature for low-grade inflammation, such as para-inflammation (an adaptive response against stress or malfunction) and meta-inflammation (metabolically triggered inflammation), has been proposed [17] [18] [19] .", [["inflammation", "DISEASE", 32, 44], ["inflammation", "DISEASE", 65, 77], ["inflammation", "DISEASE", 91, 103], ["inflammation", "DISEASE", 143, 155], ["inflammation", "DISEASE", 283, 295], ["[17] [18] [19]", "SIMPLE_CHEMICAL", 316, 330], ["inflammation", "PROBLEM", 32, 44], ["classical inflammation", "PROBLEM", 55, 77], ["homeostatic inflammation", "PROBLEM", 79, 103], ["low-grade inflammation", "PROBLEM", 133, 155], ["para-inflammation", "PROBLEM", 165, 182], ["stress or malfunction)", "PROBLEM", 213, 235], ["meta-inflammation (metabolically triggered inflammation", "PROBLEM", 240, 295], ["several forms", "OBSERVATION_MODIFIER", 15, 28], ["inflammation", "OBSERVATION", 32, 44], ["inflammation", "OBSERVATION", 65, 77], ["homeostatic", "OBSERVATION_MODIFIER", 79, 90], ["inflammation", "OBSERVATION", 91, 103], ["low-grade", "OBSERVATION_MODIFIER", 133, 142], ["inflammation", "OBSERVATION", 143, 155]]], ["As discussed above, there are various factors involved in forms of inflammation; in particular, since IL-1 is a downstream cytokine of the sensor of cell injury, the inflammasome, it is important for regulating inflammation and tissue damage beyond inflammation [20] .Biological functions of interleukin-1IL-1 is a master regulator of inflammation via controlling a variety of innate immune processes [21] .", [["cell", "ANATOMY", 149, 153], ["tissue", "ANATOMY", 228, 234], ["inflammation", "DISEASE", 67, 79], ["inflammation", "DISEASE", 211, 223], ["inflammation", "DISEASE", 249, 261], ["inflammation", "DISEASE", 335, 347], ["IL-1", "GENE_OR_GENE_PRODUCT", 102, 106], ["cell", "CELL", 149, 153], ["tissue", "TISSUE", 228, 234], ["interleukin-1IL-1", "GENE_OR_GENE_PRODUCT", 292, 309], ["IL-1", "PROTEIN", 102, 106], ["interleukin-1IL-1", "PROTEIN", 292, 309], ["inflammation", "PROBLEM", 67, 79], ["cell injury", "PROBLEM", 149, 160], ["the inflammasome", "PROBLEM", 162, 178], ["regulating inflammation", "PROBLEM", 200, 223], ["tissue damage beyond inflammation", "PROBLEM", 228, 261], ["interleukin", "TEST", 292, 303], ["inflammation", "PROBLEM", 335, 347], ["inflammation", "OBSERVATION", 67, 79], ["cell injury", "OBSERVATION", 149, 160], ["important for", "UNCERTAINTY", 186, 199], ["inflammation", "OBSERVATION", 211, 223], ["inflammation", "OBSERVATION", 335, 347]]], ["From a historical point of view, IL-1 has a wide range of biological functions, which include acting as a leukocytic pyrogen, a mediator of fever and a leukocytic endogenous mediator, and an inducer of several components of the acute-phase response and lymphocyte-activating factor (LAF) [22, 23] .", [["leukocytic", "ANATOMY", 152, 162], ["lymphocyte", "ANATOMY", 253, 263], ["fever", "DISEASE", 140, 145], ["IL-1", "GENE_OR_GENE_PRODUCT", 33, 37], ["leukocytic pyrogen", "GENE_OR_GENE_PRODUCT", 106, 124], ["lymphocyte-activating factor", "GENE_OR_GENE_PRODUCT", 253, 281], ["IL-1", "PROTEIN", 33, 37], ["leukocytic endogenous mediator", "PROTEIN", 152, 182], ["lymphocyte-activating factor", "PROTEIN", 253, 281], ["LAF", "PROTEIN", 283, 286], ["a leukocytic pyrogen", "TEST", 104, 124], ["fever", "PROBLEM", 140, 145], ["a leukocytic endogenous mediator", "PROBLEM", 150, 182], ["the acute-phase response", "PROBLEM", 224, 248], ["lymphocyte", "TEST", 253, 263], ["acute", "OBSERVATION_MODIFIER", 228, 233]]], ["LAF was later shown to be a macrophage-derived immune mediator acting on T-and B-lymphocytes and was designated as IL-1 in the Second International Lymphokine Workshop held in Switzerland in 1979 [24, 25] .", [["macrophage", "ANATOMY", 28, 38], ["T-and B-lymphocytes", "ANATOMY", 73, 92], ["LAF", "GENE_OR_GENE_PRODUCT", 0, 3], ["macrophage", "CELL", 28, 38], ["T-", "CELL", 73, 75], ["B-lymphocytes", "CELL", 79, 92], ["IL-1", "GENE_OR_GENE_PRODUCT", 115, 119], ["LAF", "PROTEIN", 0, 3], ["T-and B-lymphocytes", "CELL_TYPE", 73, 92], ["IL", "PROTEIN", 115, 117], ["a macrophage", "PROBLEM", 26, 38], ["T", "TEST", 73, 74], ["macrophage", "OBSERVATION", 28, 38], ["lymphocytes", "ANATOMY", 81, 92]]], ["In addition, serum blocking factors in breast cancer patients identified by the leukocyte adherence inhibition test were reported.", [["serum", "ANATOMY", 13, 18], ["breast cancer", "ANATOMY", 39, 52], ["leukocyte", "ANATOMY", 80, 89], ["breast cancer", "DISEASE", 39, 52], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["breast cancer", "CANCER", 39, 52], ["patients", "ORGANISM", 53, 61], ["leukocyte", "CELL", 80, 89], ["serum blocking factors", "PROTEIN", 13, 35], ["patients", "SPECIES", 53, 61], ["serum blocking factors", "PROBLEM", 13, 35], ["breast cancer", "PROBLEM", 39, 52], ["the leukocyte adherence inhibition test", "TEST", 76, 115], ["breast", "ANATOMY", 39, 45], ["cancer", "OBSERVATION", 46, 52]]], ["The serum adherence-promoting factors were regulated by IL-1 [26] [27] [28] .", [["serum", "ANATOMY", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["IL-1 [26] [27] [28]", "SIMPLE_CHEMICAL", 56, 75], ["serum adherence-promoting factors", "PROTEIN", 4, 37], ["The serum adherence", "TEST", 0, 19]]], ["To date, the tumor microenvironment has been characterized by dominant immunosuppression, being infiltrated by tumor immunosuppressive myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and tumor-associated macrophages (TAMs) [29, 30] .", [["tumor", "ANATOMY", 13, 18], ["tumor", "ANATOMY", 111, 116], ["myeloid-derived suppressor cells", "ANATOMY", 135, 167], ["MDSCs", "ANATOMY", 169, 174], ["regulatory T cells", "ANATOMY", 177, 195], ["Tregs", "ANATOMY", 197, 202], ["tumor", "ANATOMY", 209, 214], ["macrophages", "ANATOMY", 226, 237], ["TAMs", "ANATOMY", 239, 243], ["tumor", "DISEASE", 13, 18], ["tumor", "DISEASE", 111, 116], ["tumor", "DISEASE", 209, 214], ["tumor", "CANCER", 13, 18], ["tumor immunosuppressive myeloid-derived suppressor cells", "CELL", 111, 167], ["MDSCs", "CELL", 169, 174], ["regulatory T cells", "CELL", 177, 195], ["Tregs", "CELL", 197, 202], ["tumor-associated macrophages", "CELL", 209, 237], ["TAMs", "CELL", 239, 243], ["tumor immunosuppressive myeloid-derived suppressor cells", "CELL_TYPE", 111, 167], ["MDSCs", "CELL_TYPE", 169, 174], ["regulatory T cells", "CELL_TYPE", 177, 195], ["Tregs", "CELL_TYPE", 197, 202], ["tumor-associated macrophages", "CELL_TYPE", 209, 237], ["TAMs", "CELL_TYPE", 239, 243], ["dominant immunosuppression", "PROBLEM", 62, 88], ["tumor immunosuppressive myeloid-derived suppressor cells", "TREATMENT", 111, 167], ["tumor-associated macrophages", "PROBLEM", 209, 237], ["tumor", "OBSERVATION", 13, 18], ["dominant", "OBSERVATION_MODIFIER", 62, 70], ["immunosuppression", "OBSERVATION", 71, 88], ["tumor immunosuppressive myeloid", "OBSERVATION", 111, 142], ["suppressor cells", "OBSERVATION", 151, 167], ["tumor", "OBSERVATION", 209, 214]]], ["IL-1 is capable of inducing the recruitment of TAMs and MDSCs, which promote tumor development in breast cancer [31] .Interleukin-1 family membersCurrently, human sequence algorithm technologies suggest that the IL-1 family comprises a total of 11 members with similar or distinct biological effects [32, 33] .", [["TAMs", "ANATOMY", 47, 51], ["MDSCs", "ANATOMY", 56, 61], ["tumor", "ANATOMY", 77, 82], ["breast cancer", "ANATOMY", 98, 111], ["tumor", "DISEASE", 77, 82], ["breast cancer", "DISEASE", 98, 111], ["IL-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TAMs", "CELL", 47, 51], ["MDSCs", "CELL", 56, 61], ["tumor", "CANCER", 77, 82], ["breast cancer", "CANCER", 98, 111], ["Interleukin-1", "GENE_OR_GENE_PRODUCT", 118, 131], ["human", "ORGANISM", 157, 162], ["IL-1", "GENE_OR_GENE_PRODUCT", 212, 216], ["IL-1", "PROTEIN", 0, 4], ["TAMs", "CELL_TYPE", 47, 51], ["MDSCs", "CELL_TYPE", 56, 61], ["Interleukin-1 family members", "PROTEIN", 118, 146], ["IL-1 family", "PROTEIN", 212, 223], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["the recruitment of TAMs", "TREATMENT", 28, 51], ["MDSCs", "PROBLEM", 56, 61], ["breast cancer", "PROBLEM", 98, 111], ["tumor", "OBSERVATION", 77, 82], ["breast", "ANATOMY", 98, 104], ["cancer", "OBSERVATION", 105, 111]]], ["IL-1\u03b1, IL-1\u03b2, IL-1Ra, IL-18, IL-33, IL-36\u03b1, IL-36\u03b2, IL-36\u03b3, IL-36Ra IL-37, and IL-38 have been identified and characterized (Table 1 ) [32] .", [["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 7, 12], ["IL-1Ra", "GENE_OR_GENE_PRODUCT", 14, 20], ["IL-18", "GENE_OR_GENE_PRODUCT", 22, 27], ["IL-33", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL-36\u03b1", "GENE_OR_GENE_PRODUCT", 36, 42], ["IL-36\u03b2", "GENE_OR_GENE_PRODUCT", 44, 50], ["IL-36\u03b3", "GENE_OR_GENE_PRODUCT", 52, 58], ["IL-36Ra", "GENE_OR_GENE_PRODUCT", 60, 67], ["IL-37", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL-38", "GENE_OR_GENE_PRODUCT", 79, 84], ["IL", "PROTEIN", 0, 2], ["IL-38", "DNA", 79, 84], ["IL", "TREATMENT", 0, 2], ["IL", "TREATMENT", 7, 9], ["IL", "TREATMENT", 14, 16], ["IL", "TEST", 22, 24], ["IL", "TEST", 29, 31], ["IL", "TEST", 36, 38], ["IL", "TEST", 44, 46], ["IL", "TEST", 52, 54], ["IL", "TEST", 60, 62], ["IL", "TEST", 68, 70]]], ["Among them, IL-1\u03b1, IL-1\u03b2, IL-18, IL-33, and IL-36 are receptor-agonistic, and IL-1Ra, IL-36Ra, and IL-38 are receptor-antagonistic.", [["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 12, 17], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 19, 24], ["IL-18", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL-33", "GENE_OR_GENE_PRODUCT", 33, 38], ["IL-36", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL-1Ra", "SIMPLE_CHEMICAL", 78, 84], ["IL-36Ra", "GENE_OR_GENE_PRODUCT", 86, 93], ["IL-38", "GENE_OR_GENE_PRODUCT", 99, 104], ["IL", "PROTEIN", 12, 14], ["IL", "TEST", 12, 14], ["IL", "TEST", 19, 21], ["IL", "TEST", 26, 28], ["IL", "TEST", 33, 35], ["IL", "TEST", 44, 46], ["receptor", "TEST", 54, 62], ["IL", "TEST", 78, 80], ["IL", "TEST", 86, 88], ["IL", "TEST", 99, 101]]], ["IL-37 is the only anti-inflammatory cytokine.", [["IL-37", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-37", "PROTEIN", 0, 5], ["anti-inflammatory cytokine", "PROTEIN", 18, 44], ["anti-inflammatory cytokine", "TREATMENT", 18, 44], ["anti-inflammatory cytokine", "OBSERVATION", 18, 44]]], ["Although the function of each IL-1 family member is now being investigated, IL-1 is the most characterized among these members.Molecular mechanism of interleukin-1 activationThere are two individual forms of IL-1, IL-1\u03b1 and IL-1\u03b2, isolated from two distinct cDNAs, but they are indistinguishable in terms of their biological functions [34] .", [["IL-1", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-1", "GENE_OR_GENE_PRODUCT", 76, 80], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 150, 163], ["IL-1", "GENE_OR_GENE_PRODUCT", 208, 212], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 214, 219], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 224, 229], ["IL-1 family member", "PROTEIN", 30, 48], ["IL", "PROTEIN", 76, 78], ["interleukin-1", "PROTEIN", 150, 163], ["IL-1, IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 208, 229], ["cDNAs", "DNA", 258, 263], ["IL", "TEST", 208, 210], ["IL", "TEST", 214, 216], ["interleukin", "OBSERVATION", 150, 161]]], ["Although the homology between IL-1\u03b1 and IL-1\u03b2 is not high (27%) in terms of amino acid sequences, IL-1\u03b1 and IL-1\u03b2 are structurally similar and show the same functions by sharing a common receptor, IL-1 type 1 receptor (IL-1R1), and both have the same central \u03b2-barrel along with adjoining loops [35, 36] .", [["amino acid", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 76, 86], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 30, 35], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 40, 45], ["amino acid", "AMINO_ACID", 76, 86], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 108, 113], ["IL-1 type 1 receptor", "GENE_OR_GENE_PRODUCT", 197, 217], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 219, 225], ["IL-1\u03b1", "PROTEIN", 30, 35], ["IL-1\u03b2", "PROTEIN", 40, 45], ["amino acid sequences", "PROTEIN", 76, 96], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 98, 113], ["IL-1 type 1 receptor", "PROTEIN", 197, 217], ["IL", "PROTEIN", 219, 221], ["1R1", "PROTEIN", 222, 225], ["IL", "TEST", 30, 32], ["IL", "TEST", 40, 42], ["amino acid sequences", "TEST", 76, 96], ["IL", "TEST", 98, 100], ["IL", "TEST", 108, 110]]], ["The difference between IL-1\u03b1 and IL-1\u03b2 is an N-terminal extension of 14 residues beyond the N-terminus of IL-1\u03b1 and IL-1\u03b2 [37] .", [["N", "CHEMICAL", 45, 46], ["N", "CHEMICAL", 92, 93], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 33, 38], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 106, 111], ["IL-1", "GENE_OR_GENE_PRODUCT", 116, 120], ["IL-1\u03b1", "PROTEIN", 23, 28], ["IL-1\u03b2", "PROTEIN", 33, 38], ["N-terminus", "PROTEIN", 92, 102], ["IL-1\u03b1", "PROTEIN", 106, 111], ["IL", "PROTEIN", 116, 118], ["IL", "TEST", 23, 25], ["terminal extension of 14 residues", "PROBLEM", 47, 80], ["the N-terminus of IL", "TREATMENT", 88, 108], ["IL", "TEST", 116, 118]]], ["The molecular weight of each precursor is approximately 31 kDa, and IL-1\u03b1 and IL-1\u03b2 are processed by specific proteases to mature forms.", [["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 68, 83], ["proteases", "PROTEIN", 110, 119], ["IL", "TEST", 68, 70]]], ["The N-terminal domain of IL-1\u03b1 contains a nuclear localization sequence (NLS) and shows transcription activity [38] .", [["nuclear", "ANATOMY", 42, 49], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 25, 30], ["NLS", "GENE_OR_GENE_PRODUCT", 73, 76], ["N-terminal domain", "PROTEIN", 4, 21], ["IL-1\u03b1", "PROTEIN", 25, 30], ["nuclear localization sequence", "PROTEIN", 42, 71], ["NLS", "PROTEIN", 73, 76], ["a nuclear localization sequence", "TEST", 40, 71], ["transcription activity", "TEST", 88, 110]]], ["IL-1\u03b1 is produced as a 271-amino acid (AA) precursor protein.", [["271-amino acid", "CHEMICAL", 23, 37], ["AA", "CHEMICAL", 39, 41], ["271-amino acid", "CHEMICAL", 23, 37], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["271-amino acid", "SIMPLE_CHEMICAL", 23, 37], ["AA", "SIMPLE_CHEMICAL", 39, 41], ["IL-1\u03b1", "PROTEIN", 0, 5], ["271-amino acid (AA) precursor protein", "PROTEIN", 23, 60]]], ["For transcription of the IL-1\u03b1 gene, transcription factor specificity protein 1 (Sp1) activates the IL-1\u03b1 promoter activity in the 5\u2032-upstream GC box (\u2212 60 to \u2212 45 bp) [39] and NF-\u03baB, which is also activated by IL-1\u03b1 itself, and stimulates the consensus promoter region (\u2212 103 to \u2212 70 bp) to induce its own gene expression and production in an autocrine manner [40] .", [["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 25, 30], ["specificity protein 1", "GENE_OR_GENE_PRODUCT", 58, 79], ["Sp1", "GENE_OR_GENE_PRODUCT", 81, 84], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 100, 105], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 177, 182], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 211, 216], ["IL-1\u03b1 gene", "DNA", 25, 35], ["transcription factor specificity protein 1", "PROTEIN", 37, 79], ["Sp1", "PROTEIN", 81, 84], ["IL-1\u03b1 promoter", "DNA", 100, 114], ["5\u2032-upstream GC box", "DNA", 131, 149], ["NF-\u03baB", "DNA", 177, 182], ["IL-1\u03b1", "PROTEIN", 211, 216], ["consensus promoter region", "DNA", 244, 269], ["the IL", "TREATMENT", 21, 27], ["the IL", "TREATMENT", 96, 102], ["GC box", "TEST", 143, 149], ["bp", "TEST", 164, 166], ["NF", "TEST", 177, 179], ["bp", "TEST", 285, 287]]], ["The precursor of IL-1\u03b1 translocates into the nucleus to bind to chromatin and also exists in a membrane-anchored form.", [["nucleus", "ANATOMY", 45, 52], ["chromatin", "ANATOMY", 64, 73], ["membrane", "ANATOMY", 95, 103], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 17, 22], ["nucleus", "CELLULAR_COMPONENT", 45, 52], ["chromatin", "CELLULAR_COMPONENT", 64, 73], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["IL-1\u03b1", "PROTEIN", 17, 22], ["chromatin", "DNA", 64, 73], ["The precursor of IL", "TREATMENT", 0, 19], ["nucleus", "ANATOMY", 45, 52]]], ["Upon stress responses, IL-1\u03b1 is processed by Ca 2+ -dependent protease calpain or other proteases, such as cytotoxic T-lymphocytes (CTL)/natural killer (NK)-granzyme-B, mast cell chymase, or neutrophil elastase to the C-terminal 159 AA as mature IL-1\u03b1 [41] .", [["cytotoxic T-lymphocytes", "ANATOMY", 107, 130], ["NK", "ANATOMY", 153, 155], ["mast cell", "ANATOMY", 169, 178], ["neutrophil", "ANATOMY", 191, 201], ["Ca", "CHEMICAL", 45, 47], ["Ca 2+", "CHEMICAL", 45, 50], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 23, 28], ["Ca 2+", "SIMPLE_CHEMICAL", 45, 50], ["calpain", "GENE_OR_GENE_PRODUCT", 71, 78], ["T-lymphocytes", "CELL", 117, 130], ["CTL", "CELL", 132, 135], ["natural killer", "CELL", 137, 151], ["NK", "CELL", 153, 155], ["granzyme-B", "GENE_OR_GENE_PRODUCT", 157, 167], ["mast cell chymase", "GENE_OR_GENE_PRODUCT", 169, 186], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 191, 210], ["IL-1", "GENE_OR_GENE_PRODUCT", 246, 250], ["IL-1\u03b1", "PROTEIN", 23, 28], ["Ca 2+ -dependent protease calpain", "PROTEIN", 45, 78], ["proteases", "PROTEIN", 88, 97], ["cytotoxic T-lymphocytes", "CELL_TYPE", 107, 130], ["CTL", "CELL_TYPE", 132, 135], ["natural killer (NK)-granzyme-B", "PROTEIN", 137, 167], ["mast cell chymase", "PROTEIN", 169, 186], ["neutrophil elastase", "PROTEIN", 191, 210], ["IL", "TEST", 23, 25], ["Ca", "TEST", 45, 47], ["dependent protease calpain", "PROBLEM", 52, 78], ["other proteases", "PROBLEM", 82, 97], ["cytotoxic T", "TEST", 107, 118], ["lymphocytes", "TEST", 119, 130], ["CTL", "TEST", 132, 135], ["NK", "TEST", 153, 155], ["granzyme", "TEST", 157, 165], ["mast cell chymase", "TEST", 169, 186], ["neutrophil elastase", "TEST", 191, 210], ["the C-terminal", "TEST", 214, 228], ["AA", "TEST", 233, 235], ["mature IL", "TEST", 239, 248], ["mast cell chymase", "OBSERVATION", 169, 186], ["neutrophil elastase", "OBSERVATION", 191, 210]]], ["The IL-1\u03b1 processing separates NLS from its precursor, which is not linked to secretion or cell death [21] ; however, IL-1\u03b1 is a key danger signal that induces inflammation on release from necrotic cells [42] .", [["cell", "ANATOMY", 91, 95], ["necrotic cells", "ANATOMY", 189, 203], ["death", "DISEASE", 96, 101], ["inflammation", "DISEASE", 160, 172], ["necrotic", "DISEASE", 189, 197], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 4, 9], ["NLS", "GENE_OR_GENE_PRODUCT", 31, 34], ["cell", "CELL", 91, 95], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 118, 123], ["necrotic cells", "CELL", 189, 203], ["IL-1\u03b1", "PROTEIN", 4, 9], ["NLS", "PROTEIN", 31, 34], ["IL-1\u03b1", "PROTEIN", 118, 123], ["necrotic cells", "CELL_TYPE", 189, 203], ["The IL", "TREATMENT", 0, 6], ["cell death", "PROBLEM", 91, 101], ["inflammation", "PROBLEM", 160, 172], ["necrotic cells", "PROBLEM", 189, 203], ["inflammation", "OBSERVATION", 160, 172], ["necrotic cells", "OBSERVATION", 189, 203]]], ["The IL-1\u03b1 precursor triggers IL-1R1 on resident macrophages in necrotic tissues, producing IL-1\u03b2 as well as chemokines as post-necrotic inflammation [43] .Molecular mechanism of interleukin-1 activationIL-1\u03b2 is produced as a 269-AA precursor protein and processed by caspase-1, which is also known as IL-1\u03b2-converting enzyme (ICE), activated in inflammasomes, to the C-terminal 153 AA as mature IL-1\u03b2 [11, 12, 34, 44] .", [["macrophages", "ANATOMY", 48, 59], ["necrotic tissues", "ANATOMY", 63, 79], ["necrotic", "DISEASE", 63, 71], ["inflammation", "DISEASE", 136, 148], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 4, 9], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 29, 35], ["macrophages", "CELL", 48, 59], ["necrotic tissues", "TISSUE", 63, 79], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 91, 96], ["interleukin-1 activationIL-1\u03b2", "GENE_OR_GENE_PRODUCT", 178, 207], ["caspase-1", "GENE_OR_GENE_PRODUCT", 267, 276], ["IL-1\u03b2-converting enzyme", "GENE_OR_GENE_PRODUCT", 301, 324], ["ICE", "GENE_OR_GENE_PRODUCT", 326, 329], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 395, 400], ["IL-1\u03b1 precursor", "PROTEIN", 4, 19], ["IL-1R1", "PROTEIN", 29, 35], ["resident macrophages", "CELL_TYPE", 39, 59], ["IL-1\u03b2", "PROTEIN", 91, 96], ["chemokines", "PROTEIN", 108, 118], ["interleukin-1 activationIL-1\u03b2", "PROTEIN", 178, 207], ["269-AA precursor protein", "PROTEIN", 225, 249], ["caspase-1", "PROTEIN", 267, 276], ["IL-1\u03b2-converting enzyme", "PROTEIN", 301, 324], ["ICE", "PROTEIN", 326, 329], ["inflammasomes", "PROTEIN", 345, 358], ["The IL", "TREATMENT", 0, 6], ["necrotic tissues", "PROBLEM", 63, 79], ["post-necrotic inflammation", "PROBLEM", 122, 148], ["interleukin", "TEST", 178, 189], ["caspase", "TEST", 267, 274], ["IL", "TEST", 301, 303], ["necrotic tissues", "OBSERVATION", 63, 79]]], ["The IL-1\u03b2 precursor is also processed by other serine proteases [45] .", [["serine", "CHEMICAL", 47, 53], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 4, 9], ["IL-1\u03b2 precursor", "PROTEIN", 4, 19], ["serine proteases", "PROTEIN", 47, 63], ["The IL", "TREATMENT", 0, 6]]], ["Neutrophils derived from caspase-1-deficient mice release mature IL-1\u03b2 processed by elastase in response to lipopolysaccharide (LPS) stimulation [46] .", [["Neutrophils", "ANATOMY", 0, 11], ["lipopolysaccharide", "CHEMICAL", 108, 126], ["LPS", "CHEMICAL", 128, 131], ["Neutrophils", "CELL", 0, 11], ["caspase-1", "GENE_OR_GENE_PRODUCT", 25, 34], ["mice", "ORGANISM", 45, 49], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 65, 70], ["elastase", "GENE_OR_GENE_PRODUCT", 84, 92], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 108, 126], ["LPS", "SIMPLE_CHEMICAL", 128, 131], ["Neutrophils", "CELL_TYPE", 0, 11], ["caspase-1", "PROTEIN", 25, 34], ["mature IL-1\u03b2", "PROTEIN", 58, 70], ["elastase", "PROTEIN", 84, 92], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["Neutrophils", "TEST", 0, 11], ["caspase", "TEST", 25, 32], ["lipopolysaccharide (LPS) stimulation", "TREATMENT", 108, 144], ["elastase", "OBSERVATION", 84, 92]]], ["The neutrophil proteases, such as elastase, chymases, granzyme A, cathepsin G, and proteinase-3, cleave the IL-1\u03b2 precursor into a secreted, biologically active form [47] [48] [49] .", [["neutrophil", "ANATOMY", 4, 14], ["neutrophil", "CELL", 4, 14], ["elastase", "GENE_OR_GENE_PRODUCT", 34, 42], ["chymases", "GENE_OR_GENE_PRODUCT", 44, 52], ["granzyme A", "GENE_OR_GENE_PRODUCT", 54, 64], ["cathepsin G", "GENE_OR_GENE_PRODUCT", 66, 77], ["proteinase-3", "GENE_OR_GENE_PRODUCT", 83, 95], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 108, 113], ["neutrophil proteases", "PROTEIN", 4, 24], ["elastase", "PROTEIN", 34, 42], ["chymases", "PROTEIN", 44, 52], ["granzyme A", "PROTEIN", 54, 64], ["cathepsin G", "PROTEIN", 66, 77], ["proteinase-3", "PROTEIN", 83, 95], ["IL-1\u03b2 precursor", "PROTEIN", 108, 123], ["The neutrophil proteases", "TEST", 0, 24], ["elastase", "TEST", 34, 42], ["chymases", "TEST", 44, 52], ["granzyme", "TEST", 54, 62], ["cathepsin G", "TEST", 66, 77], ["proteinase", "TEST", 83, 93], ["the IL", "TEST", 104, 110], ["neutrophil proteases", "OBSERVATION", 4, 24]]], ["These alternatively cleaved forms of functional IL-1\u03b2 were detected in synovial fluid of a patient with inflammatory polyarthritis and gout [50] .", [["synovial fluid", "ANATOMY", 71, 85], ["polyarthritis", "DISEASE", 117, 130], ["gout", "DISEASE", 135, 139], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 48, 53], ["synovial fluid", "ORGANISM_SUBSTANCE", 71, 85], ["patient", "ORGANISM", 91, 98], ["IL-1\u03b2", "PROTEIN", 48, 53], ["patient", "SPECIES", 91, 98], ["functional IL", "TEST", 37, 50], ["inflammatory polyarthritis", "PROBLEM", 104, 130], ["gout", "PROBLEM", 135, 139], ["synovial", "ANATOMY", 71, 79], ["fluid", "OBSERVATION", 80, 85], ["inflammatory", "OBSERVATION_MODIFIER", 104, 116], ["polyarthritis", "OBSERVATION", 117, 130], ["gout", "OBSERVATION", 135, 139]]], ["Occasionally, massive neutrophil infiltration appeared in excess-inflammation-damaged tissues and organs, such as in septic shock or systemic inflammatory response syndrome.", [["neutrophil", "ANATOMY", 22, 32], ["tissues", "ANATOMY", 86, 93], ["organs", "ANATOMY", 98, 104], ["inflammation", "DISEASE", 65, 77], ["septic shock", "DISEASE", 117, 129], ["systemic inflammatory response syndrome", "DISEASE", 133, 172], ["neutrophil", "CELL", 22, 32], ["tissues", "TISSUE", 86, 93], ["organs", "ORGAN", 98, 104], ["massive neutrophil infiltration", "PROBLEM", 14, 45], ["inflammation", "PROBLEM", 65, 77], ["damaged tissues and organs", "PROBLEM", 78, 104], ["septic shock", "PROBLEM", 117, 129], ["systemic inflammatory response syndrome", "PROBLEM", 133, 172], ["massive", "OBSERVATION_MODIFIER", 14, 21], ["neutrophil infiltration", "OBSERVATION", 22, 45], ["excess", "OBSERVATION_MODIFIER", 58, 64], ["inflammation", "OBSERVATION", 65, 77], ["damaged tissues", "OBSERVATION_MODIFIER", 78, 93], ["organs", "ANATOMY", 98, 104], ["septic shock", "OBSERVATION", 117, 129], ["systemic", "OBSERVATION_MODIFIER", 133, 141], ["inflammatory response syndrome", "OBSERVATION", 142, 172]]], ["Thus, the NLRP3 inflammasome-related inflammation induced by a variety of factors described above may be a target of anti-IL-1 therapy [51] .", [["inflammation", "DISEASE", 37, 49], ["NLRP3", "GENE_OR_GENE_PRODUCT", 10, 15], ["anti-IL-1", "GENE_OR_GENE_PRODUCT", 117, 126], ["NLRP3", "PROTEIN", 10, 15], ["the NLRP3 inflammasome", "PROBLEM", 6, 28], ["inflammation", "PROBLEM", 37, 49], ["anti-IL-1 therapy", "TREATMENT", 117, 134], ["NLRP3 inflammasome", "OBSERVATION", 10, 28], ["inflammation", "OBSERVATION", 37, 49]]], ["Currently, a two-step model of the initiation of NLRP3 inflammasome activation is suggested.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 49, 54], ["NLRP3", "PROTEIN", 49, 54], ["NLRP3 inflammasome activation", "TREATMENT", 49, 78]]], ["The first step mediates transcriptional and post-translational priming of NLRP3 (Step1), and the second step is activation of inflammasomes (Step 2).Molecular mechanism of interleukin-1 activationStep 1 is the first synthesis of a biologically inactive IL-1\u03b2 precursor by NF-\u03baB binding to the consensus binding site (\u2212 296 to \u2212 286 bp) to transcribe the IL-1\u03b2 gene.Molecular mechanism of interleukin-1 activationStep 2 is processing into mature, biologically active IL-1\u03b2 by caspase-1 activated by a cytosolic activation platform called inflammasome [52, 53] .", [["cytosolic", "ANATOMY", 500, 509], ["NLRP3", "GENE_OR_GENE_PRODUCT", 74, 79], ["Step1", "GENE_OR_GENE_PRODUCT", 81, 86], ["Step 2", "GENE_OR_GENE_PRODUCT", 141, 147], ["interleukin-1 activationStep 1", "GENE_OR_GENE_PRODUCT", 172, 202], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 253, 258], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 272, 277], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 354, 359], ["interleukin-1 activationStep 2", "GENE_OR_GENE_PRODUCT", 388, 418], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 466, 471], ["caspase-1", "GENE_OR_GENE_PRODUCT", 475, 484], ["NLRP3", "PROTEIN", 74, 79], ["Step1", "PROTEIN", 81, 86], ["inflammasomes", "PROTEIN", 126, 139], ["Step 2", "PROTEIN", 141, 147], ["interleukin-1 activationStep 1", "PROTEIN", 172, 202], ["IL-1\u03b2 precursor", "PROTEIN", 253, 268], ["NF-\u03baB", "PROTEIN", 272, 277], ["consensus binding site", "DNA", 293, 315], ["IL-1\u03b2 gene", "DNA", 354, 364], ["interleukin-1 activationStep 2", "PROTEIN", 388, 418], ["IL-1\u03b2", "PROTEIN", 466, 471], ["caspase-1", "PROTEIN", 475, 484], ["bp", "TEST", 332, 334]]], ["The inflammasome is a large protein complex, which consists of PRRs, such as NLRs, AIM2, RIG-I or pyrin, an adaptor protein ASC, and caspase-1.", [["PRRs", "GENE_OR_GENE_PRODUCT", 63, 67], ["NLRs", "GENE_OR_GENE_PRODUCT", 77, 81], ["AIM2", "GENE_OR_GENE_PRODUCT", 83, 87], ["RIG-I", "GENE_OR_GENE_PRODUCT", 89, 94], ["pyrin", "GENE_OR_GENE_PRODUCT", 98, 103], ["ASC", "GENE_OR_GENE_PRODUCT", 124, 127], ["caspase-1", "GENE_OR_GENE_PRODUCT", 133, 142], ["protein complex", "PROTEIN", 28, 43], ["PRRs", "PROTEIN", 63, 67], ["NLRs", "PROTEIN", 77, 81], ["AIM2", "PROTEIN", 83, 87], ["RIG-I", "PROTEIN", 89, 94], ["pyrin", "PROTEIN", 98, 103], ["adaptor protein", "PROTEIN", 108, 123], ["ASC", "PROTEIN", 124, 127], ["caspase-1", "PROTEIN", 133, 142], ["The inflammasome", "PROBLEM", 0, 16], ["a large protein complex", "PROBLEM", 20, 43], ["PRRs", "PROBLEM", 63, 67], ["pyrin", "PROBLEM", 98, 103], ["an adaptor protein ASC", "TREATMENT", 105, 127], ["caspase", "TREATMENT", 133, 140], ["inflammasome", "OBSERVATION", 4, 16], ["large", "OBSERVATION_MODIFIER", 22, 27], ["protein complex", "OBSERVATION_MODIFIER", 28, 43]]], ["Among them, the NLRP3 inflammasome is a prototype inflammasome, which has been reported to be activated by a wide range of PAMPs and DAMPs [54, 55] .", [["NLRP3", "GENE_OR_GENE_PRODUCT", 16, 21], ["PAMPs", "GENE_OR_GENE_PRODUCT", 123, 128], ["DAMPs", "GENE_OR_GENE_PRODUCT", 133, 138], ["NLRP3 inflammasome", "PROTEIN", 16, 34], ["PAMPs", "PROTEIN", 123, 128], ["DAMPs", "PROTEIN", 133, 138], ["a prototype inflammasome", "PROBLEM", 38, 62]]], ["Various NLRP3-activating PAMPs have been reported, i.e., bacteria-derived RNA or DNA, pore-forming toxins, lethal toxins, flagellin/rod proteins, muramyl dipeptide (MDP), M2 protein, virus-derived RNA or DNA, fungus-derived \u03b2-glucans, hypha mannan, zymosan, and protozoon-derived hemozoin [56] .", [["muramyl dipeptide", "CHEMICAL", 146, 163], ["MDP", "CHEMICAL", 165, 168], ["zymosan", "CHEMICAL", 249, 256], ["muramyl dipeptide", "CHEMICAL", 146, 163], ["hemozoin", "CHEMICAL", 280, 288], ["NLRP3", "GENE_OR_GENE_PRODUCT", 8, 13], ["PAMPs", "GENE_OR_GENE_PRODUCT", 25, 30], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["pore-forming toxins", "SIMPLE_CHEMICAL", 86, 105], ["flagellin", "GENE_OR_GENE_PRODUCT", 122, 131], ["muramyl dipeptide", "SIMPLE_CHEMICAL", 146, 163], ["MDP", "SIMPLE_CHEMICAL", 165, 168], ["M2", "GENE_OR_GENE_PRODUCT", 171, 173], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["fungus-derived \u03b2-glucans", "SIMPLE_CHEMICAL", 209, 233], ["hypha mannan", "SIMPLE_CHEMICAL", 235, 247], ["zymosan", "SIMPLE_CHEMICAL", 249, 256], ["protozoon", "SIMPLE_CHEMICAL", 262, 271], ["hemozoin [56]", "SIMPLE_CHEMICAL", 280, 293], ["NLRP3", "PROTEIN", 8, 13], ["activating PAMPs", "PROTEIN", 14, 30], ["pore-forming toxins", "PROTEIN", 86, 105], ["lethal toxins", "PROTEIN", 107, 120], ["flagellin", "PROTEIN", 122, 131], ["rod proteins", "PROTEIN", 132, 144], ["muramyl dipeptide (MDP), M2 protein", "PROTEIN", 146, 181], ["Various NLRP3-activating PAMPs", "TREATMENT", 0, 30], ["bacteria", "PROBLEM", 57, 65], ["DNA", "PROBLEM", 81, 84], ["pore-forming toxins", "TEST", 86, 105], ["lethal toxins", "TEST", 107, 120], ["flagellin/rod proteins", "TEST", 122, 144], ["muramyl dipeptide (MDP", "TEST", 146, 168], ["M2 protein", "TEST", 171, 181], ["virus", "PROBLEM", 183, 188], ["DNA", "PROBLEM", 204, 207], ["fungus", "TEST", 209, 215], ["hypha mannan", "TEST", 235, 247], ["zymosan", "TEST", 249, 256]]], ["NLRP3-activating DAMPs have also been reported, i.e., self-derived glucose, \u03b2-amyloid, hyaluronan, ATP, cholesterol crystals, monosodium urate (MSU) crystals, calcium pyrophosphate dihydrate (CPPD) crystals, environment-derived alum, asbestos, silica, alloy particles, UV radiation, and skin irritants [56] ; however, their diverse physiological and chemical signals leading to the direct activation of NLRP3 have not been fully elucidated.", [["skin", "ANATOMY", 287, 291], ["glucose", "CHEMICAL", 67, 74], ["ATP", "CHEMICAL", 99, 102], ["cholesterol", "CHEMICAL", 104, 115], ["monosodium urate", "CHEMICAL", 126, 142], ["MSU", "CHEMICAL", 144, 147], ["calcium pyrophosphate dihydrate", "CHEMICAL", 159, 190], ["CPPD", "DISEASE", 192, 196], ["asbestos", "CHEMICAL", 234, 242], ["silica", "CHEMICAL", 244, 250], ["UV", "CHEMICAL", 269, 271], ["glucose", "CHEMICAL", 67, 74], ["ATP", "CHEMICAL", 99, 102], ["cholesterol", "CHEMICAL", 104, 115], ["monosodium urate", "CHEMICAL", 126, 142], ["calcium pyrophosphate dihydrate", "CHEMICAL", 159, 190], ["CPPD", "CHEMICAL", 192, 196], ["alum", "CHEMICAL", 228, 232], ["silica", "CHEMICAL", 244, 250], ["NLRP3", "GENE_OR_GENE_PRODUCT", 0, 5], ["DAMPs", "GENE_OR_GENE_PRODUCT", 17, 22], ["glucose", "SIMPLE_CHEMICAL", 67, 74], ["\u03b2-amyloid", "SIMPLE_CHEMICAL", 76, 85], ["hyaluronan", "SIMPLE_CHEMICAL", 87, 97], ["ATP", "SIMPLE_CHEMICAL", 99, 102], ["cholesterol crystals", "SIMPLE_CHEMICAL", 104, 124], ["monosodium urate", "SIMPLE_CHEMICAL", 126, 142], ["MSU", "SIMPLE_CHEMICAL", 144, 147], ["calcium pyrophosphate dihydrate", "SIMPLE_CHEMICAL", 159, 190], ["CPPD", "SIMPLE_CHEMICAL", 192, 196], ["alum", "SIMPLE_CHEMICAL", 228, 232], ["asbestos", "SIMPLE_CHEMICAL", 234, 242], ["silica", "SIMPLE_CHEMICAL", 244, 250], ["skin", "ORGAN", 287, 291], ["NLRP3", "GENE_OR_GENE_PRODUCT", 403, 408], ["NLRP3", "PROTEIN", 0, 5], ["DAMPs", "PROTEIN", 17, 22], ["NLRP3", "PROTEIN", 403, 408], ["NLRP3", "TREATMENT", 0, 5], ["hyaluronan", "TREATMENT", 87, 97], ["ATP, cholesterol crystals", "TEST", 99, 124], ["monosodium urate", "TEST", 126, 142], ["crystals", "TEST", 149, 157], ["calcium pyrophosphate dihydrate (CPPD) crystals", "TREATMENT", 159, 206], ["asbestos, silica, alloy particles", "TREATMENT", 234, 267], ["UV radiation", "TREATMENT", 269, 281], ["skin irritants", "PROBLEM", 287, 301], ["the direct activation of NLRP3", "TREATMENT", 378, 408], ["silica", "ANATOMY", 244, 250], ["UV radiation", "OBSERVATION", 269, 281], ["skin", "ANATOMY", 287, 291], ["irritants", "OBSERVATION", 292, 301]]], ["Instead, efflux of potassium has been identified as the common activator of most known NLRP3 step 2 signals [57, 58] .", [["potassium", "CHEMICAL", 19, 28], ["potassium", "CHEMICAL", 19, 28], ["potassium", "SIMPLE_CHEMICAL", 19, 28], ["NLRP3", "GENE_OR_GENE_PRODUCT", 87, 92], ["NLRP3", "PROTEIN", 87, 92], ["efflux of potassium", "TEST", 9, 28]]], ["The NLRP3 activation by potassium efflux suggested to lead NLRP3-Nek7 interaction to drive inflammasome activation [59] [60] [61] .", [["potassium", "CHEMICAL", 24, 33], ["potassium", "CHEMICAL", 24, 33], ["NLRP3", "GENE_OR_GENE_PRODUCT", 4, 9], ["potassium", "SIMPLE_CHEMICAL", 24, 33], ["NLRP3", "GENE_OR_GENE_PRODUCT", 59, 64], ["Nek7", "GENE_OR_GENE_PRODUCT", 65, 69], ["NLRP3", "PROTEIN", 4, 9], ["NLRP3", "PROTEIN", 59, 64], ["Nek7", "PROTEIN", 65, 69], ["The NLRP3 activation", "TREATMENT", 0, 20], ["potassium efflux", "TEST", 24, 40], ["NLRP3", "TEST", 59, 64]]], ["The mechanism underlying the secretion of IL-1\u03b2 has been suggested to overlap with IL-1\u03b1 secretion [41] .", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 83, 88], ["IL-1\u03b2", "PROTEIN", 42, 47], ["IL", "PROTEIN", 83, 85]]], ["Also, mitochondrial and phagosomal reactive oxygen species (ROS) have been proposed to activate the NLRP3 inflammasome.", [["mitochondrial", "ANATOMY", 6, 19], ["phagosomal", "ANATOMY", 24, 34], ["oxygen", "CHEMICAL", 44, 50], ["ROS", "CHEMICAL", 60, 63], ["oxygen", "CHEMICAL", 44, 50], ["mitochondrial", "CELLULAR_COMPONENT", 6, 19], ["phagosomal reactive oxygen species", "SIMPLE_CHEMICAL", 24, 58], ["ROS", "SIMPLE_CHEMICAL", 60, 63], ["NLRP3", "GENE_OR_GENE_PRODUCT", 100, 105], ["NLRP3", "PROTEIN", 100, 105], ["mitochondrial and phagosomal reactive oxygen species", "PROBLEM", 6, 58], ["phagosomal", "OBSERVATION_MODIFIER", 24, 34], ["reactive", "OBSERVATION_MODIFIER", 35, 43], ["oxygen species", "OBSERVATION", 44, 58]]], ["Alternatively, non-canonical pathways of NLRP3-inflammasome activation associated with proinflammatory caspases, caspase-4, caspase-5, and caspase-11 have been proposed.", [["NLRP3", "GENE_OR_GENE_PRODUCT", 41, 46], ["caspases", "GENE_OR_GENE_PRODUCT", 103, 111], ["caspase-4", "GENE_OR_GENE_PRODUCT", 113, 122], ["caspase-5", "GENE_OR_GENE_PRODUCT", 124, 133], ["caspase-11", "GENE_OR_GENE_PRODUCT", 139, 149], ["NLRP3", "PROTEIN", 41, 46], ["proinflammatory caspases", "PROTEIN", 87, 111], ["caspase-4", "PROTEIN", 113, 122], ["caspase-5", "PROTEIN", 124, 133], ["caspase-11", "PROTEIN", 139, 149], ["NLRP3", "PROBLEM", 41, 46], ["inflammasome activation", "PROBLEM", 47, 70], ["proinflammatory caspases", "TREATMENT", 87, 111], ["caspase", "TEST", 113, 120], ["caspase", "TREATMENT", 124, 131], ["caspase", "TREATMENT", 139, 146]]], ["In this process, LPS is recognized by the caspase-recruitment domain (CARD) of respective caspases, leading to activation [62] [63] [64] [65] .", [["LPS", "CHEMICAL", 17, 20], ["LPS", "SIMPLE_CHEMICAL", 17, 20], ["caspase", "GENE_OR_GENE_PRODUCT", 42, 49], ["CARD", "GENE_OR_GENE_PRODUCT", 70, 74], ["caspases", "GENE_OR_GENE_PRODUCT", 90, 98], ["caspase-recruitment domain", "PROTEIN", 42, 68], ["CARD", "PROTEIN", 70, 74], ["caspases", "PROTEIN", 90, 98]]], ["Caspase-8 or proteases in neutrophils are also processed and activate IL-1\u03b2.", [["neutrophils", "ANATOMY", 26, 37], ["Caspase-8", "GENE_OR_GENE_PRODUCT", 0, 9], ["neutrophils", "CELL", 26, 37], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 70, 75], ["Caspase-8", "PROTEIN", 0, 9], ["proteases", "PROTEIN", 13, 22], ["neutrophils", "CELL_TYPE", 26, 37], ["IL-1\u03b2", "PROTEIN", 70, 75], ["Caspase", "TEST", 0, 7], ["proteases in neutrophils", "PROBLEM", 13, 37]]], ["Several PRRs, such as NLRP1, NLRP3, NLRC4, pyrin, and AIM2, convert the assembly of the adaptor molecule ASC into a high-molecular-weight complex, called the pyroptosome [66] .", [["PRRs", "GENE_OR_GENE_PRODUCT", 8, 12], ["NLRP1", "GENE_OR_GENE_PRODUCT", 22, 27], ["NLRP3", "GENE_OR_GENE_PRODUCT", 29, 34], ["NLRC4", "GENE_OR_GENE_PRODUCT", 36, 41], ["pyrin", "GENE_OR_GENE_PRODUCT", 43, 48], ["AIM2", "GENE_OR_GENE_PRODUCT", 54, 58], ["ASC", "GENE_OR_GENE_PRODUCT", 105, 108], ["PRRs", "PROTEIN", 8, 12], ["NLRP1", "PROTEIN", 22, 27], ["NLRP3", "PROTEIN", 29, 34], ["NLRC4", "PROTEIN", 36, 41], ["pyrin", "PROTEIN", 43, 48], ["AIM2", "PROTEIN", 54, 58], ["adaptor molecule", "PROTEIN", 88, 104], ["ASC", "PROTEIN", 105, 108], ["high-molecular-weight complex", "PROTEIN", 116, 145], ["Several PRRs", "PROBLEM", 0, 12], ["NLRP1", "TEST", 22, 27], ["NLRP3", "TREATMENT", 29, 34], ["pyrin", "TREATMENT", 43, 48], ["AIM2", "TREATMENT", 54, 58]]], ["Then, the caspase-1 precursor is recruited to the pyroptosome to also form helical structures, which enable its proximity-induced proteolytical auto-activation.", [["caspase-1", "GENE_OR_GENE_PRODUCT", 10, 19], ["pyroptosome", "GENE_OR_GENE_PRODUCT", 50, 61], ["caspase-1 precursor", "PROTEIN", 10, 29], ["the caspase", "TREATMENT", 6, 17]]], ["With caspase-1 precursor maturation into the active p102/p202 heterotetramer, it cleaves the IL-1\u03b2 precursor, leading to pyroptotic cell death.", [["cell", "ANATOMY", 132, 136], ["death", "DISEASE", 137, 142], ["caspase-1", "GENE_OR_GENE_PRODUCT", 5, 14], ["p102", "GENE_OR_GENE_PRODUCT", 52, 56], ["p202", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 93, 98], ["cell", "CELL", 132, 136], ["p102", "PROTEIN", 52, 56], ["p202 heterotetramer", "PROTEIN", 57, 76], ["IL-1\u03b2 precursor", "PROTEIN", 93, 108], ["caspase", "TREATMENT", 5, 12], ["the active p102/p202 heterotetramer", "TREATMENT", 41, 76], ["pyroptotic cell death", "PROBLEM", 121, 142], ["pyroptotic cell death", "OBSERVATION", 121, 142]]], ["This cell death is mediated by the caspase-1-dependent cleavage of gasdermin-D (GSDMD) [67] [68] [69] .", [["cell", "ANATOMY", 5, 9], ["death", "DISEASE", 10, 15], ["gasdermin-D", "CHEMICAL", 67, 78], ["gasdermin-D (GSDMD) [67] [68]", "CHEMICAL", 67, 96], ["cell", "CELL", 5, 9], ["caspase-1", "GENE_OR_GENE_PRODUCT", 35, 44], ["gasdermin-D", "SIMPLE_CHEMICAL", 67, 78], ["GSDMD", "SIMPLE_CHEMICAL", 80, 85], ["caspase-1", "PROTEIN", 35, 44], ["This cell death", "PROBLEM", 0, 15], ["the caspase", "TEST", 31, 42], ["cell death", "OBSERVATION", 5, 15]]], ["In turn, the mature N-terminal fragment of GSDMD translocates to the inner leaflet of the plasma membrane to form round and pore-like structures of approximately 15 nm in diameter [70] [71] [72] [73] .Molecular mechanism of interleukin-1 activationTissue distributions of interleukin-1 IL-1\u03b1 and IL-1\u03b2 are expressed in a wide range of tissues and a variety of cells, especially in macrophages in lymphoid organs including the thymus, spleen, lymph nodes, Peyer's patches, and bone marrow.", [["inner leaflet", "ANATOMY", 69, 82], ["plasma membrane", "ANATOMY", 90, 105], ["pore-like structures", "ANATOMY", 124, 144], ["tissues", "ANATOMY", 335, 342], ["cells", "ANATOMY", 360, 365], ["macrophages", "ANATOMY", 381, 392], ["lymphoid organs", "ANATOMY", 396, 411], ["thymus", "ANATOMY", 426, 432], ["spleen", "ANATOMY", 434, 440], ["lymph nodes", "ANATOMY", 442, 453], ["Peyer's patches", "ANATOMY", 455, 470], ["bone marrow", "ANATOMY", 476, 487], ["N", "CHEMICAL", 20, 21], ["GSDMD", "GENE_OR_GENE_PRODUCT", 43, 48], ["inner leaflet", "CELLULAR_COMPONENT", 69, 82], ["plasma membrane", "CELLULAR_COMPONENT", 90, 105], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 224, 237], ["interleukin-1 IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 272, 291], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 296, 301], ["tissues", "TISSUE", 335, 342], ["cells", "CELL", 360, 365], ["macrophages", "CELL", 381, 392], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 396, 411], ["thymus", "ORGAN", 426, 432], ["spleen", "ORGAN", 434, 440], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 442, 453], ["Peyer's patches", "MULTI-TISSUE_STRUCTURE", 455, 470], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 476, 487], ["mature N-terminal fragment", "PROTEIN", 13, 39], ["GSDMD", "PROTEIN", 43, 48], ["interleukin-1", "PROTEIN", 224, 237], ["interleukin-1 IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 272, 301], ["macrophages", "CELL_TYPE", 381, 392], ["the mature N-terminal fragment of GSDMD", "PROBLEM", 9, 48], ["round and pore-like structures", "PROBLEM", 114, 144], ["interleukin", "TEST", 224, 235], ["interleukin", "TEST", 272, 283], ["a variety of cells", "PROBLEM", 347, 365], ["lymph nodes", "PROBLEM", 442, 453], ["Peyer's patches, and bone marrow", "PROBLEM", 455, 487], ["mature", "OBSERVATION_MODIFIER", 13, 19], ["terminal", "OBSERVATION_MODIFIER", 22, 30], ["fragment", "OBSERVATION_MODIFIER", 31, 39], ["inner", "ANATOMY_MODIFIER", 69, 74], ["leaflet", "ANATOMY_MODIFIER", 75, 82], ["plasma membrane", "OBSERVATION", 90, 105], ["round", "OBSERVATION_MODIFIER", 114, 119], ["pore", "OBSERVATION_MODIFIER", 124, 128], ["15 nm", "OBSERVATION_MODIFIER", 162, 167], ["macrophages", "OBSERVATION", 381, 392], ["lymphoid organs", "OBSERVATION", 396, 411], ["thymus", "ANATOMY", 426, 432], ["spleen", "ANATOMY", 434, 440], ["lymph nodes", "OBSERVATION", 442, 453], ["bone marrow", "ANATOMY", 476, 487]]], ["In non-lymphoid organs, IL-1\u03b1 and IL-1\u03b2 are expressed in tissue macrophages in the lung, digestive tract, and liver.", [["non-lymphoid organs", "ANATOMY", 3, 22], ["tissue macrophages", "ANATOMY", 57, 75], ["lung", "ANATOMY", 83, 87], ["digestive tract", "ANATOMY", 89, 104], ["liver", "ANATOMY", 110, 115], ["non-lymphoid organs", "MULTI-TISSUE_STRUCTURE", 3, 22], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 24, 29], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 34, 39], ["tissue macrophages", "CELL", 57, 75], ["lung", "ORGAN", 83, 87], ["digestive tract", "ORGAN", 89, 104], ["liver", "ORGAN", 110, 115], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 24, 39], ["tissue macrophages", "CELL_TYPE", 57, 75], ["IL", "TEST", 24, 26], ["IL", "TREATMENT", 34, 36], ["non-lymphoid organs", "ANATOMY", 3, 22], ["tissue macrophages", "OBSERVATION", 57, 75], ["lung", "ANATOMY", 83, 87], ["digestive tract", "ANATOMY", 89, 104], ["liver", "ANATOMY", 110, 115]]], ["They are also expressed in cellular subepithelial endometrial tissue of the uterus, in the glomeruli, in outer cortical areas of the kidney, and in various specific cell types, including neutrophils, keratinocytes, epithelial and endothelial cells, lymphocytes, smooth muscle cells, and fibroblasts [74, 75] .Interleukin-1 receptors and subcellular signalingThere are two cell surface IL-1 receptors, IL-1R1 and IL-1 type 2 receptor (IL-1R2), a decoy receptor.", [["cellular subepithelial endometrial tissue", "ANATOMY", 27, 68], ["uterus", "ANATOMY", 76, 82], ["glomeruli", "ANATOMY", 91, 100], ["outer cortical areas", "ANATOMY", 105, 125], ["kidney", "ANATOMY", 133, 139], ["cell", "ANATOMY", 165, 169], ["neutrophils", "ANATOMY", 187, 198], ["keratinocytes", "ANATOMY", 200, 213], ["epithelial", "ANATOMY", 215, 225], ["endothelial cells", "ANATOMY", 230, 247], ["lymphocytes", "ANATOMY", 249, 260], ["smooth muscle cells", "ANATOMY", 262, 281], ["fibroblasts", "ANATOMY", 287, 298], ["subcellular", "ANATOMY", 337, 348], ["cell surface", "ANATOMY", 372, 384], ["cellular subepithelial endometrial tissue", "TISSUE", 27, 68], ["uterus", "ORGAN", 76, 82], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 91, 100], ["kidney", "ORGAN", 133, 139], ["cell", "CELL", 165, 169], ["neutrophils", "CELL", 187, 198], ["keratinocytes", "CELL", 200, 213], ["epithelial", "CELL", 215, 225], ["endothelial cells", "CELL", 230, 247], ["lymphocytes", "CELL", 249, 260], ["smooth muscle cells", "CELL", 262, 281], ["fibroblasts", "CELL", 287, 298], ["Interleukin-1 receptors", "GENE_OR_GENE_PRODUCT", 309, 332], ["cell", "CELL", 372, 376], ["IL-1 receptors", "GENE_OR_GENE_PRODUCT", 385, 399], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 401, 407], ["IL-1 type 2 receptor", "GENE_OR_GENE_PRODUCT", 412, 432], ["IL-1R2", "GENE_OR_GENE_PRODUCT", 434, 440], ["neutrophils", "CELL_TYPE", 187, 198], ["keratinocytes", "CELL_TYPE", 200, 213], ["epithelial and endothelial cells", "CELL_TYPE", 215, 247], ["lymphocytes", "CELL_TYPE", 249, 260], ["smooth muscle cells", "CELL_TYPE", 262, 281], ["fibroblasts", "CELL_TYPE", 287, 298], ["Interleukin-1 receptors", "PROTEIN", 309, 332], ["cell surface IL-1 receptors", "PROTEIN", 372, 399], ["IL-1R1 and IL-1 type 2 receptor", "PROTEIN", 401, 432], ["IL", "PROTEIN", 434, 436], ["1R2", "PROTEIN", 437, 440], ["decoy receptor", "PROTEIN", 445, 459], ["neutrophils", "TEST", 187, 198], ["keratinocytes", "TEST", 200, 213], ["epithelial and endothelial cells", "TEST", 215, 247], ["lymphocytes", "TEST", 249, 260], ["smooth muscle cells", "TEST", 262, 281], ["fibroblasts", "TEST", 287, 298], ["Interleukin", "TEST", 309, 320], ["subcellular signaling", "TEST", 337, 358], ["two cell surface IL", "TEST", 368, 387], ["receptors", "TEST", 390, 399], ["IL", "TEST", 401, 403], ["IL", "TREATMENT", 412, 414], ["a decoy receptor", "TREATMENT", 443, 459], ["cellular", "ANATOMY_MODIFIER", 27, 35], ["subepithelial", "ANATOMY_MODIFIER", 36, 49], ["endometrial tissue", "OBSERVATION", 50, 68], ["uterus", "ANATOMY", 76, 82], ["glomeruli", "ANATOMY", 91, 100], ["outer", "ANATOMY_MODIFIER", 105, 110], ["cortical", "ANATOMY_MODIFIER", 111, 119], ["areas", "ANATOMY_MODIFIER", 120, 125], ["kidney", "ANATOMY", 133, 139], ["specific cell types", "OBSERVATION", 156, 175], ["neutrophils", "ANATOMY", 187, 198], ["keratinocytes", "ANATOMY", 200, 213], ["epithelial", "ANATOMY_MODIFIER", 215, 225], ["endothelial cells", "OBSERVATION", 230, 247], ["lymphocytes", "ANATOMY", 249, 260], ["smooth muscle cells", "OBSERVATION", 262, 281], ["fibroblasts", "OBSERVATION_MODIFIER", 287, 298]]], ["IL-1 binds to IL-1R1, which requires the formation of a heterodimer with the IL-1 type 3 receptor (IL-1R3) (also known as IL-1RAcP) accompanied by adaptor IL-1 receptor-associated kinase (IRAK) and myeloid differentiation primary response protein 88 (MyD88) [76] .", [["IL-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 14, 20], ["IL-1 type 3 receptor", "GENE_OR_GENE_PRODUCT", 77, 97], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 99, 105], ["IL-1RAcP", "GENE_OR_GENE_PRODUCT", 122, 130], ["IL-1 receptor-associated kinase", "GENE_OR_GENE_PRODUCT", 155, 186], ["IRAK", "GENE_OR_GENE_PRODUCT", 188, 192], ["myeloid differentiation primary response protein 88", "GENE_OR_GENE_PRODUCT", 198, 249], ["MyD88", "GENE_OR_GENE_PRODUCT", 251, 256], ["IL-1", "PROTEIN", 0, 4], ["IL-1R1", "PROTEIN", 14, 20], ["IL-1 type 3 receptor", "PROTEIN", 77, 97], ["IL", "PROTEIN", 99, 101], ["1R3", "PROTEIN", 102, 105], ["IL", "PROTEIN", 122, 124], ["1RAcP", "PROTEIN", 125, 130], ["adaptor IL-1 receptor-associated kinase", "PROTEIN", 147, 186], ["IRAK", "PROTEIN", 188, 192], ["myeloid differentiation primary response protein 88", "PROTEIN", 198, 249], ["MyD88", "PROTEIN", 251, 256], ["a heterodimer", "TREATMENT", 54, 67], ["the IL", "TREATMENT", 73, 79], ["adaptor IL", "TEST", 147, 157], ["myeloid differentiation primary response protein", "TEST", 198, 246], ["myeloid", "ANATOMY", 198, 205]]], ["IL-1R1 initiates inflammatory responses when binding to the ligands IL-1\u03b1 and IL-1\u03b2 and has been reported to be expressed by Tlymphocytes, fibroblasts, epithelial cells, and endothelial cells.", [["Tlymphocytes", "ANATOMY", 125, 137], ["fibroblasts", "ANATOMY", 139, 150], ["epithelial cells", "ANATOMY", 152, 168], ["endothelial cells", "ANATOMY", 174, 191], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 78, 83], ["Tlymphocytes", "CELL", 125, 137], ["fibroblasts", "CELL", 139, 150], ["epithelial cells", "CELL", 152, 168], ["endothelial cells", "CELL", 174, 191], ["IL-1R1", "PROTEIN", 0, 6], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 68, 83], ["Tlymphocytes", "CELL_TYPE", 125, 137], ["fibroblasts", "CELL_TYPE", 139, 150], ["epithelial cells", "CELL_TYPE", 152, 168], ["endothelial cells", "CELL_TYPE", 174, 191], ["inflammatory responses", "PROBLEM", 17, 39], ["the ligands IL", "TEST", 56, 70], ["IL", "TEST", 78, 80], ["epithelial cells", "PROBLEM", 152, 168], ["endothelial cells", "PROBLEM", 174, 191], ["inflammatory", "OBSERVATION", 17, 29], ["fibroblasts", "ANATOMY", 139, 150], ["epithelial cells", "OBSERVATION", 152, 168], ["endothelial cells", "OBSERVATION", 174, 191]]], ["IL-1R2, which does not initiate signal transduction, is expressed in a variety of hematopoietic cells, especially in B-lymphocytes, mononuclear phagocytes, polymorphonuclear leukocytes, and bone marrow cells.", [["hematopoietic cells", "ANATOMY", 82, 101], ["B-lymphocytes", "ANATOMY", 117, 130], ["mononuclear phagocytes", "ANATOMY", 132, 154], ["polymorphonuclear leukocytes", "ANATOMY", 156, 184], ["bone marrow cells", "ANATOMY", 190, 207], ["IL-1R2", "GENE_OR_GENE_PRODUCT", 0, 6], ["hematopoietic cells", "CELL", 82, 101], ["B-lymphocytes", "CELL", 117, 130], ["mononuclear phagocytes", "CELL", 132, 154], ["polymorphonuclear leukocytes", "CELL", 156, 184], ["bone marrow cells", "CELL", 190, 207], ["IL", "PROTEIN", 0, 2], ["1R2", "PROTEIN", 3, 6], ["hematopoietic cells", "CELL_TYPE", 82, 101], ["B-lymphocytes", "CELL_TYPE", 117, 130], ["mononuclear phagocytes", "CELL_TYPE", 132, 154], ["polymorphonuclear leukocytes", "CELL_TYPE", 156, 184], ["bone marrow cells", "CELL_TYPE", 190, 207], ["hematopoietic cells", "PROBLEM", 82, 101], ["mononuclear phagocytes", "TEST", 132, 154], ["polymorphonuclear leukocytes", "TEST", 156, 184], ["bone marrow cells", "PROBLEM", 190, 207], ["hematopoietic cells", "OBSERVATION", 82, 101], ["lymphocytes", "ANATOMY", 119, 130], ["mononuclear phagocytes", "OBSERVATION", 132, 154], ["polymorphonuclear leukocytes", "OBSERVATION", 156, 184], ["bone", "ANATOMY", 190, 194], ["marrow cells", "OBSERVATION", 195, 207]]], ["Notably, expression levels of IL-1R1 and IL-1R2 are different among the cell types; for example, neutrophils predominantly express IL-1R2.", [["cell", "ANATOMY", 72, 76], ["neutrophils", "ANATOMY", 97, 108], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 30, 36], ["IL-1R2", "GENE_OR_GENE_PRODUCT", 41, 47], ["cell", "CELL", 72, 76], ["neutrophils", "CELL", 97, 108], ["IL-1R2", "GENE_OR_GENE_PRODUCT", 131, 137], ["IL-1R1 and IL-1R2", "PROTEIN", 30, 47], ["neutrophils", "CELL_TYPE", 97, 108], ["IL", "PROTEIN", 131, 133], ["1R2", "PROTEIN", 134, 137], ["expression levels", "TEST", 9, 26], ["IL", "TEST", 30, 32], ["neutrophils", "TEST", 97, 108], ["cell types", "OBSERVATION", 72, 82]]], ["As a result, much higher concentrations of IL-1\u03b2 are required to activate neutrophils, whereas low concentrations of IL-1\u03b2 are sufficient to activate endothelial cells.", [["neutrophils", "ANATOMY", 74, 85], ["endothelial cells", "ANATOMY", 150, 167], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 43, 48], ["neutrophils", "CELL", 74, 85], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 117, 122], ["endothelial cells", "CELL", 150, 167], ["IL-1\u03b2", "PROTEIN", 43, 48], ["neutrophils", "CELL_TYPE", 74, 85], ["IL-1\u03b2", "PROTEIN", 117, 122], ["endothelial cells", "CELL_TYPE", 150, 167], ["much higher concentrations of IL", "TREATMENT", 13, 45], ["neutrophils", "TEST", 74, 85], ["endothelial cells", "OBSERVATION", 150, 167]]], ["The IL-1R1-mediated signaling pathways also differ according to the cell types [77, 78] .", [["cell", "ANATOMY", 68, 72], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 4, 10], ["cell", "CELL", 68, 72], ["IL", "PROTEIN", 4, 6], ["1R1", "PROTEIN", 7, 10], ["The IL", "TEST", 0, 6]]], ["IL-1R3 is a co-receptor for IL-1R1, responsible for signaling after binding ligands IL-1\u03b1 and IL-1\u03b2, and has been reported to be ubiquitously expressed by all cells responsive to IL-1.", [["cells", "ANATOMY", 159, 164], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 28, 34], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 84, 89], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 94, 99], ["cells", "CELL", 159, 164], ["IL-1", "GENE_OR_GENE_PRODUCT", 179, 183], ["IL-1R3", "PROTEIN", 0, 6], ["IL", "PROTEIN", 28, 30], ["1R1", "PROTEIN", 31, 34], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 84, 99], ["IL-1", "PROTEIN", 179, 183], ["a co-receptor for IL", "TREATMENT", 10, 30], ["binding ligands IL", "TEST", 68, 86], ["IL", "TEST", 94, 96]]], ["IL-1R3b is a brain-specific isoform of IL-1R3 generated by alternative splicing, and it has been reported to be expressed in the brain, cerebellum, and spinal cord [79] .Interleukin-1 receptors and subcellular signalingActivated IL-1 is incapable of functioning until recognized by cell surface receptors.", [["brain", "ANATOMY", 13, 18], ["brain", "ANATOMY", 129, 134], ["cerebellum", "ANATOMY", 136, 146], ["spinal cord", "ANATOMY", 152, 163], ["subcellular", "ANATOMY", 198, 209], ["cell surface", "ANATOMY", 282, 294], ["IL-1R3b", "GENE_OR_GENE_PRODUCT", 0, 7], ["brain", "ORGAN", 13, 18], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 39, 45], ["brain", "ORGAN", 129, 134], ["cerebellum", "ORGAN", 136, 146], ["spinal cord", "ORGAN", 152, 163], ["Interleukin-1 receptors", "GENE_OR_GENE_PRODUCT", 170, 193], ["IL-1", "GENE_OR_GENE_PRODUCT", 229, 233], ["cell", "CELL", 282, 286], ["IL", "PROTEIN", 0, 2], ["1R3b", "PROTEIN", 3, 7], ["IL", "PROTEIN", 39, 41], ["1R3", "PROTEIN", 42, 45], ["Interleukin-1 receptors", "PROTEIN", 170, 193], ["Activated IL-1", "PROTEIN", 219, 233], ["cell surface receptors", "PROTEIN", 282, 304], ["Interleukin-1 receptors", "TREATMENT", 170, 193], ["subcellular signalingActivated IL-1", "TREATMENT", 198, 233], ["brain", "ANATOMY", 13, 18], ["brain", "ANATOMY", 129, 134], ["cerebellum", "ANATOMY", 136, 146], ["spinal cord", "ANATOMY", 152, 163]]], ["The complex contains a motif of GTPase activity and activates GTPase-activating protein and protein kinases [80] [81] [82] .", [["GTPase-activating protein", "GENE_OR_GENE_PRODUCT", 62, 87], ["GTPase", "PROTEIN", 32, 38], ["GTPase-activating protein", "PROTEIN", 62, 87], ["protein kinases", "PROTEIN", 92, 107], ["GTPase activity", "TEST", 32, 47], ["activates GTPase", "TEST", 52, 68], ["activating protein", "TEST", 69, 87], ["protein kinases", "TEST", 92, 107], ["GTPase activity", "OBSERVATION", 32, 47]]], ["In contrast, IL-1R2 is thought to reduce the biological response to IL-1.", [["IL-1R2", "GENE_OR_GENE_PRODUCT", 13, 19], ["IL-1", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL", "PROTEIN", 13, 15], ["1R2", "PROTEIN", 16, 19], ["IL-1", "PROTEIN", 68, 72]]], ["The proximity of the two cytoplasmic domains of IL-1R1 and IL-1R3 is thought to initiate signal transduction by the hydrolysis of GTP.", [["cytoplasmic", "ANATOMY", 25, 36], ["GTP", "CHEMICAL", 130, 133], ["GTP", "CHEMICAL", 130, 133], ["cytoplasmic", "ORGANISM_SUBSTANCE", 25, 36], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 48, 54], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 59, 65], ["GTP", "SIMPLE_CHEMICAL", 130, 133], ["cytoplasmic domains", "PROTEIN", 25, 44], ["IL", "PROTEIN", 48, 50], ["1R1", "PROTEIN", 51, 54], ["IL", "PROTEIN", 59, 61], ["1R3", "PROTEIN", 62, 65], ["IL", "TEST", 48, 50], ["the hydrolysis of GTP", "PROBLEM", 112, 133], ["cytoplasmic", "OBSERVATION_MODIFIER", 25, 36], ["domains", "OBSERVATION_MODIFIER", 37, 44]]], ["This is followed by c-Jun N-terminal kinase (JNK) and p38 MAP kinase [83] .", [["N", "CHEMICAL", 26, 27], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 20, 43], ["JNK", "GENE_OR_GENE_PRODUCT", 45, 48], ["p38 MAP kinase", "GENE_OR_GENE_PRODUCT", 54, 68], ["Jun N-terminal kinase", "PROTEIN", 22, 43], ["JNK", "PROTEIN", 45, 48], ["p38 MAP kinase", "PROTEIN", 54, 68], ["p38 MAP kinase", "TEST", 54, 68]]], ["IRAK and tumor necrosis factor (TNF) receptor-associated factor (TRAF) 6 activate NF-\u03baB, as well as p38, JNKs, extracellular signal-regulated kinases (ERKs), and mitogen-activated protein kinases (MAPKs) [84] .", [["tumor", "DISEASE", 9, 14], ["necrosis", "DISEASE", 15, 23], ["IRAK", "GENE_OR_GENE_PRODUCT", 0, 4], ["tumor necrosis factor (TNF) receptor-associated factor (TRAF) 6", "GENE_OR_GENE_PRODUCT", 9, 72], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 82, 87], ["p38", "GENE_OR_GENE_PRODUCT", 100, 103], ["JNKs", "GENE_OR_GENE_PRODUCT", 105, 109], ["extracellular signal-regulated kinases", "GENE_OR_GENE_PRODUCT", 111, 149], ["ERKs", "GENE_OR_GENE_PRODUCT", 151, 155], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 162, 195], ["MAPKs", "GENE_OR_GENE_PRODUCT", 197, 202], ["IRAK", "PROTEIN", 0, 4], ["tumor necrosis factor (TNF) receptor-associated factor (TRAF) 6", "PROTEIN", 9, 72], ["NF-\u03baB", "PROTEIN", 82, 87], ["p38", "PROTEIN", 100, 103], ["JNKs", "PROTEIN", 105, 109], ["extracellular signal-regulated kinases", "PROTEIN", 111, 149], ["ERKs", "PROTEIN", 151, 155], ["mitogen-activated protein kinases", "PROTEIN", 162, 195], ["MAPKs", "PROTEIN", 197, 202], ["IRAK", "PROBLEM", 0, 4], ["tumor necrosis factor", "PROBLEM", 9, 30], ["TNF", "TEST", 32, 35], ["receptor", "TEST", 37, 45], ["factor (TRAF)", "TEST", 57, 70], ["NF", "TEST", 82, 84], ["JNKs", "TEST", 105, 109], ["extracellular signal", "TEST", 111, 131], ["ERKs", "TEST", 151, 155], ["mitogen", "TEST", 162, 169], ["activated protein kinases", "TEST", 170, 195], ["MAPKs", "TEST", 197, 202], ["tumor", "OBSERVATION_MODIFIER", 9, 14], ["necrosis", "OBSERVATION", 15, 23]]], ["The NF-\u03baB activation pathway is dependent on the I\u03ba-B kinase (IKK) complex, composed of IKK\u03b1, IKK\u03b2, and NF-\u03baB essential modulator (NEMO), via associations with TAK1, TAK2, TRAF2, and TRAF6 in the IL-1R1-signaling pathway [85] .", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 4, 9], ["I\u03ba-B kinase", "GENE_OR_GENE_PRODUCT", 49, 60], ["IKK", "GENE_OR_GENE_PRODUCT", 62, 65], ["IKK\u03b1", "GENE_OR_GENE_PRODUCT", 88, 92], ["IKK\u03b2", "GENE_OR_GENE_PRODUCT", 94, 98], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 104, 109], ["NEMO", "GENE_OR_GENE_PRODUCT", 131, 135], ["TAK1", "GENE_OR_GENE_PRODUCT", 160, 164], ["TAK2", "GENE_OR_GENE_PRODUCT", 166, 170], ["TRAF2", "GENE_OR_GENE_PRODUCT", 172, 177], ["TRAF6", "GENE_OR_GENE_PRODUCT", 183, 188], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 196, 202], ["NF-\u03baB", "PROTEIN", 4, 9], ["I\u03ba-B kinase (IKK) complex", "PROTEIN", 49, 74], ["IKK\u03b1", "PROTEIN", 88, 92], ["IKK\u03b2", "PROTEIN", 94, 98], ["NF-\u03baB", "PROTEIN", 104, 109], ["NEMO", "PROTEIN", 131, 135], ["TAK1", "PROTEIN", 160, 164], ["TAK2", "PROTEIN", 166, 170], ["TRAF2", "PROTEIN", 172, 177], ["TRAF6", "PROTEIN", 183, 188], ["IL", "PROTEIN", 196, 198], ["1R1", "PROTEIN", 199, 202], ["The NF", "TREATMENT", 0, 6], ["IKK\u03b1", "PROBLEM", 88, 92], ["IKK\u03b2", "TEST", 94, 98], ["NF", "TEST", 104, 106], ["TAK1", "TEST", 160, 164], ["TAK2", "TEST", 166, 170], ["TRAF2", "TEST", 172, 177], ["TRAF6", "TEST", 183, 188]]], ["These signals play important roles in both acute and chronic inflammation in various diseases [86] .Interleukin-1 and diseases Autoinflammatory diseasesSingle nucleotide mutation of the CIAS1 gene results in NLRP3 mutation, which induces constituted inflammasome activation causing cryopyrin-associated periodic syndrome (CAPS).", [["inflammation", "DISEASE", 61, 73], ["Autoinflammatory diseases", "DISEASE", 127, 152], ["cryopyrin", "CHEMICAL", 282, 291], ["CAPS", "DISEASE", 322, 326], ["nucleotide", "CHEMICAL", 159, 169], ["Interleukin-1", "GENE_OR_GENE_PRODUCT", 100, 113], ["CIAS1", "GENE_OR_GENE_PRODUCT", 186, 191], ["NLRP3", "GENE_OR_GENE_PRODUCT", 208, 213], ["cryopyrin", "SIMPLE_CHEMICAL", 282, 291], ["Interleukin-1", "PROTEIN", 100, 113], ["CIAS1 gene", "DNA", 186, 196], ["NLRP3", "PROTEIN", 208, 213], ["cryopyrin", "PROTEIN", 282, 291], ["both acute and chronic inflammation in various diseases", "PROBLEM", 38, 93], ["Interleukin", "TREATMENT", 100, 111], ["diseases Autoinflammatory diseases", "PROBLEM", 118, 152], ["Single nucleotide mutation", "PROBLEM", 152, 178], ["NLRP3 mutation", "PROBLEM", 208, 222], ["inflammasome activation", "PROBLEM", 250, 273], ["cryopyrin", "PROBLEM", 282, 291], ["periodic syndrome (CAPS)", "PROBLEM", 303, 327], ["both", "OBSERVATION_MODIFIER", 38, 42], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["inflammation", "OBSERVATION", 61, 73], ["inflammasome", "OBSERVATION", 250, 262], ["periodic syndrome", "OBSERVATION", 303, 320]]], ["This is termed autoinflammatory disease, including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurologic, cutaneous, and arthritis (CINCA) syndrome, which leads to greater IL-1\u03b2 secretion without any DAMPs or PAMPs [87] [88] [89] [90] [91] [92] .", [["neurologic", "ANATOMY", 206, 216], ["cutaneous", "ANATOMY", 218, 227], ["autoinflammatory disease", "DISEASE", 15, 39], ["familial cold autoinflammatory syndrome", "DISEASE", 51, 90], ["FCAS", "DISEASE", 92, 96], ["Muckle-Wells syndrome", "DISEASE", 99, 120], ["MWS", "DISEASE", 122, 125], ["multisystem inflammatory disease", "DISEASE", 147, 179], ["NOMID", "DISEASE", 181, 186], ["infantile neurologic, cutaneous, and arthritis", "DISEASE", 196, 242], ["CINCA) syndrome", "DISEASE", 244, 259], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 284, 289], ["DAMPs", "GENE_OR_GENE_PRODUCT", 312, 317], ["PAMPs [87] [88] [89] [90] [91", "SIMPLE_CHEMICAL", 321, 350], ["IL-1\u03b2", "PROTEIN", 284, 289], ["DAMPs", "PROTEIN", 312, 317], ["termed autoinflammatory disease", "PROBLEM", 8, 39], ["familial cold autoinflammatory syndrome", "PROBLEM", 51, 90], ["FCAS)", "PROBLEM", 92, 97], ["Muckle-Wells syndrome", "PROBLEM", 99, 120], ["neonatal-onset multisystem inflammatory disease", "PROBLEM", 132, 179], ["chronic infantile neurologic", "PROBLEM", 188, 216], ["arthritis (CINCA) syndrome", "PROBLEM", 233, 259], ["autoinflammatory disease", "OBSERVATION", 15, 39], ["autoinflammatory syndrome", "OBSERVATION", 65, 90], ["Wells syndrome", "OBSERVATION", 106, 120], ["multisystem", "OBSERVATION_MODIFIER", 147, 158], ["inflammatory disease", "OBSERVATION", 159, 179], ["chronic", "OBSERVATION_MODIFIER", 188, 195], ["cutaneous", "ANATOMY", 218, 227], ["arthritis", "OBSERVATION", 233, 242]]], ["The most common autoinflammatory disease is Familial Mediterranean fever (FMF).", [["autoinflammatory disease", "DISEASE", 16, 40], ["Familial Mediterranean fever", "DISEASE", 44, 72], ["FMF", "DISEASE", 74, 77], ["The most common autoinflammatory disease", "PROBLEM", 0, 40], ["Familial Mediterranean fever", "PROBLEM", 44, 72], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["autoinflammatory", "OBSERVATION_MODIFIER", 16, 32], ["disease", "OBSERVATION", 33, 40], ["Familial", "OBSERVATION_MODIFIER", 44, 52], ["Mediterranean", "OBSERVATION_MODIFIER", 53, 66]]], ["FMF is autosomal recessive; however, mutations in the causative MEFV gene, encoding mutated pyrin, leads to active pyrin inflammasome [93] .", [["FMF", "DISEASE", 0, 3], ["autosomal recessive", "DISEASE", 7, 26], ["MEFV", "GENE_OR_GENE_PRODUCT", 64, 68], ["pyrin", "GENE_OR_GENE_PRODUCT", 92, 97], ["pyrin", "GENE_OR_GENE_PRODUCT", 115, 120], ["causative MEFV gene", "DNA", 54, 73], ["mutated pyrin", "PROTEIN", 84, 97], ["autosomal recessive", "PROBLEM", 7, 26], ["mutations in the causative MEFV gene", "PROBLEM", 37, 73], ["encoding mutated pyrin", "PROBLEM", 75, 97], ["active pyrin inflammasome", "TEST", 108, 133], ["autosomal", "OBSERVATION_MODIFIER", 7, 16], ["recessive", "OBSERVATION", 17, 26]]], ["Inflammatory diseases like those above, characterized by the enhanced secretion of IL-1\u03b2, include a group of autoinflammatory diseases such as NLRP12 autoinflammatory syndrome; hyperimmunoglobulinemia D and periodic fever syndrome (HIDS)/mevalonate kinase deficiency (MKD); pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome; pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) syndrome; pyogenic arthritis, acne, pyoderma gangrenosum, and suppurative hidradenitis (PAPASH); Majeed syndrome; and TNF-receptor-1-associated syndrome (TRAPS) [93] [94] [95] [96] [97] [98] [99] [100] .", [["pyoderma gangrenosum", "ANATOMY", 294, 314], ["Inflammatory diseases", "DISEASE", 0, 21], ["autoinflammatory diseases", "DISEASE", 109, 134], ["NLRP12 autoinflammatory syndrome", "DISEASE", 143, 175], ["hyperimmunoglobulinemia D", "DISEASE", 177, 202], ["periodic fever syndrome", "DISEASE", 207, 230], ["HIDS", "DISEASE", 232, 236], ["mevalonate", "CHEMICAL", 238, 248], ["MKD", "DISEASE", 268, 271], ["pyogenic arthritis", "DISEASE", 274, 292], ["pyoderma gangrenosum", "DISEASE", 294, 314], ["acne", "DISEASE", 320, 324], ["PAPA) syndrome", "DISEASE", 326, 340], ["pyoderma gangrenosum", "DISEASE", 342, 362], ["acne", "DISEASE", 364, 368], ["suppurative hidradenitis", "DISEASE", 374, 398], ["PASH) syndrome", "DISEASE", 400, 414], ["pyogenic arthritis", "DISEASE", 416, 434], ["acne", "DISEASE", 436, 440], ["pyoderma gangrenosum", "DISEASE", 442, 462], ["suppurative hidradenitis", "DISEASE", 468, 492], ["PAPASH", "DISEASE", 494, 500], ["Majeed syndrome", "DISEASE", 503, 518], ["mevalonate", "CHEMICAL", 238, 248], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 83, 88], ["mevalonate kinase", "GENE_OR_GENE_PRODUCT", 238, 255], ["TNF-receptor-1", "GENE_OR_GENE_PRODUCT", 524, 538], ["[93] [94] [95] [96] [97] [98] [99] [100]", "SIMPLE_CHEMICAL", 567, 607], ["IL-1\u03b2", "PROTEIN", 83, 88], ["mevalonate kinase", "PROTEIN", 238, 255], ["TNF", "PROTEIN", 524, 527], ["Inflammatory diseases", "PROBLEM", 0, 21], ["autoinflammatory diseases", "PROBLEM", 109, 134], ["NLRP12 autoinflammatory syndrome", "PROBLEM", 143, 175], ["hyperimmunoglobulinemia D", "PROBLEM", 177, 202], ["periodic fever syndrome", "PROBLEM", 207, 230], ["HIDS", "TEST", 232, 236], ["mevalonate kinase deficiency", "PROBLEM", 238, 266], ["MKD)", "PROBLEM", 268, 272], ["pyogenic arthritis", "PROBLEM", 274, 292], ["pyoderma gangrenosum", "PROBLEM", 294, 314], ["acne (PAPA) syndrome", "PROBLEM", 320, 340], ["pyoderma gangrenosum", "PROBLEM", 342, 362], ["acne", "PROBLEM", 364, 368], ["suppurative hidradenitis", "PROBLEM", 374, 398], ["PASH) syndrome", "PROBLEM", 400, 414], ["pyogenic arthritis", "PROBLEM", 416, 434], ["acne", "PROBLEM", 436, 440], ["pyoderma gangrenosum", "PROBLEM", 442, 462], ["suppurative hidradenitis", "PROBLEM", 468, 492], ["Majeed syndrome", "PROBLEM", 503, 518], ["TNF", "TEST", 524, 527], ["receptor", "TEST", 528, 536], ["associated syndrome", "PROBLEM", 539, 558], ["diseases", "OBSERVATION", 13, 21], ["autoinflammatory", "OBSERVATION", 109, 125], ["autoinflammatory syndrome", "OBSERVATION", 150, 175], ["fever syndrome", "OBSERVATION", 216, 230], ["mevalonate kinase deficiency", "OBSERVATION", 238, 266], ["pyogenic", "OBSERVATION_MODIFIER", 274, 282], ["arthritis", "OBSERVATION", 283, 292], ["pyoderma gangrenosum", "OBSERVATION", 294, 314], ["pyoderma gangrenosum", "OBSERVATION", 342, 362], ["suppurative", "OBSERVATION_MODIFIER", 374, 385], ["hidradenitis", "OBSERVATION", 386, 398], ["pyogenic", "OBSERVATION_MODIFIER", 416, 424], ["arthritis", "OBSERVATION", 425, 434], ["pyoderma gangrenosum", "OBSERVATION", 442, 462], ["suppurative", "OBSERVATION_MODIFIER", 468, 479], ["hidradenitis", "OBSERVATION", 480, 492]]], ["On deficiency of the IL-1-receptor antagonist (DIRA), excess IL-1\u03b2 induces other proinflammatory cytokines and chemokines [101] .Metabolic syndromesExcess stress responses disrupt body homeostasis under physiological conditions and lead to excess cytokine production.", [["body", "ANATOMY", 180, 184], ["Metabolic syndromes", "DISEASE", 129, 148], ["IL-1-receptor antagonist", "GENE_OR_GENE_PRODUCT", 21, 45], ["DIRA", "SIMPLE_CHEMICAL", 47, 51], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 61, 66], ["body", "ORGANISM_SUBDIVISION", 180, 184], ["IL-1-receptor antagonist", "PROTEIN", 21, 45], ["DIRA", "PROTEIN", 47, 51], ["IL-1\u03b2", "PROTEIN", 61, 66], ["proinflammatory cytokines", "PROTEIN", 81, 106], ["chemokines", "PROTEIN", 111, 121], ["cytokine", "PROTEIN", 247, 255], ["the IL", "TREATMENT", 17, 23], ["receptor antagonist", "TREATMENT", 26, 45], ["excess IL", "TREATMENT", 54, 63], ["chemokines", "TEST", 111, 121], ["Metabolic syndromes", "PROBLEM", 129, 148], ["Excess stress responses", "PROBLEM", 148, 171], ["excess cytokine production", "PROBLEM", 240, 266], ["deficiency", "OBSERVATION", 3, 13], ["syndromes", "OBSERVATION", 139, 148]]], ["NLRP3 inflammasomes have also been reported to be involved in low-grade subclinical inflammation induced by chronic exposure to high levels of free fatty acids and glucose, leading to increased apoptosis and impaired insulin secretion of \u03b2-cells in obese type 2 diabetes mellitus (T2D) patients [102] [103] [104] .", [["\u03b2-cells", "ANATOMY", 238, 245], ["inflammation", "DISEASE", 84, 96], ["fatty acids", "CHEMICAL", 148, 159], ["glucose", "CHEMICAL", 164, 171], ["type 2 diabetes mellitus", "DISEASE", 255, 279], ["T2D", "DISEASE", 281, 284], ["fatty acids", "CHEMICAL", 148, 159], ["glucose", "CHEMICAL", 164, 171], ["NLRP3", "GENE_OR_GENE_PRODUCT", 0, 5], ["free fatty acids", "SIMPLE_CHEMICAL", 143, 159], ["glucose", "SIMPLE_CHEMICAL", 164, 171], ["insulin", "GENE_OR_GENE_PRODUCT", 217, 224], ["patients", "ORGANISM", 286, 294], ["NLRP3 inflammasomes", "PROTEIN", 0, 19], ["patients", "SPECIES", 286, 294], ["NLRP3 inflammasomes", "PROBLEM", 0, 19], ["low-grade subclinical inflammation", "PROBLEM", 62, 96], ["chronic exposure", "PROBLEM", 108, 124], ["free fatty acids", "TEST", 143, 159], ["glucose", "TEST", 164, 171], ["increased apoptosis", "PROBLEM", 184, 203], ["impaired insulin secretion of \u03b2-cells", "PROBLEM", 208, 245], ["obese type 2 diabetes mellitus", "PROBLEM", 249, 279], ["subclinical", "OBSERVATION_MODIFIER", 72, 83], ["inflammation", "OBSERVATION", 84, 96], ["chronic", "OBSERVATION_MODIFIER", 108, 115], ["increased", "OBSERVATION_MODIFIER", 184, 193], ["apoptosis", "OBSERVATION", 194, 203], ["impaired", "OBSERVATION_MODIFIER", 208, 216], ["insulin secretion", "OBSERVATION", 217, 234]]], ["Indeed, islet amyloid polypeptide (IAPP) oligomers activated NLRP3 inflammasomes to induce significant IL-1\u03b2 production by infiltrating macrophages in an in vivo study [105, 106] .", [["macrophages", "ANATOMY", 136, 147], ["islet amyloid polypeptide", "GENE_OR_GENE_PRODUCT", 8, 33], ["IAPP", "GENE_OR_GENE_PRODUCT", 35, 39], ["NLRP3", "GENE_OR_GENE_PRODUCT", 61, 66], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 103, 108], ["macrophages", "CELL", 136, 147], ["IAPP", "PROTEIN", 35, 39], ["NLRP3 inflammasomes", "PROTEIN", 61, 80], ["IL-1\u03b2", "PROTEIN", 103, 108], ["infiltrating macrophages", "CELL_TYPE", 123, 147], ["islet amyloid polypeptide", "TREATMENT", 8, 33], ["NLRP3 inflammasomes", "TREATMENT", 61, 80], ["significant IL", "PROBLEM", 91, 105], ["infiltrating macrophages", "PROBLEM", 123, 147], ["an in vivo study", "TEST", 151, 167], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["infiltrating macrophages", "OBSERVATION", 123, 147]]], ["Higher concentrations of glucose activate NF-\u03baB and IL-1 precursors in cells [102] .", [["cells", "ANATOMY", 71, 76], ["glucose", "CHEMICAL", 25, 32], ["glucose", "CHEMICAL", 25, 32], ["glucose", "SIMPLE_CHEMICAL", 25, 32], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-1", "GENE_OR_GENE_PRODUCT", 52, 56], ["cells", "CELL", 71, 76], ["NF-\u03baB", "PROTEIN", 42, 47], ["glucose activate", "TEST", 25, 41], ["NF", "TEST", 42, 44]]], ["Minimally oxidized low-density lipoproteins stimulate TLR4, which triggers IL-1\u03b2 expression [104, 105] , and accumulations of islet amyloid polypeptides are deposited and mediate NLRP3 inflammasome activation in islet macrophages [107] .", [["islet", "ANATOMY", 126, 131], ["islet macrophages", "ANATOMY", 212, 229], ["TLR4", "GENE_OR_GENE_PRODUCT", 54, 58], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 75, 80], ["islet amyloid polypeptides", "GENE_OR_GENE_PRODUCT", 126, 152], ["NLRP3", "GENE_OR_GENE_PRODUCT", 179, 184], ["islet macrophages [107]", "CELL", 212, 235], ["low-density lipoproteins", "PROTEIN", 19, 43], ["TLR4", "PROTEIN", 54, 58], ["IL-1\u03b2", "PROTEIN", 75, 80], ["NLRP3", "PROTEIN", 179, 184], ["islet macrophages", "CELL_TYPE", 212, 229], ["Minimally oxidized low-density lipoproteins stimulate TLR4", "PROBLEM", 0, 58], ["islet amyloid polypeptides", "PROBLEM", 126, 152], ["islet macrophages", "PROBLEM", 212, 229], ["oxidized", "OBSERVATION_MODIFIER", 10, 18], ["low-density", "OBSERVATION_MODIFIER", 19, 30], ["lipoproteins", "OBSERVATION_MODIFIER", 31, 43], ["islet", "ANATOMY", 126, 131], ["amyloid polypeptides", "OBSERVATION", 132, 152], ["mediate", "UNCERTAINTY", 171, 178], ["NLRP3 inflammasome", "OBSERVATION", 179, 197], ["islet macrophages", "OBSERVATION", 212, 229]]], ["Another oligomer of amyloid, amyloid \u03b2, can induce IL-1\u03b2 via NLRP3 inflammasomes in a process involving the phagocytosis of amyloid \u03b2 in glial cells in patients with Alzheimer's disease (AD) and subsequent lysosomal damage and release of cathepsin B [108] .", [["glial cells", "ANATOMY", 137, 148], ["lysosomal", "ANATOMY", 206, 215], ["Alzheimer's disease", "DISEASE", 166, 185], ["AD", "DISEASE", 187, 189], ["lysosomal damage", "DISEASE", 206, 222], ["amyloid", "GENE_OR_GENE_PRODUCT", 20, 27], ["amyloid \u03b2", "GENE_OR_GENE_PRODUCT", 29, 38], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 51, 56], ["NLRP3", "GENE_OR_GENE_PRODUCT", 61, 66], ["amyloid \u03b2", "GENE_OR_GENE_PRODUCT", 124, 133], ["glial cells", "CELL", 137, 148], ["patients", "ORGANISM", 152, 160], ["lysosomal", "CELLULAR_COMPONENT", 206, 215], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 238, 249], ["amyloid \u03b2", "PROTEIN", 29, 38], ["IL-1\u03b2", "PROTEIN", 51, 56], ["NLRP3 inflammasomes", "PROTEIN", 61, 80], ["amyloid \u03b2", "PROTEIN", 124, 133], ["glial cells", "CELL_TYPE", 137, 148], ["cathepsin B", "PROTEIN", 238, 249], ["patients", "SPECIES", 152, 160], ["amyloid", "PROBLEM", 20, 27], ["amyloid \u03b2", "TREATMENT", 29, 38], ["IL", "TEST", 51, 53], ["NLRP3 inflammasomes", "PROBLEM", 61, 80], ["amyloid \u03b2 in glial cells", "PROBLEM", 124, 148], ["Alzheimer's disease", "PROBLEM", 166, 185], ["subsequent lysosomal damage", "PROBLEM", 195, 222], ["amyloid", "OBSERVATION", 20, 27], ["amyloid", "OBSERVATION", 124, 131], ["glial cells", "OBSERVATION", 137, 148], ["lysosomal damage", "OBSERVATION", 206, 222]]], ["ROS are considered to be involved in the activation of NLRP3 inflammasomes, and it was suggested that direct interaction between amyloidogenic peptide and NLRP3 could initiate NLRP3 inflammasome formation in a cell-free system [109, 110] .", [["cell", "ANATOMY", 210, 214], ["ROS", "CHEMICAL", 0, 3], ["ROS", "SIMPLE_CHEMICAL", 0, 3], ["NLRP3", "GENE_OR_GENE_PRODUCT", 55, 60], ["NLRP3", "GENE_OR_GENE_PRODUCT", 155, 160], ["NLRP3", "GENE_OR_GENE_PRODUCT", 176, 181], ["cell", "CELL", 210, 214], ["NLRP3 inflammasomes", "PROTEIN", 55, 74], ["NLRP3", "PROTEIN", 155, 160], ["NLRP3", "PROTEIN", 176, 181], ["direct interaction between amyloidogenic peptide", "PROBLEM", 102, 150], ["NLRP3", "TREATMENT", 155, 160], ["NLRP3 inflammasome formation", "PROBLEM", 176, 204]]], ["Both IL-1\u03b1 and IL-1\u03b2 gene polymorphisms have been reported to be associated with central obesity and metabolic syndrome in a population with coronary heart disease in an epidemiologic study [111] .", [["coronary", "ANATOMY", 141, 149], ["heart", "ANATOMY", 150, 155], ["obesity", "DISEASE", 89, 96], ["metabolic syndrome", "DISEASE", 101, 119], ["coronary heart disease", "DISEASE", 141, 163], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 5, 10], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 15, 20], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 141, 155], ["IL-1\u03b1 and IL-1\u03b2 gene polymorphisms", "DNA", 5, 39], ["Both IL", "TREATMENT", 0, 7], ["IL", "TREATMENT", 15, 17], ["gene polymorphisms", "PROBLEM", 21, 39], ["central obesity", "PROBLEM", 81, 96], ["metabolic syndrome", "PROBLEM", 101, 119], ["coronary heart disease", "PROBLEM", 141, 163], ["an epidemiologic study", "TEST", 167, 189], ["central", "ANATOMY_MODIFIER", 81, 88], ["obesity", "OBSERVATION", 89, 96], ["metabolic syndrome", "OBSERVATION", 101, 119], ["coronary heart", "ANATOMY", 141, 155], ["disease", "OBSERVATION", 156, 163]]], ["Thus, these diseases are IL-1dependent cytokinopathies (interleukinoneopathies).Acute inflammationBesides the above diseases, numerous inflammatory diseases related to excess IL-1 signaling have also been identified [112] [113] [114] .", [["interleukinoneopathies", "DISEASE", 56, 78], ["IL-1dependent cytokinopathies", "SIMPLE_CHEMICAL", 25, 54], ["interleukinoneopathies", "CANCER", 56, 78], ["IL-1", "GENE_OR_GENE_PRODUCT", 175, 179], ["IL", "PROTEIN", 175, 177], ["these diseases", "PROBLEM", 6, 20], ["IL-1dependent cytokinopathies (interleukinoneopathies)", "PROBLEM", 25, 79], ["Acute inflammationBesides the above diseases", "PROBLEM", 80, 124], ["numerous inflammatory diseases", "PROBLEM", 126, 156], ["excess IL", "PROBLEM", 168, 177], ["diseases", "OBSERVATION", 12, 20], ["IL", "OBSERVATION_MODIFIER", 25, 27], ["above diseases", "OBSERVATION", 110, 124], ["numerous", "OBSERVATION_MODIFIER", 126, 134], ["inflammatory", "OBSERVATION_MODIFIER", 135, 147]]], ["For example, high IL-1\u03b2 levels in humans and mice result in increased Th17-dominant immunopathology, and IL-1\u03b2 expression was limited to macrophages and neutrophils, which account for a large proportion of the CD45\u03b1 cells in the cervix upon Chlamydia muridarum infection [115] .", [["macrophages", "ANATOMY", 137, 148], ["neutrophils", "ANATOMY", 153, 164], ["CD45\u03b1 cells", "ANATOMY", 210, 221], ["cervix", "ANATOMY", 229, 235], ["Chlamydia muridarum infection", "DISEASE", 241, 270], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 18, 23], ["humans", "ORGANISM", 34, 40], ["mice", "ORGANISM", 45, 49], ["Th17", "CELL", 70, 74], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 105, 110], ["macrophages", "CELL", 137, 148], ["neutrophils", "CELL", 153, 164], ["CD45", "GENE_OR_GENE_PRODUCT", 210, 214], ["cervix", "ORGAN", 229, 235], ["Chlamydia muridarum", "ORGANISM", 241, 260], ["IL-1\u03b2", "PROTEIN", 18, 23], ["IL-1\u03b2", "PROTEIN", 105, 110], ["macrophages", "CELL_TYPE", 137, 148], ["neutrophils", "CELL_TYPE", 153, 164], ["CD45\u03b1 cells", "CELL_TYPE", 210, 221], ["humans", "SPECIES", 34, 40], ["mice", "SPECIES", 45, 49], ["Chlamydia muridarum", "SPECIES", 241, 260], ["humans", "SPECIES", 34, 40], ["mice", "SPECIES", 45, 49], ["Chlamydia muridarum", "SPECIES", 241, 260], ["high IL", "TEST", 13, 20], ["increased Th17-dominant immunopathology", "PROBLEM", 60, 99], ["IL", "TEST", 105, 107], ["macrophages", "PROBLEM", 137, 148], ["neutrophils", "TEST", 153, 164], ["Chlamydia muridarum infection", "PROBLEM", 241, 270], ["high", "OBSERVATION_MODIFIER", 13, 17], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["Th17", "OBSERVATION", 70, 74], ["dominant", "OBSERVATION_MODIFIER", 75, 83], ["immunopathology", "OBSERVATION", 84, 99], ["macrophages", "OBSERVATION", 137, 148], ["large", "OBSERVATION_MODIFIER", 186, 191], ["CD45\u03b1 cells", "OBSERVATION", 210, 221], ["cervix", "ANATOMY", 229, 235], ["Chlamydia muridarum infection", "OBSERVATION", 241, 270]]], ["Consequently, IL-1\u03b2 promotes the differentiation of monocytes into conventional dendritic cells (DCs) and M1-like macrophages and supports the proliferation of activated B-lymphocytes and their differentiation into plasma cells [116] [117] [118] .", [["monocytes", "ANATOMY", 52, 61], ["dendritic cells", "ANATOMY", 80, 95], ["DCs", "ANATOMY", 97, 100], ["M1-like macrophages", "ANATOMY", 106, 125], ["B-lymphocytes", "ANATOMY", 170, 183], ["plasma cells", "ANATOMY", 215, 227], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 14, 19], ["monocytes", "CELL", 52, 61], ["dendritic cells", "CELL", 80, 95], ["DCs", "CELL", 97, 100], ["M1-like macrophages", "CELL", 106, 125], ["B-lymphocytes", "CELL", 170, 183], ["plasma cells", "CELL", 215, 227], ["IL-1\u03b2", "PROTEIN", 14, 19], ["monocytes", "CELL_TYPE", 52, 61], ["dendritic cells", "CELL_TYPE", 80, 95], ["DCs", "CELL_TYPE", 97, 100], ["M1-like macrophages", "CELL_TYPE", 106, 125], ["activated B-lymphocytes", "CELL_TYPE", 160, 183], ["plasma cells", "CELL_TYPE", 215, 227], ["plasma cells", "TEST", 215, 227], ["dendritic cells", "OBSERVATION", 80, 95], ["M1", "ANATOMY", 106, 108], ["macrophages", "OBSERVATION", 114, 125]]], ["IL-1 in combination with IL-2 promoted not only the expansion of NK cells but also CD4+ CD8+ T-lymphocytes [119] .", [["NK cells", "ANATOMY", 65, 73], ["CD4+ CD8+ T-lymphocytes", "ANATOMY", 83, 106], ["IL-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-2", "GENE_OR_GENE_PRODUCT", 25, 29], ["NK cells", "CELL", 65, 73], ["CD4", "GENE_OR_GENE_PRODUCT", 83, 86], ["CD8", "GENE_OR_GENE_PRODUCT", 88, 91], ["IL-1", "PROTEIN", 0, 4], ["IL-2", "PROTEIN", 25, 29], ["NK cells", "CELL_TYPE", 65, 73], ["CD4", "PROTEIN", 83, 86], ["CD8", "PROTEIN", 88, 91], ["IL", "TREATMENT", 0, 2], ["IL", "TREATMENT", 25, 27], ["NK cells", "PROBLEM", 65, 73], ["CD4", "TEST", 83, 86], ["CD8", "TEST", 88, 91], ["lymphocytes", "TEST", 95, 106], ["NK cells", "OBSERVATION", 65, 73]]], ["IL-1\u03b2 generated by activated antigen-presenting cells (APCs) induced type 1 immune responses, which produced CTL and led to the polarization of CD4+ T -lymphocytes towards T-helper cell type 1 (Th1) [120, 121] .Chronic inflammation and malignancyIL-1\u03b2 plays a role in resolving acute inflammation resulting in the initiation of adaptive anti-tumor responses; however, chronic inflammatory conditions increase the risk of developing cancer [122] .", [["antigen-presenting cells", "ANATOMY", 29, 53], ["APCs", "ANATOMY", 55, 59], ["CTL", "ANATOMY", 109, 112], ["CD4+ T -lymphocytes", "ANATOMY", 144, 163], ["cancer", "ANATOMY", 432, 438], ["inflammation", "DISEASE", 219, 231], ["inflammation", "DISEASE", 284, 296], ["cancer", "DISEASE", 432, 438], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["antigen-presenting cells", "CELL", 29, 53], ["APCs", "CELL", 55, 59], ["CTL", "CELL", 109, 112], ["CD4", "GENE_OR_GENE_PRODUCT", 144, 147], ["T-helper cell type 1", "GENE_OR_GENE_PRODUCT", 172, 192], ["malignancyIL-1\u03b2", "GENE_OR_GENE_PRODUCT", 236, 251], ["anti-tumor", "CANCER", 337, 347], ["cancer", "CANCER", 432, 438], ["IL-1\u03b2", "PROTEIN", 0, 5], ["activated antigen-presenting cells", "CELL_TYPE", 19, 53], ["APCs", "CELL_TYPE", 55, 59], ["CTL", "CELL_TYPE", 109, 112], ["CD4", "PROTEIN", 144, 147], ["malignancyIL-1\u03b2", "PROTEIN", 236, 251], ["IL", "TEST", 0, 2], ["CTL", "PROBLEM", 109, 112], ["CD4", "TEST", 144, 147], ["T", "TEST", 172, 173], ["Chronic inflammation", "PROBLEM", 211, 231], ["malignancyIL", "TREATMENT", 236, 248], ["acute inflammation", "PROBLEM", 278, 296], ["adaptive anti-tumor responses", "TREATMENT", 328, 357], ["chronic inflammatory conditions", "PROBLEM", 368, 399], ["developing cancer", "PROBLEM", 421, 438], ["inflammation", "OBSERVATION", 219, 231], ["resolving", "OBSERVATION_MODIFIER", 268, 277], ["acute", "OBSERVATION_MODIFIER", 278, 283], ["inflammation", "OBSERVATION", 284, 296], ["chronic", "OBSERVATION_MODIFIER", 368, 375], ["inflammatory", "OBSERVATION", 376, 388], ["cancer", "OBSERVATION", 432, 438]]], ["In human breast cancer, higher expression of IL-1\u03b2 is associated with tumor invasiveness and aggressive tumor biology [123] .", [["breast cancer", "ANATOMY", 9, 22], ["tumor", "ANATOMY", 70, 75], ["tumor", "ANATOMY", 104, 109], ["breast cancer", "DISEASE", 9, 22], ["tumor", "DISEASE", 70, 75], ["tumor", "DISEASE", 104, 109], ["human", "ORGANISM", 3, 8], ["breast cancer", "CANCER", 9, 22], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 45, 50], ["tumor", "CANCER", 70, 75], ["tumor", "CANCER", 104, 109], ["IL-1\u03b2", "PROTEIN", 45, 50], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["human breast cancer", "PROBLEM", 3, 22], ["tumor invasiveness", "PROBLEM", 70, 88], ["breast", "ANATOMY", 9, 15], ["cancer", "OBSERVATION", 16, 22], ["associated with", "UNCERTAINTY", 54, 69], ["tumor", "OBSERVATION", 70, 75], ["aggressive", "OBSERVATION_MODIFIER", 93, 103], ["tumor", "OBSERVATION", 104, 109]]], ["Expression of IL-1\u03b1, IL-1\u03b2, and their receptors in human breast cancer tissues results in the activation of a population of cells and subsequently contributes to angiogenesis, tumor proliferation, and tumor invasion in the microenvironment [124] .", [["breast cancer tissues", "ANATOMY", 57, 78], ["cells", "ANATOMY", 124, 129], ["tumor", "ANATOMY", 176, 181], ["tumor", "ANATOMY", 201, 206], ["breast cancer", "DISEASE", 57, 70], ["tumor", "DISEASE", 176, 181], ["tumor", "DISEASE", 201, 206], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 21, 26], ["human", "ORGANISM", 51, 56], ["breast cancer tissues", "TISSUE", 57, 78], ["cells", "CELL", 124, 129], ["tumor", "CANCER", 176, 181], ["tumor", "CANCER", 201, 206], ["IL-1\u03b1, IL-1\u03b2", "PROTEIN", 14, 26], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["IL", "TEST", 14, 16], ["human breast cancer tissues", "PROBLEM", 51, 78], ["angiogenesis", "PROBLEM", 162, 174], ["tumor proliferation", "PROBLEM", 176, 195], ["tumor invasion in the microenvironment", "PROBLEM", 201, 239], ["breast", "ANATOMY", 57, 63], ["cancer", "OBSERVATION", 64, 70], ["angiogenesis", "OBSERVATION", 162, 174], ["tumor proliferation", "OBSERVATION", 176, 195], ["tumor", "OBSERVATION_MODIFIER", 201, 206], ["invasion", "OBSERVATION_MODIFIER", 207, 215]]], ["In a spontaneous MMTV-PyMT mouse mammary gland tumor model, mature IL-1\u03b2 levels in primary mammary tumors and metastasis sites were significantly elevated, being associated with inflammasome activation and the infiltration of myeloid cells in tumor microenvironments.", [["mammary gland tumor", "ANATOMY", 33, 52], ["mammary tumors", "ANATOMY", 91, 105], ["metastasis sites", "ANATOMY", 110, 126], ["myeloid cells", "ANATOMY", 226, 239], ["tumor", "ANATOMY", 243, 248], ["mammary gland tumor", "DISEASE", 33, 52], ["primary mammary tumors", "DISEASE", 83, 105], ["tumor", "DISEASE", 243, 248], ["MMTV", "ORGANISM", 17, 21], ["mouse", "ORGANISM", 27, 32], ["mammary gland tumor", "CANCER", 33, 52], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 67, 72], ["mammary tumors", "CANCER", 91, 105], ["myeloid cells", "CELL", 226, 239], ["tumor", "CANCER", 243, 248], ["IL-1\u03b2", "PROTEIN", 67, 72], ["myeloid cells", "CELL_TYPE", 226, 239], ["mouse", "SPECIES", 27, 32], ["mouse", "SPECIES", 27, 32], ["mature IL", "TEST", 60, 69], ["primary mammary tumors", "PROBLEM", 83, 105], ["metastasis sites", "PROBLEM", 110, 126], ["significantly elevated", "PROBLEM", 132, 154], ["inflammasome activation", "PROBLEM", 178, 201], ["the infiltration of myeloid cells in tumor microenvironments", "PROBLEM", 206, 266], ["spontaneous MMTV", "OBSERVATION", 5, 21], ["mammary gland", "ANATOMY", 33, 46], ["tumor", "OBSERVATION", 47, 52], ["mature", "OBSERVATION_MODIFIER", 60, 66], ["IL", "OBSERVATION_MODIFIER", 67, 69], ["mammary", "ANATOMY", 91, 98], ["tumors", "OBSERVATION", 99, 105], ["metastasis", "OBSERVATION", 110, 120], ["infiltration", "OBSERVATION", 210, 222], ["myeloid cells", "OBSERVATION", 226, 239], ["tumor", "OBSERVATION", 243, 248]]], ["In this model, CD11b + Gr1 + and CD11b + Gr1 \u2212 myeloid cell populations were also significantly increased in both tumor tissues [31] .", [["CD11b + Gr1 +", "ANATOMY", 15, 28], ["CD11b + Gr1 \u2212 myeloid cell", "ANATOMY", 33, 59], ["tumor tissues", "ANATOMY", 114, 127], ["tumor", "DISEASE", 114, 119], ["CD11b", "GENE_OR_GENE_PRODUCT", 15, 20], ["Gr1", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD11b", "GENE_OR_GENE_PRODUCT", 33, 38], ["tumor tissues", "TISSUE", 114, 127], ["CD11b", "PROTEIN", 15, 20], ["Gr1", "PROTEIN", 23, 26], ["Gr1 \u2212 myeloid cell populations", "CELL_LINE", 41, 71], ["CD11", "TEST", 15, 19], ["Gr1", "TEST", 23, 26], ["CD11", "TEST", 33, 37], ["myeloid cell populations", "TEST", 47, 71], ["+ Gr1", "ANATOMY", 39, 44], ["myeloid cell", "OBSERVATION", 47, 59], ["significantly", "OBSERVATION_MODIFIER", 82, 95], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["both", "OBSERVATION_MODIFIER", 109, 113], ["tumor", "OBSERVATION", 114, 119]]], ["IL-1\u03b2 generated in a tissue with a tumor microenvironment dominated by TAMs promotes tumor growth and metastasis in breast cancer [122, 125] .", [["tissue", "ANATOMY", 21, 27], ["tumor", "ANATOMY", 35, 40], ["TAMs", "ANATOMY", 71, 75], ["tumor", "ANATOMY", 85, 90], ["breast cancer", "ANATOMY", 116, 129], ["tumor", "DISEASE", 35, 40], ["tumor", "DISEASE", 85, 90], ["breast cancer", "DISEASE", 116, 129], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 0, 5], ["tissue", "TISSUE", 21, 27], ["tumor", "CANCER", 35, 40], ["TAMs", "CELL", 71, 75], ["tumor", "CANCER", 85, 90], ["breast cancer", "CANCER", 116, 129], ["IL-1\u03b2", "PROTEIN", 0, 5], ["TAMs", "CELL_TYPE", 71, 75], ["IL", "TREATMENT", 0, 2], ["a tumor microenvironment", "TREATMENT", 33, 57], ["tumor growth", "PROBLEM", 85, 97], ["metastasis in breast cancer", "PROBLEM", 102, 129], ["tissue", "ANATOMY", 21, 27], ["tumor", "OBSERVATION", 35, 40], ["tumor", "OBSERVATION_MODIFIER", 85, 90], ["growth", "OBSERVATION_MODIFIER", 91, 97], ["metastasis", "OBSERVATION", 102, 112], ["breast", "ANATOMY", 116, 122], ["cancer", "OBSERVATION", 123, 129]]], ["IL-1, by promoting MDSCs and sustaining the immunosuppressive activity of TAMs, contributes to the suppression of effective adaptive anti-tumor immune responses [126] .", [["MDSCs", "ANATOMY", 19, 24], ["TAMs", "ANATOMY", 74, 78], ["IL-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["MDSCs", "CELL", 19, 24], ["TAMs", "CELL", 74, 78], ["anti-tumor", "CANCER", 133, 143], ["IL-1", "PROTEIN", 0, 4], ["MDSCs", "CELL_TYPE", 19, 24], ["TAMs", "CELL_TYPE", 74, 78], ["the immunosuppressive activity of TAMs", "TREATMENT", 40, 78], ["MDSCs", "OBSERVATION", 19, 24]]], ["Actually, the sphingolipid sphingosine-1-phosphate (S1P) on TAMs promotes lymphangiogenesis and lung metastasis via NLRP3/IL-1\u03b2 in mouse breast cancer model [127] .", [["TAMs", "ANATOMY", 60, 64], ["lung", "ANATOMY", 96, 100], ["breast cancer", "ANATOMY", 137, 150], ["sphingosine-1-phosphate", "CHEMICAL", 27, 50], ["S1P", "CHEMICAL", 52, 55], ["breast cancer", "DISEASE", 137, 150], ["sphingosine-1-phosphate", "CHEMICAL", 27, 50], ["S1P", "CHEMICAL", 52, 55], ["sphingolipid sphingosine-1-phosphate", "GENE_OR_GENE_PRODUCT", 14, 50], ["S1P", "GENE_OR_GENE_PRODUCT", 52, 55], ["TAMs", "CELL", 60, 64], ["lung", "ORGAN", 96, 100], ["NLRP3", "GENE_OR_GENE_PRODUCT", 116, 121], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 122, 127], ["mouse", "ORGANISM", 131, 136], ["breast cancer", "CANCER", 137, 150], ["TAMs", "CELL_TYPE", 60, 64], ["NLRP3", "PROTEIN", 116, 121], ["IL-1\u03b2", "PROTEIN", 122, 127], ["mouse", "SPECIES", 131, 136], ["mouse", "SPECIES", 131, 136], ["the sphingolipid sphingosine", "TEST", 10, 38], ["phosphate (S1P)", "TREATMENT", 41, 56], ["TAMs promotes lymphangiogenesis", "TREATMENT", 60, 91], ["lung metastasis", "PROBLEM", 96, 111], ["NLRP3/IL", "TREATMENT", 116, 124], ["lymphangiogenesis", "OBSERVATION", 74, 91], ["lung", "ANATOMY", 96, 100], ["metastasis", "OBSERVATION", 101, 111], ["breast", "ANATOMY", 137, 143], ["cancer", "OBSERVATION", 144, 150]]], ["For example, obesity induces an increase in tumor-infiltrating MDSCs with activated NLRC4 inflammasome, leading to IL-1\u03b2 production, which drives tumor progression through adipocyte-mediated vascular endothelial growth factor (VEGF) A expression and angiogenesis [128] .", [["tumor", "ANATOMY", 44, 49], ["MDSCs", "ANATOMY", 63, 68], ["tumor", "ANATOMY", 146, 151], ["adipocyte", "ANATOMY", 172, 181], ["obesity", "DISEASE", 13, 20], ["tumor", "DISEASE", 44, 49], ["tumor", "DISEASE", 146, 151], ["tumor", "CANCER", 44, 49], ["MDSCs", "CELL", 63, 68], ["NLRC4", "GENE_OR_GENE_PRODUCT", 84, 89], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 115, 120], ["tumor", "CANCER", 146, 151], ["adipocyte", "CELL", 172, 181], ["vascular endothelial growth factor (VEGF) A", "GENE_OR_GENE_PRODUCT", 191, 234], ["tumor-infiltrating MDSCs", "CELL_TYPE", 44, 68], ["NLRC4", "PROTEIN", 84, 89], ["vascular endothelial growth factor (VEGF) A", "PROTEIN", 191, 234], ["obesity", "PROBLEM", 13, 20], ["an increase in tumor", "PROBLEM", 29, 49], ["infiltrating MDSCs", "PROBLEM", 50, 68], ["activated NLRC4 inflammasome", "PROBLEM", 74, 102], ["tumor progression", "PROBLEM", 146, 163], ["adipocyte-mediated vascular endothelial growth factor", "PROBLEM", 172, 225], ["obesity", "OBSERVATION", 13, 20], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["tumor", "OBSERVATION", 44, 49], ["infiltrating MDSCs", "OBSERVATION", 50, 68], ["NLRC4 inflammasome", "OBSERVATION", 84, 102], ["tumor", "OBSERVATION", 146, 151], ["adipocyte", "ANATOMY", 172, 181], ["vascular endothelial", "ANATOMY", 191, 211]]], ["A recent report showed that IL-1\u03b2 orchestrates tumor-promoting inflammation in patients with high-risk HER2-negative breast cancer who would benefit from IL-1-blocking therapeutics with anakinra (described later on).", [["tumor", "ANATOMY", 47, 52], ["breast cancer", "ANATOMY", 117, 130], ["tumor", "DISEASE", 47, 52], ["inflammation", "DISEASE", 63, 75], ["breast cancer", "DISEASE", 117, 130], ["anakinra", "CHEMICAL", 186, 194], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 28, 33], ["tumor", "CANCER", 47, 52], ["patients", "ORGANISM", 79, 87], ["HER2", "GENE_OR_GENE_PRODUCT", 103, 107], ["breast cancer", "CANCER", 117, 130], ["IL-1", "GENE_OR_GENE_PRODUCT", 154, 158], ["anakinra", "SIMPLE_CHEMICAL", 186, 194], ["IL-1\u03b2", "PROTEIN", 28, 33], ["HER2", "PROTEIN", 103, 107], ["patients", "SPECIES", 79, 87], ["IL", "TEST", 28, 30], ["orchestrates tumor", "PROBLEM", 34, 52], ["inflammation", "PROBLEM", 63, 75], ["breast cancer", "PROBLEM", 117, 130], ["IL", "TREATMENT", 154, 156], ["anakinra", "TREATMENT", 186, 194], ["tumor", "OBSERVATION", 47, 52], ["inflammation", "OBSERVATION", 63, 75], ["breast", "ANATOMY", 117, 123], ["cancer", "OBSERVATION", 124, 130]]], ["The report indicates that while anakinra downregulates gene expressions for IL-1\u03b2, IL-1R1, IL-1R2, and IL-1R3, increased gene expressions of NK cells and CTLs are observed [129] .Interleukin-18 and diseasesAlthough IL-1 has been well-characterized, IL-18 and other IL-1 family members have been less comprehensively investigated.", [["NK cells", "ANATOMY", 141, 149], ["anakinra", "CHEMICAL", 32, 40], ["anakinra", "SIMPLE_CHEMICAL", 32, 40], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 83, 89], ["IL-1R2", "GENE_OR_GENE_PRODUCT", 91, 97], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 103, 109], ["NK cells", "CELL", 141, 149], ["CTLs", "CELL", 154, 158], ["Interleukin-18", "GENE_OR_GENE_PRODUCT", 179, 193], ["IL-1", "GENE_OR_GENE_PRODUCT", 215, 219], ["IL-18", "GENE_OR_GENE_PRODUCT", 249, 254], ["IL-1", "GENE_OR_GENE_PRODUCT", 265, 269], ["IL", "PROTEIN", 76, 78], ["IL-1R1, IL-1R2, and IL-1R3", "PROTEIN", 83, 109], ["NK cells", "CELL_TYPE", 141, 149], ["CTLs", "CELL_TYPE", 154, 158], ["Interleukin-18", "PROTEIN", 179, 193], ["IL-1", "PROTEIN", 215, 219], ["IL-18", "PROTEIN", 249, 254], ["IL-1 family members", "PROTEIN", 265, 284], ["gene expressions", "TEST", 55, 71], ["IL", "TEST", 76, 78], ["IL", "TEST", 83, 85], ["IL", "TEST", 91, 93], ["IL", "TREATMENT", 103, 105], ["NK cells", "TREATMENT", 141, 149], ["CTLs", "TEST", 154, 158], ["Interleukin", "TEST", 179, 190], ["diseases", "PROBLEM", 198, 206], ["NK cells", "OBSERVATION", 141, 149]]], ["IL-18 can be processed by caspase-1 and proteinase-3 as well as IL-1\u03b2, to be activated [130] [131] [132] .", [["IL-18", "GENE_OR_GENE_PRODUCT", 0, 5], ["caspase-1", "GENE_OR_GENE_PRODUCT", 26, 35], ["proteinase-3", "GENE_OR_GENE_PRODUCT", 40, 52], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-18", "PROTEIN", 0, 5], ["caspase-1", "PROTEIN", 26, 35], ["proteinase-3", "PROTEIN", 40, 52], ["IL-1\u03b2", "PROTEIN", 64, 69], ["IL", "TREATMENT", 0, 2], ["caspase", "TEST", 26, 33], ["proteinase", "TEST", 40, 50], ["IL", "TEST", 64, 66]]], ["Considering the pathogenesis of IL-1-related diseases, IL-18 could be involved [133] .Interleukin-18 and diseasesIL-18 was originally identified as interferon (IFN)-\u03b3-inducing factor [134] .", [["IL-1", "GENE_OR_GENE_PRODUCT", 32, 36], ["IL-18", "GENE_OR_GENE_PRODUCT", 55, 60], ["Interleukin-18", "GENE_OR_GENE_PRODUCT", 86, 100], ["diseasesIL-18", "GENE_OR_GENE_PRODUCT", 105, 118], ["interferon (IFN)-\u03b3-", "GENE_OR_GENE_PRODUCT", 148, 167], ["IL", "PROTEIN", 32, 34], ["IL-18", "PROTEIN", 55, 60], ["Interleukin-18", "PROTEIN", 86, 100], ["diseasesIL-18", "PROTEIN", 105, 118], ["interferon (IFN)-\u03b3-inducing factor", "PROTEIN", 148, 182], ["related diseases", "PROBLEM", 37, 53], ["IL", "TREATMENT", 55, 57], ["Interleukin", "TEST", 86, 97], ["diseasesIL", "TEST", 105, 115]]], ["IL-18 is the most structurally related to IL-1\u03b2.", [["IL-18", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-18", "PROTEIN", 0, 5], ["IL-1\u03b2", "PROTEIN", 42, 47], ["most structurally", "OBSERVATION_MODIFIER", 13, 30]]], ["IL-18 is synthesized as a 24-kDa inactivated precursor and is cleaved by caspase-1 to a biologically active 17-kDa mature form [131, 132] .", [["IL-18", "GENE_OR_GENE_PRODUCT", 0, 5], ["caspase-1", "GENE_OR_GENE_PRODUCT", 73, 82], ["IL-18", "PROTEIN", 0, 5], ["caspase-1", "PROTEIN", 73, 82], ["IL", "TEST", 0, 2]]], ["Although IL-1\u03b2 is biologically active within the pg/mL range, IL-18 requires 10-20 ng/mL and sometimes higher levels for in vitro activation [135, 136] .", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 9, 14], ["IL-18", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL-1\u03b2", "PROTEIN", 9, 14], ["IL-18", "PROTEIN", 62, 67], ["IL", "TEST", 62, 64], ["active", "OBSERVATION", 31, 37]]], ["Since the IL-18 precursor is expressed ubiquitously in tissues [137] , IL-18 signaling is thought to be regulated concentration-dependently.", [["tissues", "ANATOMY", 55, 62], ["IL-18", "GENE_OR_GENE_PRODUCT", 10, 15], ["tissues", "TISSUE", 55, 62], ["IL-18", "GENE_OR_GENE_PRODUCT", 71, 76], ["IL-18 precursor", "PROTEIN", 10, 25], ["IL-18", "PROTEIN", 71, 76], ["IL", "TEST", 71, 73], ["thought to be", "UNCERTAINTY", 90, 103], ["concentration", "OBSERVATION_MODIFIER", 114, 127], ["dependently", "OBSERVATION_MODIFIER", 128, 139]]], ["Mature IL-18 forms a signaling complex with the IL-18 receptor alpha chain (IL-18R\u03b1) with low affinity.", [["IL-18", "GENE_OR_GENE_PRODUCT", 7, 12], ["IL-18 receptor alpha chain", "GENE_OR_GENE_PRODUCT", 48, 74], ["IL-18R\u03b1", "GENE_OR_GENE_PRODUCT", 76, 83], ["IL-18", "PROTEIN", 7, 12], ["signaling complex", "PROTEIN", 21, 38], ["IL-18 receptor alpha chain", "PROTEIN", 48, 74], ["IL", "PROTEIN", 76, 78], ["18R\u03b1", "PROTEIN", 79, 83], ["the IL", "TEST", 44, 50], ["low affinity", "PROBLEM", 90, 102], ["low affinity", "OBSERVATION_MODIFIER", 90, 102]]], ["If the cell expresses an IL-18 receptor \u03b2 chain (IL-18R\u03b2), a high affinity complex is formed like the IL-1R accessory chain IL-1R3.", [["cell", "ANATOMY", 7, 11], ["cell", "CELL", 7, 11], ["IL-18 receptor \u03b2 chain", "GENE_OR_GENE_PRODUCT", 25, 47], ["IL-18R\u03b2", "GENE_OR_GENE_PRODUCT", 49, 56], ["IL-1R", "GENE_OR_GENE_PRODUCT", 102, 107], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 124, 130], ["IL-18 receptor \u03b2 chain", "PROTEIN", 25, 47], ["IL-18R\u03b2", "PROTEIN", 49, 56], ["high affinity complex", "PROTEIN", 61, 82], ["IL-1R accessory chain IL-1R3", "PROTEIN", 102, 130], ["an IL", "TEST", 22, 27], ["a high affinity complex", "PROBLEM", 59, 82]]], ["The complex of the heterodimer recruits MyD88 through the Toll-IL-1 receptor (TIR), four IRAKs, and TRAF-6, leading to the degradation of I-\u03baB and activation of NF-\u03baB, as that for IL-1 signaling [83] .Interleukin-18 and diseasesIL-18 is involved in regulation of the Th1 response by modulating the production of IFN-\u03b3.", [["MyD88", "GENE_OR_GENE_PRODUCT", 40, 45], ["Toll-IL-1 receptor", "GENE_OR_GENE_PRODUCT", 58, 76], ["TIR", "GENE_OR_GENE_PRODUCT", 78, 81], ["IRAKs", "GENE_OR_GENE_PRODUCT", 89, 94], ["TRAF-6", "GENE_OR_GENE_PRODUCT", 100, 106], ["I-\u03baB", "GENE_OR_GENE_PRODUCT", 138, 142], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 161, 166], ["IL-1", "GENE_OR_GENE_PRODUCT", 180, 184], ["Interleukin-18", "GENE_OR_GENE_PRODUCT", 201, 215], ["diseasesIL-18", "GENE_OR_GENE_PRODUCT", 220, 233], ["Th1", "GENE_OR_GENE_PRODUCT", 267, 270], ["MyD88", "PROTEIN", 40, 45], ["Toll-IL-1 receptor", "PROTEIN", 58, 76], ["TIR", "PROTEIN", 78, 81], ["IRAKs", "PROTEIN", 89, 94], ["TRAF-6", "PROTEIN", 100, 106], ["I-\u03baB", "PROTEIN", 138, 142], ["NF-\u03baB", "PROTEIN", 161, 166], ["IL", "PROTEIN", 180, 182], ["Interleukin-18", "PROTEIN", 201, 215], ["diseasesIL-18", "PROTEIN", 220, 233], ["IFN", "PROTEIN", 312, 315], ["TRAF", "TEST", 100, 104], ["NF", "TEST", 161, 163], ["IL", "TEST", 180, 182], ["Interleukin", "TEST", 201, 212], ["diseasesIL", "TEST", 220, 230], ["complex", "OBSERVATION_MODIFIER", 4, 11]]], ["For example, in synergy with either IL-12 or IL-15, which upregulates the expression of the IL-18R\u03b2 co-receptor, IL-18 induces the production of IFN-\u03b3 by T cells [138] .", [["T cells", "ANATOMY", 154, 161], ["IL-12", "GENE_OR_GENE_PRODUCT", 36, 41], ["IL-15", "GENE_OR_GENE_PRODUCT", 45, 50], ["IL-18R\u03b2", "GENE_OR_GENE_PRODUCT", 92, 99], ["IL-18", "GENE_OR_GENE_PRODUCT", 113, 118], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 145, 150], ["T cells", "CELL", 154, 161], ["IL-12", "PROTEIN", 36, 41], ["IL-15", "PROTEIN", 45, 50], ["IL-18R\u03b2 co-receptor", "PROTEIN", 92, 111], ["IL-18", "PROTEIN", 113, 118], ["IFN-\u03b3", "PROTEIN", 145, 150], ["T cells", "CELL_TYPE", 154, 161], ["IL", "TEST", 36, 38], ["the IL", "TEST", 88, 94], ["IFN", "PROBLEM", 145, 148]]], ["IL-18 induces IFN-\u03b3 production by NK cells, and NK cells express CCR7 and produce high levels of IFN-\u03b3 [139] .", [["NK cells", "ANATOMY", 34, 42], ["NK cells", "ANATOMY", 48, 56], ["IL-18", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 14, 19], ["NK cells", "CELL", 34, 42], ["NK cells", "CELL", 48, 56], ["CCR7", "GENE_OR_GENE_PRODUCT", 65, 69], ["IL-18", "PROTEIN", 0, 5], ["IFN-\u03b3", "PROTEIN", 14, 19], ["NK cells", "CELL_TYPE", 34, 42], ["NK cells", "CELL_TYPE", 48, 56], ["CCR7", "PROTEIN", 65, 69], ["IFN", "PROTEIN", 97, 100], ["IL", "TEST", 0, 2], ["IFN", "TEST", 14, 17], ["NK cells", "TEST", 34, 42], ["NK cells", "TEST", 48, 56], ["CCR7", "TEST", 65, 69], ["IFN", "TEST", 97, 100]]], ["The combination of IL-18 and IL-12 induced high levels of IFN-\u03b3 upon hypoglycemia, intestinal inflammation, and inanition [140] .", [["intestinal", "ANATOMY", 83, 93], ["hypoglycemia", "DISEASE", 69, 81], ["intestinal inflammation", "DISEASE", 83, 106], ["IL-18", "GENE_OR_GENE_PRODUCT", 19, 24], ["IL-12", "GENE_OR_GENE_PRODUCT", 29, 34], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 58, 63], ["intestinal", "ORGAN", 83, 93], ["IL-18", "PROTEIN", 19, 24], ["IL-12", "PROTEIN", 29, 34], ["IFN-\u03b3", "PROTEIN", 58, 63], ["IL", "TEST", 19, 21], ["IL", "TREATMENT", 29, 31], ["IFN", "TEST", 58, 61], ["hypoglycemia", "PROBLEM", 69, 81], ["intestinal inflammation", "PROBLEM", 83, 106], ["intestinal", "ANATOMY", 83, 93], ["inflammation", "OBSERVATION", 94, 106]]], ["Some human autoimmune diseases are associated with the elevated production of IFN-\u03b3 and IL-18.", [["autoimmune diseases", "DISEASE", 11, 30], ["human", "ORGANISM", 5, 10], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL-18", "GENE_OR_GENE_PRODUCT", 88, 93], ["IFN-\u03b3 and IL-18", "PROTEIN", 78, 93], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["Some human autoimmune diseases", "PROBLEM", 0, 30], ["the elevated production of IFN", "PROBLEM", 51, 81], ["IL", "TEST", 88, 90], ["autoimmune", "OBSERVATION", 11, 21], ["elevated", "OBSERVATION_MODIFIER", 55, 63], ["production", "OBSERVATION_MODIFIER", 64, 74]]], ["Autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis (RA), type-1 diabetes mellitus, Crohn's disease and psoriasis, and graft versus host disease are thought to be mediated by IL-18 [141] .", [["graft", "ANATOMY", 146, 151], ["Autoimmune diseases", "DISEASE", 0, 19], ["systemic lupus erythematosus", "DISEASE", 28, 56], ["rheumatoid arthritis", "DISEASE", 58, 78], ["RA", "DISEASE", 80, 82], ["type-1 diabetes mellitus", "DISEASE", 85, 109], ["Crohn's disease", "DISEASE", 111, 126], ["psoriasis", "DISEASE", 131, 140], ["graft versus host disease", "DISEASE", 146, 171], ["graft", "TISSUE", 146, 151], ["IL-18", "GENE_OR_GENE_PRODUCT", 202, 207], ["IL", "PROTEIN", 202, 204], ["Autoimmune diseases", "PROBLEM", 0, 19], ["systemic lupus erythematosus", "PROBLEM", 28, 56], ["rheumatoid arthritis", "PROBLEM", 58, 78], ["type-1 diabetes mellitus", "PROBLEM", 85, 109], ["Crohn's disease", "PROBLEM", 111, 126], ["psoriasis", "PROBLEM", 131, 140], ["graft versus host disease", "PROBLEM", 146, 171], ["IL", "TEST", 202, 204], ["systemic", "OBSERVATION_MODIFIER", 28, 36], ["lupus erythematosus", "OBSERVATION", 37, 56], ["rheumatoid arthritis", "OBSERVATION", 58, 78], ["RA", "ANATOMY", 80, 82], ["Crohn", "OBSERVATION", 111, 116], ["psoriasis", "OBSERVATION", 131, 140], ["graft versus host disease", "OBSERVATION", 146, 171]]], ["So far, several anti-IL-18 therapies have been reported.", [["anti-IL-18", "GENE_OR_GENE_PRODUCT", 16, 26], ["several anti-IL-18 therapies", "TREATMENT", 8, 36]]], ["An anti-IL-18, multicenter, randomized, single-blind, placebo-controlled, parallel-group, phase IIa trial for the treatment of T2D was reported whereby anti-IL-18 monoclonal antibody, GSK1070806, was well-tolerated; however, the anti-IL-18 therapy did not lead to any improvements in glucose control [142] .", [["T2D", "DISEASE", 127, 130], ["GSK1070806", "CHEMICAL", 184, 194], ["glucose", "CHEMICAL", 284, 291], ["GSK1070806", "CHEMICAL", 184, 194], ["glucose", "CHEMICAL", 284, 291], ["anti-IL-18", "GENE_OR_GENE_PRODUCT", 3, 13], ["anti-IL-18", "GENE_OR_GENE_PRODUCT", 152, 162], ["GSK1070806", "SIMPLE_CHEMICAL", 184, 194], ["anti-IL-18", "GENE_OR_GENE_PRODUCT", 229, 239], ["glucose", "SIMPLE_CHEMICAL", 284, 291], ["anti-IL-18 monoclonal antibody", "PROTEIN", 152, 182], ["An anti-IL", "TREATMENT", 0, 10], ["placebo", "TREATMENT", 54, 61], ["parallel-group, phase IIa trial", "TREATMENT", 74, 105], ["T2D", "PROBLEM", 127, 130], ["anti-IL", "TEST", 152, 159], ["monoclonal antibody", "TEST", 163, 182], ["the anti-IL-18 therapy", "TREATMENT", 225, 247], ["glucose control", "TREATMENT", 284, 299]]], ["Interleukin-18 binding protein (IL-18BP) was purified from urine by chromatography on IL-18 beads that abolished IL-18 induction of IFN-\u03b3, IL-8, and activation of NF-\u03baB in vitro [143] .", [["urine", "ANATOMY", 59, 64], ["Interleukin-18 binding protein", "GENE_OR_GENE_PRODUCT", 0, 30], ["IL-18BP", "GENE_OR_GENE_PRODUCT", 32, 39], ["urine", "ORGANISM_SUBSTANCE", 59, 64], ["IL-18 beads", "SIMPLE_CHEMICAL", 86, 97], ["IL-18", "GENE_OR_GENE_PRODUCT", 113, 118], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 132, 137], ["IL-8", "GENE_OR_GENE_PRODUCT", 139, 143], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 163, 168], ["Interleukin-18 binding protein", "PROTEIN", 0, 30], ["IL", "PROTEIN", 32, 34], ["18BP", "PROTEIN", 35, 39], ["IL", "PROTEIN", 86, 88], ["IL-18", "PROTEIN", 113, 118], ["IFN", "PROTEIN", 132, 135], ["IL-8", "PROTEIN", 139, 143], ["NF-\u03baB", "PROTEIN", 163, 168], ["Interleukin", "TEST", 0, 11], ["binding protein", "TEST", 15, 30], ["IL", "TEST", 32, 34], ["IL", "TEST", 86, 88], ["IL", "TEST", 113, 115], ["IFN", "TEST", 132, 135], ["IL", "TEST", 139, 141], ["NF", "TEST", 163, 165]]], ["The IL-18 inhibition using IL-18BP significantly decreased MDSCs in the tumor microenvironment in a preclinical osteosarcoma mouse model [144] .", [["MDSCs", "ANATOMY", 59, 64], ["tumor", "ANATOMY", 72, 77], ["osteosarcoma", "ANATOMY", 112, 124], ["tumor", "DISEASE", 72, 77], ["osteosarcoma", "DISEASE", 112, 124], ["IL-18", "GENE_OR_GENE_PRODUCT", 4, 9], ["IL-18BP", "SIMPLE_CHEMICAL", 27, 34], ["MDSCs", "CELL", 59, 64], ["tumor", "CANCER", 72, 77], ["osteosarcoma", "CANCER", 112, 124], ["mouse", "ORGANISM", 125, 130], ["IL-18", "PROTEIN", 4, 9], ["IL-18BP", "PROTEIN", 27, 34], ["MDSCs", "CELL_TYPE", 59, 64], ["mouse", "SPECIES", 125, 130], ["mouse", "SPECIES", 125, 130], ["The IL", "TREATMENT", 0, 6], ["IL", "TREATMENT", 27, 29], ["significantly decreased MDSCs", "PROBLEM", 35, 64], ["decreased", "OBSERVATION_MODIFIER", 49, 58], ["MDSCs", "OBSERVATION", 59, 64], ["tumor microenvironment", "OBSERVATION", 72, 94], ["osteosarcoma", "OBSERVATION", 112, 124]]], ["IL-18BP (Tadekinig \u03b1\u00ae) was successful in the treatment of Still's disease and NLRC4-mutated autoinflammatory macrophage activation syndrome (MAS), for which anti-IL-1 treatment had failed [145, 146] .Biologics against interleukin-1 signaling and their applicationsSeveral inhibitors of IL-1 signaling have been clinically approved (Fig. 1) .AnakinraOne is a recombinant human intrinsic IL-1 receptor antagonist (IL-1Ra), anakinra [147] .", [["macrophage", "ANATOMY", 109, 119], ["Tadekinig \u03b1\u00ae", "CHEMICAL", 9, 21], ["Still's disease", "DISEASE", 58, 73], ["autoinflammatory macrophage activation syndrome", "DISEASE", 92, 139], ["MAS", "DISEASE", 141, 144], ["AnakinraOne", "CHEMICAL", 341, 352], ["AnakinraOne", "CHEMICAL", 341, 352], ["IL-18BP", "SIMPLE_CHEMICAL", 0, 7], ["Tadekinig \u03b1\u00ae", "SIMPLE_CHEMICAL", 9, 21], ["NLRC4", "GENE_OR_GENE_PRODUCT", 78, 83], ["anti-IL-1", "GENE_OR_GENE_PRODUCT", 157, 166], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 218, 231], ["IL-1", "GENE_OR_GENE_PRODUCT", 286, 290], ["AnakinraOne", "SIMPLE_CHEMICAL", 341, 352], ["human", "ORGANISM", 370, 375], ["IL-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 386, 410], ["IL-1Ra", "SIMPLE_CHEMICAL", 412, 418], ["anakinra [147]", "SIMPLE_CHEMICAL", 421, 435], ["NLRC4", "PROTEIN", 78, 83], ["interleukin-1", "PROTEIN", 218, 231], ["IL", "PROTEIN", 286, 288], ["recombinant human intrinsic IL-1 receptor antagonist", "PROTEIN", 358, 410], ["human", "SPECIES", 370, 375], ["human", "SPECIES", 370, 375], ["IL", "TEST", 0, 2], ["Still's disease", "PROBLEM", 58, 73], ["NLRC4", "PROBLEM", 78, 83], ["mutated autoinflammatory macrophage activation syndrome", "PROBLEM", 84, 139], ["anti-IL-1 treatment", "TREATMENT", 157, 176], ["Biologics", "TREATMENT", 200, 209], ["interleukin", "TREATMENT", 218, 229], ["Several inhibitors of IL", "TREATMENT", 264, 288], ["AnakinraOne", "TREATMENT", 341, 352], ["a recombinant human intrinsic IL", "TREATMENT", 356, 388], ["anakinra", "TREATMENT", 421, 429], ["autoinflammatory macrophage activation syndrome", "OBSERVATION", 92, 139]]], ["Anakinra is the pharmaceutical name of a recombinant form of intrinsic human IL-1Ra, a 17.2-kDa protein consisting of 153 amino acid residues.", [["Anakinra", "CHEMICAL", 0, 8], ["amino acid", "CHEMICAL", 122, 132], ["Anakinra", "CHEMICAL", 0, 8], ["amino acid", "CHEMICAL", 122, 132], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["human", "ORGANISM", 71, 76], ["IL-1Ra", "GENE_OR_GENE_PRODUCT", 77, 83], ["amino acid", "AMINO_ACID", 122, 132], ["intrinsic human IL-1Ra", "PROTEIN", 61, 83], ["17.2-kDa protein", "PROTEIN", 87, 103], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["Anakinra", "TREATMENT", 0, 8], ["intrinsic human IL", "TREATMENT", 61, 79], ["amino acid residues", "TREATMENT", 122, 141]]], ["IL-1Ra was first reported in 1985 as a bioactive IL-1 inhibitor of 22-25 kDa in the supernatants of human monocyte culture, and it was independently identified as an IL-1 inhibitor from the urine of febrile patients [148, 149] .", [["supernatants", "ANATOMY", 84, 96], ["monocyte culture", "ANATOMY", 106, 122], ["urine", "ANATOMY", 190, 195], ["febrile", "DISEASE", 199, 206], ["IL-1Ra", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-1", "GENE_OR_GENE_PRODUCT", 49, 53], ["human", "ORGANISM", 100, 105], ["monocyte", "CELL", 106, 114], ["IL-1", "GENE_OR_GENE_PRODUCT", 166, 170], ["urine", "ORGANISM_SUBSTANCE", 190, 195], ["patients", "ORGANISM", 207, 215], ["IL-1Ra", "PROTEIN", 0, 6], ["human monocyte culture", "CELL_LINE", 100, 122], ["human", "SPECIES", 100, 105], ["patients", "SPECIES", 207, 215], ["human", "SPECIES", 100, 105], ["a bioactive IL", "TREATMENT", 37, 51], ["human monocyte culture", "TEST", 100, 122], ["an IL", "TEST", 163, 168], ["the urine", "TEST", 186, 195], ["febrile patients", "PROBLEM", 199, 215]]], ["Anakinra was the first biological drug of a selective IL-1R1 antagonist to receive approval from the US Food and Drug Administration (FDA).", [["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 54, 60], ["Anakinra", "TREATMENT", 0, 8], ["a selective IL-1R1 antagonist", "TREATMENT", 42, 71]]], ["Since anakinra is an IL-1 receptor antagonist, it can prevent the activity of both IL-1\u03b1 and IL-1\u03b2 by competitively blocking their binding to IL-1R1 and IL-1R2.", [["anakinra", "CHEMICAL", 6, 14], ["anakinra", "CHEMICAL", 6, 14], ["anakinra", "SIMPLE_CHEMICAL", 6, 14], ["IL-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 21, 45], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 83, 88], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 93, 98], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 142, 148], ["IL-1R2", "GENE_OR_GENE_PRODUCT", 153, 159], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 83, 98], ["IL-1R1 and IL-1R2", "PROTEIN", 142, 159], ["anakinra", "TREATMENT", 6, 14], ["an IL-1 receptor antagonist", "TREATMENT", 18, 45], ["both IL", "TREATMENT", 78, 85]]], ["Anakinra has been applied for a wide range of diseases including autoinflammatory diseases, non-cancer inflammatory diseases, and malignancies [150] .", [["non-cancer", "ANATOMY", 92, 102], ["malignancies", "ANATOMY", 130, 142], ["Anakinra", "CHEMICAL", 0, 8], ["autoinflammatory diseases", "DISEASE", 65, 90], ["non-cancer inflammatory diseases", "DISEASE", 92, 124], ["malignancies", "DISEASE", 130, 142], ["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["malignancies", "CANCER", 130, 142], ["Anakinra", "TREATMENT", 0, 8], ["diseases", "PROBLEM", 46, 54], ["autoinflammatory diseases", "PROBLEM", 65, 90], ["non-cancer inflammatory diseases", "PROBLEM", 92, 124], ["malignancies", "PROBLEM", 130, 142], ["diseases", "OBSERVATION", 46, 54], ["autoinflammatory diseases", "OBSERVATION", 65, 90], ["non-cancer", "OBSERVATION_MODIFIER", 92, 102], ["inflammatory", "OBSERVATION_MODIFIER", 103, 115]]], ["To date, no serious adverse effect of anakinra has been reported [151] .RilonaceptAnother is rilonacept (ril on' a sept), a soluble decoy receptor (Fig. 1) .", [["anakinra", "CHEMICAL", 38, 46], ["RilonaceptAnother", "CHEMICAL", 72, 89], ["rilonacept", "CHEMICAL", 93, 103], ["anakinra", "CHEMICAL", 38, 46], ["RilonaceptAnother", "CHEMICAL", 72, 89], ["rilonacept", "CHEMICAL", 93, 103], ["anakinra", "SIMPLE_CHEMICAL", 38, 46], ["RilonaceptAnother", "SIMPLE_CHEMICAL", 72, 89], ["rilonacept", "SIMPLE_CHEMICAL", 93, 103], ["soluble decoy receptor", "PROTEIN", 124, 146], ["anakinra", "TREATMENT", 38, 46], ["a soluble decoy receptor (Fig", "TREATMENT", 122, 151]]], ["Rilonacept is a recombinant fusion protein consisting of the extracellular portion of human IL-1R1 and IL-1R3 fused with the Fc portion of human IgG1 [152] [153] [154] .", [["extracellular", "ANATOMY", 61, 74], ["Rilonacept", "CHEMICAL", 0, 10], ["Rilonacept", "CHEMICAL", 0, 10], ["Rilonacept", "SIMPLE_CHEMICAL", 0, 10], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["human", "ORGANISM", 86, 91], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 92, 98], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 103, 109], ["human", "ORGANISM", 139, 144], ["IgG1", "GENE_OR_GENE_PRODUCT", 145, 149], ["recombinant fusion protein", "PROTEIN", 16, 42], ["extracellular portion", "PROTEIN", 61, 82], ["human IL-1R1 and IL-1R3", "PROTEIN", 86, 109], ["Fc portion", "PROTEIN", 125, 135], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 139, 144], ["Rilonacept", "TREATMENT", 0, 10], ["a recombinant fusion protein", "TREATMENT", 14, 42], ["the extracellular portion of human IL", "TREATMENT", 57, 94], ["IL", "TREATMENT", 103, 105]]], ["Rilonacept binds to both IL-1\u03b1 and IL-1\u03b2 with high affinity and inhibits the activity of both with a long-term inhibitory effect.", [["Rilonacept", "CHEMICAL", 0, 10], ["Rilonacept", "CHEMICAL", 0, 10], ["Rilonacept", "SIMPLE_CHEMICAL", 0, 10], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 25, 30], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 35, 40], ["Rilonacept", "PROTEIN", 0, 10], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 25, 40], ["Rilonacept binds", "TREATMENT", 0, 16], ["IL", "TREATMENT", 35, 37], ["high affinity", "PROBLEM", 46, 59], ["a long-term inhibitory effect", "TREATMENT", 99, 128], ["high affinity", "OBSERVATION", 46, 59]]], ["Rilonacept was first approved by the FDA for the treatment of CAPS in 2008.", [["Rilonacept", "CHEMICAL", 0, 10], ["CAPS", "DISEASE", 62, 66], ["Rilonacept", "CHEMICAL", 0, 10], ["Rilonacept", "SIMPLE_CHEMICAL", 0, 10], ["Rilonacept", "TREATMENT", 0, 10], ["the treatment of CAPS", "TREATMENT", 45, 66]]], ["Subcutaneous injection with a loading dose and a weekly injection of half the loading dose was administered [154] .", [["Subcutaneous", "ANATOMY", 0, 12], ["Subcutaneous injection", "TREATMENT", 0, 22], ["a loading dose", "TREATMENT", 28, 42], ["a weekly injection of half the loading dose", "TREATMENT", 47, 90]]], ["There are no known severe adverse effects of rilonacept due to IL-1 signaling inhibition.", [["rilonacept", "CHEMICAL", 45, 55], ["rilonacept", "CHEMICAL", 45, 55], ["rilonacept", "SIMPLE_CHEMICAL", 45, 55], ["IL-1", "GENE_OR_GENE_PRODUCT", 63, 67], ["IL", "PROTEIN", 63, 65], ["known severe adverse effects", "PROBLEM", 13, 41], ["rilonacept", "TREATMENT", 45, 55], ["IL", "TREATMENT", 63, 65], ["no known", "UNCERTAINTY", 10, 18], ["severe", "OBSERVATION_MODIFIER", 19, 25]]], ["These drugs could modulate the immune response.", [["These drugs", "TREATMENT", 0, 11], ["immune response", "OBSERVATION", 31, 46]]], ["The most common side effects (> 10% of treated patients) are inflammation of the upper respiratory tract or sinuses, headache, and redness at the injection site [154] .CanakinumabThe third is canakinumab (Fig. 1) .", [["upper respiratory tract", "ANATOMY", 81, 104], ["sinuses", "ANATOMY", 108, 115], ["inflammation of the upper respiratory tract or sinuses", "DISEASE", 61, 115], ["headache", "DISEASE", 117, 125], ["redness", "DISEASE", 131, 138], ["Canakinumab", "CHEMICAL", 168, 179], ["canakinumab", "CHEMICAL", 192, 203], ["Canakinumab", "CHEMICAL", 168, 179], ["canakinumab", "CHEMICAL", 192, 203], ["patients", "ORGANISM", 47, 55], ["upper respiratory", "ORGANISM_SUBDIVISION", 81, 98], ["tract", "ORGANISM_SUBDIVISION", 99, 104], ["sinuses", "ORGAN", 108, 115], ["canakinumab", "SIMPLE_CHEMICAL", 192, 203], ["patients", "SPECIES", 47, 55], ["inflammation of the upper respiratory tract", "PROBLEM", 61, 104], ["sinuses", "PROBLEM", 108, 115], ["headache", "PROBLEM", 117, 125], ["redness at the injection site", "PROBLEM", 131, 160], ["Canakinumab", "TREATMENT", 168, 179], ["canakinumab (Fig", "TREATMENT", 192, 208], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["inflammation", "OBSERVATION", 61, 73], ["upper", "ANATOMY_MODIFIER", 81, 86], ["respiratory tract", "ANATOMY", 87, 104], ["sinuses", "ANATOMY", 108, 115], ["headache", "OBSERVATION", 117, 125], ["redness", "OBSERVATION", 131, 138], ["canakinumab", "OBSERVATION", 192, 203]]], ["Canakinumab, a specific human monoclonal IgG1 antibody targeting IL-1\u03b2, is intravenously or subcutaneously infused to neutralize the bioactivity of human IL-1\u03b2 [155, 156] .", [["intravenously", "ANATOMY", 75, 88], ["subcutaneously", "ANATOMY", 92, 106], ["Canakinumab", "CHEMICAL", 0, 11], ["Canakinumab", "CHEMICAL", 0, 11], ["Canakinumab", "SIMPLE_CHEMICAL", 0, 11], ["human", "ORGANISM", 24, 29], ["IgG1", "GENE_OR_GENE_PRODUCT", 41, 45], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 65, 70], ["human", "ORGANISM", 148, 153], ["IL-1", "GENE_OR_GENE_PRODUCT", 154, 158], ["human monoclonal IgG1 antibody", "PROTEIN", 24, 54], ["IL-1\u03b2", "PROTEIN", 65, 70], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 148, 153], ["Canakinumab", "TREATMENT", 0, 11], ["a specific human monoclonal IgG1 antibody targeting IL", "TREATMENT", 13, 67]]], ["Canakinumab does not react with IL-1\u03b1 or IL-1R1.", [["Canakinumab", "CHEMICAL", 0, 11], ["Canakinumab", "CHEMICAL", 0, 11], ["Canakinumab", "SIMPLE_CHEMICAL", 0, 11], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 32, 37], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 41, 47], ["IL-1\u03b1 or IL-1R1", "PROTEIN", 32, 47], ["Canakinumab", "TREATMENT", 0, 11]]], ["Therefore, canakinumab is a more specific inhibitor of IL-1\u03b2, expected to have no effect on IL-1\u03b1-dependent host defense [154] .", [["canakinumab", "CHEMICAL", 11, 22], ["canakinumab", "CHEMICAL", 11, 22], ["canakinumab", "SIMPLE_CHEMICAL", 11, 22], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 92, 97], ["IL-1\u03b2", "PROTEIN", 55, 60], ["IL-1\u03b1", "PROTEIN", 92, 97], ["canakinumab", "TREATMENT", 11, 22], ["IL", "TEST", 92, 94], ["host defense", "OBSERVATION_MODIFIER", 108, 120]]], ["Early clinical trials established the administration of canakinumab every 2 weeks as safe and effective against several inflammatory diseases [155, 156] .MABp1There are several agents currently undergoing clinical trials.", [["canakinumab", "CHEMICAL", 56, 67], ["canakinumab", "CHEMICAL", 56, 67], ["canakinumab", "SIMPLE_CHEMICAL", 56, 67], ["canakinumab", "TREATMENT", 56, 67], ["several inflammatory diseases", "PROBLEM", 112, 141], ["MABp", "TEST", 154, 158], ["clinical trials", "TREATMENT", 205, 220], ["inflammatory", "OBSERVATION_MODIFIER", 120, 132]]], ["IL-1\u03b1 production is a very early step in the sterile inflammatory response at the center of the malignant phenotype that drives angiogenesis, tumor stromal remodeling, tumor invasiveness, metastasis, and cachexia [150, [157] [158] [159] .", [["tumor stromal", "ANATOMY", 142, 155], ["tumor", "ANATOMY", 168, 173], ["tumor", "DISEASE", 142, 147], ["tumor", "DISEASE", 168, 173], ["metastasis", "DISEASE", 188, 198], ["cachexia", "DISEASE", 204, 212], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor stromal", "TISSUE", 142, 155], ["tumor", "CANCER", 168, 173], ["IL-1\u03b1", "PROTEIN", 0, 5], ["IL", "TREATMENT", 0, 2], ["the sterile inflammatory response", "PROBLEM", 41, 74], ["the malignant phenotype", "PROBLEM", 92, 115], ["tumor stromal remodeling", "PROBLEM", 142, 166], ["tumor invasiveness", "PROBLEM", 168, 186], ["metastasis", "PROBLEM", 188, 198], ["cachexia", "PROBLEM", 204, 212], ["inflammatory", "OBSERVATION", 53, 65], ["malignant phenotype", "OBSERVATION", 96, 115], ["tumor stromal", "OBSERVATION", 142, 155], ["remodeling", "OBSERVATION_MODIFIER", 156, 166], ["tumor", "OBSERVATION_MODIFIER", 168, 173], ["invasiveness", "OBSERVATION_MODIFIER", 174, 186], ["metastasis", "OBSERVATION", 188, 198]]], ["Thus, IL-1\u03b1 may be a particularly important target for the treatment of cancer.", [["cancer", "ANATOMY", 72, 78], ["cancer", "DISEASE", 72, 78], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 6, 11], ["cancer", "CANCER", 72, 78], ["IL-1\u03b1", "PROTEIN", 6, 11], ["cancer", "PROBLEM", 72, 78], ["cancer", "OBSERVATION", 72, 78]]], ["A neutralizing true human IgG1\u03ba a b d c Fig. 1 Interleukin-1 receptors and inhibitors of IL-1 signaling. a IL-1R1 interacts with both IL-1\u03b1 and IL-1\u03b2 and promotes signal transduction, together with its co-receptor IL-1R3 (IL-1RAcP).", [["human", "ORGANISM", 20, 25], ["IgG1", "GENE_OR_GENE_PRODUCT", 26, 30], ["Interleukin-1 receptors", "GENE_OR_GENE_PRODUCT", 47, 70], ["IL-1", "GENE_OR_GENE_PRODUCT", 89, 93], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 107, 113], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 134, 139], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 144, 149], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 214, 220], ["IL-1RAcP", "GENE_OR_GENE_PRODUCT", 222, 230], ["human IgG1\u03ba", "PROTEIN", 20, 31], ["Interleukin-1 receptors", "PROTEIN", 47, 70], ["IL", "PROTEIN", 89, 91], ["IL", "PROTEIN", 107, 109], ["1R1", "PROTEIN", 110, 113], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 134, 149], ["co-receptor IL-1R3 (IL-1RAcP", "PROTEIN", 202, 230], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["A neutralizing true human IgG1", "TEST", 0, 30], ["a b d c Fig.", "TREATMENT", 32, 44], ["1 Interleukin-1 receptors", "TREATMENT", 45, 70], ["inhibitors of IL", "TREATMENT", 75, 91], ["a IL", "TREATMENT", 105, 109], ["both IL", "TREATMENT", 129, 136], ["IL", "TREATMENT", 144, 146], ["its co-receptor IL", "TREATMENT", 198, 216]]], ["IL-1Ra is a protein that binds to IL-1R1 but not IL-1R3, and it is as an inhibitor of IL-1 signaling.", [["IL-1Ra", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 34, 40], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 49, 55], ["IL-1", "GENE_OR_GENE_PRODUCT", 86, 90], ["IL-1Ra", "PROTEIN", 0, 6], ["IL", "PROTEIN", 34, 36], ["1R1", "PROTEIN", 37, 40], ["IL-1R3", "PROTEIN", 49, 55], ["IL", "PROTEIN", 86, 88], ["IL", "TEST", 34, 36], ["IL", "TEST", 49, 51]]], ["IL-1R2 is a decoy receptor because it lacks a cytoplasmic segment. b Anakinra is a recombinant form of intrinsic human IL-1Ra.", [["cytoplasmic", "ANATOMY", 46, 57], ["Anakinra", "CHEMICAL", 69, 77], ["IL-1R2", "GENE_OR_GENE_PRODUCT", 0, 6], ["cytoplasmic", "ORGANISM_SUBSTANCE", 46, 57], ["Anakinra", "GENE_OR_GENE_PRODUCT", 69, 77], ["human", "ORGANISM", 113, 118], ["IL-1Ra", "GENE_OR_GENE_PRODUCT", 119, 125], ["IL", "PROTEIN", 0, 2], ["1R2", "PROTEIN", 3, 6], ["decoy receptor", "PROTEIN", 12, 26], ["cytoplasmic segment", "PROTEIN", 46, 65], ["intrinsic human IL-1Ra", "PROTEIN", 103, 125], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["IL", "TREATMENT", 0, 2], ["a decoy receptor", "TREATMENT", 10, 26], ["intrinsic human IL", "TREATMENT", 103, 121], ["cytoplasmic segment", "OBSERVATION", 46, 65], ["Anakinra", "OBSERVATION", 69, 77]]], ["It works as an antagonist of IL-1R1, and it is able to inhibit both IL-1\u03b1 and IL-1\u03b2. c Rilonacept is a recombinant fusion protein including the extracellular protein of human IL-1R1 and IL-1R3 fused with the Fc portion of human IgG1.", [["extracellular", "ANATOMY", 144, 157], ["Rilonacept", "CHEMICAL", 87, 97], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 29, 35], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 78, 83], ["c Rilonacept", "GENE_OR_GENE_PRODUCT", 85, 97], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 144, 157], ["human", "ORGANISM", 169, 174], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 175, 181], ["IL-1R3", "GENE_OR_GENE_PRODUCT", 186, 192], ["human", "ORGANISM", 222, 227], ["IgG1", "GENE_OR_GENE_PRODUCT", 228, 232], ["IL-1R1", "PROTEIN", 29, 35], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 68, 83], ["recombinant fusion protein", "PROTEIN", 103, 129], ["extracellular protein", "PROTEIN", 144, 165], ["human IL-1R1 and IL-1R3", "PROTEIN", 169, 192], ["Fc portion", "PROTEIN", 208, 218], ["human IgG1", "PROTEIN", 222, 232], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 222, 227], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 222, 227], ["an antagonist of IL", "TREATMENT", 12, 31], ["Rilonacept", "TREATMENT", 87, 97], ["a recombinant fusion protein", "TREATMENT", 101, 129], ["the extracellular protein of human IL", "TREATMENT", 140, 177], ["IL", "TREATMENT", 186, 188]]], ["It binds to both IL-1\u03b1 and IL-1\u03b2 with high affinity and has a long-term inhibitory effect. d Canakinumab and MABp1 are monoclonal antibodies against IL-1\u03b2 and IL-1\u03b1, respectively.", [["Canakinumab", "CHEMICAL", 93, 104], ["MABp1", "CHEMICAL", 109, 114], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 17, 22], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 27, 32], ["Canakinumab", "SIMPLE_CHEMICAL", 93, 104], ["MABp1", "SIMPLE_CHEMICAL", 109, 114], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 149, 154], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 159, 164], ["IL-1\u03b1 and IL-1\u03b2", "PROTEIN", 17, 32], ["Canakinumab", "PROTEIN", 93, 104], ["MABp1", "PROTEIN", 109, 114], ["monoclonal antibodies", "PROTEIN", 119, 140], ["IL-1\u03b2 and IL-1\u03b1", "PROTEIN", 149, 164], ["high affinity", "PROBLEM", 38, 51], ["a long-term inhibitory effect", "PROBLEM", 60, 89], ["d Canakinumab", "TREATMENT", 91, 104], ["MABp1", "TREATMENT", 109, 114], ["monoclonal antibodies", "TEST", 119, 140], ["IL", "TEST", 149, 151], ["high affinity", "OBSERVATION_MODIFIER", 38, 51], ["long-term inhibitory", "OBSERVATION_MODIFIER", 62, 82]]], ["They bind to and neutralize their targets specifically monoclonal antibody specific for human IL-1\u03b1, MABp1, has been developed, and it was well-tolerated with no dose-limiting toxicities or immunogenicity [160, 161] (Fig. 1) .", [["toxicities", "DISEASE", 176, 186], ["human", "ORGANISM", 88, 93], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 94, 99], ["MABp1", "GENE_OR_GENE_PRODUCT", 101, 106], ["monoclonal antibody", "PROTEIN", 55, 74], ["human IL-1\u03b1", "PROTEIN", 88, 99], ["MABp1", "PROTEIN", 101, 106], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["monoclonal antibody", "TEST", 55, 74], ["human IL", "TEST", 88, 96], ["MABp1", "TREATMENT", 101, 106], ["limiting toxicities", "PROBLEM", 167, 186]]], ["MABp1 treatment for patients with advanced colorectal cancer in a randomized, double-blind, placebocontrolled, phase 3 study revealed that MABp1 improved clinical performance in patients with advanced colorectal cancer [161] .", [["colorectal cancer", "ANATOMY", 43, 60], ["colorectal cancer", "ANATOMY", 201, 218], ["MABp1", "CHEMICAL", 0, 5], ["colorectal cancer", "DISEASE", 43, 60], ["colorectal cancer", "DISEASE", 201, 218], ["MABp1", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 20, 28], ["colorectal cancer", "CANCER", 43, 60], ["MABp1", "SIMPLE_CHEMICAL", 139, 144], ["patients", "ORGANISM", 178, 186], ["colorectal cancer", "CANCER", 201, 218], ["MABp1", "PROTEIN", 0, 5], ["MABp1", "PROTEIN", 139, 144], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 178, 186], ["MABp1 treatment", "TREATMENT", 0, 15], ["advanced colorectal cancer", "PROBLEM", 34, 60], ["phase 3 study", "TEST", 111, 124], ["MABp1", "PROBLEM", 139, 144], ["advanced colorectal cancer", "PROBLEM", 192, 218], ["colorectal", "ANATOMY", 43, 53], ["cancer", "OBSERVATION", 54, 60], ["colorectal", "ANATOMY", 201, 211], ["cancer", "OBSERVATION", 212, 218]]], ["MABp1 is a promising treatment for patients with hidradenitis suppurativa not eligible for the anti-TNF-\u03b1 antibody adalimumab [162] .GevokizumabGevokizumab is an anti-IL-1\u03b2 monoclonal antibody, IgG2, which improved glucose control and \u03b2-cell function in a diet-induced-obesity mouse model [163] and in the presence of IL-1\u03b2-driven inflammatory diseases [164] .LY2189102LY2189102 is a humanized monoclonal antibody (IgG4) that binds to IL-1\u03b2 to neutralize its activity.", [["\u03b2-cell", "ANATOMY", 235, 241], ["MABp1", "CHEMICAL", 0, 5], ["hidradenitis suppurativa", "DISEASE", 49, 73], ["adalimumab", "CHEMICAL", 115, 125], ["GevokizumabGevokizumab", "CHEMICAL", 133, 155], ["glucose", "CHEMICAL", 215, 222], ["obesity", "DISEASE", 269, 276], ["inflammatory diseases", "DISEASE", 331, 352], ["LY2189102LY2189102", "CHEMICAL", 360, 378], ["GevokizumabGevokizumab", "CHEMICAL", 133, 155], ["glucose", "CHEMICAL", 215, 222], ["LY2189102LY2189102", "CHEMICAL", 360, 378], ["MABp1", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 35, 43], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 100, 105], ["GevokizumabGevokizumab", "SIMPLE_CHEMICAL", 133, 155], ["-IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 166, 172], ["IgG2", "GENE_OR_GENE_PRODUCT", 194, 198], ["glucose", "SIMPLE_CHEMICAL", 215, 222], ["\u03b2-cell", "MULTI-TISSUE_STRUCTURE", 235, 241], ["mouse", "ORGANISM", 277, 282], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 318, 323], ["LY2189102LY2189102", "SIMPLE_CHEMICAL", 360, 378], ["IgG4", "GENE_OR_GENE_PRODUCT", 415, 419], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 435, 440], ["MABp1", "PROTEIN", 0, 5], ["TNF", "PROTEIN", 100, 103], ["anti-IL-1\u03b2 monoclonal antibody", "PROTEIN", 162, 192], ["IgG2", "PROTEIN", 194, 198], ["IL-1\u03b2", "PROTEIN", 318, 323], ["humanized monoclonal antibody", "PROTEIN", 384, 413], ["IgG4", "PROTEIN", 415, 419], ["IL-1\u03b2", "PROTEIN", 435, 440], ["patients", "SPECIES", 35, 43], ["mouse", "SPECIES", 277, 282], ["mouse", "SPECIES", 277, 282], ["a promising treatment", "TREATMENT", 9, 30], ["hidradenitis suppurativa", "PROBLEM", 49, 73], ["the anti-TNF", "TEST", 91, 103], ["GevokizumabGevokizumab", "TEST", 133, 155], ["an anti-IL", "TEST", 159, 169], ["monoclonal antibody", "TEST", 173, 192], ["IgG2", "TEST", 194, 198], ["obesity mouse model", "PROBLEM", 269, 288], ["IL", "TEST", 318, 320], ["inflammatory diseases", "PROBLEM", 331, 352], ["a humanized monoclonal antibody", "TEST", 382, 413], ["IL", "TEST", 435, 437], ["hidradenitis", "OBSERVATION", 49, 61], ["inflammatory", "OBSERVATION_MODIFIER", 331, 343]]], ["Its affinity is comparatively high (2.8 pmol/L).", [["Its affinity", "PROBLEM", 0, 12], ["affinity", "OBSERVATION_MODIFIER", 4, 12], ["high", "OBSERVATION_MODIFIER", 30, 34]]], ["Previous clinical studies evaluated not only its safety and pharmacokinetics but also its effects on RA (NCT00380744).", [["RA", "DISEASE", 101, 103], ["Previous clinical studies", "TEST", 0, 25]]], ["Weekly treatment of T2D patients with LY2189103 for 3 months resulted in modest reductions in glycated hemoglobin and blood glucose [165] .", [["blood", "ANATOMY", 118, 123], ["T2D", "DISEASE", 20, 23], ["LY2189103", "CHEMICAL", 38, 47], ["glucose", "CHEMICAL", 124, 131], ["LY2189103", "CHEMICAL", 38, 47], ["glucose", "CHEMICAL", 124, 131], ["patients", "ORGANISM", 24, 32], ["LY2189103", "SIMPLE_CHEMICAL", 38, 47], ["glycated hemoglobin", "GENE_OR_GENE_PRODUCT", 94, 113], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["glucose", "SIMPLE_CHEMICAL", 124, 131], ["glycated hemoglobin", "PROTEIN", 94, 113], ["patients", "SPECIES", 24, 32], ["modest reductions", "PROBLEM", 73, 90], ["glycated hemoglobin", "TEST", 94, 113], ["blood glucose", "TEST", 118, 131]]], ["Population pharmacokinetics (PK) of LY2189102 were characterized using data from 79 T2D subjects (Study H9C-MC-BBDK) who received 13 weekly subcutaneous doses of LY2189102 (0.6, 18, and 180 mg) and 96 RA subjects (Study H9C-MC-BBDE) who received five weekly intravenous (IV) doses (0.02-2.5 mg/kg) [166] .", [["subcutaneous", "ANATOMY", 140, 152], ["intravenous", "ANATOMY", 258, 269], ["LY2189102", "CHEMICAL", 36, 45], ["T2D", "DISEASE", 84, 87], ["LY2189102", "CHEMICAL", 162, 171], ["RA", "DISEASE", 201, 203], ["LY2189102", "CHEMICAL", 36, 45], ["LY2189102", "CHEMICAL", 162, 171], ["LY2189102", "SIMPLE_CHEMICAL", 36, 45], ["LY2189102", "SIMPLE_CHEMICAL", 162, 171], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 258, 269], ["Population pharmacokinetics", "TEST", 0, 27], ["Study H9C", "TEST", 98, 107], ["RA subjects", "TEST", 201, 212], ["Study H9C", "TEST", 214, 223], ["intravenous (IV) doses", "TREATMENT", 258, 280]]], ["No additional study has been reported.AMG 108AMG 108 is a fully human, IgG2 monoclonal antibody that binds to human IL-1R1, inhibiting the activity of IL-1\u03b1 and IL-1\u03b2 [167] .", [["AMG 108", "CHEMICAL", 38, 45], ["AMG 108", "CHEMICAL", 45, 52], ["AMG 108AMG 108", "SIMPLE_CHEMICAL", 38, 52], ["human", "ORGANISM", 64, 69], ["IgG2", "GENE_OR_GENE_PRODUCT", 71, 75], ["human", "ORGANISM", 110, 115], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 116, 122], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 151, 156], ["IL-1", "GENE_OR_GENE_PRODUCT", 161, 165], ["IgG2 monoclonal antibody", "PROTEIN", 71, 95], ["human IL-1R1", "PROTEIN", 110, 122], ["IL-1\u03b1", "PROTEIN", 151, 156], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 110, 115], ["additional study", "TEST", 3, 19], ["AMG", "TEST", 38, 41], ["AMG", "TEST", 45, 48], ["IgG2 monoclonal antibody", "TEST", 71, 95], ["human IL", "TEST", 110, 118], ["IL", "TEST", 151, 153], ["IL", "TEST", 161, 163]]], ["Patients with osteoarthritis received placebo or AMG 108 subcutaneously (SC, 75 or 300 mg) or intravenously (IV, 100 or 300 mg) once every 4 weeks for 12 weeks or received placebo or 300 mg AMG 108 SC, once every 4 weeks for 12 weeks; however, there was non-significant but numerically greater improvement in pain compared with the placebo group based on WOMAC pain scores [168] .", [["subcutaneously", "ANATOMY", 57, 71], ["intravenously", "ANATOMY", 94, 107], ["osteoarthritis", "DISEASE", 14, 28], ["AMG 108", "CHEMICAL", 49, 56], ["pain", "DISEASE", 309, 313], ["pain", "DISEASE", 361, 365], ["Patients", "ORGANISM", 0, 8], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 107], ["Patients", "SPECIES", 0, 8], ["osteoarthritis", "PROBLEM", 14, 28], ["placebo", "TREATMENT", 38, 45], ["AMG", "TREATMENT", 49, 52], ["placebo", "TREATMENT", 172, 179], ["pain", "PROBLEM", 309, 313], ["the placebo group", "TREATMENT", 328, 345], ["WOMAC pain scores", "TEST", 355, 372], ["osteoarthritis", "OBSERVATION", 14, 28]]], ["AMG108 is now termed MEDI-8968 which has been studied in not only osteoarthritis, but also chronic obstructive pulmonary disease.", [["pulmonary", "ANATOMY", 111, 120], ["AMG108", "CHEMICAL", 0, 6], ["MEDI-8968", "CHEMICAL", 21, 30], ["osteoarthritis", "DISEASE", 66, 80], ["chronic obstructive pulmonary disease", "DISEASE", 91, 128], ["MEDI-8968", "CHEMICAL", 21, 30], ["AMG108", "SIMPLE_CHEMICAL", 0, 6], ["MEDI-8968", "CELL", 21, 30], ["pulmonary", "ORGAN", 111, 120], ["osteoarthritis", "PROBLEM", 66, 80], ["chronic obstructive pulmonary disease", "PROBLEM", 91, 128], ["osteoarthritis", "OBSERVATION", 66, 80], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["obstructive", "OBSERVATION_MODIFIER", 99, 110], ["pulmonary", "ANATOMY", 111, 120], ["disease", "OBSERVATION", 121, 128]]], ["In all cases, the benefit is limited [168, 169] .EBI-005EBI-005 is a protein chimera of IL-1\u03b2 and IL-1 receptor antagonists (IL-1Ra or anakinra).", [["EBI-005EBI-005", "CHEMICAL", 49, 63], ["anakinra", "CHEMICAL", 135, 143], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 88, 93], ["IL-1 receptor antagonists", "GENE_OR_GENE_PRODUCT", 98, 123], ["IL-1Ra", "SIMPLE_CHEMICAL", 125, 131], ["anakinra", "SIMPLE_CHEMICAL", 135, 143], ["IL-1\u03b2", "PROTEIN", 88, 93], ["IL", "PROTEIN", 125, 127], ["EBI", "TEST", 49, 52], ["a protein chimera", "TEST", 67, 84], ["IL", "TEST", 88, 90], ["IL", "TEST", 98, 100], ["receptor antagonists", "TREATMENT", 103, 123], ["IL", "TEST", 125, 127], ["anakinra", "TREATMENT", 135, 143]]], ["EBI-005 binds to IL-1R1 and inhibits IL-1 signaling and has been studied for the treatment of ocular surface inflammatory diseases [170] .VX-765Since IL-1\u03b2 is known to be processed and activated by caspase-1, caspase-1 could be an indirect target for IL-1\u03b2 signaling.", [["ocular surface", "ANATOMY", 94, 108], ["EBI-005", "CHEMICAL", 0, 7], ["EBI-005", "SIMPLE_CHEMICAL", 0, 7], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 17, 23], ["IL-1", "GENE_OR_GENE_PRODUCT", 37, 41], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 150, 155], ["caspase-1", "GENE_OR_GENE_PRODUCT", 198, 207], ["caspase-1", "GENE_OR_GENE_PRODUCT", 209, 218], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 251, 256], ["IL-1R1", "PROTEIN", 17, 23], ["IL", "PROTEIN", 37, 39], ["IL-1\u03b2", "PROTEIN", 150, 155], ["caspase-1", "PROTEIN", 198, 207], ["caspase-1", "PROTEIN", 209, 218], ["IL-1\u03b2", "PROTEIN", 251, 256], ["EBI", "TEST", 0, 3], ["IL", "TEST", 17, 19], ["ocular surface inflammatory diseases", "PROBLEM", 94, 130], [".VX", "TEST", 137, 140], ["IL", "TEST", 150, 152], ["caspase", "TEST", 198, 205], ["caspase", "TREATMENT", 209, 216], ["IL", "TEST", 251, 253], ["ocular", "ANATOMY", 94, 100]]], ["To examine this, the highly selective caspase-1 inhibitor VX-765 was applied to a rat model of myocardial infarction (MI) and mouse model of AD [171, 172] .Applications of IL-1 blockade for diseases For autoinflammatory diseasesThe recombinant human IL-1-receptor antagonist anakinra is markedly effective against CAPS such as MWS, FCAS, and NOMID/CINCA.", [["myocardial", "ANATOMY", 95, 105], ["VX-765", "CHEMICAL", 58, 64], ["myocardial infarction", "DISEASE", 95, 116], ["MI", "DISEASE", 118, 120], ["AD", "DISEASE", 141, 143], ["autoinflammatory diseases", "DISEASE", 203, 228], ["anakinra", "CHEMICAL", 275, 283], ["MWS", "DISEASE", 327, 330], ["VX-765", "CHEMICAL", 58, 64], ["caspase-1", "GENE_OR_GENE_PRODUCT", 38, 47], ["VX-765", "SIMPLE_CHEMICAL", 58, 64], ["rat", "ORGANISM", 82, 85], ["myocardial", "MULTI-TISSUE_STRUCTURE", 95, 105], ["mouse", "ORGANISM", 126, 131], ["IL-1", "GENE_OR_GENE_PRODUCT", 172, 176], ["human", "ORGANISM", 244, 249], ["IL-1-receptor", "GENE_OR_GENE_PRODUCT", 250, 263], ["anakinra", "SIMPLE_CHEMICAL", 275, 283], ["IL", "PROTEIN", 172, 174], ["recombinant human IL-1-receptor", "PROTEIN", 232, 263], ["rat", "SPECIES", 82, 85], ["mouse", "SPECIES", 126, 131], ["human", "SPECIES", 244, 249], ["rat", "SPECIES", 82, 85], ["mouse", "SPECIES", 126, 131], ["human", "SPECIES", 244, 249], ["the highly selective caspase", "TREATMENT", 17, 45], ["myocardial infarction", "PROBLEM", 95, 116], ["MI", "PROBLEM", 118, 120], ["IL-1 blockade", "TREATMENT", 172, 185], ["diseases", "PROBLEM", 190, 198], ["autoinflammatory diseases", "PROBLEM", 203, 228], ["The recombinant human IL", "TREATMENT", 228, 252], ["receptor antagonist anakinra", "TREATMENT", 255, 283], ["CAPS", "PROBLEM", 314, 318], ["MWS", "PROBLEM", 327, 330], ["myocardial", "ANATOMY", 95, 105], ["infarction", "OBSERVATION", 106, 116], ["autoinflammatory", "OBSERVATION", 203, 219]]], ["Weekly rilonacept treatment markedly improved the clinical symptoms of CAPS and normalized the levels of SAA in those at risk of developing amyloidosis [90, 153, 173, 174] .", [["rilonacept", "CHEMICAL", 7, 17], ["CAPS", "DISEASE", 71, 75], ["SAA", "DISEASE", 105, 108], ["amyloidosis", "DISEASE", 140, 151], ["rilonacept", "CHEMICAL", 7, 17], ["rilonacept", "SIMPLE_CHEMICAL", 7, 17], ["SAA", "GENE_OR_GENE_PRODUCT", 105, 108], ["SAA", "PROTEIN", 105, 108], ["Weekly rilonacept treatment", "TREATMENT", 0, 27], ["the clinical symptoms of CAPS", "PROBLEM", 46, 75], ["developing amyloidosis", "PROBLEM", 129, 151], ["amyloidosis", "OBSERVATION", 140, 151]]], ["In several case reports of patients with FMF, anti-IL-1 treatment with anakinra, canakinumab, or rilonacept in colchicine-resistant patients was highly effective [175] [176] [177] [178] .", [["FMF", "DISEASE", 41, 44], ["anakinra", "CHEMICAL", 71, 79], ["canakinumab", "CHEMICAL", 81, 92], ["rilonacept", "CHEMICAL", 97, 107], ["colchicine", "CHEMICAL", 111, 121], ["anakinra", "CHEMICAL", 71, 79], ["canakinumab", "CHEMICAL", 81, 92], ["rilonacept", "CHEMICAL", 97, 107], ["colchicine", "CHEMICAL", 111, 121], ["patients", "ORGANISM", 27, 35], ["anti-IL-1", "GENE_OR_GENE_PRODUCT", 46, 55], ["anakinra", "SIMPLE_CHEMICAL", 71, 79], ["canakinumab", "SIMPLE_CHEMICAL", 81, 92], ["rilonacept", "SIMPLE_CHEMICAL", 97, 107], ["colchicine", "SIMPLE_CHEMICAL", 111, 121], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 132, 140], ["FMF", "PROBLEM", 41, 44], ["anti-IL", "TREATMENT", 46, 53], ["anakinra", "TREATMENT", 71, 79], ["canakinumab", "TREATMENT", 81, 92], ["rilonacept", "TREATMENT", 97, 107], ["colchicine", "TREATMENT", 111, 121]]], ["It was also reported that there was a rapid and lasting response of pyoderma gangrenosum to targeted treatment with anakinra in a patient with PAPA syndrome [179] .", [["pyoderma gangrenosum", "ANATOMY", 68, 88], ["pyoderma gangrenosum", "DISEASE", 68, 88], ["anakinra", "CHEMICAL", 116, 124], ["PAPA syndrome", "DISEASE", 143, 156], ["pyoderma gangrenosum", "PATHOLOGICAL_FORMATION", 68, 88], ["anakinra", "SIMPLE_CHEMICAL", 116, 124], ["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137], ["a rapid", "PROBLEM", 36, 43], ["pyoderma gangrenosum", "PROBLEM", 68, 88], ["anakinra", "TREATMENT", 116, 124], ["PAPA syndrome", "PROBLEM", 143, 156], ["pyoderma gangrenosum", "OBSERVATION", 68, 88]]], ["Anakinra and canakinumab therapies were also reported to be effective in patients with MKD/HIDS [180] .", [["Anakinra", "CHEMICAL", 0, 8], ["canakinumab", "CHEMICAL", 13, 24], ["Anakinra", "CHEMICAL", 0, 8], ["canakinumab", "CHEMICAL", 13, 24], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["canakinumab", "SIMPLE_CHEMICAL", 13, 24], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["Anakinra", "TREATMENT", 0, 8], ["canakinumab therapies", "TREATMENT", 13, 34]]], ["In the case of TRAPS, although TNF-\u03b1 is considered to be mainly involved in clinical manifestations, marked improvement following IL-1\u03b2 blockade occurred [112, 181] .", [["TRAPS", "GENE_OR_GENE_PRODUCT", 15, 20], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 130, 135], ["TRAPS", "PROTEIN", 15, 20], ["TNF-\u03b1", "PROTEIN", 31, 36], ["IL", "PROTEIN", 130, 132], ["TNF", "TEST", 31, 34], ["IL-1\u03b2 blockade", "TREATMENT", 130, 144], ["marked", "OBSERVATION_MODIFIER", 101, 107], ["improvement", "OBSERVATION_MODIFIER", 108, 119]]], ["An open-label, phase II study was reported whereby 19 patients with active recurrent or chronic TRAPS (19/20, 95%; 95% CI 75.1% to 99.9%) achieved the primary efficacy endpoint.", [["TRAPS", "DISEASE", 96, 101], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["An open-label, phase II study", "TEST", 0, 29], ["active recurrent or chronic TRAPS", "PROBLEM", 68, 101], ["CI", "TEST", 119, 121], ["chronic", "OBSERVATION_MODIFIER", 88, 95]]], ["Canakinumab treatment for TRAPS rapidly improved the median time to clinical remission to 4 days (95% CI 3 to 8 days) [182] .", [["Canakinumab", "CHEMICAL", 0, 11], ["TRAPS", "CHEMICAL", 26, 31], ["Canakinumab", "CHEMICAL", 0, 11], ["Canakinumab", "SIMPLE_CHEMICAL", 0, 11], ["Canakinumab treatment", "TREATMENT", 0, 21], ["TRAPS", "PROBLEM", 26, 31]]], ["Skin findings also promptly improved upon anakinra treatment in a patient with DIRA [183] .", [["Skin", "ANATOMY", 0, 4], ["anakinra", "CHEMICAL", 42, 50], ["DIRA", "DISEASE", 79, 83], ["Skin", "ORGAN", 0, 4], ["anakinra", "SIMPLE_CHEMICAL", 42, 50], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["anakinra treatment", "TREATMENT", 42, 60], ["improved", "OBSERVATION_MODIFIER", 28, 36]]], ["Monotherapy involving canakinumab for the treatment of FMF has been reported [184] .", [["canakinumab", "CHEMICAL", 22, 33], ["FMF", "DISEASE", 55, 58], ["canakinumab", "CHEMICAL", 22, 33], ["canakinumab", "SIMPLE_CHEMICAL", 22, 33], ["Monotherapy", "TREATMENT", 0, 11], ["canakinumab", "TREATMENT", 22, 33], ["the treatment", "TREATMENT", 38, 51], ["FMF", "PROBLEM", 55, 58]]], ["A nationwide report on IL-1 treatment of patients with FMF revealed that 172 FMF patients (83 [48%] female; mean age, 36.2 years [range, ) were included; the mean age at onset was 12.6 years (range, 1-48), and the mean colchicine dose was 1.7 mg/day (range, 0.5-4.0).", [["FMF", "DISEASE", 55, 58], ["FMF", "DISEASE", 77, 80], ["colchicine", "CHEMICAL", 219, 229], ["colchicine", "CHEMICAL", 219, 229], ["IL-1", "GENE_OR_GENE_PRODUCT", 23, 27], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 81, 89], ["colchicine", "SIMPLE_CHEMICAL", 219, 229], ["IL", "PROTEIN", 23, 25], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 81, 89], ["IL", "TREATMENT", 23, 25], ["FMF", "PROBLEM", 55, 58], ["the mean colchicine dose", "TREATMENT", 210, 234]]], ["Anakinra was administered to 151 patients, and canakinumab was administered to 21 patients.", [["Anakinra", "CHEMICAL", 0, 8], ["canakinumab", "CHEMICAL", 47, 58], ["Anakinra", "CHEMICAL", 0, 8], ["canakinumab", "CHEMICAL", 47, 58], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["patients", "ORGANISM", 33, 41], ["canakinumab", "SIMPLE_CHEMICAL", 47, 58], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 82, 90], ["Anakinra", "TREATMENT", 0, 8], ["canakinumab", "TREATMENT", 47, 58]]], ["Anti-IL-1 treatment was used in 84% of colchicine-resistant patients and 12% of amyloidosis patients.", [["Anti-IL-1", "CHEMICAL", 0, 9], ["colchicine", "CHEMICAL", 39, 49], ["amyloidosis", "DISEASE", 80, 91], ["colchicine", "CHEMICAL", 39, 49], ["Anti-IL-1", "GENE_OR_GENE_PRODUCT", 0, 9], ["colchicine", "SIMPLE_CHEMICAL", 39, 49], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 92, 100], ["Anti-IL-1 treatment", "TREATMENT", 0, 19], ["colchicine", "TREATMENT", 39, 49], ["amyloidosis", "PROBLEM", 80, 91], ["amyloidosis", "OBSERVATION", 80, 91]]], ["During the mean of 19.6 months of treatment (range, 6-98), the attack frequency per year was significantly decreased (from 16.8 to 2.4; P < 0.001), and symptoms of 42.1% of colchicine-resistant patients with FMF were ameliorated.", [["colchicine", "CHEMICAL", 173, 183], ["FMF", "DISEASE", 208, 211], ["colchicine", "CHEMICAL", 173, 183], ["colchicine", "SIMPLE_CHEMICAL", 173, 183], ["patients", "ORGANISM", 194, 202], ["patients", "SPECIES", 194, 202], ["treatment", "TREATMENT", 34, 43], ["P", "TEST", 136, 137], ["symptoms", "PROBLEM", 152, 160], ["colchicine", "TREATMENT", 173, 183], ["FMF", "PROBLEM", 208, 211], ["decreased", "OBSERVATION_MODIFIER", 107, 116]]], ["In this study, the complete remission rate was 40% and inefficacy rate was 8% in patients treated with anakinra, whereas the complete remission rate was 65% and inefficacy rate was 6% for patients treated with canakinumab [185] .", [["anakinra", "CHEMICAL", 103, 111], ["canakinumab", "CHEMICAL", 210, 221], ["canakinumab", "CHEMICAL", 210, 221], ["patients", "ORGANISM", 81, 89], ["anakinra", "SIMPLE_CHEMICAL", 103, 111], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 188, 196], ["this study", "TEST", 3, 13], ["the complete remission rate", "TEST", 15, 42], ["inefficacy rate", "TEST", 55, 70], ["anakinra", "TREATMENT", 103, 111], ["the complete remission rate", "TEST", 121, 148], ["inefficacy rate", "TEST", 161, 176], ["canakinumab", "TREATMENT", 210, 221]]], ["Although the response rates were not significant (P = 0.144 and \u03c72 = 3.872606) in the study above [185] , in our opinion, long-acting canakinumab may be more efficacious than anakinra, considering the necessity of daily subcutaneous anakinra injection because of its short half-time clearance of less than 12 h [185] .For miscellaneous autoinflammatory diseasesThere are suspected etiologies of autoinflammatory disorders, but all lack a known genetic basis.", [["subcutaneous", "ANATOMY", 220, 232], ["canakinumab", "CHEMICAL", 134, 145], ["anakinra", "CHEMICAL", 175, 183], ["anakinra", "CHEMICAL", 233, 241], ["autoinflammatory diseases", "DISEASE", 336, 361], ["autoinflammatory disorders", "DISEASE", 395, 421], ["canakinumab", "CHEMICAL", 134, 145], ["canakinumab", "SIMPLE_CHEMICAL", 134, 145], ["anakinra", "SIMPLE_CHEMICAL", 175, 183], ["anakinra", "SIMPLE_CHEMICAL", 233, 241], ["the response rates", "TEST", 9, 27], ["P", "TEST", 50, 51], ["the study", "TEST", 82, 91], ["long-acting canakinumab", "TREATMENT", 122, 145], ["anakinra", "TREATMENT", 175, 183], ["daily subcutaneous anakinra injection", "TREATMENT", 214, 251], ["miscellaneous autoinflammatory diseases", "PROBLEM", 322, 361], ["autoinflammatory disorders", "PROBLEM", 395, 421], ["autoinflammatory diseases", "OBSERVATION", 336, 361], ["suspected etiologies of", "UNCERTAINTY", 371, 394], ["autoinflammatory disorders", "OBSERVATION", 395, 421]]], ["In patients with adult-onset Still's disease (AOSD), anakinra monotherapy is significantly effective and has become the standard therapy, especially in prednisone-resistant patients.", [["Still's disease", "DISEASE", 29, 44], ["AOSD", "DISEASE", 46, 50], ["anakinra", "CHEMICAL", 53, 61], ["prednisone", "CHEMICAL", 152, 162], ["anakinra", "CHEMICAL", 53, 61], ["prednisone", "CHEMICAL", 152, 162], ["patients", "ORGANISM", 3, 11], ["anakinra", "SIMPLE_CHEMICAL", 53, 61], ["prednisone", "SIMPLE_CHEMICAL", 152, 162], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 173, 181], ["Still's disease", "PROBLEM", 29, 44], ["AOSD", "PROBLEM", 46, 50], ["anakinra monotherapy", "TREATMENT", 53, 73], ["the standard therapy", "TREATMENT", 116, 136], ["prednisone", "TREATMENT", 152, 162], ["disease", "OBSERVATION", 37, 44], ["AOSD", "OBSERVATION", 46, 50]]], ["Commercially available anti-IL-1 agents (anakinra/Kineret\u00ae, canakinumab/ Ilaris\u00ae, or rilonacept/Arcalyst\u00ae) for patients with treatmentresistant AOSD are effective.", [["anti-IL-1 agents", "CHEMICAL", 23, 39], ["anakinra", "CHEMICAL", 41, 49], ["Kineret\u00ae", "CHEMICAL", 50, 58], ["canakinumab", "CHEMICAL", 60, 71], ["Ilaris\u00ae", "CHEMICAL", 73, 80], ["rilonacept", "CHEMICAL", 85, 95], ["Arcalyst\u00ae", "CHEMICAL", 96, 105], ["AOSD", "DISEASE", 144, 148], ["canakinumab", "CHEMICAL", 60, 71], ["rilonacept", "CHEMICAL", 85, 95], ["anti-IL-1 agents", "SIMPLE_CHEMICAL", 23, 39], ["anakinra", "SIMPLE_CHEMICAL", 41, 49], ["Kineret\u00ae", "SIMPLE_CHEMICAL", 50, 58], ["canakinumab", "SIMPLE_CHEMICAL", 60, 71], ["Ilaris\u00ae", "SIMPLE_CHEMICAL", 73, 80], ["rilonacept", "SIMPLE_CHEMICAL", 85, 95], ["Arcalyst\u00ae", "SIMPLE_CHEMICAL", 96, 105], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["anti-IL", "TREATMENT", 23, 30], ["anakinra", "TREATMENT", 41, 49], ["Kineret\u00ae", "TREATMENT", 50, 58], ["canakinumab", "TREATMENT", 60, 71], ["Ilaris\u00ae", "TREATMENT", 73, 80], ["rilonacept", "TREATMENT", 85, 95], ["Arcalyst\u00ae", "TREATMENT", 96, 105], ["treatmentresistant AOSD", "PROBLEM", 125, 148]]], ["Canakinumab and anakinra were also effective for patients with Schnitzler syndrome, an adult-onset autoinflammatory disease characterized by focal urticaria and systemic inflammation including fever with bone and muscle pain, in the first placebo-controlled study, and several clinical trials are currently ongoing [186] [187] [188] [189] .For autoimmune diseasesIL-1 blockade therapy using anakinra is successful in patients with psoriatic arthritis, ankylosing spondylitis, and RA.", [["bone", "ANATOMY", 204, 208], ["muscle", "ANATOMY", 213, 219], ["Canakinumab", "CHEMICAL", 0, 11], ["anakinra", "CHEMICAL", 16, 24], ["Schnitzler syndrome", "DISEASE", 63, 82], ["autoinflammatory disease", "DISEASE", 99, 123], ["urticaria", "DISEASE", 147, 156], ["systemic inflammation", "DISEASE", 161, 182], ["fever", "DISEASE", 193, 198], ["bone and muscle pain", "DISEASE", 204, 224], ["anakinra", "CHEMICAL", 391, 399], ["psoriatic arthritis", "DISEASE", 431, 450], ["ankylosing spondylitis", "DISEASE", 452, 474], ["RA", "DISEASE", 480, 482], ["Canakinumab", "CHEMICAL", 0, 11], ["anakinra", "CHEMICAL", 16, 24], ["Canakinumab", "SIMPLE_CHEMICAL", 0, 11], ["anakinra", "SIMPLE_CHEMICAL", 16, 24], ["patients", "ORGANISM", 49, 57], ["bone", "TISSUE", 204, 208], ["muscle", "ORGAN", 213, 219], ["[186] [187] [188] [189]", "SIMPLE_CHEMICAL", 315, 338], ["diseasesIL-1", "GENE_OR_GENE_PRODUCT", 355, 367], ["anakinra", "SIMPLE_CHEMICAL", 391, 399], ["patients", "ORGANISM", 417, 425], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 417, 425], ["Canakinumab", "TREATMENT", 0, 11], ["anakinra", "TREATMENT", 16, 24], ["Schnitzler syndrome", "PROBLEM", 63, 82], ["an adult-onset autoinflammatory disease", "PROBLEM", 84, 123], ["focal urticaria", "PROBLEM", 141, 156], ["systemic inflammation", "PROBLEM", 161, 182], ["fever", "PROBLEM", 193, 198], ["bone and muscle pain", "PROBLEM", 204, 224], ["autoimmune diseasesIL", "TREATMENT", 344, 365], ["1 blockade therapy", "TREATMENT", 366, 384], ["anakinra", "TREATMENT", 391, 399], ["psoriatic arthritis", "PROBLEM", 431, 450], ["ankylosing spondylitis", "PROBLEM", 452, 474], ["anakinra", "OBSERVATION", 16, 24], ["-onset", "OBSERVATION_MODIFIER", 92, 98], ["autoinflammatory disease", "OBSERVATION", 99, 123], ["focal", "OBSERVATION_MODIFIER", 141, 146], ["urticaria", "OBSERVATION", 147, 156], ["systemic", "OBSERVATION_MODIFIER", 161, 169], ["inflammation", "OBSERVATION", 170, 182], ["bone", "ANATOMY", 204, 208], ["muscle", "ANATOMY", 213, 219], ["pain", "OBSERVATION", 220, 224], ["psoriatic", "ANATOMY", 431, 440], ["arthritis", "OBSERVATION", 441, 450], ["ankylosing spondylitis", "OBSERVATION", 452, 474], ["RA", "ANATOMY", 480, 482]]], ["On the other hand, its efficacy and safety are insufficient, precluding use for patients with systemic lupus erythematosus or Sj\u00f6gren syndrome, and IL-1\u03b2 inhibition using canakinumab had no effect on the decline in \u03b2-cell function after diabetes onset in patients with type 1 diabetes mellitus resulting from autoimmune-mediated \u03b2-cell loss [190] [191] [192] [193] [194] .", [["\u03b2-cell", "ANATOMY", 215, 221], ["\u03b2-cell", "ANATOMY", 329, 335], ["systemic lupus erythematosus", "DISEASE", 94, 122], ["Sj\u00f6gren syndrome", "DISEASE", 126, 142], ["canakinumab", "CHEMICAL", 171, 182], ["diabetes", "DISEASE", 237, 245], ["type 1 diabetes mellitus", "DISEASE", 269, 293], ["canakinumab", "CHEMICAL", 171, 182], ["patients", "ORGANISM", 80, 88], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 148, 153], ["canakinumab", "SIMPLE_CHEMICAL", 171, 182], ["\u03b2-cell", "CELL", 215, 221], ["patients", "ORGANISM", 255, 263], ["\u03b2-cell", "CELL", 329, 335], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 255, 263], ["systemic lupus erythematosus", "PROBLEM", 94, 122], ["Sj\u00f6gren syndrome", "PROBLEM", 126, 142], ["IL", "TREATMENT", 148, 150], ["canakinumab", "TREATMENT", 171, 182], ["the decline in \u03b2-cell function", "PROBLEM", 200, 230], ["diabetes onset", "PROBLEM", 237, 251], ["type 1 diabetes mellitus", "PROBLEM", 269, 293], ["autoimmune-mediated \u03b2-cell loss", "PROBLEM", 309, 340], ["lupus", "OBSERVATION", 103, 108]]], ["As for RA, the enhanced release of other proinflammatory cytokines such as TNF-\u03b1 and IL-6 plays important roles in the inflamed synovium of RA patients [195] .", [["synovium", "ANATOMY", 128, 136], ["RA", "DISEASE", 7, 9], ["RA", "DISEASE", 140, 142], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 75, 80], ["IL-6", "GENE_OR_GENE_PRODUCT", 85, 89], ["synovium", "TISSUE", 128, 136], ["patients", "ORGANISM", 143, 151], ["proinflammatory cytokines", "PROTEIN", 41, 66], ["TNF", "PROTEIN", 75, 78], ["IL-6", "PROTEIN", 85, 89], ["patients", "SPECIES", 143, 151], ["RA", "PROBLEM", 7, 9], ["other proinflammatory cytokines", "PROBLEM", 35, 66], ["TNF", "TEST", 75, 78], ["IL-6 plays", "TREATMENT", 85, 95], ["inflamed synovium", "ANATOMY", 119, 136], ["RA", "ANATOMY", 140, 142]]], ["In patients for whom TNF-\u03b1 blockers are contraindicated, anakinra is effective in controlling the disease activity of RA and has been licensed for treatment at a dose of 100 mg/day by subcutaneous injection every day [196, 197] .", [["subcutaneous", "ANATOMY", 184, 196], ["anakinra", "CHEMICAL", 57, 65], ["RA", "DISEASE", 118, 120], ["patients", "ORGANISM", 3, 11], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 21, 26], ["anakinra", "SIMPLE_CHEMICAL", 57, 65], ["TNF", "PROTEIN", 21, 24], ["patients", "SPECIES", 3, 11], ["TNF-\u03b1 blockers", "TREATMENT", 21, 35], ["anakinra", "TREATMENT", 57, 65], ["treatment", "TREATMENT", 147, 156], ["RA", "ANATOMY", 118, 120]]], ["Compared with anakinra, TNF inhibitors, such as the anti-TNF-\u03b1 monoclonal antibody infliximab, or etanercept that fuse the TNF receptor to the end of the IgG1 antibody, dominate the field of biologics for RA because of the sense of well-being experienced by patients within hours of treatment [198] .", [["anakinra", "CHEMICAL", 14, 22], ["infliximab", "CHEMICAL", 83, 93], ["etanercept", "CHEMICAL", 98, 108], ["RA", "DISEASE", 205, 207], ["anakinra", "SIMPLE_CHEMICAL", 14, 22], ["TNF", "GENE_OR_GENE_PRODUCT", 24, 27], ["anti-TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 52, 62], ["infliximab", "SIMPLE_CHEMICAL", 83, 93], ["etanercept", "SIMPLE_CHEMICAL", 98, 108], ["TNF receptor", "GENE_OR_GENE_PRODUCT", 123, 135], ["IgG1", "GENE_OR_GENE_PRODUCT", 154, 158], ["patients", "ORGANISM", 258, 266], ["TNF", "PROTEIN", 24, 27], ["anti-TNF-\u03b1 monoclonal antibody", "PROTEIN", 52, 82], ["TNF receptor", "PROTEIN", 123, 135], ["IgG1 antibody", "PROTEIN", 154, 167], ["patients", "SPECIES", 258, 266], ["anakinra", "TREATMENT", 14, 22], ["TNF inhibitors", "TREATMENT", 24, 38], ["the anti-TNF", "TREATMENT", 48, 60], ["\u03b1 monoclonal antibody infliximab", "TREATMENT", 61, 93], ["etanercept", "TREATMENT", 98, 108], ["the TNF receptor", "TREATMENT", 119, 135], ["the IgG1 antibody", "TEST", 150, 167], ["RA", "TREATMENT", 205, 207], ["treatment", "TREATMENT", 283, 292]]], ["Tocilizumab, a humanized anti-IL-6 receptor (IL-6R) monoclonal antibody, has also been shown to improve the symptoms of patients with RA [199] .", [["Tocilizumab", "CHEMICAL", 0, 11], ["RA", "DISEASE", 134, 136], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["anti-IL-6 receptor", "GENE_OR_GENE_PRODUCT", 25, 43], ["IL-6R", "GENE_OR_GENE_PRODUCT", 45, 50], ["patients", "ORGANISM", 120, 128], ["humanized anti-IL-6 receptor (IL-6R) monoclonal antibody", "PROTEIN", 15, 71], ["patients", "SPECIES", 120, 128], ["Tocilizumab", "TREATMENT", 0, 11], ["a humanized anti-IL-6 receptor (IL-6R) monoclonal antibody", "TREATMENT", 13, 71], ["the symptoms", "PROBLEM", 104, 116], ["RA", "ANATOMY", 134, 136]]], ["However, those agents are associated with the risk of reactivating bacterial pathogens such as tuberculosis (TB) and malignancies [197] .", [["malignancies", "ANATOMY", 117, 129], ["tuberculosis", "DISEASE", 95, 107], ["TB", "DISEASE", 109, 111], ["malignancies", "DISEASE", 117, 129], ["malignancies", "CANCER", 117, 129], ["reactivating bacterial pathogens", "PROBLEM", 54, 86], ["tuberculosis (TB)", "PROBLEM", 95, 112], ["malignancies", "PROBLEM", 117, 129], ["bacterial pathogens", "OBSERVATION", 67, 86], ["tuberculosis", "OBSERVATION", 95, 107]]], ["Notably, no cases of TB reactivation were reported in 7964 RA patients after anakinra treatment, whereas 8 cases of TB reactivation were reported in 10,281 RA patients after tocilizumab treatment, and 7 and 10 cases of TB reactivation were reported in 2626 and 3167 RA patients after TNF-inhibitor treatment with golimumab and certolizumab pegol, respectively.", [["TB", "DISEASE", 21, 23], ["RA", "DISEASE", 59, 61], ["anakinra", "CHEMICAL", 77, 85], ["TB", "DISEASE", 116, 118], ["RA", "DISEASE", 156, 158], ["tocilizumab", "CHEMICAL", 174, 185], ["TB", "DISEASE", 219, 221], ["RA", "DISEASE", 266, 268], ["golimumab", "CHEMICAL", 313, 322], ["certolizumab pegol", "CHEMICAL", 327, 345], ["golimumab", "CHEMICAL", 313, 322], ["patients", "ORGANISM", 62, 70], ["anakinra", "SIMPLE_CHEMICAL", 77, 85], ["patients", "ORGANISM", 159, 167], ["tocilizumab", "SIMPLE_CHEMICAL", 174, 185], ["patients", "ORGANISM", 269, 277], ["TNF", "GENE_OR_GENE_PRODUCT", 284, 287], ["golimumab", "SIMPLE_CHEMICAL", 313, 322], ["certolizumab pegol", "SIMPLE_CHEMICAL", 327, 345], ["TNF", "PROTEIN", 284, 287], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 159, 167], ["patients", "SPECIES", 269, 277], ["TB reactivation", "PROBLEM", 21, 36], ["anakinra treatment", "TREATMENT", 77, 95], ["TB reactivation", "PROBLEM", 116, 131], ["tocilizumab treatment", "TREATMENT", 174, 195], ["TB reactivation", "PROBLEM", 219, 234], ["TNF-inhibitor treatment", "TREATMENT", 284, 307], ["golimumab", "TREATMENT", 313, 322], ["certolizumab pegol", "TREATMENT", 327, 345], ["no", "UNCERTAINTY", 9, 11]]], ["This suggests the low risk of TB reactivation in RA patients treated with anti-IL-1 therapy [197] .For infectious diseasesAnakinra is safe and may be associated with a dose-related survival advantage in patients with septic shock syndrome complicated by acute respiratory distress syndrome, disseminated intravascular coagulation, and renal dysfunction, and subsequent secondary hemophagocytic lymphohistiocytosis (HLH), or macrophage-activating syndrome (MAS) [200, 201] .", [["respiratory", "ANATOMY", 260, 271], ["intravascular", "ANATOMY", 304, 317], ["renal", "ANATOMY", 335, 340], ["macrophage", "ANATOMY", 424, 434], ["TB", "DISEASE", 30, 32], ["RA", "DISEASE", 49, 51], ["anti-IL-1", "CHEMICAL", 74, 83], ["infectious diseases", "DISEASE", 103, 122], ["Anakinra", "CHEMICAL", 122, 130], ["septic shock syndrome", "DISEASE", 217, 238], ["acute respiratory distress syndrome", "DISEASE", 254, 289], ["disseminated intravascular coagulation", "DISEASE", 291, 329], ["renal dysfunction", "DISEASE", 335, 352], ["hemophagocytic lymphohistiocytosis", "DISEASE", 379, 413], ["HLH", "DISEASE", 415, 418], ["MAS", "DISEASE", 456, 459], ["patients", "ORGANISM", 52, 60], ["anti-IL-1", "GENE_OR_GENE_PRODUCT", 74, 83], ["patients", "ORGANISM", 203, 211], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 304, 317], ["renal", "ORGAN", 335, 340], ["macrophage", "CELL", 424, 434], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 203, 211], ["TB reactivation", "PROBLEM", 30, 45], ["anti-IL-1 therapy", "TREATMENT", 74, 91], ["Anakinra", "TREATMENT", 122, 130], ["survival advantage", "TREATMENT", 181, 199], ["septic shock syndrome", "PROBLEM", 217, 238], ["acute respiratory distress syndrome", "PROBLEM", 254, 289], ["disseminated intravascular coagulation", "PROBLEM", 291, 329], ["renal dysfunction", "PROBLEM", 335, 352], ["secondary hemophagocytic lymphohistiocytosis", "PROBLEM", 369, 413], ["HLH)", "PROBLEM", 415, 419], ["macrophage-activating syndrome", "PROBLEM", 424, 454], ["low risk", "OBSERVATION_MODIFIER", 18, 26], ["TB reactivation", "OBSERVATION", 30, 45], ["RA", "ANATOMY", 49, 51], ["septic shock syndrome", "OBSERVATION", 217, 238], ["acute", "OBSERVATION_MODIFIER", 254, 259], ["respiratory distress syndrome", "OBSERVATION", 260, 289], ["disseminated", "OBSERVATION_MODIFIER", 291, 303], ["intravascular coagulation", "OBSERVATION", 304, 329], ["renal", "ANATOMY", 335, 340], ["dysfunction", "OBSERVATION", 341, 352], ["secondary", "OBSERVATION_MODIFIER", 369, 378], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 379, 413], ["macrophage", "OBSERVATION_MODIFIER", 424, 434]]], ["For sepsis with MAS, anakinra treatment led to significant improvements in hepatobiliary dysfunction and disseminated intravascular coagulation in patients (65.4% anakinra vs. 35.3% placebo) and the 28-day survival rate, with the hazard ratio for death being 0.28 (0.11-0.71; p = 0.0071) for the treatment group on Cox regression.", [["hepatobiliary", "ANATOMY", 75, 88], ["intravascular", "ANATOMY", 118, 131], ["sepsis", "DISEASE", 4, 10], ["MAS", "DISEASE", 16, 19], ["anakinra", "CHEMICAL", 21, 29], ["hepatobiliary dysfunction", "DISEASE", 75, 100], ["disseminated intravascular coagulation", "DISEASE", 105, 143], ["anakinra", "CHEMICAL", 163, 171], ["death", "DISEASE", 247, 252], ["anakinra", "SIMPLE_CHEMICAL", 21, 29], ["hepatobiliary", "ORGAN", 75, 88], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 118, 131], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["sepsis", "PROBLEM", 4, 10], ["MAS", "PROBLEM", 16, 19], ["anakinra treatment", "TREATMENT", 21, 39], ["hepatobiliary dysfunction", "PROBLEM", 75, 100], ["disseminated intravascular coagulation", "PROBLEM", 105, 143], ["anakinra", "TEST", 163, 171], ["placebo", "TEST", 182, 189], ["survival rate", "TEST", 206, 219], ["the hazard ratio", "TEST", 226, 242], ["death", "PROBLEM", 247, 252], ["Cox regression", "PROBLEM", 315, 329], ["sepsis", "OBSERVATION", 4, 10], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["improvements", "OBSERVATION_MODIFIER", 59, 71], ["hepatobiliary", "ANATOMY", 75, 88], ["dysfunction", "OBSERVATION", 89, 100], ["disseminated", "OBSERVATION_MODIFIER", 105, 117], ["intravascular coagulation", "OBSERVATION", 118, 143]]], ["The data included 763 adults in the original study cohort, randomized to receive either anakinra or placebo [202] .For infectious diseasesFor metabolic syndromes IL-1 inhibition by anakinra, rilonacept, or canakinumab is efficacious for gout patients [203] .", [["anakinra", "CHEMICAL", 88, 96], ["infectious diseases", "DISEASE", 119, 138], ["metabolic syndromes", "DISEASE", 142, 161], ["anakinra", "CHEMICAL", 181, 189], ["rilonacept", "CHEMICAL", 191, 201], ["canakinumab", "CHEMICAL", 206, 217], ["gout", "DISEASE", 237, 241], ["anakinra", "CHEMICAL", 88, 96], ["anakinra", "CHEMICAL", 181, 189], ["rilonacept", "CHEMICAL", 191, 201], ["canakinumab", "CHEMICAL", 206, 217], ["anakinra", "SIMPLE_CHEMICAL", 88, 96], ["IL-1", "GENE_OR_GENE_PRODUCT", 162, 166], ["anakinra", "SIMPLE_CHEMICAL", 181, 189], ["rilonacept", "SIMPLE_CHEMICAL", 191, 201], ["canakinumab", "SIMPLE_CHEMICAL", 206, 217], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 242, 250], ["anakinra", "TREATMENT", 88, 96], ["placebo", "TREATMENT", 100, 107], ["infectious diseases", "PROBLEM", 119, 138], ["metabolic syndromes IL", "TREATMENT", 142, 164], ["anakinra", "TREATMENT", 181, 189], ["rilonacept", "TREATMENT", 191, 201], ["canakinumab", "TREATMENT", 206, 217], ["gout", "PROBLEM", 237, 241]]], ["IL-1 plays a role in the progression of atherosclerosis as well [204] .", [["atherosclerosis", "DISEASE", 40, 55], ["IL-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-1", "PROTEIN", 0, 4], ["atherosclerosis", "PROBLEM", 40, 55], ["atherosclerosis", "OBSERVATION", 40, 55]]], ["In patients with a history of MI, canakinumab significantly reduced the high-sensitive serum CRP concentration from the baseline, as compared with a placebo, without affecting the LDL-cholesterol concentration.", [["serum", "ANATOMY", 87, 92], ["MI", "DISEASE", 30, 32], ["canakinumab", "CHEMICAL", 34, 45], ["cholesterol", "CHEMICAL", 184, 195], ["canakinumab", "CHEMICAL", 34, 45], ["cholesterol", "CHEMICAL", 184, 195], ["patients", "ORGANISM", 3, 11], ["canakinumab", "SIMPLE_CHEMICAL", 34, 45], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["CRP", "GENE_OR_GENE_PRODUCT", 93, 96], ["LDL-cholesterol", "SIMPLE_CHEMICAL", 180, 195], ["CRP", "PROTEIN", 93, 96], ["LDL", "PROTEIN", 180, 183], ["patients", "SPECIES", 3, 11], ["MI", "PROBLEM", 30, 32], ["canakinumab", "PROBLEM", 34, 45], ["the high-sensitive serum CRP concentration", "PROBLEM", 68, 110], ["the LDL", "TEST", 176, 183], ["MI", "OBSERVATION", 30, 32], ["high", "OBSERVATION_MODIFIER", 72, 76]]], ["A 150-mg dose of canakinumab resulted in a significantly reduced risk of recurrent cardiovascular events compared with a placebo [205] .", [["cardiovascular", "ANATOMY", 83, 97], ["canakinumab", "CHEMICAL", 17, 28], ["canakinumab", "CHEMICAL", 17, 28], ["canakinumab", "SIMPLE_CHEMICAL", 17, 28], ["cardiovascular", "ANATOMICAL_SYSTEM", 83, 97], ["canakinumab", "TREATMENT", 17, 28], ["recurrent cardiovascular events", "PROBLEM", 73, 104], ["recurrent", "OBSERVATION_MODIFIER", 73, 82], ["cardiovascular events", "OBSERVATION", 83, 104]]], ["The inhibition of IL-1 with anakinra improved glycemia and the pancreatic \u03b2-cell function and reduced systemic inflammation [205] .", [["pancreatic \u03b2-cell", "ANATOMY", 63, 80], ["anakinra", "CHEMICAL", 28, 36], ["inflammation", "DISEASE", 111, 123], ["IL-1", "GENE_OR_GENE_PRODUCT", 18, 22], ["anakinra", "SIMPLE_CHEMICAL", 28, 36], ["pancreatic \u03b2-cell", "MULTI-TISSUE_STRUCTURE", 63, 80], ["IL-1", "PROTEIN", 18, 22], ["The inhibition of IL", "TREATMENT", 0, 20], ["anakinra", "TREATMENT", 28, 36], ["glycemia", "TEST", 46, 54], ["the pancreatic \u03b2-cell function", "TEST", 59, 89], ["reduced systemic inflammation", "PROBLEM", 94, 123], ["pancreatic", "ANATOMY", 63, 73], ["reduced", "OBSERVATION_MODIFIER", 94, 101], ["systemic", "OBSERVATION_MODIFIER", 102, 110], ["inflammation", "OBSERVATION", 111, 123]]], ["Although IL-1\u03b2 inhibition with canakinumab had similar effects on major cardiovascular events among those with and without diabetes, treatment over a median period of 3.7 years did not reduce incident diabetes [206] .", [["cardiovascular", "ANATOMY", 72, 86], ["canakinumab", "CHEMICAL", 31, 42], ["major cardiovascular events", "DISEASE", 66, 93], ["diabetes", "DISEASE", 123, 131], ["diabetes", "DISEASE", 201, 209], ["canakinumab", "CHEMICAL", 31, 42], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 9, 14], ["canakinumab", "SIMPLE_CHEMICAL", 31, 42], ["cardiovascular", "ANATOMICAL_SYSTEM", 72, 86], ["IL-1\u03b2", "PROTEIN", 9, 14], ["IL", "TREATMENT", 9, 11], ["canakinumab", "TREATMENT", 31, 42], ["diabetes", "PROBLEM", 123, 131], ["treatment", "TREATMENT", 133, 142], ["diabetes", "PROBLEM", 201, 209]]], ["The blockade of IL-1 with anakinra improved glycemia and the \u03b2-cell secretory function and reduced markers of systemic inflammation [104] .", [["\u03b2-cell secretory", "ANATOMY", 61, 77], ["anakinra", "CHEMICAL", 26, 34], ["inflammation", "DISEASE", 119, 131], ["IL-1", "GENE_OR_GENE_PRODUCT", 16, 20], ["anakinra", "SIMPLE_CHEMICAL", 26, 34], ["\u03b2-cell", "CELL", 61, 67], ["IL-1", "PROTEIN", 16, 20], ["The blockade of IL", "TREATMENT", 0, 18], ["anakinra", "TREATMENT", 26, 34], ["the \u03b2-cell secretory function", "TEST", 57, 86], ["systemic inflammation", "PROBLEM", 110, 131], ["reduced", "OBSERVATION_MODIFIER", 91, 98], ["systemic", "OBSERVATION_MODIFIER", 110, 118], ["inflammation", "OBSERVATION", 119, 131]]], ["Anakinra also prevented transthyretin extracellular deposition in the sciatic nerve in a familial amyloidotic polyneuropathy mouse model [207] .For ischemic diseasesDuring ischemic disease, such as MI or cerebral infarction, or tissue injury, cell death by necrosis takes place and the IL-1\u03b1 precursor is released in sterile inflammation [208] .", [["extracellular", "ANATOMY", 38, 51], ["sciatic nerve", "ANATOMY", 70, 83], ["cerebral", "ANATOMY", 204, 212], ["tissue", "ANATOMY", 228, 234], ["cell", "ANATOMY", 243, 247], ["Anakinra", "CHEMICAL", 0, 8], ["amyloidotic polyneuropathy", "DISEASE", 98, 124], ["ischemic diseasesDuring ischemic disease", "DISEASE", 148, 188], ["MI", "DISEASE", 198, 200], ["cerebral infarction", "DISEASE", 204, 223], ["tissue injury", "DISEASE", 228, 241], ["death", "DISEASE", 248, 253], ["necrosis", "DISEASE", 257, 265], ["inflammation", "DISEASE", 325, 337], ["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["transthyretin", "GENE_OR_GENE_PRODUCT", 24, 37], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["sciatic nerve", "MULTI-TISSUE_STRUCTURE", 70, 83], ["mouse", "ORGANISM", 125, 130], ["cerebral", "MULTI-TISSUE_STRUCTURE", 204, 212], ["tissue", "TISSUE", 228, 234], ["cell", "CELL", 243, 247], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 286, 291], ["transthyretin", "PROTEIN", 24, 37], ["IL-1\u03b1 precursor", "PROTEIN", 286, 301], ["mouse", "SPECIES", 125, 130], ["Anakinra", "TREATMENT", 0, 8], ["transthyretin extracellular deposition in the sciatic nerve", "PROBLEM", 24, 83], ["a familial amyloidotic polyneuropathy mouse model", "PROBLEM", 87, 136], ["ischemic diseasesDuring ischemic disease", "PROBLEM", 148, 188], ["MI", "PROBLEM", 198, 200], ["cerebral infarction", "PROBLEM", 204, 223], ["tissue injury", "PROBLEM", 228, 241], ["cell death", "PROBLEM", 243, 253], ["necrosis", "PROBLEM", 257, 265], ["the IL", "TREATMENT", 282, 288], ["sterile inflammation", "PROBLEM", 317, 337], ["transthyretin", "OBSERVATION", 24, 37], ["extracellular deposition", "OBSERVATION", 38, 62], ["sciatic nerve", "ANATOMY", 70, 83], ["familial", "OBSERVATION_MODIFIER", 89, 97], ["amyloidotic polyneuropathy", "OBSERVATION", 98, 124], ["ischemic", "OBSERVATION_MODIFIER", 148, 156], ["diseasesDuring", "OBSERVATION_MODIFIER", 157, 171], ["ischemic", "OBSERVATION", 172, 180], ["cerebral", "ANATOMY", 204, 212], ["infarction", "OBSERVATION", 213, 223], ["tissue", "ANATOMY", 228, 234], ["injury", "OBSERVATION", 235, 241], ["cell death", "OBSERVATION", 243, 253], ["necrosis", "OBSERVATION", 257, 265], ["inflammation", "OBSERVATION", 325, 337]]], ["When there is no time for the synthesis of IL-1\u03b1, IL-1\u03b1 is ready to function as soon as it leaves the dying cell in the first few hours following tissue ischemia or injury [209] .", [["cell", "ANATOMY", 108, 112], ["tissue", "ANATOMY", 146, 152], ["ischemia", "DISEASE", 153, 161], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 43, 48], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 50, 55], ["cell", "CELL", 108, 112], ["tissue", "TISSUE", 146, 152], ["IL-1\u03b1", "PROTEIN", 43, 48], ["IL-1\u03b1", "PROTEIN", 50, 55], ["dying cell", "CELL_TYPE", 102, 112], ["the synthesis of IL", "TREATMENT", 26, 45], ["tissue ischemia", "PROBLEM", 146, 161], ["injury", "PROBLEM", 165, 171], ["ischemia", "OBSERVATION", 153, 161]]], ["In fact, animal studies showed that the inhibition of IL-1 is effective in limiting atherosclerosis and cardiovascular events and improving the symptoms of acute MI and ischemic stroke [210, 211] .", [["cardiovascular", "ANATOMY", 104, 118], ["atherosclerosis", "DISEASE", 84, 99], ["MI", "DISEASE", 162, 164], ["ischemic stroke", "DISEASE", 169, 184], ["IL-1", "GENE_OR_GENE_PRODUCT", 54, 58], ["cardiovascular", "ANATOMICAL_SYSTEM", 104, 118], ["IL-1", "PROTEIN", 54, 58], ["animal studies", "TEST", 9, 23], ["atherosclerosis", "PROBLEM", 84, 99], ["cardiovascular events", "PROBLEM", 104, 125], ["the symptoms", "PROBLEM", 140, 152], ["acute MI", "PROBLEM", 156, 164], ["ischemic stroke", "PROBLEM", 169, 184], ["atherosclerosis", "OBSERVATION", 84, 99], ["acute", "OBSERVATION_MODIFIER", 156, 161], ["MI", "OBSERVATION", 162, 164], ["ischemic", "OBSERVATION_MODIFIER", 169, 177], ["stroke", "OBSERVATION", 178, 184]]], ["Two pilot studies of IL-1 inhibition in ST-segment elevation MI revealed a reduced acute inflammatory response and favorable overall performance at the 3-month follow-up [212] .For malignant diseasesIL-1\u03b2 is thought to play an important role in cancer invasiveness, progression, and metastases via inflammation in the tumor microenvironment.", [["malignant diseasesIL-1\u03b2", "ANATOMY", 181, 204], ["cancer", "ANATOMY", 245, 251], ["metastases", "ANATOMY", 283, 293], ["tumor", "ANATOMY", 318, 323], ["MI", "DISEASE", 61, 63], ["cancer", "DISEASE", 245, 251], ["metastases", "DISEASE", 283, 293], ["inflammation", "DISEASE", 298, 310], ["tumor", "DISEASE", 318, 323], ["IL-1", "GENE_OR_GENE_PRODUCT", 21, 25], ["malignant diseasesIL-1\u03b2", "GENE_OR_GENE_PRODUCT", 181, 204], ["cancer", "CANCER", 245, 251], ["tumor", "CANCER", 318, 323], ["IL", "PROTEIN", 21, 23], ["malignant diseasesIL-1\u03b2", "PROTEIN", 181, 204], ["Two pilot studies", "TEST", 0, 17], ["IL", "TEST", 21, 23], ["ST-segment elevation MI", "PROBLEM", 40, 63], ["a reduced acute inflammatory response", "PROBLEM", 73, 110], ["malignant diseasesIL", "PROBLEM", 181, 201], ["cancer invasiveness", "PROBLEM", 245, 264], ["metastases", "PROBLEM", 283, 293], ["inflammation in the tumor microenvironment", "PROBLEM", 298, 340], ["segment elevation", "ANATOMY", 43, 60], ["reduced", "OBSERVATION_MODIFIER", 75, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["inflammatory response", "OBSERVATION", 89, 110], ["favorable", "OBSERVATION_MODIFIER", 115, 124], ["thought to play", "UNCERTAINTY", 208, 223], ["cancer", "OBSERVATION", 245, 251], ["progression", "OBSERVATION_MODIFIER", 266, 277], ["metastases", "OBSERVATION", 283, 293], ["inflammation", "OBSERVATION", 298, 310], ["tumor", "OBSERVATION", 318, 323]]], ["A further analysis in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomized trial of the role of inhibition of IL-1\u03b2 in atherosclerosis, revealed that anti-inflammatory therapy with canakinumab targeting the IL-1\u03b2 innate immunity pathway could significantly reduce lung cancer mortality [213] .", [["lung cancer", "ANATOMY", 294, 305], ["Thrombosis", "DISEASE", 56, 66], ["atherosclerosis", "DISEASE", 149, 164], ["canakinumab", "CHEMICAL", 211, 222], ["lung cancer", "DISEASE", 294, 305], ["Canakinumab", "CHEMICAL", 26, 37], ["canakinumab", "CHEMICAL", 211, 222], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 140, 145], ["canakinumab", "SIMPLE_CHEMICAL", 211, 222], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 237, 242], ["lung cancer", "CANCER", 294, 305], ["IL-1\u03b2", "PROTEIN", 140, 145], ["A further analysis", "TEST", 0, 18], ["the Canakinumab Anti-inflammatory Thrombosis", "TREATMENT", 22, 66], ["inhibition of IL", "TREATMENT", 126, 142], ["atherosclerosis", "PROBLEM", 149, 164], ["anti-inflammatory therapy", "TREATMENT", 180, 205], ["canakinumab", "TREATMENT", 211, 222], ["the IL", "TREATMENT", 233, 239], ["lung cancer mortality", "PROBLEM", 294, 315], ["Thrombosis", "OBSERVATION", 56, 66], ["atherosclerosis", "OBSERVATION", 149, 164], ["anti-inflammatory therapy", "OBSERVATION", 180, 205], ["lung", "ANATOMY", 294, 298], ["cancer", "OBSERVATION", 299, 305]]], ["Moreover, treatment of patients with metastatic breast cancer-related with anakinra eliminates a systemic transcriptional signature of IL-1-associated inflammation in blood cells.", [["metastatic breast cancer", "ANATOMY", 37, 61], ["blood cells", "ANATOMY", 167, 178], ["breast cancer", "DISEASE", 48, 61], ["anakinra", "CHEMICAL", 75, 83], ["inflammation", "DISEASE", 151, 163], ["anakinra", "CHEMICAL", 75, 83], ["patients", "ORGANISM", 23, 31], ["breast cancer", "CANCER", 48, 61], ["anakinra", "SIMPLE_CHEMICAL", 75, 83], ["IL-1", "GENE_OR_GENE_PRODUCT", 135, 139], ["blood cells", "CELL", 167, 178], ["IL-1", "PROTEIN", 135, 139], ["blood cells", "CELL_TYPE", 167, 178], ["patients", "SPECIES", 23, 31], ["metastatic breast cancer", "PROBLEM", 37, 61], ["anakinra", "TREATMENT", 75, 83], ["IL", "TEST", 135, 137], ["associated inflammation in blood cells", "PROBLEM", 140, 178], ["metastatic", "OBSERVATION_MODIFIER", 37, 47], ["breast", "ANATOMY", 48, 54], ["cancer", "OBSERVATION", 55, 61], ["inflammation", "OBSERVATION", 151, 163], ["blood cells", "ANATOMY", 167, 178]]], ["The inflammatory signature in primary breast cancers identifies a subset of patients that could potentially benefit from IL-1\u03b2-targeted therapies [129] .Safety profilesSafety profiles of both anakinra and canakinumab were reported [214] .", [["primary breast cancers", "ANATOMY", 30, 52], ["breast cancers", "DISEASE", 38, 52], ["anakinra", "CHEMICAL", 192, 200], ["canakinumab", "CHEMICAL", 205, 216], ["anakinra", "CHEMICAL", 192, 200], ["canakinumab", "CHEMICAL", 205, 216], ["primary breast cancers", "CANCER", 30, 52], ["patients", "ORGANISM", 76, 84], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 121, 126], ["anakinra", "SIMPLE_CHEMICAL", 192, 200], ["canakinumab", "SIMPLE_CHEMICAL", 205, 216], ["IL", "PROTEIN", 121, 123], ["patients", "SPECIES", 76, 84], ["The inflammatory signature", "PROBLEM", 0, 26], ["primary breast cancers", "PROBLEM", 30, 52], ["IL", "TEST", 121, 123], ["targeted therapies", "TREATMENT", 127, 145], ["both anakinra and canakinumab", "TREATMENT", 187, 216], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16], ["primary", "OBSERVATION_MODIFIER", 30, 37], ["breast", "ANATOMY", 38, 44], ["cancers", "OBSERVATION", 45, 52]]], ["In this study, several clinical and therapeutic data on patients treated with either anakinra or canakinumab were retrospectively analyzed.", [["anakinra", "CHEMICAL", 85, 93], ["canakinumab", "CHEMICAL", 97, 108], ["canakinumab", "CHEMICAL", 97, 108], ["patients", "ORGANISM", 56, 64], ["anakinra", "SIMPLE_CHEMICAL", 85, 93], ["canakinumab", "SIMPLE_CHEMICAL", 97, 108], ["patients", "SPECIES", 56, 64], ["this study", "TEST", 3, 13], ["anakinra", "TREATMENT", 85, 93], ["canakinumab", "TREATMENT", 97, 108]]], ["Four hundred and seventy-five patients participated; anakinra and canakinumab were prescribed in 421 and 105 treatment courses, respectively.", [["anakinra", "CHEMICAL", 53, 61], ["canakinumab", "CHEMICAL", 66, 77], ["anakinra", "CHEMICAL", 53, 61], ["canakinumab", "CHEMICAL", 66, 77], ["patients", "ORGANISM", 30, 38], ["anakinra", "SIMPLE_CHEMICAL", 53, 61], ["canakinumab", "SIMPLE_CHEMICAL", 66, 77], ["patients", "SPECIES", 30, 38], ["anakinra", "TREATMENT", 53, 61], ["canakinumab", "TREATMENT", 66, 77]]], ["Eighty-nine adverse events were recorded; 13 (14.61%) were classified as serious adverse events during a mean follow-up of 24.39 \u00b1 27.04 months.", [["serious adverse events", "PROBLEM", 73, 95]]], ["In addition, anakinra is applied to metastatic cancer.", [["metastatic cancer", "ANATOMY", 36, 53], ["anakinra", "CHEMICAL", 13, 21], ["cancer", "DISEASE", 47, 53], ["anakinra", "SIMPLE_CHEMICAL", 13, 21], ["metastatic cancer", "CANCER", 36, 53], ["anakinra", "TREATMENT", 13, 21], ["metastatic cancer", "PROBLEM", 36, 53], ["anakinra", "OBSERVATION", 13, 21], ["metastatic", "OBSERVATION_MODIFIER", 36, 46], ["cancer", "OBSERVATION", 47, 53]]], ["A trial involving metastatic colorectal cancer patients showed significantly increased survival when anakinra was added to standard chemotherapy for colorectal cancer and patients with HER2-negative breast cancer [129, 215] .", [["metastatic colorectal cancer", "ANATOMY", 18, 46], ["colorectal cancer", "ANATOMY", 149, 166], ["HER2-negative breast cancer", "ANATOMY", 185, 212], ["colorectal cancer", "DISEASE", 29, 46], ["anakinra", "CHEMICAL", 101, 109], ["colorectal cancer", "DISEASE", 149, 166], ["breast cancer", "DISEASE", 199, 212], ["metastatic colorectal cancer", "CANCER", 18, 46], ["patients", "ORGANISM", 47, 55], ["anakinra", "SIMPLE_CHEMICAL", 101, 109], ["colorectal cancer", "CANCER", 149, 166], ["patients", "ORGANISM", 171, 179], ["HER2", "GENE_OR_GENE_PRODUCT", 185, 189], ["breast cancer", "CANCER", 199, 212], ["HER2", "PROTEIN", 185, 189], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 171, 179], ["A trial involving metastatic colorectal cancer", "PROBLEM", 0, 46], ["significantly increased survival", "PROBLEM", 63, 95], ["anakinra", "TREATMENT", 101, 109], ["standard chemotherapy", "TREATMENT", 123, 144], ["colorectal cancer", "PROBLEM", 149, 166], ["HER2", "TEST", 185, 189], ["breast cancer", "PROBLEM", 199, 212], ["metastatic", "OBSERVATION_MODIFIER", 18, 28], ["colorectal cancer", "OBSERVATION", 29, 46], ["significantly", "OBSERVATION_MODIFIER", 63, 76], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["survival", "OBSERVATION_MODIFIER", 87, 95], ["colorectal", "ANATOMY", 149, 159], ["cancer", "OBSERVATION", 160, 166], ["breast", "ANATOMY", 199, 205], ["cancer", "OBSERVATION", 206, 212]]], ["The IL-1 blockade will reduce IL1-driven inflammation and immunosuppression that may contribute to the tumor metastatic Table 2 Effective anti-IL-1 therapy for inflammatory diseases Autoinflammatory diseases:Safety profilesCryopyrin-associated periodic syndrome (CAPS) [87, 88] Familial Mediterranean fever (FMF) [95] Pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA) [96] NLRP12 autoinflammatory syndrome [97] Tumor necrosis factor receptor-1-associated syndrome (TRAPS) [100] Hyperimmunoglobulinemia D and periodic fever syndrome (HIDS)/ mevalonate kinase deficiency (MKD) [180] Deficiency of the interleukin-1-receptor antagonist (DIRA) [183] Autoimmune diseases:Safety profilesPsoriatic arthritis [191] Ankylosing spondylitis [192] Rheumatoid arthritis (RA) [196] Metabolic syndrome:Safety profilesGout [203] Atherosclerosis [204] Type 2 diabetes mellitus (T2D) [204] Amyloidosis [207] Neurodegenerative disease:Safety profilesAlzheimer's disease (AD) [111] Infections and inflammatory responses: Septic shock syndrome [199] Acute respiratory distress syndrome (ARDS) [199] Disseminated intravascular coagulation (DIC) [199] Hemophagocytic lymphohistiocytosis (HLH) [200] Macrophage-activating syndrome (MAS) [200] Ischemic diseases:Safety profilesMyocardial infarction (MI) [209] Stroke [209] Malignant rumor:Safety profilesBreast cancer [129] microenvironment [216] .", [["tumor", "ANATOMY", 103, 108], ["intravascular", "ANATOMY", 1107, 1120], ["Myocardial", "ANATOMY", 1268, 1278], ["Breast cancer", "ANATOMY", 1345, 1358], ["inflammation", "DISEASE", 41, 53], ["tumor", "DISEASE", 103, 108], ["Autoinflammatory diseases", "DISEASE", 182, 207], ["Cryopyrin-associated periodic syndrome", "DISEASE", 223, 261], ["CAPS", "DISEASE", 263, 267], ["Familial Mediterranean fever", "DISEASE", 278, 306], ["FMF", "DISEASE", 308, 311], ["Pyogenic arthritis", "DISEASE", 318, 336], ["pyoderma gangrenosum", "DISEASE", 338, 358], ["acne syndrome", "DISEASE", 363, 376], ["PAPA", "DISEASE", 378, 382], ["autoinflammatory syndrome", "DISEASE", 396, 421], ["Tumor necrosis", "DISEASE", 427, 441], ["periodic fever syndrome", "DISEASE", 524, 547], ["HIDS", "DISEASE", 549, 553], ["mevalonate", "CHEMICAL", 556, 566], ["Autoimmune diseases", "DISEASE", 662, 681], ["Psoriatic arthritis", "DISEASE", 697, 716], ["Ankylosing spondylitis", "DISEASE", 723, 745], ["Rheumatoid arthritis", "DISEASE", 752, 772], ["RA", "DISEASE", 774, 776], ["Metabolic syndrome", "DISEASE", 784, 802], ["Gout", "DISEASE", 818, 822], ["Atherosclerosis", "DISEASE", 829, 844], ["Type 2 diabetes mellitus", "DISEASE", 851, 875], ["T2D", "DISEASE", 877, 880], ["Amyloidosis", "DISEASE", 888, 899], ["Neurodegenerative disease", "DISEASE", 906, 931], ["Alzheimer's disease", "DISEASE", 947, 966], ["AD", "DISEASE", 968, 970], ["Infections", "DISEASE", 978, 988], ["Septic shock syndrome", "DISEASE", 1017, 1038], ["Acute respiratory distress syndrome", "DISEASE", 1045, 1080], ["ARDS", "DISEASE", 1082, 1086], ["Disseminated intravascular coagulation", "DISEASE", 1094, 1132], ["DIC", "DISEASE", 1134, 1137], ["Hemophagocytic lymphohistiocytosis", "DISEASE", 1145, 1179], ["HLH", "DISEASE", 1181, 1184], ["MAS", "DISEASE", 1224, 1227], ["Ischemic diseases", "DISEASE", 1235, 1252], ["Myocardial infarction", "DISEASE", 1268, 1289], ["MI", "DISEASE", 1291, 1293], ["Stroke", "DISEASE", 1301, 1307], ["Malignant rumor", "DISEASE", 1314, 1329], ["Breast cancer", "DISEASE", 1345, 1358], ["mevalonate", "CHEMICAL", 556, 566], ["IL-1", "GENE_OR_GENE_PRODUCT", 4, 8], ["IL1", "GENE_OR_GENE_PRODUCT", 30, 33], ["tumor", "CANCER", 103, 108], ["anti-IL-1", "GENE_OR_GENE_PRODUCT", 138, 147], ["Cryopyrin", "SIMPLE_CHEMICAL", 223, 232], ["Tumor necrosis factor receptor-1", "GENE_OR_GENE_PRODUCT", 427, 459], ["mevalonate kinase", "GENE_OR_GENE_PRODUCT", 556, 573], ["interleukin-1-receptor antagonist", "SIMPLE_CHEMICAL", 615, 648], ["DIRA", "SIMPLE_CHEMICAL", 650, 654], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 1268, 1278], ["Breast cancer", "CANCER", 1345, 1358], ["IL", "PROTEIN", 4, 6], ["IL1", "PROTEIN", 30, 33], ["Tumor necrosis factor receptor", "PROTEIN", 427, 457], ["mevalonate kinase", "PROTEIN", 556, 573], ["interleukin-1", "PROTEIN", 615, 628], ["The IL-1 blockade", "TREATMENT", 0, 17], ["IL1", "PROBLEM", 30, 33], ["inflammation", "PROBLEM", 41, 53], ["immunosuppression", "TREATMENT", 58, 75], ["the tumor metastatic Table", "PROBLEM", 99, 125], ["Effective anti-IL-1 therapy", "TREATMENT", 128, 155], ["inflammatory diseases", "PROBLEM", 160, 181], ["Autoinflammatory diseases", "PROBLEM", 182, 207], ["Safety profiles", "TEST", 208, 223], ["Cryopyrin", "TEST", 223, 232], ["periodic syndrome", "PROBLEM", 244, 261], ["Familial Mediterranean fever (FMF)", "PROBLEM", 278, 312], ["Pyogenic arthritis", "PROBLEM", 318, 336], ["pyoderma gangrenosum", "PROBLEM", 338, 358], ["acne syndrome", "PROBLEM", 363, 376], ["autoinflammatory syndrome", "PROBLEM", 396, 421], ["Tumor necrosis", "PROBLEM", 427, 441], ["factor receptor", "TEST", 442, 457], ["associated syndrome (TRAPS)", "PROBLEM", 460, 487], ["Hyperimmunoglobulinemia D", "PROBLEM", 494, 519], ["periodic fever syndrome", "PROBLEM", 524, 547], ["HIDS", "TEST", 549, 553], ["mevalonate kinase deficiency (MKD)", "PROBLEM", 556, 590], ["Deficiency", "PROBLEM", 597, 607], ["the interleukin-1", "TEST", 611, 628], ["receptor antagonist", "TREATMENT", 629, 648], ["Autoimmune diseases", "PROBLEM", 662, 681], ["Safety profiles", "PROBLEM", 682, 697], ["Psoriatic arthritis", "PROBLEM", 697, 716], ["Ankylosing spondylitis", "PROBLEM", 723, 745], ["Rheumatoid arthritis (RA)", "PROBLEM", 752, 777], ["Metabolic syndrome", "PROBLEM", 784, 802], ["Safety profiles", "TEST", 803, 818], ["Gout", "PROBLEM", 818, 822], ["Atherosclerosis", "PROBLEM", 829, 844], ["Type 2 diabetes mellitus (T2D)", "PROBLEM", 851, 881], ["Amyloidosis", "PROBLEM", 888, 899], ["Neurodegenerative disease", "PROBLEM", 906, 931], ["Safety profiles", "PROBLEM", 932, 947], ["Alzheimer's disease (AD) [111] Infections", "PROBLEM", 947, 988], ["inflammatory responses", "PROBLEM", 993, 1015], ["Septic shock syndrome", "PROBLEM", 1017, 1038], ["Acute respiratory distress syndrome", "PROBLEM", 1045, 1080], ["ARDS)", "PROBLEM", 1082, 1087], ["Disseminated intravascular coagulation", "PROBLEM", 1094, 1132], ["DIC)", "PROBLEM", 1134, 1138], ["Hemophagocytic lymphohistiocytosis", "PROBLEM", 1145, 1179], ["HLH)", "PROBLEM", 1181, 1185], ["Macrophage", "TEST", 1192, 1202], ["activating syndrome (MAS)", "PROBLEM", 1203, 1228], ["Ischemic diseases", "PROBLEM", 1235, 1252], ["Myocardial infarction (MI)", "PROBLEM", 1268, 1294], ["Stroke", "PROBLEM", 1301, 1307], ["Malignant rumor", "PROBLEM", 1314, 1329], ["Breast cancer", "PROBLEM", 1345, 1358], ["inflammation", "OBSERVATION", 41, 53], ["tumor", "OBSERVATION", 103, 108], ["inflammatory", "OBSERVATION_MODIFIER", 160, 172], ["periodic syndrome", "OBSERVATION", 244, 261], ["Pyogenic", "OBSERVATION_MODIFIER", 318, 326], ["arthritis", "OBSERVATION", 327, 336], ["pyoderma gangrenosum", "OBSERVATION", 338, 358], ["Tumor", "OBSERVATION_MODIFIER", 427, 432], ["necrosis", "OBSERVATION", 433, 441], ["Ankylosing spondylitis", "OBSERVATION", 723, 745], ["Rheumatoid arthritis", "OBSERVATION", 752, 772], ["RA", "ANATOMY", 774, 776], ["Metabolic syndrome", "OBSERVATION", 784, 802], ["Atherosclerosis", "OBSERVATION", 829, 844], ["Neurodegenerative disease", "OBSERVATION", 906, 931], ["inflammatory", "OBSERVATION_MODIFIER", 993, 1005], ["Septic shock syndrome", "OBSERVATION", 1017, 1038], ["Acute", "OBSERVATION_MODIFIER", 1045, 1050], ["respiratory distress", "OBSERVATION", 1051, 1071], ["Hemophagocytic lymphohistiocytosis", "OBSERVATION", 1145, 1179], ["infarction", "OBSERVATION", 1279, 1289], ["Breast", "ANATOMY", 1345, 1351], ["cancer", "OBSERVATION", 1352, 1358]]], ["The timeline of therapeutics is summarized in Fig. 2 .ConclusionsWe described IL-1 as an important cytokine for not only inflammation related to cell injury but also homeostasis of cells, tissues, and organs in view of the general pathology.", [["cell", "ANATOMY", 145, 149], ["cells", "ANATOMY", 181, 186], ["tissues", "ANATOMY", 188, 195], ["organs", "ANATOMY", 201, 207], ["inflammation", "DISEASE", 121, 133], ["IL-1", "GENE_OR_GENE_PRODUCT", 78, 82], ["cell", "CELL", 145, 149], ["cells", "CELL", 181, 186], ["tissues", "TISSUE", 188, 195], ["organs", "ORGAN", 201, 207], ["IL-1", "PROTEIN", 78, 82], ["cytokine", "PROTEIN", 99, 107], ["inflammation", "PROBLEM", 121, 133], ["cell injury", "PROBLEM", 145, 156], ["homeostasis of cells, tissues", "PROBLEM", 166, 195], ["inflammation", "OBSERVATION", 121, 133], ["cell injury", "OBSERVATION", 145, 156], ["organs", "ANATOMY", 201, 207], ["pathology", "OBSERVATION", 231, 240]]], ["In addition, we also described recent expanding IL-1 signal-targeting for the treatment of diseases.", [["IL-1", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL-1", "PROTEIN", 48, 52], ["recent expanding IL-1 signal", "PROBLEM", 31, 59], ["diseases", "PROBLEM", 91, 99], ["diseases", "OBSERVATION", 91, 99]]], ["Once the balance of IL-1 signaling is disrupted, it may markedly contribute to the pathogenesis of not only inflammatory disease, but also malignancies.", [["malignancies", "ANATOMY", 139, 151], ["malignancies", "DISEASE", 139, 151], ["IL-1", "GENE_OR_GENE_PRODUCT", 20, 24], ["malignancies", "CANCER", 139, 151], ["IL", "PROTEIN", 20, 22], ["inflammatory disease", "PROBLEM", 108, 128], ["malignancies", "PROBLEM", 139, 151], ["not only", "UNCERTAINTY", 99, 107], ["inflammatory", "OBSERVATION_MODIFIER", 108, 120], ["disease", "OBSERVATION", 121, 128], ["malignancies", "OBSERVATION", 139, 151]]], ["IL-1-targeted biologics have been expanding, as there are no known serious adverse effects such as lymphoproliferative disorder or virus reactivation like TNF or IL-6-targeting therapies.", [["lymphoproliferative disorder", "DISEASE", 99, 127], ["IL-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TNF", "GENE_OR_GENE_PRODUCT", 155, 158], ["IL-6", "GENE_OR_GENE_PRODUCT", 162, 166], ["TNF", "PROTEIN", 155, 158], ["IL-6", "PROTEIN", 162, 166], ["IL", "TREATMENT", 0, 2], ["targeted biologics", "TREATMENT", 5, 23], ["known serious adverse effects", "PROBLEM", 61, 90], ["lymphoproliferative disorder", "PROBLEM", 99, 127], ["virus reactivation", "PROBLEM", 131, 149], ["TNF or IL", "TREATMENT", 155, 164], ["targeting therapies", "TREATMENT", 167, 186], ["no known", "UNCERTAINTY", 58, 66], ["serious", "OBSERVATION_MODIFIER", 67, 74], ["lymphoproliferative disorder", "OBSERVATION", 99, 127]]], ["Therefore, IL-1 is expected to become an attractive molecular target to treat a wide range of diseases such as autoinflammatory diseases, autoimmune diseases, infectious disease, metabolic syndromes, ischemic diseases, and malignant tumors [217, 218] (Table 2) .", [["malignant tumors", "ANATOMY", 223, 239], ["autoinflammatory diseases", "DISEASE", 111, 136], ["autoimmune diseases", "DISEASE", 138, 157], ["infectious disease", "DISEASE", 159, 177], ["metabolic syndromes", "DISEASE", 179, 198], ["ischemic diseases", "DISEASE", 200, 217], ["malignant tumors", "DISEASE", 223, 239], ["IL-1", "GENE_OR_GENE_PRODUCT", 11, 15], ["malignant tumors", "CANCER", 223, 239], ["IL-1", "PROTEIN", 11, 15], ["a wide range of diseases", "PROBLEM", 78, 102], ["autoinflammatory diseases", "PROBLEM", 111, 136], ["autoimmune diseases", "PROBLEM", 138, 157], ["infectious disease", "PROBLEM", 159, 177], ["metabolic syndromes", "PROBLEM", 179, 198], ["ischemic diseases", "PROBLEM", 200, 217], ["malignant tumors", "PROBLEM", 223, 239], ["autoinflammatory", "OBSERVATION_MODIFIER", 111, 127], ["infectious", "OBSERVATION_MODIFIER", 159, 169], ["metabolic syndromes", "OBSERVATION", 179, 198], ["ischemic", "OBSERVATION_MODIFIER", 200, 208], ["malignant", "OBSERVATION_MODIFIER", 223, 232], ["tumors", "OBSERVATION", 233, 239]]], ["Availability of data and materials Not applicable.Authors' contributionsThe manuscript was written by NK and JM, and all authors read and approved the final manuscript.Authors' contributionsEthics approval and consent to participate Not applicable.Consent for publicationNot applicable.", [["NK", "ANATOMY", 102, 104], ["NK", "CELL", 102, 104]]]], "7df33b5b59205feabc1b3d0b8936052a57e8e2bd": [["I. IntroductionAlthough primary genetic defects of interferon (IFN) production have not been described in man, various patients with different viral infec-* Corresponding author: Tel.: + 358 0 4713691; fax + 358 0 4715010. tions have been identified to have disturbances of IFN production (Isaacs et al., 1981; Bondestam et al., 1984; Rossol et al., 1989; Kakumu et al., 1990) .", [["interferon", "GENE_OR_GENE_PRODUCT", 51, 61], ["IFN", "GENE_OR_GENE_PRODUCT", 63, 66], ["man", "ORGANISM", 106, 109], ["patients", "ORGANISM", 119, 127], ["IFN", "GENE_OR_GENE_PRODUCT", 274, 277], ["interferon", "PROTEIN", 51, 61], ["IFN", "PROTEIN", 63, 66], ["IFN", "PROTEIN", 274, 277], ["man", "SPECIES", 106, 109], ["patients", "SPECIES", 119, 127], ["primary genetic defects", "PROBLEM", 24, 47], ["interferon (IFN)", "TREATMENT", 51, 67], ["different viral infec", "PROBLEM", 133, 154], ["disturbances of IFN production", "PROBLEM", 258, 288], ["defects of interferon", "OBSERVATION", 40, 61]]], ["This phenomenon is usually considered to be secondary to the underlying disease.", [["the underlying disease", "PROBLEM", 57, 79], ["usually considered to be", "UNCERTAINTY", 19, 43], ["disease", "OBSERVATION", 72, 79]]], ["However, in the above studies it was not known how the patients had previously (or afterwards) handled viral infections.", [["viral infections", "DISEASE", 103, 119], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["the above studies", "TEST", 12, 29], ["handled viral infections", "PROBLEM", 95, 119], ["viral", "OBSERVATION_MODIFIER", 103, 108], ["infections", "OBSERVATION", 109, 119]]], ["Hence, the lowered IFN production might also represent a primary disorder.", [["IFN", "GENE_OR_GENE_PRODUCT", 19, 22], ["IFN", "PROTEIN", 19, 22], ["the lowered IFN production", "PROBLEM", 7, 33], ["a primary disorder", "PROBLEM", 55, 73], ["might also represent", "UNCERTAINTY", 34, 54], ["primary disorder", "OBSERVATION", 57, 73]]], ["0928-0197/96/$15.00 \u00a9 1996 Elsevier Science B.V. All rights reserved PH S0928-0197(96) Leukocyte cultures from healthy individuals produce varying quantities of IFN when stimulated by standard amounts of a given inducer virus and the yields obtained with different viruses in successive blood specimens show a fairly regular donor-specific pattern (Pitk/iranta et al., 1991) .", [["Leukocyte cultures", "ANATOMY", 87, 105], ["blood specimens", "ANATOMY", 287, 302], ["S0928-0197(96", "CHEMICAL", 72, 85], ["IFN", "CHEMICAL", 161, 164], ["Leukocyte cultures", "CELL", 87, 105], ["IFN", "GENE_OR_GENE_PRODUCT", 161, 164], ["blood specimens", "ORGANISM_SUBSTANCE", 287, 302], ["Leukocyte cultures", "CELL_LINE", 87, 105], ["IFN", "PROTEIN", 161, 164], ["PH", "TEST", 69, 71], ["Leukocyte cultures", "TEST", 87, 105], ["healthy individuals", "PROBLEM", 111, 130], ["varying quantities of IFN", "PROBLEM", 139, 164], ["a given inducer virus", "TREATMENT", 204, 225], ["different viruses", "PROBLEM", 255, 272], ["successive blood specimens", "TEST", 276, 302], ["donor-specific pattern", "OBSERVATION", 325, 347]]], ["We reported previously that leukocyte cultures of children suffering from recurrent respiratory tract infections produce less IFN than those of healthy children (Pitk/iranta et al., 1993) .", [["leukocyte", "ANATOMY", 28, 37], ["respiratory tract", "ANATOMY", 84, 101], ["respiratory tract infections", "DISEASE", 84, 112], ["leukocyte cultures", "CELL", 28, 46], ["children", "ORGANISM", 50, 58], ["respiratory tract", "ORGANISM_SUBDIVISION", 84, 101], ["children", "ORGANISM", 152, 160], ["leukocyte cultures", "CELL_LINE", 28, 46], ["IFN", "PROTEIN", 126, 129], ["children", "SPECIES", 50, 58], ["children", "SPECIES", 152, 160], ["leukocyte cultures", "TEST", 28, 46], ["recurrent respiratory tract infections", "PROBLEM", 74, 112], ["recurrent", "OBSERVATION_MODIFIER", 74, 83], ["respiratory tract infections", "OBSERVATION", 84, 112]]], ["This also raised the question whether the phenomenon was secondary to the underlying disease, or whether it was a genetic trait of the children possibly predisposing them to recurrent respiratory infections.I. IntroductionWe have now reinvestigated the IFN production in leukocyte cultures of these infection-prone children after a two year interval, and report here that IFN responses have changed in a virus-specific manner.I. PatientsFifty children were admitted in May-August 1992 for scheduled operations (adenoidectomy and/or tympanostomy) to the Department of Otolaryngology, Helsinki University Central Hospital, because of a history of frequently recurring upper respiratory tract infections and/or frequent middle ear infections.", [["respiratory", "ANATOMY", 184, 195], ["leukocyte cultures", "ANATOMY", 271, 289], ["upper respiratory tract", "ANATOMY", 666, 689], ["ear", "ANATOMY", 724, 727], ["respiratory infections", "DISEASE", 184, 206], ["infection", "DISEASE", 299, 308], ["respiratory tract infections", "DISEASE", 672, 700], ["middle ear infections", "DISEASE", 717, 738], ["children", "ORGANISM", 135, 143], ["IFN", "GENE_OR_GENE_PRODUCT", 253, 256], ["leukocyte cultures", "CELL", 271, 289], ["children", "ORGANISM", 315, 323], ["IFN", "GENE_OR_GENE_PRODUCT", 372, 375], ["Patients", "ORGANISM", 429, 437], ["children", "ORGANISM", 443, 451], ["upper", "ORGANISM_SUBDIVISION", 666, 671], ["respiratory tract", "ORGANISM_SUBDIVISION", 672, 689], ["ear", "ORGAN", 724, 727], ["IFN", "PROTEIN", 253, 256], ["leukocyte cultures", "CELL_LINE", 271, 289], ["IFN", "PROTEIN", 372, 375], ["children", "SPECIES", 135, 143], ["children", "SPECIES", 315, 323], ["Patients", "SPECIES", 429, 437], ["children", "SPECIES", 443, 451], ["the phenomenon", "PROBLEM", 38, 52], ["the underlying disease", "PROBLEM", 70, 92], ["recurrent respiratory infections", "PROBLEM", 174, 206], ["the IFN production", "PROBLEM", 249, 267], ["leukocyte cultures", "TEST", 271, 289], ["scheduled operations", "TREATMENT", 489, 509], ["adenoidectomy", "TREATMENT", 511, 524], ["tympanostomy", "TREATMENT", 532, 544], ["frequently recurring upper respiratory tract infections", "PROBLEM", 645, 700], ["frequent middle ear infections", "PROBLEM", 708, 738], ["disease", "OBSERVATION", 85, 92], ["recurrent", "OBSERVATION_MODIFIER", 174, 183], ["respiratory", "ANATOMY", 184, 195], ["infections", "OBSERVATION", 196, 206], ["adenoidectomy", "OBSERVATION", 511, 524], ["tympanostomy", "OBSERVATION", 532, 544], ["upper", "ANATOMY_MODIFIER", 666, 671], ["respiratory tract", "ANATOMY", 672, 689], ["infections", "OBSERVATION", 690, 700], ["middle", "ANATOMY_MODIFIER", 717, 723], ["ear", "ANATOMY", 724, 727], ["infections", "OBSERVATION", 728, 738]]], ["Inclusion criteria comprised at least six episodes of upper respiratory tract infection and/or at least four attacks of acute otitis media within the last 6 months.", [["upper respiratory tract", "ANATOMY", 54, 77], ["respiratory tract infection", "DISEASE", 60, 87], ["otitis", "DISEASE", 126, 132], ["upper", "ORGANISM_SUBDIVISION", 54, 59], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["upper respiratory tract infection", "PROBLEM", 54, 87], ["acute otitis media", "PROBLEM", 120, 138], ["at least", "OBSERVATION_MODIFIER", 29, 37], ["upper", "ANATOMY_MODIFIER", 54, 59], ["respiratory tract", "ANATOMY", 60, 77], ["infection", "OBSERVATION", 78, 87], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["otitis", "OBSERVATION", 126, 132]]], ["In May August 1994 the patients were invited for a second voluntary visit by sending an information letter to the parents.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["Two children could not come.", [["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12]]], ["Characteristics of the 48 children, who came for this examination are presented in Table 1 .", [["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34], ["this examination", "TEST", 49, 65]]], ["Like 2 years previously, history was taken and routine ear, nose and throat examination was performed and a heparinized blood sample was drawn.", [["ear", "ANATOMY", 55, 58], ["nose", "ANATOMY", 60, 64], ["throat", "ANATOMY", 69, 75], ["blood sample", "ANATOMY", 120, 132], ["ear", "ORGAN", 55, 58], ["nose", "ORGANISM_SUBDIVISION", 60, 64], ["throat", "ORGANISM_SUBDIVISION", 69, 75], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["routine ear, nose and throat examination", "TEST", 47, 87], ["a heparinized blood sample", "TEST", 106, 132], ["ear", "ANATOMY", 55, 58], ["nose", "ANATOMY", 60, 64], ["throat", "ANATOMY", 69, 75]]], ["During this visit two patients had an ongoing mild respiratory tract infection, while two were suffering from a chronic respiratory condition.1FN inductionPreparation of mononuclear leukocytes from heparinized blood has been described earlier (Bryum, 1968; Pitk/iranta et al., 1988) .", [["respiratory tract", "ANATOMY", 51, 68], ["respiratory", "ANATOMY", 120, 131], ["mononuclear leukocytes", "ANATOMY", 170, 192], ["blood", "ANATOMY", 210, 215], ["respiratory tract infection", "DISEASE", 51, 78], ["patients", "ORGANISM", 22, 30], ["respiratory tract", "ORGANISM_SUBDIVISION", 51, 68], ["1FN", "SIMPLE_CHEMICAL", 142, 145], ["mononuclear leukocytes", "CELL", 170, 192], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["mononuclear leukocytes", "CELL_TYPE", 170, 192], ["patients", "SPECIES", 22, 30], ["an ongoing mild respiratory tract infection", "PROBLEM", 35, 78], ["a chronic respiratory condition", "PROBLEM", 110, 141], ["mononuclear leukocytes", "PROBLEM", 170, 192], ["heparinized blood", "TEST", 198, 215], ["mild", "OBSERVATION_MODIFIER", 46, 50], ["respiratory tract", "ANATOMY", 51, 68], ["infection", "OBSERVATION", 69, 78], ["chronic", "OBSERVATION_MODIFIER", 112, 119], ["respiratory condition", "OBSERVATION", 120, 141], ["mononuclear leukocytes", "OBSERVATION", 170, 192], ["heparinized blood", "OBSERVATION", 198, 215]]], ["Freshly made parallel leukocyte cultures were inoculated with standard amounts of five crude virus preparations.", [["leukocyte cultures", "ANATOMY", 22, 40], ["leukocyte cultures", "CELL", 22, 40], ["parallel leukocyte cultures", "CELL_LINE", 13, 40], ["parallel leukocyte cultures", "TEST", 13, 40], ["five crude virus preparations", "TREATMENT", 82, 111], ["leukocyte", "ANATOMY", 22, 31]]], ["Propagation of adenovirus 7a, rhinovirus strain 4270 (a local isolate), coronavirus 229E, and respiratory syncytial (RS) A3 virus took place as earlier reported (Pitk/iranta et al., 1993) .", [["adenovirus 7a, rhinovirus strain 4270", "CHEMICAL", 15, 52], ["coronavirus 229E", "DISEASE", 72, 88], ["respiratory syncytial (RS) A3 virus", "DISEASE", 94, 129], ["adenovirus 7a", "ORGANISM", 15, 28], ["rhinovirus strain 4270", "ORGANISM", 30, 52], ["coronavirus 229E", "ORGANISM", 72, 88], ["respiratory syncytial (RS) A3 virus", "ORGANISM", 94, 129], ["coronavirus", "SPECIES", 72, 83], ["adenovirus 7a", "SPECIES", 15, 28], ["respiratory syncytial (RS) A3 virus", "SPECIES", 94, 129], ["adenovirus", "PROBLEM", 15, 25], ["rhinovirus strain", "PROBLEM", 30, 47], ["a local isolate", "TEST", 54, 69], ["coronavirus 229E", "TEST", 72, 88], ["respiratory syncytial (RS) A3 virus", "PROBLEM", 94, 129], ["respiratory syncytial", "ANATOMY", 94, 115]]], ["Influenza A H3N2 virus (a gift from Dr. R. Pyh/il/i) was grown in embryonated eggs.", [["eggs", "ANATOMY", 78, 82], ["Influenza A H3N2 virus", "DISEASE", 0, 22], ["Influenza A H3N2 virus", "ORGANISM", 0, 22], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 78, 82], ["Influenza A H3N2 virus", "SPECIES", 0, 22], ["Influenza A H3N2 virus", "SPECIES", 0, 22], ["Dr. R. Pyh/il/i", "SPECIES", 36, 51], ["Influenza", "PROBLEM", 0, 9], ["A H3N2 virus", "PROBLEM", 10, 22], ["embryonated eggs", "OBSERVATION", 66, 82]]], ["A single preparation of each inducer virus was used throughout the study and a fresh aliquot was thawed for each experiment.", [["A single preparation of each inducer virus", "TREATMENT", 0, 42], ["the study", "TEST", 63, 72], ["a fresh aliquot", "TREATMENT", 77, 92], ["virus", "OBSERVATION", 37, 42]]], ["The leukocyte culture conditions were strictly standardized with the inducer dosage being standardized according to the infectivity as described before (Pitkfiranta et al., 1993) .", [["leukocyte", "ANATOMY", 4, 13], ["leukocyte", "CELL", 4, 13], ["The leukocyte culture conditions", "TEST", 0, 32], ["the inducer dosage", "TREATMENT", 65, 83], ["leukocyte", "ANATOMY", 4, 13]]], ["Virus TCIDso titres were rechecked by end-point dilution in tube cultures since the time between these two experiments was two years.", [["tube cultures", "ANATOMY", 60, 73], ["Virus", "ORGANISM", 0, 5], ["tube cultures", "CELL", 60, 73], ["Virus TCIDso titres", "TEST", 0, 19], ["tube cultures", "TEST", 60, 73]]], ["Culture medium for IFN assay was harvested on day 2 (Pitk/iranta et al., 1988), cleared from cells by centrifugation, and stored at 20\u00b0C until assayed.IFN assayIFN concentrations were measured by a micromethod based on the reduction of cytopathic effect caused by vesicular stomatitis virus in monolayers of NBL cells (Linnavuori, 1988) .", [["cells", "ANATOMY", 93, 98], ["monolayers", "ANATOMY", 294, 304], ["NBL cells", "ANATOMY", 308, 317], ["IFN", "CHEMICAL", 151, 154], ["vesicular stomatitis virus", "DISEASE", 264, 290], ["cells", "CELL", 93, 98], ["C", "GENE_OR_GENE_PRODUCT", 135, 136], ["IFN", "GENE_OR_GENE_PRODUCT", 151, 154], ["vesicular stomatitis virus", "ORGANISM", 264, 290], ["monolayers", "CELL", 294, 304], ["NBL cells", "CELL", 308, 317], ["IFN", "PROTEIN", 19, 22], ["IFN", "PROTEIN", 151, 154], ["NBL cells", "CELL_LINE", 308, 317], ["vesicular stomatitis virus", "SPECIES", 264, 290], ["Culture medium", "TEST", 0, 14], ["IFN assay", "TEST", 19, 28], ["IFN assayIFN concentrations", "PROBLEM", 151, 178], ["a micromethod", "TEST", 196, 209], ["cytopathic effect", "PROBLEM", 236, 253], ["vesicular stomatitis virus", "PROBLEM", 264, 290], ["NBL cells", "PROBLEM", 308, 317], ["cytopathic", "OBSERVATION_MODIFIER", 236, 246], ["vesicular stomatitis virus", "OBSERVATION", 264, 290], ["NBL cells", "OBSERVATION", 308, 317]]], ["A standardized human leukocyte IFN preparation (a gift from Dr. K. Cantell, National Public Health Institute, Helsinki) was included in each assay so that results could be expressed in IU/ml.", [["leukocyte", "ANATOMY", 21, 30], ["human", "ORGANISM", 15, 20], ["leukocyte", "CELL", 21, 30], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["A standardized human leukocyte IFN preparation", "TREATMENT", 0, 46]]], ["Results given are means of two parallel cultures; a maximum of 2-fold difference was seen between the parallel cultures.", [["two parallel cultures", "TEST", 27, 48], ["2-fold difference", "PROBLEM", 63, 80], ["the parallel cultures", "TEST", 98, 119]]], ["The subtype of IFN was not specifically assessed in these studies.", [["IFN", "GENE_OR_GENE_PRODUCT", 15, 18], ["IFN", "PROTEIN", 15, 18], ["these studies", "TEST", 52, 65], ["subtype", "OBSERVATION_MODIFIER", 4, 11], ["IFN", "OBSERVATION", 15, 18]]], ["Virus-induced leukocyte IFN is mostly a mixture of different alpha IFNs and the bovine cell line (NBL) used in the assays is not sensitive to human gamma IFN.Statistical methodsDifferences between groups were measured with the Mann-Whitney U-test.ResultsChildren segregated into three groups according to their clinical condition after the follow-up period (Table 1 ): in 24 children health had strikingly improved, i.e. they had no significant respiratory tract infections at all during the last 6 months (Group 1), in 12 children the health had mildly improved (respiratory tract infections less than 6 episodes and/or acute otitis media less than 4 episodes during the last 6 months, (Group 2), while 12 children had suffered 6 or more upper respiratory tract infections and/or 4 or more episodes of acute otitis media during the last 6 months (Group 3).", [["leukocyte", "ANATOMY", 14, 23], ["cell line", "ANATOMY", 87, 96], ["NBL", "ANATOMY", 98, 101], ["respiratory tract", "ANATOMY", 445, 462], ["respiratory tract", "ANATOMY", 564, 581], ["upper respiratory tract", "ANATOMY", 739, 762], ["respiratory tract infections", "DISEASE", 445, 473], ["respiratory tract infections", "DISEASE", 564, 592], ["otitis", "DISEASE", 627, 633], ["respiratory tract infections", "DISEASE", 745, 773], ["otitis", "DISEASE", 809, 815], ["Virus", "ORGANISM", 0, 5], ["leukocyte", "CELL", 14, 23], ["alpha IFNs", "GENE_OR_GENE_PRODUCT", 61, 71], ["bovine", "ORGANISM", 80, 86], ["cell line", "CELL", 87, 96], ["NBL", "CELL", 98, 101], ["human", "ORGANISM", 142, 147], ["gamma IFN", "GENE_OR_GENE_PRODUCT", 148, 157], ["Children", "ORGANISM", 254, 262], ["children", "ORGANISM", 375, 383], ["respiratory tract", "ORGANISM_SUBDIVISION", 445, 462], ["children", "ORGANISM", 523, 531], ["tract", "ORGANISM_SUBDIVISION", 576, 581], ["children", "ORGANISM", 707, 715], ["upper", "ORGANISM_SUBDIVISION", 739, 744], ["respiratory tract", "ORGANISM_SUBDIVISION", 745, 762], ["Virus-induced leukocyte IFN", "PROTEIN", 0, 27], ["alpha IFNs", "PROTEIN", 61, 71], ["bovine cell line", "CELL_LINE", 80, 96], ["NBL", "CELL_LINE", 98, 101], ["human gamma IFN", "PROTEIN", 142, 157], ["bovine", "SPECIES", 80, 86], ["human", "SPECIES", 142, 147], ["Children", "SPECIES", 254, 262], ["children", "SPECIES", 375, 383], ["children", "SPECIES", 523, 531], ["children", "SPECIES", 707, 715], ["human", "SPECIES", 142, 147], ["Virus", "TEST", 0, 5], ["leukocyte IFN", "PROBLEM", 14, 27], ["different alpha IFNs", "PROBLEM", 51, 71], ["the bovine cell line", "TREATMENT", 76, 96], ["the assays", "TEST", 111, 121], ["significant respiratory tract infections", "PROBLEM", 433, 473], ["mildly improved (respiratory tract infections", "PROBLEM", 547, 592], ["acute otitis media", "PROBLEM", 621, 639], ["more upper respiratory tract infections", "PROBLEM", 734, 773], ["acute otitis media", "PROBLEM", 803, 821], ["leukocyte IFN", "OBSERVATION", 14, 27], ["alpha IFNs", "OBSERVATION", 61, 71], ["bovine cell line", "OBSERVATION", 80, 96], ["respiratory tract", "ANATOMY", 445, 462], ["infections", "OBSERVATION", 463, 473], ["mildly", "OBSERVATION_MODIFIER", 547, 553], ["improved", "OBSERVATION_MODIFIER", 554, 562], ["respiratory tract", "ANATOMY", 564, 581], ["acute", "OBSERVATION_MODIFIER", 621, 626], ["otitis", "OBSERVATION", 627, 633], ["upper", "ANATOMY_MODIFIER", 739, 744], ["respiratory tract", "ANATOMY", 745, 762], ["infections", "OBSERVATION", 763, 773], ["acute", "OBSERVATION_MODIFIER", 803, 808], ["otitis", "OBSERVATION", 809, 815]]], ["The children of Group 3 were significantly younger than those in the improved Group 1 (P<0.02), ( had not yet come to an end (P < 0.05), (Table 1) .", [["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12]]], ["Duration of the infection chain in Groups 1 and 2 did not differ from each other.", [["infection", "DISEASE", 16, 25], ["infection", "OBSERVATION", 16, 25], ["chain", "OBSERVATION_MODIFIER", 26, 31]]], ["Median age at the onset of the infections differed also between Groups 1 and 3 (P < 0.05), (Table 1) .", [["infections", "DISEASE", 31, 41], ["the infections", "PROBLEM", 27, 41], ["infections", "OBSERVATION", 31, 41]]], ["Six out of the 12 children in Group 3 had their onset before the age of 6 months while in Group 2 and 3 only 2/12 and 3/24 children did so.ResultsIn Group 1 children with improved health, geometric means of the IFN titres were now higher than 2 years previously, and a statistically significant difference was seen in cultures stimulated with corona-and RS-viruses (Fig. 1) .", [["cultures", "ANATOMY", 318, 326], ["children", "ORGANISM", 18, 26], ["children", "ORGANISM", 123, 131], ["children", "ORGANISM", 157, 165], ["IFN", "GENE_OR_GENE_PRODUCT", 211, 214], ["corona-and RS-viruses", "ORGANISM", 343, 364], ["IFN", "PROTEIN", 211, 214], ["children", "SPECIES", 18, 26], ["children", "SPECIES", 123, 131], ["children", "SPECIES", 157, 165], ["the IFN titres", "TREATMENT", 207, 221], ["a statistically significant difference", "PROBLEM", 267, 305], ["cultures", "TEST", 318, 326]]], ["In the third group, where the children were still suffering from recurrent respiratory tract infections, the mean IFN titres had not changed during the two years (Fig. 3) .ResultsRelatively little variation in individual IFN yields between the two specimens was seen among the children in Group 3.", [["respiratory tract", "ANATOMY", 75, 92], ["specimens", "ANATOMY", 248, 257], ["respiratory tract infections", "DISEASE", 75, 103], ["children", "ORGANISM", 30, 38], ["respiratory tract", "ORGANISM_SUBDIVISION", 75, 92], ["IFN", "GENE_OR_GENE_PRODUCT", 221, 224], ["children", "ORGANISM", 277, 285], ["IFN", "PROTEIN", 114, 117], ["IFN", "PROTEIN", 221, 224], ["children", "SPECIES", 30, 38], ["children", "SPECIES", 277, 285], ["recurrent respiratory tract infections", "PROBLEM", 65, 103], ["the mean IFN titres", "TEST", 105, 124], ["respiratory tract", "ANATOMY", 75, 92], ["infections", "OBSERVATION", 93, 103], ["little", "OBSERVATION_MODIFIER", 190, 196], ["variation", "OBSERVATION_MODIFIER", 197, 206]]], ["Leukocyte cultures from all the children showed a maximum difference of 1-2 dilution steps in the IFN assay between 1992 and 1994, when stimulated with four out of the five different viruses.", [["Leukocyte cultures", "ANATOMY", 0, 18], ["Leukocyte cultures", "CELL", 0, 18], ["children", "ORGANISM", 32, 40], ["Leukocyte cultures", "CELL_LINE", 0, 18], ["IFN", "PROTEIN", 98, 101], ["children", "SPECIES", 32, 40], ["Leukocyte cultures", "TEST", 0, 18], ["the IFN assay", "TEST", 94, 107], ["viruses", "OBSERVATION", 183, 190]]], ["Somewhat more variation was seen in cultures stimulated with rhinovirus.", [["cultures", "ANATOMY", 36, 44], ["rhinovirus", "ORGANISM", 61, 71], ["Somewhat more variation", "PROBLEM", 0, 23], ["cultures", "TEST", 36, 44], ["rhinovirus", "PROBLEM", 61, 71], ["more variation", "OBSERVATION_MODIFIER", 9, 23]]], ["In Group 1, the IFN levels had increased or remained similar to those obtained in 1992 except one child who showed a decline.", [["IFN", "GENE_OR_GENE_PRODUCT", 16, 19], ["IFN", "PROTEIN", 16, 19], ["the IFN levels", "TEST", 12, 26], ["a decline", "PROBLEM", 115, 124]]], ["In Group 2, the IFN responses showed quite a similar tendency as in the group 1.", [["IFN", "PROTEIN", 16, 19], ["the IFN responses", "TEST", 12, 29]]], ["Of the 10 children whose leukocytes in 1992 failed to produce any detectable IFN when stimulated with either adeno-, rhinoor coronavirus, none showed now a total lack of IFN production, and some showed a striking increase in the IFN yields produced.", [["leukocytes", "ANATOMY", 25, 35], ["children", "ORGANISM", 10, 18], ["leukocytes", "CELL", 25, 35], ["IFN", "GENE_OR_GENE_PRODUCT", 77, 80], ["rhinoor coronavirus", "ORGANISM", 117, 136], ["IFN", "GENE_OR_GENE_PRODUCT", 170, 173], ["leukocytes", "CELL_TYPE", 25, 35], ["IFN", "PROTEIN", 77, 80], ["IFN", "PROTEIN", 170, 173], ["IFN", "PROTEIN", 229, 232], ["children", "SPECIES", 10, 18], ["rhinoor coronavirus", "SPECIES", 117, 136], ["rhinoor coronavirus", "PROBLEM", 117, 136], ["IFN production", "PROBLEM", 170, 184], ["increase", "OBSERVATION_MODIFIER", 213, 221]]], ["Only two of them still suffered from recurrent infections.ResultsSpontaneous IFN production was not detected in any leukocyte cultures.", [["leukocyte cultures", "ANATOMY", 116, 134], ["infections", "DISEASE", 47, 57], ["IFN", "GENE_OR_GENE_PRODUCT", 77, 80], ["leukocyte cultures", "CELL", 116, 134], ["IFN", "PROTEIN", 77, 80], ["leukocyte cultures", "CELL_LINE", 116, 134], ["recurrent infections", "PROBLEM", 37, 57], ["ResultsSpontaneous IFN production", "PROBLEM", 58, 91], ["any leukocyte cultures", "TEST", 112, 134], ["recurrent", "OBSERVATION_MODIFIER", 37, 46], ["infections", "OBSERVATION", 47, 57]]], ["The production of IFN was influenced by neither the age nor the sex of the children.DiscussionThe present investigation was designed to study the correlation of production of IFN in leukocyte cultures and continuation of infections in children known to be prone to respiratory tract infections.", [["leukocyte cultures", "ANATOMY", 182, 200], ["respiratory tract", "ANATOMY", 265, 282], ["infections", "DISEASE", 221, 231], ["respiratory tract infections", "DISEASE", 265, 293], ["IFN", "GENE_OR_GENE_PRODUCT", 18, 21], ["children", "ORGANISM", 75, 83], ["IFN", "GENE_OR_GENE_PRODUCT", 175, 178], ["leukocyte cultures", "CELL", 182, 200], ["children", "ORGANISM", 235, 243], ["tract", "ORGANISM_SUBDIVISION", 277, 282], ["IFN", "PROTEIN", 18, 21], ["IFN", "PROTEIN", 175, 178], ["leukocyte cultures", "CELL_LINE", 182, 200], ["children", "SPECIES", 75, 83], ["children", "SPECIES", 235, 243], ["IFN", "PROBLEM", 18, 21], ["IFN", "PROBLEM", 175, 178], ["leukocyte cultures", "TEST", 182, 200], ["infections", "PROBLEM", 221, 231], ["respiratory tract infections", "PROBLEM", 265, 293], ["respiratory tract", "ANATOMY", 265, 282], ["infections", "OBSERVATION", 283, 293]]], ["The yields of IFN obtained in leukocyte cultures are known to vary according to both the inducer used and the cell donor.", [["leukocyte cultures", "ANATOMY", 30, 48], ["cell", "ANATOMY", 110, 114], ["IFN", "GENE_OR_GENE_PRODUCT", 14, 17], ["leukocyte cultures", "CELL", 30, 48], ["cell", "CELL", 110, 114], ["IFN", "PROTEIN", 14, 17], ["leukocyte cultures", "CELL_LINE", 30, 48], ["IFN", "TREATMENT", 14, 17], ["leukocyte cultures", "TEST", 30, 48], ["the cell donor", "TREATMENT", 106, 120], ["cell donor", "OBSERVATION", 110, 120]]], ["The inducer can be standardized but the inherent time-dependent variation of blood leukocyte composition and of physiological status of the donor might compromise attempts to determine an IFN yield typical of an individual.", [["blood leukocyte", "ANATOMY", 77, 92], ["blood leukocyte", "CELL", 77, 92], ["IFN", "PROTEIN", 188, 191], ["The inducer", "TREATMENT", 0, 11], ["blood leukocyte composition", "TEST", 77, 104], ["blood leukocyte", "OBSERVATION", 77, 92]]], ["Previously, we reported that by using a set of different inducer viruses, it is possible to demonstrate that the yields of IFN obtained under standard conditions remain relative constant for successive blood specimens of healthy individuals, and that especially the ratio of 1FN induced by different viruses shows a reproducible typical pattern (Pitkfiranta et al., 1991) .", [["blood specimens", "ANATOMY", 202, 217], ["1FN", "CHEMICAL", 275, 278], ["IFN", "GENE_OR_GENE_PRODUCT", 123, 126], ["blood specimens", "ORGANISM_SUBSTANCE", 202, 217], ["1FN", "GENE_OR_GENE_PRODUCT", 275, 278], ["IFN", "PROTEIN", 123, 126], ["1FN", "PROTEIN", 275, 278], ["different inducer viruses", "PROBLEM", 47, 72], ["IFN", "TREATMENT", 123, 126], ["successive blood specimens of healthy individuals", "PROBLEM", 191, 240], ["different viruses", "PROBLEM", 290, 307], ["viruses", "OBSERVATION", 65, 72], ["reproducible", "OBSERVATION_MODIFIER", 316, 328], ["typical", "OBSERVATION_MODIFIER", 329, 336]]], ["In a subsequent study, we showed that leukocytes from children with recurrent respiratory tract infections produce significantly less IFN than cells from normal children, when stimulated with standard amounts of common respiratory pathogenic viruses (Pitkfiranta et al., 1993) .", [["leukocytes", "ANATOMY", 38, 48], ["respiratory tract", "ANATOMY", 78, 95], ["cells", "ANATOMY", 143, 148], ["respiratory tract infections", "DISEASE", 78, 106], ["respiratory pathogenic viruses", "DISEASE", 219, 249], ["leukocytes", "CELL", 38, 48], ["children", "ORGANISM", 54, 62], ["tract", "ORGANISM_SUBDIVISION", 90, 95], ["IFN", "GENE_OR_GENE_PRODUCT", 134, 137], ["cells", "CELL", 143, 148], ["children", "ORGANISM", 161, 169], ["leukocytes", "CELL_TYPE", 38, 48], ["IFN", "PROTEIN", 134, 137], ["children", "SPECIES", 54, 62], ["children", "SPECIES", 161, 169], ["a subsequent study", "TEST", 3, 21], ["leukocytes", "PROBLEM", 38, 48], ["recurrent respiratory tract infections", "PROBLEM", 68, 106], ["common respiratory pathogenic viruses", "PROBLEM", 212, 249], ["respiratory tract", "ANATOMY", 78, 95], ["common respiratory", "ANATOMY", 212, 230], ["pathogenic viruses", "OBSERVATION", 231, 249]]], ["It has been earlier suggested, based on circumstantial evidence, that the lowered IFN yields in this group of patients may be secondary to the underlying disease, as some children had been shown to present improved responses after the cycle of recurrent respiratory infections was over (Chadda et al., 1983) .", [["respiratory", "ANATOMY", 254, 265], ["IFN", "CHEMICAL", 82, 85], ["respiratory infections", "DISEASE", 254, 276], ["IFN", "GENE_OR_GENE_PRODUCT", 82, 85], ["patients", "ORGANISM", 110, 118], ["children", "ORGANISM", 171, 179], ["IFN", "PROTEIN", 82, 85], ["patients", "SPECIES", 110, 118], ["children", "SPECIES", 171, 179], ["the lowered IFN yields", "PROBLEM", 70, 92], ["the underlying disease", "PROBLEM", 139, 161], ["recurrent respiratory infections", "PROBLEM", 244, 276], ["disease", "OBSERVATION", 154, 161], ["respiratory", "ANATOMY", 254, 265], ["infections", "OBSERVATION", 266, 276]]], ["Our current follow-up study tested this hypothesis with a larger group of patients and with five different natural respiratory pathogens as IFN inducers.", [["patients", "ORGANISM", 74, 82], ["IFN", "GENE_OR_GENE_PRODUCT", 140, 143], ["IFN", "PROTEIN", 140, 143], ["patients", "SPECIES", 74, 82], ["up study", "TEST", 19, 27], ["five different natural respiratory pathogens", "PROBLEM", 92, 136], ["IFN inducers", "TREATMENT", 140, 152], ["respiratory pathogens", "OBSERVATION", 115, 136]]], ["To avoid possible seasonal variation (Pugliese et al., 1985) retesting was perlbrmed during the same summer months, May August, similar to the initial study two years earlier.", [["seasonal variation", "PROBLEM", 18, 36], ["the initial study", "TEST", 139, 156], ["possible", "UNCERTAINTY", 9, 17]]], ["Unfortunately, it was not possible to collect follow-up specimens from the healthy control children of our previous study (Pitkfiranta et al., 1993) .DiscussionWhile responses of leukocytes stimulated with corona-or RS-viruses improved in accordance with the improved health, those due to rhino-and influenza viruses did not.", [["specimens", "ANATOMY", 56, 65], ["leukocytes", "ANATOMY", 179, 189], ["rhino-and influenza viruses", "DISEASE", 289, 316], ["children", "ORGANISM", 91, 99], ["leukocytes", "CELL", 179, 189], ["corona-or RS-viruses", "ORGANISM", 206, 226], ["leukocytes", "CELL_TYPE", 179, 189], ["children", "SPECIES", 91, 99], ["our previous study", "TEST", 103, 121], ["leukocytes", "TEST", 179, 189], ["corona-or RS", "PROBLEM", 206, 218], ["viruses", "PROBLEM", 219, 226], ["rhino", "PROBLEM", 289, 294], ["influenza viruses", "PROBLEM", 299, 316], ["viruses", "OBSERVATION", 219, 226]]], ["This virus-dependent divergence of correlations is, as such, not surprising, as leukocyte cultures of individual donors were also previously shown to differ strikingly in their relative IFN responses to a given virus (Pitk/iranta et al., 1991 (Pitk/iranta et al., , 1993 .", [["leukocyte cultures", "ANATOMY", 80, 98], ["leukocyte cultures", "CELL", 80, 98], ["donors", "ORGANISM", 113, 119], ["IFN", "GENE_OR_GENE_PRODUCT", 186, 189], ["leukocyte cultures", "CELL_LINE", 80, 98], ["IFN", "PROTEIN", 186, 189], ["This virus", "PROBLEM", 0, 10], ["leukocyte cultures", "TEST", 80, 98], ["individual donors", "PROBLEM", 102, 119], ["virus", "PROBLEM", 211, 216], ["dependent", "OBSERVATION_MODIFIER", 11, 20], ["divergence", "OBSERVATION_MODIFIER", 21, 31]]], ["It appears that if we had tested the responses only with corona-or RS-virus, we could have easily concluded that the observed lowered IFN responses of leukocyte cultures from children with recurrent respiratory infections are only secondary to the underlying disease.", [["leukocyte cultures", "ANATOMY", 151, 169], ["respiratory", "ANATOMY", 199, 210], ["respiratory infections", "DISEASE", 199, 221], ["corona-or RS-virus", "ORGANISM", 57, 75], ["IFN", "GENE_OR_GENE_PRODUCT", 134, 137], ["leukocyte cultures", "CELL", 151, 169], ["children", "ORGANISM", 175, 183], ["IFN", "PROTEIN", 134, 137], ["leukocyte cultures", "CELL_LINE", 151, 169], ["children", "SPECIES", 175, 183], ["corona-or RS-virus", "SPECIES", 57, 75], ["corona-or RS-virus", "PROBLEM", 57, 75], ["leukocyte cultures", "TEST", 151, 169], ["recurrent respiratory infections", "PROBLEM", 189, 221], ["the underlying disease", "PROBLEM", 244, 266], ["respiratory infections", "OBSERVATION", 199, 221], ["disease", "OBSERVATION", 259, 266]]], ["However, the lack of statistically significant improvement of the responses obtained with the other inducers makes the interpretation more difficult.", [["significant", "OBSERVATION_MODIFIER", 35, 46], ["improvement", "OBSERVATION_MODIFIER", 47, 58]]], ["While the lowered response to coronaand RS-virus stimulation appears to be associated with the continuing infectious situation, for the time being, it cannot be suggested as a diagnostic marker for this condition as the yields of IFN from leukocytes of healthy children vary widely (Pitk~ranta et al., 1993) .", [["leukocytes", "ANATOMY", 239, 249], ["coronaand RS-virus", "ORGANISM", 30, 48], ["IFN", "GENE_OR_GENE_PRODUCT", 230, 233], ["leukocytes", "CELL", 239, 249], ["children", "ORGANISM", 261, 269], ["IFN", "PROTEIN", 230, 233], ["leukocytes", "CELL_TYPE", 239, 249], ["children", "SPECIES", 261, 269], ["coronaand RS-virus stimulation", "TREATMENT", 30, 60], ["the continuing infectious situation", "PROBLEM", 91, 126], ["infectious", "OBSERVATION", 106, 116]]], ["One possible explanation for lower IFN-responses in children suffering from recurrent infections may be due to putative continuous stimulation of the IFN system which may lead to hyporeactivity.", [["infections", "DISEASE", 86, 96], ["hyporeactivity", "DISEASE", 179, 193], ["IFN", "GENE_OR_GENE_PRODUCT", 35, 38], ["children", "ORGANISM", 52, 60], ["IFN", "PROTEIN", 35, 38], ["IFN", "PROTEIN", 150, 153], ["children", "SPECIES", 52, 60], ["recurrent infections", "PROBLEM", 76, 96], ["putative continuous stimulation of the IFN system", "PROBLEM", 111, 160], ["hyporeactivity", "PROBLEM", 179, 193], ["possible explanation for", "UNCERTAINTY", 4, 28], ["infections", "OBSERVATION", 86, 96], ["may lead to", "UNCERTAINTY", 167, 178], ["hyporeactivity", "OBSERVATION", 179, 193]]], ["However acute respiratory infection has not been found to impair IFN production by leukocytes in vitro (Bondestam et al., 1984; Vanecek and Lehovcova, 1985; Pitk/iranta et al., 1993) .", [["respiratory", "ANATOMY", 14, 25], ["leukocytes", "ANATOMY", 83, 93], ["respiratory infection", "DISEASE", 14, 35], ["IFN", "GENE_OR_GENE_PRODUCT", 65, 68], ["leukocytes", "CELL", 83, 93], ["IFN", "PROTEIN", 65, 68], ["leukocytes", "CELL_TYPE", 83, 93], ["acute respiratory infection", "PROBLEM", 8, 35], ["IFN production", "PROBLEM", 65, 79], ["acute", "OBSERVATION_MODIFIER", 8, 13], ["respiratory", "ANATOMY", 14, 25], ["infection", "OBSERVATION", 26, 35]]], ["The age of the child is an important factor in predicting the risk of respiratory tract infections.", [["respiratory tract", "ANATOMY", 70, 87], ["respiratory tract infections", "DISEASE", 70, 98], ["child", "ORGANISM", 15, 20], ["respiratory tract", "ORGANISM_SUBDIVISION", 70, 87], ["respiratory tract infections", "PROBLEM", 70, 98], ["respiratory tract", "ANATOMY", 70, 87], ["infections", "OBSERVATION", 88, 98]]], ["The age of the continuously sick children was lower than that of those children whose infections had come to an end.", [["infections", "DISEASE", 86, 96], ["children", "ORGANISM", 33, 41], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 33, 41], ["children", "SPECIES", 71, 79]]], ["The incidence of the illness has been shown to be higher in children under the age of three years than among older children (Wald et al., 1988; Pfnk/i et al., 1991) .", [["illness", "DISEASE", 21, 28], ["children", "ORGANISM", 60, 68], ["children", "ORGANISM", 115, 123], ["children", "SPECIES", 60, 68], ["children", "SPECIES", 115, 123], ["higher", "OBSERVATION_MODIFIER", 50, 56]]], ["The number of respiratory tract infections in early childhood can partly be due to immunological immaturity (Prellner et al., 1992) .", [["respiratory tract", "ANATOMY", 14, 31], ["respiratory tract infections", "DISEASE", 14, 42], ["respiratory tract", "ORGANISM_SUBDIVISION", 14, 31], ["respiratory tract infections", "PROBLEM", 14, 42], ["immunological immaturity", "PROBLEM", 83, 107], ["number", "OBSERVATION_MODIFIER", 4, 10], ["respiratory tract", "ANATOMY", 14, 31], ["infections", "OBSERVATION", 32, 42], ["can partly be due to", "UNCERTAINTY", 62, 82]]], ["Although contradictory findings of age-dependence in IFN production have been reported (Abb et al., 1984; Kishida et al., 1986 ) the ages within the range they showed in our study children do not affect IFN production (Cantell et al., 1968) .", [["IFN", "GENE_OR_GENE_PRODUCT", 53, 56], ["children", "ORGANISM", 180, 188], ["IFN", "GENE_OR_GENE_PRODUCT", 203, 206], ["IFN", "PROTEIN", 53, 56], ["IFN", "PROTEIN", 203, 206], ["children", "SPECIES", 180, 188], ["IFN production", "PROBLEM", 53, 67]]], ["Thus the age factor cannot explain the differences in our IFN yields.", [["IFN", "PROTEIN", 58, 61]]], ["Furthermore, when IFN yields of leukocytes from the youngest and oldest thirds out of the entire follow-up group were compared, we could not find any differences (data not shown).", [["leukocytes", "ANATOMY", 32, 42], ["leukocytes", "CELL", 32, 42], ["IFN", "PROTEIN", 18, 21], ["leukocytes", "CELL_TYPE", 32, 42], ["leukocytes", "PROBLEM", 32, 42]]], ["This corroborates previously published findings (Bondestam et al., 1984; Pitk~iranta et al., 1993) .DiscussionThe children still suffering from the recurrent disease were younger than those who showed improved health.", [["children", "ORGANISM", 114, 122], ["children", "SPECIES", 114, 122], ["the recurrent disease", "PROBLEM", 144, 165]]], ["Yet they already had a longer history of disease and, accordingly, had had an earlier onset of the chain of infections known to be a characteristic of some selected children suffering from recurrent respiratory tract infections (Klein, 1994) .", [["respiratory tract", "ANATOMY", 199, 216], ["infections", "DISEASE", 108, 118], ["respiratory tract infections", "DISEASE", 199, 227], ["children", "ORGANISM", 165, 173], ["tract", "ORGANISM_SUBDIVISION", 211, 216], ["children", "SPECIES", 165, 173], ["disease", "PROBLEM", 41, 48], ["infections", "PROBLEM", 108, 118], ["recurrent respiratory tract infections", "PROBLEM", 189, 227], ["disease", "OBSERVATION", 41, 48], ["infections", "OBSERVATION", 108, 118], ["recurrent", "OBSERVATION_MODIFIER", 189, 198], ["respiratory tract", "ANATOMY", 199, 216], ["infections", "OBSERVATION", 217, 227]]], ["It is obvious that children suffering from recurrent respiratory tract infections are not a homogeneous group of patients but rather may comprise distinct pathogenetic subgroups.", [["respiratory tract", "ANATOMY", 53, 70], ["respiratory tract infections", "DISEASE", 53, 81], ["children", "ORGANISM", 19, 27], ["tract", "ORGANISM_SUBDIVISION", 65, 70], ["patients", "ORGANISM", 113, 121], ["children", "SPECIES", 19, 27], ["patients", "SPECIES", 113, 121], ["recurrent respiratory tract infections", "PROBLEM", 43, 81], ["respiratory tract", "ANATOMY", 53, 70]]], ["Our current results do not exclude the possibility that a subset of patients has a genetic trait resulting in lowered IFN production connected to proneness to respiratory infections.", [["respiratory", "ANATOMY", 159, 170], ["respiratory infections", "DISEASE", 159, 181], ["patients", "ORGANISM", 68, 76], ["IFN", "GENE_OR_GENE_PRODUCT", 118, 121], ["IFN", "PROTEIN", 118, 121], ["patients", "SPECIES", 68, 76], ["a genetic trait", "PROBLEM", 81, 96], ["lowered IFN production", "PROBLEM", 110, 132], ["respiratory infections", "PROBLEM", 159, 181], ["respiratory", "ANATOMY", 159, 170], ["infections", "OBSERVATION", 171, 181]]], ["This possibility should be investigated in a prospective cohort assessing the predictive value of IFN yields produced by leukocytes in relation to later respiratory infections.", [["leukocytes", "ANATOMY", 121, 131], ["respiratory", "ANATOMY", 153, 164], ["respiratory infections", "DISEASE", 153, 175], ["IFN", "GENE_OR_GENE_PRODUCT", 98, 101], ["leukocytes", "CELL", 121, 131], ["IFN", "PROTEIN", 98, 101], ["leukocytes", "CELL_TYPE", 121, 131], ["IFN yields", "PROBLEM", 98, 108], ["leukocytes", "PROBLEM", 121, 131], ["later respiratory infections", "PROBLEM", 147, 175], ["respiratory", "ANATOMY", 153, 164], ["infections", "OBSERVATION", 165, 175]]]], "PMC3372348": [["To the Editor: Chikungunya virus disease, caused by a mosquitoborne alphavirus, is endemic to Africa and Southeast Asia.", [["Chikungunya virus disease", "DISEASE", 15, 40], ["mosquitoborne alphavirus", "DISEASE", 54, 78], ["Chikungunya virus", "ORGANISM", 15, 32], ["mosquitoborne alphavirus", "ORGANISM", 54, 78], ["Chikungunya virus", "SPECIES", 15, 32], ["Chikungunya virus", "SPECIES", 15, 32], ["Chikungunya virus disease", "PROBLEM", 15, 40], ["a mosquitoborne alphavirus", "PROBLEM", 52, 78], ["Chikungunya virus disease", "OBSERVATION", 15, 40]]], ["It typically causes an acute febrile illness, with joint pain and a skin rash.", [["joint", "ANATOMY", 51, 56], ["skin", "ANATOMY", 68, 72], ["febrile illness", "DISEASE", 29, 44], ["joint pain", "DISEASE", 51, 61], ["skin rash", "DISEASE", 68, 77], ["joint", "ORGANISM_SUBDIVISION", 51, 56], ["skin", "ORGAN", 68, 72], ["an acute febrile illness", "PROBLEM", 20, 44], ["joint pain", "PROBLEM", 51, 61], ["a skin rash", "PROBLEM", 66, 77], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["febrile", "OBSERVATION_MODIFIER", 29, 36], ["illness", "OBSERVATION", 37, 44], ["joint", "ANATOMY", 51, 56], ["pain", "OBSERVATION", 57, 61], ["skin", "ANATOMY", 68, 72], ["rash", "OBSERVATION", 73, 77]]], ["Chronic arthropathy may develop (1,2).", [["arthropathy", "DISEASE", 8, 19], ["Chronic arthropathy", "PROBLEM", 0, 19], ["arthropathy", "OBSERVATION", 8, 19]]], ["No treatment or vaccine is available, and relatively little research has been conducted into its pathogenesis, compared with that of other arboviruses, such as dengue.", [["arboviruses", "DISEASE", 139, 150], ["dengue", "DISEASE", 160, 166], ["dengue", "SPECIES", 160, 166], ["treatment", "TREATMENT", 3, 12], ["vaccine", "TREATMENT", 16, 23]]], ["Recent reports have described a massive outbreak of chikungunya disease occurring on islands in the Indian Ocean, off the east coast of Africa (1).", [["chikungunya disease", "DISEASE", 52, 71], ["chikungunya disease", "PROBLEM", 52, 71], ["massive", "OBSERVATION_MODIFIER", 32, 39], ["outbreak", "OBSERVATION_MODIFIER", 40, 48], ["chikungunya disease", "OBSERVATION", 52, 71]]], ["Reemergence of chikungunya has also been reported from Indonesia (2).", [["chikungunya", "DISEASE", 15, 26], ["chikungunya", "ORGANISM", 15, 26], ["chikungunya", "PROBLEM", 15, 26], ["chikungunya", "OBSERVATION", 15, 26]]]]}